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The data collected and analyzed within the context of this dissertation project 
contribute to the emerging body of knowledge about factors affecting entry of people living 
with HIV in HIV cure-related research.  
This DrPH dissertation project: 
1) Examines whether perceived risks and benefits of studies act as deterrents and 
motivators of participation using a semi-structured survey;  
2) Explores how various stakeholders perceive risks and benefits of HIV cure-related 
studies using qualitative methods;  
3) Seeks to understand some of the pragmatic issues affecting participation in and 
implementation of HIV cure-related studies using qualitative methods. 
Key survey findings include: 
 Willingness to participate in HIV cure-related research is high, but may not translate into 
actual research participation.  
 Although HIV cure studies confer no expectation of direct benefit, potential volunteers may 
still perceive the likelihood of benefits when deciding to join studies. Psychosocial factors, 
such as feeling good about contributing to the biomedical HIV cure-related research agenda, 
should not be under-estimated when planning studies.  
 More education is needed around risks and benefits of HIV cure research. 
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Key qualitative findings include: 
 Factors affecting participation in HIV cure-related research are multi-faceted. Main 
motivators related to the desire to contribute to HIV cure science. Altruism also plays a 
significant role.  
 It is possible to derive factors that facilitate recruitment and retention of study participants 
in HIV cure-related studies, as well as effective and ethical implementation of research.  
Plan for Change 
Drawing from principles of research ethics, implementation science and leadership 
theories, the plan for change focuses on the need to avoid unintended consequences during 
HIV cure-related research implementation. There are five main elements of the plan for 
change: summation of research findings in usable format, community engagement and 
coalition building, considerations and tools to facilitate the implementation of HIV cure 
research, development and implementation of an HIV cure research training curriculum (the 
“CUREiculum”) and possible avenues for future research. 
 
 v 
I dedicate this DrPH dissertation to all those we lost to HIV/AIDS and Ebola 
 vi 
ACKNOWLEDGEMENTS 
 Several individuals have helped me throughout the preparation of the DrPH research 
and dissertation. 
 First and foremost, I am most grateful to all the study participants who couragesouly 
shared their experiences and perspectives.  
 I want to wholeheartedly thank Professor Sandra Greene, my dissertation Chair, for her 
most helpful feedback, encouragements and guidance, and for being willing to “take me on.” I 
feel so fortunate to have had such a wonderful Chair. I also thank Asheley Skinner for her all 
her support during the disseration process, particularly during the literature review class. Bryan 
Weiner provided expert input planning the key informant interviews and with the 
implementation component of the dissertation. I also want to thank Stuart Rennie for his 
guidance on the ethical dimension of my dissertation and in-depth conversations about HIV 
cure-related research. Harsha Thirumurthy provided guidance on the survey and quantitative 
section. I am so lucky to have had the chance to work with the most amazing dissertation 
committee I could have ever hoped for.  
Thank you, Committee!  
 Acknowledgements must also go to the the UNC-CH HPM department, the searcHIV 
team, the CUREiculum steering committtee, the International AIDS Society (IAS) Psychosocial 
Working group and the Forum for Collaborative HIV Research. I thank Tom Ricketts for teaching 
me about consilience and its importance as a public health leader and practitioner.  
 vii 
 I would also like to thank Jeff Taylor, my co-investigator, who serves tiredlessly on the 
Collaboratory of AIDS Researchers for Eradication (CARE) Community Advisory Board and who 
inspired me to do this work.  
 Finally, I wish to thank my husband, Shadi, and my family for all their wonderful 
support throughout the DrPH program and for giving me the mental space to do this work.I 
also want to thank Shadi for his assistance with the statistical analyses found in this 
dissertation.  
 It is with the uppermost gratefulness that I submit this dissertation towards the 
completion of my Executive DrPH degree at the University of North Carolina at Chapel Hill.  
  
 viii 
TABLE OF CONTENTS 
LIST OF TABLES .............................................................................................................................. xiv 
LIST OF FIGURES ............................................................................................................................ xvi 
LIST OF ABBREVIATIONS .............................................................................................................. xviii 
CHAPTER 1 | BACKGROUND ............................................................................................................ 1 
HIV Cure-Related Research ...................................................................................................... 3 
HIV Cure-Related Research Modalities.................................................................................... 3 
Participation in HIV Cure-Related Studies and Willingness to Participate .............................. 5 
Conceptual Framework: Participation in HIV Cure-Related Research and                                   
Willingness to “Participate” ..................................................................................................... 6 
Significance .............................................................................................................................. 7 
Effective Implementation ........................................................................................................ 8 
Ethical Implementation ........................................................................................................... 9 
Risks and Benefits .................................................................................................................. 13 
Therapeutic (or Curative) Misconception.............................................................................. 13 
CHAPTER 2 | METHODS ................................................................................................................. 17 
Overview ................................................................................................................................ 17 
Rationale for Mixed Design ................................................................................................... 20 
Data Collection Methods: Quantitative Inquiry .................................................................... 21 
Semi-Structured Survey (Potential Participants of HIV Cure-Related                                           
Studies) ............................................................................................................................. 21 
Data Collection Methods: Qualitative Inquiry ....................................................................... 23 
Document Review ............................................................................................................ 25 
Key Informant Interviews ................................................................................................. 26 
 ix 
Inclusion/Exclusion of Study Participants and Delimitations ................................................ 28 
Study Participation Duration ................................................................................................. 29 
Reliability and Validity ........................................................................................................... 29 
Strengths and Limitations ...................................................................................................... 31 
Confidentiality and Protection of Study Participants ............................................................ 31 
Informed Consent .................................................................................................................. 33 
Institutional Review Board Approval ..................................................................................... 34 
Compensation for Study Participation .................................................................................. 34 
Study Management ............................................................................................................... 35 
CHAPTER 3 | DATA MANAGEMENT AND ANALYSIS ...................................................................... 36 
Document Review .................................................................................................................. 38 
Quantitative Data Management and Analysis: Survey Data ................................................. 38 
Quantitative Data Management ............................................................................................ 38 
Quantitative Data Analysis .................................................................................................... 40 
Survey Variables ............................................................................................................... 40 
Survey Data Inclusion and Cleaning ................................................................................. 40 
Baseline (Descriptive) Quantitative Data Analysis ........................................................... 49 
Presentation of Quantitative Results .................................................................................... 68 
Qualitative Data Management and Analysis: Key Informant Interviews .............................. 70 
Qualitative Data Management .............................................................................................. 70 
Qualitative Data Analysis ....................................................................................................... 72 
Presentation of Qualitative Data and Interpretation of Results ........................................... 74 
Reliability and Validity ........................................................................................................... 74 
Comparison between Quantitative and Qualitative Study Results ....................................... 74 
CHAPTER 4 | QUANTITATIVE SURVEY RESULTS ............................................................................ 76 
 x 
Descriptive Statistics .............................................................................................................. 77 
Bivariate Association Analyses .............................................................................................. 95 
Multivariate Regression Analyses ........................................................................................ 111 
CHAPTER 5 | QUALITATIVE STUDY RESULTS ............................................................................... 129 
Factors to Consider during Decision-Making ....................................................................... 130 
Motivators to HIV Cure-Related Research Participation ..................................................... 133 
Deterrents to HIV Cure-Related Research Participation ..................................................... 137 
Perceived Risks of HIV Cure-Related Research Participation .............................................. 140 
Clinical or Medical Risks ................................................................................................. 140 
Social Risks ...................................................................................................................... 145 
Financial Risks ................................................................................................................. 146 
No Perceived Risks ......................................................................................................... 146 
Riskiest HIV Cure-Related Research Modalities .................................................................. 147 
Stem Cell Transplants/Gene Therapy ............................................................................. 147 
Latency-Reversing Agents .............................................................................................. 148 
Combination Approaches ............................................................................................... 149 
“Too Much” or Unacceptable Risks of HIV Cure Research Participation ............................ 149 
Regulations and Clinical Holds ....................................................................................... 150 
Patient-Participant Perspectives .................................................................................... 151 
Unacceptable Strategies ................................................................................................. 152 
Treatment Interruptions and Associated Risks .............................................................. 153 
“Healthy Subjects” .......................................................................................................... 154 
Beyond Clinical Risks: Social and Financial Risks ............................................................ 157 
Concerns, Burdens and Barriers around HIV Cure-Related Research                                            
Participation ........................................................................................................................ 161 
Perceived Burdens of HIV Cure-Related Research Participation ................................... 165 
 xi 
Perceived Barriers to HIV Cure Research Participation .................................................. 166 
Safest HIV Cure-Related Research Strategies ...................................................................... 170 
General Considerations .................................................................................................. 170 
Perceived Safe HIV Cure Research Strategies ................................................................ 171 
Perceived Benefits of HIV Cure Research Participation ...................................................... 172 
No Expectation of Direct Benefits .................................................................................. 173 
Societal Benefits ............................................................................................................. 173 
Personal Benefits ............................................................................................................ 174 
“Risk-Benefit Ratios” and Equipoise in HIV Cure Research ................................................. 177 
Equipoise ........................................................................................................................ 180 
Perceptions of Treatment Interruptions ............................................................................. 185 
General Attitudes around Treatment Interruptions ...................................................... 186 
Motivations for Treatment Interruptions ...................................................................... 188 
Concerns around Treatment Interruptions .................................................................... 190 
Considerations for Treatment Interruptions .................................................................. 191 
Factors Facilitating Recruitment in, Retention in and Implementation of HIV                                
Cure Studies ......................................................................................................................... 193 
Expectations and Hopes in HIV Cure Research .................................................................... 200 
Factors Facilitating Ethical Implementation of HIV Cure Research ..................................... 203 
General Considerations in HIV Cure Research .................................................................... 205 
Justification for HIV Cure Research ................................................................................ 205 
Meanings of HIV Cure ..................................................................................................... 206 
Language of HIV Cure Research ..................................................................................... 208 
CHAPTER 6 | DISCUSSION OF STUDY RESULTS ............................................................................ 212 
Discussion of Quantitative Findings .................................................................................... 213 
Discussion of Bivariate Study Results .................................................................................. 216 
 xii 
Discussion of Multivariate Study Results ............................................................................. 217 
Discussion of Qualitative Findings ....................................................................................... 219 
Reflections on the Ethical Implementation of HIV Cure Studies ......................................... 223 
Principle of Respect for Persons ..................................................................................... 224 
Therapeutic Misconception or Fallacy ........................................................................... 229 
Revisiting the Principle of Respect for Persons .............................................................. 233 
Principles of Nonmaleficence and Beneficence ............................................................. 235 
Risks in HIV Cure Research ............................................................................................. 236 
Benefits in HIV Cure Research ........................................................................................ 239 
Risk-Benefit Ratios .......................................................................................................... 240 
Equipoise ........................................................................................................................ 241 
“Healthy Subjects” .......................................................................................................... 243 
Standard of Care and Treatment Interruptions ............................................................. 244 
Scientific Uncertainty ..................................................................................................... 244 
Gaining Medical Knowledge and Returning Study Results ............................................ 247 
Principle of Justice .......................................................................................................... 247 
Reflections on the Effective Implementation of HIV Cure Studies ...................................... 252 
The Role of Implementation Research ........................................................................... 256 
Towards a Possible Implementation Ethics Framework in HIV Cure                                                 
Research .............................................................................................................................. 259 
Strengths and Limitations of Research ................................................................................ 266 
CHAPTER 7 | PLAN FOR CHANGE/LEADERSHIP/IMPLEMENTATION ........................................... 271 
Plan for Change Overview ................................................................................................... 271 
Principles of Leading Change and Inspired Actions ............................................................. 274 
Participative Processes ........................................................................................................ 275 
Guiding Leadership Theory: Team Leadership [128] ........................................................... 276 
 xiii 
Guiding Leadership Theory: Servant Leadership [128] ....................................................... 277 
Effective Implementation .................................................................................................... 277 
Guiding Leadership Theory: Authentic Leadership [128] .................................................... 279 
Ethical Implementation, Moral Courage and Professional Issues ....................................... 280 
Guiding Leadership Theory: Ethical Leadership [128] ......................................................... 281 
Plan for Change/Leadership/Implementation Deliverables ................................................ 282 
Dissemination of Research Findings .................................................................................... 282 
Journal Articles and Abstracts (Formal Channels) .......................................................... 282 
Blog Posts (Informal Channels) ...................................................................................... 286 
Community Engagement and Coalition Building/Strengthening ........................................ 286 
Engagement in and Contribution to Research and Policy and Implementation                            
Dialogues and Development of Tools to Facilitate Research Implementation ................... 287 
Development and Implementation of HIV Cure Research Training                                            
Curriculum: The CUREiculum ............................................................................................... 293 
Possible Avenues for Future Research ................................................................................ 299 
CHAPTER 8 | CONCLUDING REMARKS ........................................................................................ 302 
APPENDIX 1: List of Recruitment Channels and/or Key Informants ............................................ 306 
APPENDIX 2: Sample Recruitment Emails/Scripts for Listservs (Approved by                                              
UNC IRB) ...................................................................................................................................... 307 
APPENDIX 3: Project Fact Sheet (Approved by UNC IRB) ............................................................ 309 
APPENDIX 4: Informed Consent Forms (Approved by UNC IRB) ................................................. 310 
APPENDIX 5: Patient/Participant Questionnaire (Approved by UNC IRB) .................................. 316 
APPENDIX 6: Key Informant Interview Guides (Approved by UNC IRB) ...................................... 331 
APPENDIX 7: grey literature reviewed and key informant interviews ........................................ 336 
REFERENCES ................................................................................................................................ 340 
  
 xiv 
LIST OF TABLES  
Table 1. Requirements for Ethical Implementation of Clinical Research                                                        
that Affect Participants’ Recruitment and Participation ...................................................................... 10 
Table 2. Summary Statistics of the Dependent Variable ...................................................................... 47 
Table 3. Survey Sample Size ................................................................................................................. 77 
Table 4. Bivariate Association between Perceptions of Potential Benefits as                                              
Very Important Motivators and Willingness to Participate (WTP) in all Types of                                           
HIV Cure-Related Studies ..................................................................................................................... 97 
Table 5. Bivariate Association between Perceptions of Potential Risks as Very Likely                                       
to Discourage Participation and Willingness to Participate (WTP) in all Types of HIV                                  
Cure-Related Studies .......................................................................................................................... 101 
Table 6. Bivariate Association between Socio-Demographic Characteristics and                                 
Willingness to Participate in All Types of HIV Cure-Related Studies .................................................. 106 
Table 7. Multivariate Logistic Regression of Willingness to Participate in All                                               
Types of HIV Cure-Related Studies on Individual-Level Socio-Demographic                                     
Characteristics (Model 1) ................................................................................................................... 112 
Table 8. Odds Ratios of Willingness to Participate in All Types of HIV Cure-Related                                    
Studies and Perception of Potential Benefits as Very Important Motivating Factors                                         
for Considering Participation, Controlling for Socio-Demographic Characteristics in                                         
21 Individual Logistic Models (Models 2 – 22) ................................................................................... 117 
Table 9. Odds Ratios of Willingness to Participate in All Types of HIV Cure-Related                                   
Studies and Perception of Potential Risks as Very Likely to Discourage Participation,                                  
Controlling for Socio-Demographic Characteristics in 35 Individual Logistic Models                                
(Models 23 – 57) ................................................................................................................................. 120 
Table 10. Multivariate Logistic Regression of Willingness to Participate in All Types                                 
of HIV Cure-Related Studies and the Number of Potential Benefits Deemed Very                                    
Important Motivators and Number of Potential Risks Deemed Very Likely to                                     
Discourage Motivation, Controlling for Socio-Demographic Characteristics (Model 58) .................. 125 
Table 11. Key Informant Interviews by Type of Informants ............................................................... 130 
Table 12. Perceived Clinical – Medical Risks by Clinician-Researchers .............................................. 142 
Table 13. Perceived Clinical – Medical Risks by Policy-Makers/Regulators ....................................... 144 
Table 14. Concerns around Treatment Interruption .......................................................................... 191 
Table 15. Considerations for Implementation of Treatment Interruptions ....................................... 192 
 xv 
Table 16. Possible Recommendations to Facilitate Recruitment in HIV Cure Studies ....................... 194 
Table 17. Possible Recommendations to Facilitate Retention in HIV Cure Studies ........................... 196 
Table 18. Recommendations to Help Execute HIV Cure Studies Effectively ...................................... 197 
Table 19. Main Expectations from the Study Participation Experience ............................................. 200 
Table 20. Recommendations to Facilitate Ethical Implementation of HIV Cure                                         
Studies ................................................................................................................................................ 204 
Table 21. Recommendations for Informed Consent Forms in Early Phase Clinical                                    
Studies ................................................................................................................................................ 232 
Table 22. Types of Risks in HIV Cure Research and Ways to Tackle ................................................... 237 
Table 23. Ways to Tackle Benefits in HIV Cure Research ................................................................... 240 
Table 24. Steps to Evaluate Risks and Benefits in Biomedical Research ............................................ 241 
Table 25. Alternatives to Equipoise Relevant to HIV Cure Research.................................................. 242 
Table 26. Four Steps to Facilitate Decision-Making in Situations of Uncertainty .............................. 246 
Table 27. Factors Relevant in the Effective Implementation of HIV Cure Research –                         
Perspectives and Opportunities from the Implementation Science Literature ................................. 257 
Table 28. Strengths and Limitations of Methods ............................................................................... 267 
Table 29. Ethical Principles under Conditions of Clinical Uncertainty................................................ 281 
Table 30. Possible Considerations for Stakeholders to Facilitate Effective and                                         
Ethical Implementation of HIV Cure Research ................................................................................... 291 
Table 31. Ethical Considerations for Various HIV Cure Research Modalities –                                              
The CUREiculum ................................................................................................................................. 298 
Table 32. Future Possible Social Sciences Questions around HIV Cure Research .............................. 300  
 xvi 
LIST OF FIGURES 
Figure 1. Conceptual Framework for Assessing Factors Affecting Participation in                                         
HIV Cure-Related Research: Implications for Effective and Ethical Implementation ............................ 6 
Figure 2. Logic Flow for Methods and Derivation of Samples .............................................................. 19 
Figure 3. Logic Flow for Data Collection and Analysis .......................................................................... 37 
Figure 4. Distribution of Values of the Dependent Variable ................................................................ 47 
Figure 5. Flow of Qualitative Data Analysis (Adapted from Creswell, Chapter 9,                                        
Qualitative Methods, p. 197) ............................................................................................................... 71 
Figure 6. Gender of Respondents (n=400) ........................................................................................... 78 
Figure 7. Age Group of Respondents (n=400) ...................................................................................... 78 
Figure 8. Ethnicity of Respondents (n=400) ......................................................................................... 79 
Figure 9. Highest Level of Education Completed (n=399) .................................................................... 79 
Figure 10. Yearly Household Income (U.S. Dollars) of Respondents (n=399) ...................................... 80 
Figure 11. Residence of Survey Respondents (n=394) ......................................................................... 80 
Figure 12. Self-Reported Health Status of Respondents (n=400) ........................................................ 81 
Figure 13. Respondents’ Feeling of Control over Health Care (n=400) ................................................ 81 
Figure 14. Percentage of Respondents’ Lifetime Living with HIV Diagnosis                                             
(n=394) ................................................................................................................................................. 82 
Figure 15. Respondents have Ever Been in or Volunteered for an HIV Cure Study                                 
(n=400) ................................................................................................................................................. 83 
Figure 16. Willingness to Consider Participating in HIV Cure-Related Studies .................................... 84 
Figure 17. Total Number of Types of HIV Cure-Related Studies respondents are                                     
Willing to Consider Participating in (n=361) ......................................................................................... 85 
Figure 18. Willingness to Consider Participating in HIV Cure-Related Studies after                                 
Having Previously Participated in Similar (HIV or non-HIV) Health Study in the Past .......................... 87 
Figure 19. Importance of Factors to Motivate Considering Participating in HIV                                        
Cure-Related Studies ............................................................................................................................ 88 
Figure 20. Likelihood of Factors to Discourage Considering Participation in HIV                                       
Cure-Related Studies ............................................................................................................................ 90 
 xvii 
Figure 21. Willingness to Stop HIV Treatment as Part of an HIV Cure-Related                                          
Study (n=359) ....................................................................................................................................... 91 
Figure 22. Importance of Factors in Making a Decision about Considering                                     
Participation in an HIV Cure-Related Study .......................................................................................... 92 
Figure 23. How would Participants Most Likely Describe Themselves in they                                          
were to Participate in an HIV Cure-Related Study (n=348) .................................................................. 93 
Figure 24. Personal Beliefs about an HIV Cure ..................................................................................... 93 
Figure 25. How Many Years Do Participants Think it will take to Find a Cure for                                         
HIV (n=350) ........................................................................................................................................... 94 
Figure 26. What does a Cure Mean to Participants? (n=350) .............................................................. 94 
Figure 27. Building Blocks for Proposed Plan for Change/Leadership/                                          
Implementation .................................................................................................................................. 273 
Figure 28. Principles of Leading Change and Inspired Actions ........................................................... 274 
Figure 29. The CUREiculum ................................................................................................................ 297 
Figure 30. Critical Questions to Address in the Integration of Social Science in                                      
the HIV Cure Research Agenda[41] .................................................................................................... 301 
Figure 31. Research with Ebola Survivors .......................................................................................... 302 
  
 xviii 
LIST OF ABBREVIATIONS 
ACTG  AIDS Clinical Trials Group 
AIDS  Acquired Immunodeficiency Syndrome  
ART  Antiretroviral Therapy  
ATI  Analytical Treatment Interruption  
AVAC  Formerly the AIDS Vaccine Advocacy Coalition 
CAB  Community Advisory Board  
CAR  Chimeric Antigen Receptor  
CARE  Collaboratory of AIDS Researchers for Eradication 
CCR5  C-C Chemokine Receptor Type 5 
CD4+  Cluster of Differentiation 4 (T Helper Lymphocytes)  
CFAR  Center for AIDS Research 
CFR  Code of Federal Regulations  
CUREiculum HIV Cure Research Training Curriculum  
CXCR4  C-X-C Chemokine Receptor Type 4  
DAIDS  Division of AIDS 
DHHS  Department of Health and Human Services 
DNA  Deoxyribonucleic Acid  
DrPH  Doctor of Public Health  
DSMB  Data Safety Monitoring Board  
EC  Ethics Committee  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GPP  Good Participatory Practice  
 xix 
Ho  Null Hypothesis  
HAART  Highly Active Antiretroviral Therapy  
HDACi  Histone Deacetylase Inhibitor  
HIPAA  Health Insurance Portability and Accountability Act  
HIV  Human Immunodeficiency Virus  
HPM  Health Policy and Management  
HPTN  HIV Prevention Trials Network  
HSV  Herpes Simplex Virus  
IAS  International AIDS Society  
IC  Informed Consent  
ICH  International Conference on Harmonization 
IPDAS  International Patient Decision Aids Standards  
IMAP  Intensively Monitored Antiretroviral Pause  
IND  Investigational New Drug  
IOM  Institute of Medicine  
IRB  Institutional Review Board  
IT  Information Technology  
LRA  Latency-Reversing Agent  
NIH  National Institutes of Health  
NIMH  National Institute of Mental Health  
PD-1  Programmed Cell Death Protein 1  
PrEP  Pre-Exposure Prophylaxis  
QVOA  Quantitative Viral Outgrowth Assay 
RAC  Recombinant Advisory Committee  
 xx 
RNA  Ribonucleic Acid  
SAE  Serious Adverse Event 
SAHA  Suberanilohydroxamic Acid  
SCT  Stem Cell Transplant(ation)  
START  Strategic Timing of AntiRetroviral Treatment  
TLR  Toll-Like Receptors  
UNC-CH University of North Carolina at Chapel Hill  
USD  United States Dollars 
VSOT  Virological Suppression Off Treatment  
WTP  Willingness to Participate  
 1 
CHAPTER 1 | BACKGROUND  
The long-held assumption that HIV/AIDS is incurable is being challenged. There is one 
person who has been cured from HIV – Timothy Ray Brown, also known as the “Berlin patient” [1]. 
The Mississippi child – an infant who was seemingly cured of HIV in 2013 – was reported to have 
detectable levels of HIV in July 2014, after more than two years off treatment without evidence of 
the virus  [2][3]. Timothy Brown inspired cautious optimism that it may be possible to cure HIV 
infection, but the relapse of the Mississippi child along with other case reports, such as the Boston 
patients [4], raised new questions and challenges for the field.  While the advent of highly potent 
and well-tolerated antiretroviral therapy (ART) for HIV infection has substantially decreased AIDS-
related morbidity and mortality worldwide, ART alone does not eliminate HIV infection. Patients 
must continue therapy throughout life at all stages of HIV disease. Millions of HIV-positive 
individuals are now currently taking ART to remain alive. While HIV is no longer a fatal disease, the 
virus persists in the human body by establishing latent proviral reservoirs [5].  Furthermore, the 
highly innovative nature of HIV cure research and the prospect of ART interruption indicated in 
some study designs create unique implementation challenges and raise critical technical, regulatory 
and ethical questions for HIV clinical research scientists. These challenges are heightened because 
people living with HIV have access to highly effective antiretroviral therapy and most are able to 
lead normal lives.  
It is unclear what would motivate or deter people living with HIV to participate in HIV cure 
research in the United States. This study seeks to fill this information gap by attempting to answer 
the following question:  What factors affect participation in HIV cure-related research in order to 
facilitate the effective and ethical implementation of studies in the United States? 
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In early 2016, there were more than 120 ongoing or completed HIV cure-related clinical 
studies conducted worldwide (http://www.treatmentactiongroup.org/cure/trials). This number is 
expected to grow in the coming year as HIV cure research progresses and novel compounds move 
through the drug development pathway [6]. On December 2, 2013, President Obama announced 
that $USD 100 million were redirected towards HIV cure research in the next three years. HIV cure 
research is a top scientific priority of the United States government and the United States National 
Institutes of Health (NIH). Furthermore, HIV cure research is a strategic priority of the International 
AIDS Society (IAS), which launched the “Towards an HIV Cure” initiative to promote multi-
disciplinary research for a safe and scalable HIV cure [7].  
Despite major advances in HIV prevention and HIV drug development, including the 
development of five distinct classes of antiretroviral drugs, there is now a strong rationale to pursue 
a cure for HIV infection. The costs of delivering ART are overwhelming, not to mention the potential 
for ART resistance and the stigma associated with HIV disease [7][8][9]. Furthermore, in order to 
test a new scientific intervention, it is vital that a sufficient number of participants join the study in 
order to test the intervention adequately. The sample size usually depends on the phase of the 
study, with latter phase trials requiring larger sample sizes. Reduced study participant rates are 
problematic because they can slow down research progress, increase research costs and threaten 
the validity and generalizability of research results [10].  HIV cure studies are no different. HIV cure 
research is highly complex, multi-faceted and remains in the early phases of investigation, but 
efforts will be scaled up in the coming years requiring more participants to join studies. Currently, 
almost all of the proposed HIV cure research modalities remain at the proof-of-concept stage and 
involve high risks to study participants with little prospect of individual benefit [11]. Moving 
forward, we will need to gain a deep and meaningful understanding of HIV-positive patients’ 
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expectations and perceptions of HIV cure research, and understand the factors that affect their 
willingness to participate in HIV cure-related studies.  
The literature on decision-making reveals that decisions to join clinical studies have two 
main elements: 1) a technical component, which requires knowledge of the risks, benefits and 
possible side effects associated with a study, and 2) a value component which requires input from 
patients about their values and preferences [12]. Besides evaluating technical aspects and 
perceptions of participants, it is necessary to bridge these perceptions with the scientific and clinical 
realities of HIV cure research study implementation. As with other fields or diseases, such as cancer, 
several factors affect participation in clinical studies ranging from patients’ perceptions of studies to 
the practical and scientific aspects of specific interventions, inclusion/exclusion criteria for entry into 
clinical research as well as the physicians/researchers’ preferences for specific modalities. The 
perspectives of policy-makers and regulators – such as those working for Institutional Review Boards 
(IRBs) or Ethics Committee (ECs), are also important to take into consideration.   
HIV Cure-Related Research 
The Food and Drug Administration (FDA) defines HIV cure research as an investigation 
evaluating therapeutic interventions that would control or eliminate HIV infection to the point 
where no more HIV treatment would be needed to maintain health [13]. Two main approaches are 
being investigated: 1) a sterilizing cure, which would clear all latent viral reservoirs in the body 
(eradication); and 2) a functional cure, which would allow a person’s immune response to control 
HIV without medication [14]. A functional cure, or post-treatment control, may be much easier to 
achieve than a completely sterilizing cure.  
HIV Cure-Related Research Modalities  
 Researchers contend that it will be unlikely that we will find the “one cure” – or the single 
magic bullet that will lead to HIV eradication or a functional cure [14]. Rather, scientists will likely 
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explore several research pathways that will intersect. There are different types of HIV-cure research 
modalities being explored, as well as scientific and practical challenges and realities associated with 
each approach. Essentially, finding a cure for HIV will be a daunting task [15] and a long arduous 
journey [9]. Initial investigations towards an HIV cure should be framed as clinical experiments [11]. 
Early experiments will be used to direct future scientific and drug development efforts and pave the 
way for future HIV cure-related research efforts [13]. Very unlikely will these studies lead directly to 
a cure for HIV or even to substantial benefits for people living with HIV. Initial HIV cure research 
efforts will carry great risks, some of which remain unknown at this time [13].  
Several approaches are being investigated in HIV cure research, including:  
1. Reactivation of latent HIV from resting CD4+ T lymphocyte cells and other cellular and tissue 
compartments;  
2. Early therapy as seen with pediatric HIV cure research (i.e. Mississippi child) or using HAART 
and megaHAART in acutely infected patients;  
3. Intensification of ART;  
4. Immune-based therapies to boost HIV specific immune responses (such as therapeutic 
vaccinations);  
5. Gene therapy;  
6. Autologous and allogeneic stem cell transplant (as seen with Timothy Brown); and  
7. Combinatorial approaches.  
 The significance of HIV cure research rests in finding the right approach or combination of 
approaches that will be safe and effective at managing acute or chronic HIV infections without ART 
(functional cure) or at clearing HIV infection (sterilizing cure).  
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Participation in HIV Cure-Related Studies and Willingness to Participate 
Willingness to participate (WTP) refers to the state of readiness to participate in a clinical 
study. The study of WTP is usually divided between the consideration of the motivators and the 
barriers to participation [16]. In the context of clinical study implementation, motivators/facilitators 
to participation are any factors that would increase likelihood of eligible individuals to participate in 
studies. Barriers/inhibitors/deterrents to participation are any factor that would decrease likelihood 
of eligible individuals to participate in studies. The main criticism related to the WTP concept is that 
it relies on hypotheticals (or stated preferences). The WTP concept has predictive value nonetheless  
[16], especially in the initial exploratory phase. Some authors have studied the determinants of 
actual participation (or revealed preferences) in clinical studies [17] or conversely, determinants 
associated with refusal to participate [18].  
In the context of HIV cure research, social scientists are considering broadening the theme 
of “willingness to participate” due to the complexity of the research (personal communication with 
J. Sugarman). We should consider exploring “willingness to take risks” and/or “willingness to 
donate” in the context of early HIV cure studies. 
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Conceptual Framework: Participation in HIV Cure-Related Research and Willingness to 
“Participate”  
 
Figure 1. Conceptual Framework for Assessing Factors Affecting Participation in HIV Cure-Related 
Research: Implications for Effective and Ethical Implementation   
The above conceptual framework provided the initial foundation to help identify motivators 
and barriers to participation in HIV studies. Broad sets of variables and their linkages were 
identified, including involvement of clinical researchers in study implementation and the need for 
scientific evidence in other to move closer towards a cure for HIV infection. Individuals living with 
the disease need to make decisions about whether or not to participate in HIV cure-related 
research. The decisional element is accentuated by the magnifying glass and represents the topic 
under investigation. For my literature review, I relied extensively on the proxy fields to determine 
potential factors that influence participation in HIV cure-related research, due to the transient 
shortage of social science publications on HIV cure research. My literature review informed the 
development of interview questions and survey instruments.  
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Significance 
Moving forward, it is essential that we pursue HIV cure-related research in a way that places 
the needs and perspectives of people living with HIV at the center of the process. In June 2013, the 
FDA launched an initiative on patient-focused drug development and HIV cure research.1 To ensure 
successful implementation of HIV cure studies, it is necessary to engage people living with HIV in a 
significant and sustained dialogue to address the factors that affect their participation in HIV cure-
related studies. People living with HIV should in turn help co-create the research implementation, 
regulatory and policy agendas about these studies. The research enterprise is thus an exchange of 
knowledge between the participants and the clinical researchers and an act of active collaborative 
knowledge building [19]. 
The topic of participation in HIV cure-related research is evidently ripe for future research. 
Social sciences related to HIV cure research should also keep pace with the exponentially growing 
translational and clinical sciences.  Social scientists are in fact calling for “[A] proactive and 
multidisciplinary exploration of social dimensions of an HIV cure (…) [to] inform the conduct of 
clinical research studies and perhaps help ensure that an HIV cure is accurately perceived and 
appropriately implemented” [7].  Human studies in HIV cure are part of a nascent field that raises 
several complex implementation challenges as well as ethical issues related to participation. HIV 
cure studies will increase in scale and scope in the coming years concurrently with increased 
research funding.  Understanding perceptions of risks and benefits of HIV cure research 
participation and factors that affect decisions to participate can thus help inform study design and 
the development of ethical informed consent procedures, not to mention help determine the 
community acceptability of various methodologies. 




Factors affecting willingness to participate in clinical studies have been extensively 
examined in the context of HIV prevention, particularly HIV vaccine trials. Willingness to participate 
has also been described for HIV treatment trial participation, although to a much lesser extent. One 
could wonder whether the HIV prevention literature could help inform the HIV curative field since 
there are fundamental differences between HIV  prevention interventions (aimed a higher-risk HIV-
negative individuals) and HIV curative interventions (aimed at HIV-infected patients). Similarly, there 
can be similarities and differences between HIV treatment interventions and HIV cure interventions. 
The definitive test for a cure, however, will be the interruption of antiretroviral treatment [6].  
Alternatively, in the absence of a robust ‘willingness to participate’ literature on HIV cure 
research, a proxy or surrogate literature can help inform the debate and provide helpful frames of 
reference. For example, oncology research is older than HIV cure research, but involves early-phase 
studies, risky interventions and overlapping themes. In fact, some of the compounds being tested in 
clinical studies to reactivate latent HIV, such as Vorinostat or SAHA (suberanilohydroxamic acid), 
Romidepsin and Panobinostat, are used as anti-cancer drugs, notably in the treatment of Hodgkin’s 
lymphoma [20]. Participation in HIV cure research is hitherto not emerging in a vacuum and may 
gain from a thorough assessment of applicable concepts found in the proxy medical research 
literature.  
Effective Implementation 
Clinical research implementation – including HIV cure-related research – would fit well 
within an implementation science framework. In fact, translational research and implementation 
science are akin to each other, with their attempts at closing the gap between the creation of 
evidence and translation into practice [21]. Implementation science has been widely described in 
the context of HIV prevention and treatment [22][23] and seeks to identify success factors [21], as 
well as possible obstacles [24], to implementation. In the context of translational research, Khoury 
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and colleagues developed a classification framework for translational researchers involving four 
categories: 1) T1 – development of applications and interventions; 2) T2 – development of evidence-
based guidelines; 3) T3 – transition to practice; and 4) T4 – transition to improve population health 
[25]. Implementation of HIV cure research in human populations would thus correspond to the 
transition between T1 and T2. With its focus on collecting any vital information about any factor 
affecting successful implementation (including risks/benefits or deterrents/motivators), the 
attention to practical issues and the onus on planning proactively for change, implementation 
science can provide helpful considerations for the effective and detailed planning of HIV cure 
research execution.  Aim 3 of this dissertation project seeks to explore some of these issues in more 
detail. We will revisit the topic of effective implementation in the discussion and plan for change 
sections.  
Ethical Implementation 
Since medical research is oftentimes viewed as conferring access to first class novel 
therapies and since patient-participants expect clinician-researchers to act in their best interest 
(under the Hippocratic Oath), it is not surprising that people living with HIV may enroll in studies 
with the hope that they will be “cured.” The aims of the research – to obtain generalizable 
knowledge and identify new paradigms to cure the disease –  may not coincide with the personal 
interests of people living with HIV. In an attempt to determine what factors affect HIV-positive 
patients’ decisions to participate in HIV cure studies, it is therefore important to acknowledge the 
underlying applicable ethical considerations. At this time, most HIV cure studies represent proof-of-
concept activities with no expectation of positive clinical outcomes [11]. In fact, HIV cure studies 
face many of the same ethical dilemmas surrounding early-phase trials, such as the need to carefully 
assess risks and benefits, the scientific validity of the study and the voluntary aspect of the informed 
consent process [26].  
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In their seminal article on “What makes clinical research ethical?” [27], Emanuel and 
colleagues outlined seven requirements that provide an ethical framework for clinical studies. Their 
ethical framework was drawn by synthesizing the literature on the ethics of research with human 
participants, including the Nuremberg Core (1947), the Declaration of Helsinki (1964, 1975, 1983, 
1989, 1996), the Belmont Report (1979) and the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (1982, 1993), among others. The seven requirements include: 1) 
social and scientific value; 2) scientific validity; 3) fair selection of research participants; 4) favorable 
risk-benefit ratio; 5) independent review; 6) informed consent and 7) respect for potential or 
enrolled study participants.  
Of the seven principles, four pertain specifically to the topic of recruitment/participation of 
people living with HIV in HIV cure-related studies: 
Table 1. Requirements for Ethical Implementation of Clinical Research that Affect Participants’ 
Recruitment and Participation 




1. Fair selection of  
research 
participants 
Selection of participants so that 
stigmatized and vulnerable 
individuals are not targeted for 
risky research 
Justice Scientific knowledge 




Minimization of risks; 
enhancement of potential 
benefits, risks to the participant 
are proportionate to the 







of social values 
3. Informed consent  Provision of information to 
participants about the purpose 
of the research, its procedures, 
potential risks, benefits and 
alternatives, so that the 
individual understands this 
information and can make a 
voluntary decision whether to 
enroll and continue to 
participate 
Respect for participant 
Autonomy 
Scientific knowledge 
Ethical and legal 
knowledge 
4. Respect for 
potential and 
enrolled study 
Respect for participants by: 
1) Permitting withdrawal 
from the research 




Ethical and legal 
knowledge 
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 participants (and  
respect for 
community)* 
2) Protecting privacy 
through confidentiality 
3) Informing participants 
of newly discovered 
risks and benefits 
4) Informing participants 
of results of clinical 
research 





*Participation in clinical studies is not isolated from societal influences 
Adapted from Emanuel Ej, Wendley D, Grady C. What Makes Clinical Research Ethical? Jama 2000; 283(20): 
2701 – 11.[27]  
Furthermore, in their article on the “Ethical Considerations for HIV Cure Research: Points to 
Consider [28]”, Lo and Grady argued that while established guidelines provide an ethical foundation 
for HIV cure research, the cutting-edge nature of the research presents novel ethical dilemmas. For 
example, while ethical guidelines postulate that participants must be selected fairly and equitably, 
most HIV cure-related studies usually include participants on long-term, stable antiretroviral 
therapy. There are difficulties in enrolling women [29][30][31] and special considerations for HIV 
cure-related studies with newborns [32]. The risk-benefit ratio may not be favorable in these early-
phase studies that do not have a direct therapeutic  or curative intent. Finally, the desire for a cure 
may distort the informed consent and decision-making process, and special efforts should be made 
to ensure that participants understand the potential risks as well as lack of direct clinical benefits.   
To discuss the ethical implementation of HIV cure-related studies, we must thus rely on the 
established ethical guidelines as well as special ethical considerations for HIV cure-related studies 
[28][33]. The three principles of the Belmont Report [34] – 1) respect for autonomy, 2) beneficence 
and 3) justice – remain at the cornerstone of an ethical implementation framework and provide a 
convenient way to analyze several issues pertaining to participation of people living with in cure-
related studies. Justice refers to “fairness in distribution” of the risks and benefits of research [34] 
and access to HIV cure research on the part of minority populations. Furthermore, the standard of 
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care debate falls under the principles of respect or justice, because removal of the standard of care, 
as in the case of antiretroviral treatment interruption or intensively monitored antiretroviral pause 
(IMAP), may unfairly raise the burden of risks on study participants relative to those in the future 
who may benefit [35]. The principle of beneficence –or the converse, nonmaleficence – highlights 
the importance of maximizing possible benefits while minimizing possible harms (doing absolutely 
no harm being practically impossible) [34]. Finally, the principle of respect for autonomy demands 
that individuals should have the opportunity to act as “autonomous agents”  [34]. Participants 
should evaluate the pros and cons and arrive at a considered decision about whether or not 
participate in research. It is important to note that these important considerations can also come 
into conflict and need to be managed. For instance, respecting autonomy can conflict with concerns 
about the risks participants take and the disproportional burdens they may bear.  
The application of these principles for ethical implementation of research leads to 
considerations for informed consent, assessments of risks/benefits and the selection of study 
participants [34]. In the case of HIV cure research, the informed consent document should clearly 
state the lack of therapeutic – or curative – intent, as well as the unique requirements for the 
research (i.e. invasive procedures) and the associated risks and benefits (or lack thereof). Possible 
harms can include physical, psychosocial, legal, social as well as economic harms [34]. Finally, the 
principle of justice brings up moral requirements about what constitute fair procedures in the 
selection of study participants [34].  These principles must all be operationalized in the design, 
protocol development and implementation of HIV cure studies. Aims 2 and 3 of this dissertation 
research seek to explore some of these issues in more detail, such as perceptions of risks and 
benefits. A qualitative design and interview approach confers a great way to begin exploring some of 
these elements in the formative stage of the research.  We also revisit the topic of ethical 
implementation in the discussion and plan for change sections. 
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Risks and Benefits 
Each clinical study or experiment has its own risks and benefits – some of which are known 
or unknown. Risks of clinical study participation include possibilities for harm or injury or negative 
consequences, such as a decrease in CD4+ count or increase in HIV viral load when taken off 
antiretroviral treatment. In turn, benefits are possible advantages gained from taking part in a 
clinical study – some of which are collateral benefits – such as access to state-of-the art medical 
“care.” There remains a controversy about whether these collateral benefits ought to be counted as 
weighing against the risks of the research. While IRBs tend to say that they ought not to count, 
participants may think that they do count and these may affect their decision to participate in 
studies. Risks and benefits provide an organizing framework for the entire dissertation research.   
Therapeutic (or Curative) Misconception 
The topic of therapeutic misconception provides a valuable framework to conclude the 
background section. Appelbaum and colleagues first described therapeutic misconception in 1982 in 
the context of psychiatry [36]. One definition of therapeutic misconception, from the National 
Bioethics Advisory Commission, is “the belief that the purpose of a clinical trial is to benefit the 
individual patient rather than to gather data for the purpose of contributing to scientific knowledge” 
[37]. Therapeutic misconception occurs when a study participant does not fully understand the 
boundaries between standard clinical care and experimental or clinical research [37]. For example, a 
research participant can misestimate the likelihood of direct medical benefits, miscontrue the 
purpose of a study or join a study in order to obtain therapeutic benefit, when none should be 
expected [37]. Most of the therapeutic misconception literature draws from discussion in early-
phase cancer experiments (i.e. gene therapy transfer, when no therapy should in fact be expected). 
Therapeutic – or curative – misconception is enlightening and can definitely be transposed 
to the context of HIV cure research. Possible future benefits of the science accruing to to society or 
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future people living with HIV should be separated from possible benefits to individual participants 
[38]. As stated before, most clinical experiments in HIV cure research at this juncture represent 
proof-of-concept activities with no direct expectation of positive clinical outcomes [11]. They remain 
a critical step in the translational research process, and allow us to transfer interventions into initial 
human testing [11]. Furthermore, the occurrence of concomitant clinical care and treatment should 
not be confounded with the scientific objectives of HIV cure studies [37]. It is thus imperative to 
understand the motivations, expectations and understandings of people living with HIV who would 
be eligible, willing or unwilling to participate in HIV cure-related research. Clinician-researchers and 
IRB members may also be subject to the therapeutic misconception [37]. It is also important to 
understand the extent HIV cure-related research participants will be prey to these misconceptions. 
Hopes to be cured could be a strong motivator, but one considered ethically dubious from the 
standpoint of having genuine informed consent.  
Project Aims 
Therefore, the main objective of this study is to help inform the planning of HIV cure-related 
research in the United States by exploring the factors that may affect participation in HIV cure-
related studies. The study isolates, articulates and communicates opinions of people living with HIV, 
clinician-researchers and policy-makers (i.e. regulators), broadly defined, about participation in HIV 
cure-related studies, and derive possible considerations to propel the field forward.  
Knowledge emanating from biomedical and social science research is a valuable social good, and 
such research should live up to the highest ethical, scientific and implementation standards [39]. 
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My three specific research aims include:  
Aim 1: Do the perceived risks/benefits from HIV cure-related research act as deterrents/motivators 
to participation? 
I developed a semi-structured quantitative survey instrument based on my literature 
review of the reported risks and benefits (or surrogate clinical markers) of 14 different types of 
HIV cure-related research. For this aim, I surveyed adults living with HIV in the United States. 
The quantitative portion sought to provide descriptive statistics, distribution of responses and 
strengths of association and derive respondent profiles.  This component also allowed to derive 
a sample of volunteers willing to be interviewed in more depth (aims 2 and 3).   
Aim 2:  Explore how various stakeholders perceive risks and benefits of HIV cure-related 
research using qualitative methods. 
This aim was closely linked to aim 1, but was purely qualitative and exploratory in 
nature. I performed 12 key informant interviews with people living with HIV in order to gain 
more meaning and depth regarding perceived risks and benefits from HIV cure-related studies 
(convergent parallel mixed methods). I also interviewed key informants such as 11 clinician-
researchers and 13 policy-makers (broadly defined – such as bioethicists, members of IRBs and 
FDA representatives) in order to obtain their perspectives as well. This aim sought to derive 
meanings and deeper understandings about how/whether risks and benefits acted as 
deterrents/motivators to participation in HIV cure-related studies. Attention was placed on 
actual perceptions of risks and benefits of participating in HIV cure-related research. For 
example, I probed about what constituted “too much” risk or “too little” benefit. The 
perceptions of risks and benefits, even if they did not represent actual experiences, are 
important because they can influence individuals’ decisions to participate in studies and shape 
public perceptions around the various HIV cure-related research modalities.    
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Aim 3: What are some of the practical or pragmatic issues affecting participation in HIV cure-
related studies? 
I conducted key informant interviews with people living with HIV and clinician-
researchers in order to better understand the practical and pragmatic issues affecting 
participation in and implementation of HIV cure-related studies. This portion was fact-finding 
and informed possible considerations for the effective implementation of HIV cure-related 
research. 
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CHAPTER 2 | METHODS 
The literature review revealed the dearth of information regarding the factors that would 
influence people living with HIV to join cure-related studies – thus the need to borrow from the 
proxy fields of literature until more social sciences data are available. The purpose of this mixed-
methods study is to obtain the perspectives of patient-participants, clinician-researchers and other 
stakeholders about factors influencing participation in HIV cure-related research. The study used a 
non-experimental, descriptive, mixed methods and exploratory sequential design. The schema 
below (Figure 3) illustrates the logical flow of the aims and methods. 
Overview 
Aim 1: Based on the literature review, I implemented a cross-sectional, internet-based, 
semi-structured survey of people living with HIV to assess whether potential benefits and risks (or 
surrogate clinical endpoints) of HIV cure-related research would act as motivators or deterrents of 
participation. Most questions were closed-ended. Targeted respondents were potential HIV cure-
related research participants who were openly HIV-positive (to prevent stigma and discrimination), 
living in the United States or its territories, relatively knowledgeable about the state of HIV cure-
related research and who served as advocates for other people living with HIV for the most part. 
This convenience, purposive national sample represented patient-participants who were as diverse 
as possible with respect to age, gender, race/ethnicity, educational attainment, income, time since 
diagnosis, health status and history of participation in HIV-related studies.  The target survey sample 
was least 100 (n >= 100) due to time constraints to complete this study; however, participation rate 
during the data collection phase of the research was higher than anticipated and the survey sample 
size reached n = 400. This increased the precision of the survey results.  
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Aim 2: Based on a sample of HIV-positive respondents derived from Aim 1, I interviewed key 
informants in order to better explore perceptions of risks and benefits of HIV cure-related research. 
I also interviewed people living with HIV, clinician-researchers and other stakeholders to derive 
meanings and deep understandings about perceived risks and benefits of HIV cure-related studies. 
Targeted respondents included 12 – 15 people living with HIV (n = 12 actual); 6 clinician-researchers 
(n = 11 actual) and 6 policy-makers/regulators (broadly defined) (n = 13 actual).2  
 Aim 3: During the key informant interviews, I also sought to better understand the 
practical and pragmatic issues affecting participation in HIV cure studies. The targeted 
respondents interviewed in Aim 2 were also asked questions related to this aim.3  
Since aims 2 and 3 are more qualitative in nature and involved the same key informants, 
they are connected with one another. I attempted to make the information flow between the topics 
covered in aims 2 and 3 in the data analysis section, as themes were closely interconnected. While 
HIV-positive key informants were recruited via the survey instrument based on specific responses, I 
recruited clinician-researchers and policy-makers/regulators via individual formal requests for their 
time. Policy-makers were defined broadly to include regulators of HIV cure-related studies such as 
IRB representatives as well as known advocates and policy-makers in the field. I supplemented these 
primary data collection methods with a document review including peer-reviewed journal articles 
and documents from the grey literature on HIV cure-related research.   
                                                          
2
Beyond the scope of this dissertation, I am conducting focus group discussions in 4 U.S. locales (Seattle, San 
Francisco/Los Angeles, San Diego/Palm Springs and Chapel Hill). The plan for the focus group discussions was 
approved by the UNC IRB in January 2016 via an amendment to the main protocol and is part of my research 
but not my dissertation. 
3
Similarly, the focus group discussions that are taking place in four U.S. locales will be used to further 
investigate the practical and pragmatic issues, but the focus groups are not included as part of my dissertation 
findings. 
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Figure 2. Logic Flow for Methods and Derivation of Samples 
1
Original, primary data   
2
Actual sample size  
3
Representing various HIV cure research modalities  
4
Part of research protocol but not DrPH dissertation; analysis deferred until completion   
  
Document Review  
 Information about participation in and implementation of HIV cure studies  
Aim 1: Potential Risks/Benefits as Possible Deterrents/Motivations of Participation  
 Semi-structured survey1 based on literature review 
 Respondents: n = 400 patients/participants1,2 
Aim 2: Perceptions of Risks and Benefits of HIV Cure Studies  
 Key informant interviews1  
o 12 people living with HIV2 (sample derived from respondents under Aim 1) 
 Exploratory sequential design 
o 11 clinicians/researchers 2,3 
o 13 policy-makers (broadly defined)2  
 Focus groups in 4 U.S. cities (n = 100 targeted])4 
Aim 3: Practical/Pragmatic Challenges to Participation and Implementation   
 Key informant interviews1  
o 12 people living with HIV2 (sample derived from respondents under Aim 1) 
 Exploratory sequential design 
o 11 clinicians/researchers 2,3 
o 13 policy-makers (broadly defined)2  
 Focus groups in 4 U.S. cities (n = 100 targeted])4 
  
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Rationale for Mixed Design  
This section provides a rationale for the use of a mixed methods approach. Since the social 
sciences in HIV cure-related research remains relatively nascent [7][41], there is a strong justification 
for combining and capitalizing on the strengths of both quantitative and qualitative methods within 
a single study. This design permitted both breadth and depth of understanding to occur [42]. The 
use of multiple methods and specifically the use of a quantitative method (survey) with qualitative 
methods (document review and key informant interviews4) provided better traction and insight into 
the topic of participation in HIV cure-related research than the use of a single method alone. This 
approach also helped compensate for the constraints of each method. In fact, the key to strong 
mixed methods research rests in the effective integration of the methods used.  The explanatory 
sequential design allowed quantitative data to be collected first, followed by the collection of 
qualitative data that helped explain (or refute) the quantitative data.  
Since my topic of inquiry involved participation in HIV cure-related research, it was 
important to understand contextual factors that would facilitate implementation, including the 
barriers and facilitators of entry into research.  The use of mixed methods added validity to my 
inquiry, as multiple strategies for validation can be necessary to obtain accurate information [42]. 
Tensions between the results obtained from quantitative versus qualitative inquiry may themselves 
be revealing and lead to new insights. I analyzed results from the survey separately from the 
qualitative results, and then attempted comparisons to determine whether the findings confirmed 
or contradicted each other. Additionally, I attempted to compare, whenever possible, the 
perspectives between patient-participants, clinician-researchers and policy-makers/regulators. This 
juxtaposition proved enlightening in some cases, especially where gaps, contrasts and contradictions 
were revealed (see Qualitative Analysis Section for details).   
                                                          
4
Focus group discussed deferred 
 21 
Data Collection Methods: Quantitative Inquiry  
Quantitative methods emphasize the use of an objective, deductive and generalizing 
approach. Researchers use them to help prove or disprove a hypothesis based on a conceptual 
model. Quantitative methods also help obtain breadth, rather than depth, of understanding of the 
predictors of successful implementation, and yield numeric descriptions of opinions or attitudes of a 
study sample [42]. Survey instruments are efficient data collection tools and offer a uniform 
modality to administer simple questions. They are also cost-effective and can be standardized. In my 
study design, the survey implementation further helped derive a study sample for later qualitative 
inquiry.  
Semi-Structured Survey (Potential Participants of HIV Cure-Related Studies) 
I implemented a semi-structured survey with potential HIV-positive participants (aim 1) 
developed to determine whether reported potential risks and benefits (or surrogate clinical 
endpoints) of HIV cure-related studies acted as deterrents and/or motivators for considering 
participation in HIV cure-related studies. The sample size reached was n = 400 (four times the initial 
target of n = 100 respondents), which, at a 95% confidence level, produced an interval of 
approximately +/- 5%. The sample size was still limited due to time constraints to complete the 
study in the allotted time, and because of the difficulty of recruiting people living with HIV who were 
at least partly aware of HIV cure-related research. Nonetheless, the sample size obtained was 
satisfactory given the extensive length of the survey.  
I tested the hypothesis of whether potential risks acted as deterrents and potential benefits 
(or positive surrogate clinical endpoints) acted as motivators of participation in HIV cure-related 
research. Most of the questions were closed-ended, with few open-ended questions. I constructed 
the survey instrument/questionnaire based on my literature review[40] of the possible deterrents 
and motivators of participation in clinical research.  Most of the closed-ended questions were either 
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dichotomous (Yes/No), ordinal (i.e. on a Likert scale), categorical (i.e. groupings) or continuous (i.e. 
spectrum such as age). Most of the socio-demographic variables were categorical and/or 
continuous, whereas the questions related to potential study participation (dependent variable) 
were dichotomous, and the questions related to perceptions of risks and benefits (key independent 
variables) were ordinal, on a Likert scale. Some of the variables were aggregated into newly 
structured constructs (see Data Management and Analysis for details). 
A quantitative analysis of the variables provided preliminary empirical evidence about which 
potential risks or benefits (or surrogate clinical endpoints) of HIV cure studies may act as deterrents 
or motivators to participation in HIV cure-related research. The results may lead to greater 
discussion among researchers and policy-makers and a prioritization of which risks and/or benefits 
HIV cure research implementers must pay attention to during study design and implementation.   
I administered the semi-structured survey online only, via the UNC-CH Qualtrics portal. The 
online survey was designed to use skip logic between questions and required responses to certain 
questions where necessary. Target respondents were adults living with HIV in the United States who 
were willing to answer questions around perceptions of HIV cure-related research. The sample was 
purposively derived using various HIV cure research listservs, such as the immune-based therapy 
(IBT) listserv, the Martin Delaney Collaboratories Community Advisory Board (MDC CAB) listservs, 
and other listservs of patient advocates (such as the AIDS Clinical Trials Group (ACTG)). We 
administered the survey from September – October 2015. To encourage participation in the survey, 
we did a random drawing of 1 for every 25 survey respondents who completed the survey and 
awarded each a $25 gift card. Funds for the gift cards were provided from my own money and not 
funded by an external agency. The random drawing was conducted after the last day of the survey, 
on October 31, 2015, and 13 gift cards were awarded to 13 random-draw prize winners from the 
345 survey respondents who completed the full survey and provided their contact information for 
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the prize drawing. Please see Appendix II for the IRB-approved recruitment script that was 
disseminated via listservs and/or emails. I also provided a copy of the IRB-approved dissertation 
project fact sheet to prospective respondents (see Appendix III).  
In order to establish content and construct validity, I asked members of the CARE 
Community Advisory Board to review the survey instrument.  Main categories of questions 
comprising the survey instrument related to demographic characteristics, health perceptions, 
history with and willingness to participate in HIV cure-related research, perceptions around different 
HIV cure-related research modalities, personal benefits, personal risks, social benefits and social 
risks. The survey instrument also asked questions related to the risk of therapeutic/curative 
misconception and barriers and facilitators of HIV cure-related research implementation. The survey 
was extensively reviewed with people living with HIV who provided feedback on the validity of 
constructs and terms used in the survey. One person suggested using the survey as a teaching 
opportunity and we therefore embedded basic definitions of difficult terms (e.g. allogeneic vs. 
autologous stem cell transplant) directly in the survey. The questionnaire was amended and IRB-
approved in August 2015 in order to allow for community input and better validity of constructs 
(after initial IRB approval in May 2015). A copy of the final questionnaire can be found in Appendix 
V.  
Data Collection Methods: Qualitative Inquiry  
Qualitative research emphasizes breadth of knowledge and can be helpful in the formative 
stage. The design is emergent and the inquiry is interpretive and iterative, involving a sustained and 
intensive experience with a small group of participants [42]. Qualitative inquiry involves a subjective, 
contextual and inductive approach, and is helpful when one needs to examine the intentions, 
motivations, perspectives, values and opinions of individuals, as well as to generate hypotheses 
from the information gained. Due to the exploratory nature of this study and the relative novelty of 
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the topic of HIV cure-related research participation, I found it appropriate to integrate qualitative 
methods in order to obtain new knowledge and contribute to the body of research in a meaningful 
way.   
In this dissertation, the emphasis on the voice of the patients and on participative and 
servant leadership as well community engagement created an intrinsic need for the utilization of 
qualitative methods. Additionally, qualitative inquiry proved helpful to understand the reasons 
behind deterrents and motivators to participation in HIV cure-related research, and behind 
successes or challenges of implementation. Qualitative research further helped inform the ethical 
and effective implementation of research.  
The qualitative approach in aims 2 and 3 gave voice to and explored the lived experiences 
and perceptions of people living with HIV (as well as clinician-researchers and policy-
makers/regulators). The qualitative orientation in aims 2 and 3 allowed a submersion into the 
complexity of the lived experiences of people living with HIV who may have participated in, 
currently participate in or are candidates for future HIV cure-related studies. This exploration 
informed ethical HIV cure study design, development and implementation.  In fact, the emergent 
and innovative nature of the field of participation in HIV cure-related research calls for an approach 
that permits a more meaningful engagement of people living with HIV during the research design 
process. This co-agency allows patients and their advocates to become active co-creators of the HIV 
cure-related research agenda and a better integration of the biomedical and the social sciences [41]. 
The qualitative inquiry also included a review of key documents and key informant interviews. The 
combination of methods permitted gaining a deep understanding around perceptions of risks 
and/or benefits of HIV cure-related research and pragmatic challenges of study implementation. 
Data sources included adults living with HIV in the United States, clinician-researchers and policy-
makers (broadly defined), as described above. I attempted to triangulate these multiple data 
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sources, including data from the potential volunteer survey implemented in aim 1. For example, I 
selected key informants from survey respondents who were the most and least willing to participate 
in HIV cure-related studies, stratified by gender, in order to determine differences in perceptions 
and attitudes between these different groups.  
Document Review 
The document review included systematically written notes from conferences and meetings 
on the topic of participation in HIV cure-related research. I took notes methodically from 
conferences and meetings as part of my work with the Collaboratory of AIDS Researchers for 
Eradication (CARE) from 2013 – 2015 in order to provide an unbiased way of capturing information. 
This included conference reports, meeting proceedings and working documents from subject matter 
experts relating to the topic of participation in HIV cure-related research, as available. For example, I 
reviewed notes from NIH meetings on the topic of the social sciences in HIV cure-related research 
and notes from conference calls with the Forum for Collaborative HIV Research – subgroup 3 on 
patient recruitment, education and informed consent.  The reference section contains the list of 
documents reviewed. I also scouted for and reviewed policy documents related to HIV cure-related 
research, including meeting reports from FDA, such as The Voice of the Patient report [43]. I did not 
need to request permission to use these documents, as there was no custodian of the data or they 
were publicly available.  
The document review served two purposes. First, it provided a secondary data source for 
possible deterrents and/or motivators of participation in HIV cure-related research as well as 
possible implementation realities, challenges and opportunities. Secondly, it identified organizations 
and/or key informants to tap into for interviews. I conducted the document review in a systematic 
fashion. The main goal was to extract information on the possible barriers and facilitators of 
participation and implementation of HIV cure-related research. In conjunction with primary data 
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collection and analysis, the summary informed possible considerations to ensure the effective and 
ethical implementation of HIV cure studies. Document review considerations are included in the 
discussion section instead of the qualitative results section. Further, as peer-reviewed articles 
became available on the topic of participation in HIV cure-related research during the study period, I 
incorporated them as well, to the extent possible. 
Key Informant Interviews  
I conducted key informant interviews with patient-participants, clinician-researchers and 
policy-makers/regulators to obtain their expert opinions and to better understand perceptions of 
risks and benefits (or surrogate clinical endpoints) of HIV cure-related studies. I also gained insights 
into the pragmatic challenges affecting implementation of these studies. Key informant interviews 
permitted the collection of information from knowledgeable individuals as well as the flexibility to 
explore emerging themes.  I developed the key informant interview guides based my review of the 
literature. I refined them further as needed based on the semi-structured survey responses, on the 
document review and following discussions with seasoned community advisory board members 
who were willing to provide feedback.  In order to establish content validity, I asked members of the 
CARE Community Advisory Board to review the interview guides prior to implementation.  See 
Appendix VI for the IRB-approved interview guides with patient-participants, clinician-researchers 
and policy-makers, respectively.  
For feasibility reasons, I conducted around n = 12 interviews with people living with HIV, n = 
11 clinician-researchers and n = 13 policy-makers/regulators. I found that I reached saturation of key 
themes and exhausted study questions for all three groups of key informants. In fact, qualitative 
data analysis guidelines suggest that purposive samples should be determined on the basis of 
theoretical saturation – or “the point in data analysis when new incoming data produce little or no 
change to the existing code network” [44]. I reached saturation and data redundancy in the 
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qualitative inquiry.  I derived the sample of patient-participant key informants from the survey. 
These selected patient-participants had indicated that they would be willing to be contacted to 
answer additional questions around the topic of participation in HIV cure-related research. Based on 
the results from the survey, the categories of key informants who were purposively interviewed 
corresponded to the following 4 groups: 1) male more willing to participate in HIV cure research; 2) 
male less willing, 3) female more willing and 4) female less willing. This selection was based on: 1) a 
separation of respondents between males and females; 2) an assessment of the number of types of 
HIV cure-related studies potential volunteers would be willing to participate in; 3) diversity of 
respondents by age, education and geography/location across the United States; 4) willingness to 
participate in the interviews.  Further, I identified clinician-researchers and regulators/policy-makers 
using my experience working in the field of HIV cure-related research, from meeting lists and/or the 
relationships that I had built with colleague organizations. I selected these respondents purposefully 
and used recommendations from experts and a snowballing approach to identify additional key 
informants. I also strived to interview clinical research coordinators and study nurses who were in 
direct contact with people living with HIV and who were actual implementers of HIV cure research.  
The analysis section provides a summary of key informants. 
I contacted all potential key informants by email and/or phone and explained the purpose of 
the study and the reasons for requesting their participation and assistance. I provided a copy of the 
IRB-approved dissertation project fact sheet (see Appendix III). I tracked all efforts to reach key 
informants in a contact log. During initial contacts, I emphasized that I was interested in their 
personal opinion – not the official position of their organization – due to their experience with HIV 
cure-related research. If individuals were willing to be interviewed, I deferred to their preferences as 
to the best modality for interview (e.g. telephone or face-to-face) as well as time for the interview. 
Most interviews were conducted by phone and a few interviews were done in person, as expected.  
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I provided a copy of the informed consent form and interview guide in advance of the scheduled 
interview to give informants the time to think about their participation in the study and about each 
question. I also asked for their permission to record the interview – if not granted, I took notes 
systematically. I assigned a unique identifier code for each key informant interview (patient-
participants: 101 and above; clinician-researchers: 201 and above; policy/makers/regulators: 301 
and above).  I transcribed all key informant interviews in order to have a deeper experience with the 
data (see Data Management and Analysis for details).  
Inclusion/Exclusion of Study Participants and Delimitations  
Inclusion criteria for participation in this study5 were: 1) persons living with HIV; 2) 
willingness to answer survey questions and/or participate in key informant interviews; 3) being at 
least 18 years of age; 4) living in the United States or its territories; and 5) willingness to provide 
informed consent.  The survey was conducted amongst self-disclosed HIV-positive individuals. 
Interviews with people living with HIV were conducted with those who were willing to disclose their 
status to me.6 I also attempted to select study participants who were representative of the various 
HIV cure research modalities and who were diverse in gender, age, education, income and 
geography/location, and had different degrees of willingness to participate in HIV cure-related 
studies. ART status did not affect participation in the study, meaning that those who were HIV-
positive on ART or not on ART could be in the study. There was no exclusion criterion.  In order to 
gain entry into the reality of people living with HIV and to secure permission to ask them sensitive 
research questions, I worked closely with the leader of the CARE Community Advisory Board and 
other Community Advisory Boards (i.e. DARE and defeatHIV) as they were important gatekeepers.  
                                                          
5
We added two inclusion criteria for the focus group discussions during the amendment in January 2016: 6) 
comfortable discussing HIV cure-related research with other people living with HIV and 7) willingness to keep 
information shared in the focus groups confidential. 
6
Focus group discussions will be conducted with openly HIV-positive individuals in order to reduce the risk for 
harm, stigma and discrimination. 
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Delimitations refer to the boundaries of the research. This dissertation project was 
delimited to HIV cure-related studies implemented in the United States and focused on the Martin 
Delaney Collaboratories. The main reason was that the United States provided a research-rich 
environment to conduct HIV cure-related studies. There are much deeper ethical concerns with 
implementing HIV cure-related studies in resource-limited settings that are beyond the scope of this 
dissertation. Furthermore, I have focused most of my recent work with advocates located in the 
United States.   
Study Participation Duration 
The survey/questionnaire took most respondents between 15 minutes and 30 minutes to 
complete.  Key informant interview lasted between 30 minutes to 1 hour for the most part. All key 
informant interviews were scheduled a few days in advance.  As expected during study planning, the 
discussion of the perceptions of risks and benefits bled into topics related to the pragmatic 
challenges of implementing HIV cure studies. I derived considerations related to the ethical 
implementation of HIV cure-related studies and explicitly asked about them during the interviews.  
Reliability and Validity 
Aim 1 of this dissertation intended to test the hypothesis of whether potential risks and 
benefits of HIV cure research acted as deterrents/motivators of participation in HIV cure-related 
studies. Aims 2 and 3 intended to generate knowledge and they were more descriptive and 
exploratory in nature. Aim 2 explored how various stakeholders perceived risks and benefits of HIV 
cure-related studies. Aim 3 probed about the pragmatic issues affecting participation in and 
implementation of HIV cure studies, both using qualitative methods.  As described earlier, I 
attempted to reach validity by matching the aims of the study with the appropriate study methods. 
This allowed for the best approximation to the “truth” although most of the research was centered 
on hypothetical willingness to participate in HIV cure-related research, since we were not recruiting 
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for actual HIV cure-related studies. I tried to augment internal validity by minimizing bias in the 
selection of study participants and by the careful inference of conclusions related to the study 
findings. I tried to maximize external validity by obtaining a diverse, yet purposeful sample of people 
living with HIV. The discussion section explores the extent to which the results of the study can be 
generalizable to a wider sample. For qualitative study findings, I was reminded that particularity, 
rather than generalizability, was the hallmark of robust qualitative research and therefore 
attempted to avoid the generalizability fallacy [42].  
I tried to reach construct validity by carefully selecting key themes and concepts, such as 
risks, benefits, deterrents and motivators.  I developed the survey instrument and interview guides 
with the understanding and assumption that the potential burdens/risks and benefits of 
participation in HIV cure-related studies extended beyond those inherent to specific studies, such as 
clinical endpoints. Taken together, I attempted to capture the complexity of factors that may 
influence decision-making and found out that factors extend way beyond considerations of risks and 
benefits. Furthermore, I designed the survey instrument and key informant interview guides in a 
stepwise process, using a comprehensive literature review, discussion with experts and community 
leaders in the field, drafting and re-drafting, review, pilot testing and revising.   Furthermore, I 
attempted to reach reliability by attempting to make the research findings consistent and replicable 
as much as possible. I kept a log of notes after each key informant interview, and wrote the 
transcripts as close as possible to the end of each interview. I used an Olympus digital voice recorder 
(VN-7200) that provided outstanding sound quality for the recordings. Finally, I debriefed with the 
study community co-investigator regularly in order to enhance the accuracy of each account.  
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Strengths and Limitations  
The strengths and limitations of this dissertation project can be found in the Discussion 
section.  
Confidentiality and Protection of Study Participants  
This study was classified as “minimal risk.” No HIV testing or biomedical procedure was 
conducted with anyone involved in this research. HIV-seropositive statused were self-disclosed. I 
followed the utmost confidentiality and data security guidelines. Most potential participants were 
actively involved in HIV treatment and cure activism, had openly disclosed their seropositive status 
and were fairly knowledgeable about the topic of HIV cure-related research. Several HIV-positive 
patient advocates were also known and respected community leaders and spoke on behalf of other 
patients about HIV treatment and cure research issues. 
In order to minimize the risk of harm, study participants self-selected. Vulnerability of 
patient-participants was minimized and protected via the informed consent process. For the survey 
and key informant interviews, risks to participants were minimal. Furthermore, some participants 
divulged private information, such as health insurance status, health and health care information 
and past study participation and special attention was taken to keep this information confidential. 
All key informant interviews were conducted in private. Participants were free to join and/or stop 
the study at any time. If participants felt uncomfortable or vulnerable in the study, they had the 
option to continue in the study or not. As there are rather limited opportunities to provide a voice to 
the experiences of people living with HIV, this study presented an opportunity for patient advocates 
to articulate their concerns about participation in HIV cure-related research. Some participants 
actually found the interview to be quite cathartic. Because of the research methods applied in this 
project, the research provided rich insights into the possible factors affecting participation in HIV 
cure-related studies and can guide the implementation of future studies. The benefits of the study 
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extended to the broader scientific community, although no immediate benefits could be anticipated 
from the survey or key informant interview participation. 
Every  attempt was made to maintain the confidentiality of study participants.7 No study 
data were linked with personal identifiers under any circumstances. Where participant name was 
provided (e.g. in order to participate in the survey prize drawing or to volunteer for follow-up 
interviews), the names and contact information were extracted into a separate file (with no survey 
data) and deleted from the survey data files in order to anonymize the survey data. All semi-
structured survey data were kept on the password-protected UNC-CH Qualtrics system, which could 
only be accessed by myself using my UNC-CH Onyen and password. After my DrPH dissertation 
defense, the survey data downloaded into Excel and STATA (all of which do not include participant 
names or identifying numbers) and analyzed will be removed from the UNC-CH Qualtrics system to 
minimize any risk of data interception. I did not store any audio file electronically since my recording 
device did not permit downloading of audio files. My recording device is being kept under lock and 
key. After I successfully defend my DrPH dissertation, I will destroy the audio recordings.  This will 
minimize the risks of linking any study data to an individual respondent.   
Study results are presented as aggregate data, with no personal information.  All names of 
study participants and key informants are kept confidential and private. Broad descriptors of study 
participants and key informants are included in the narrative; however, no unique personal 
identifier is included. I further stored all paper copies of the informed consent forms in a locked 
cabinet for written consents given. Access to electronic and hard copies of notes and study 
documents is restricted to myself and my dissertation committee only. The only inadvertent 
disclosure of information may include HIV status. To minimize risks, the online survey could be 
                                                          
7
For the focus group discussions, participants will be told that confidentiality could not be guaranteed but we 
will ask them not to talk about anything shared in the focus group with third parties. 
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completed anonymously (amongst self-disclosed adults living with HIV) without the need to share 
name or contact information. I only interviewed people living with HIV who were willing to 
disclosure their status to me.8 I transcribed all interview data verbatim. Please see Data 
Management and Analysis for further details regarding qualitative data analysis.    
Informed Consent 
I requested informed consent from all study participants. For the online semi-structured 
survey, participants were prompted to read the informed consent form and to give their online 
consent before proceeding to the survey. For the key informant interview, informed consent was 
requested in writing if the interview was conducted face-to-face and was requested verbally if the 
interview was done by phone.9 Some informants interviewed by phone sent a signed, scanned 
consent form to be prior to the interview. All others provided verbal consent. Due to the minimal 
risk involved with this study, I sought to waive the requirement for written informed consent for the 
key informant interviews and this was granted by the UNC-CH non-biomedical IRB.  All key 
informants were sent a copy of the IRB-approved informed consent form together with a fact sheet 
describing the research project electronically ahead the time.   
Prior to giving consent, participants were given the opportunity to ask any questions about 
the study. All study participants were consented and interviewed in English. All the study procedures 
were explained in detail so that participants were fully informed about their requirements for the 
study. All potential study participants were reminded that they were free to choose to participate in 
the study or not. For people living with HIV, decisions of whether or not to participate in this study 
did not affect the health care they normally received as well as their employment status or 
                                                          
8
Focus groups will be conducted with HIV-positive individuals who are willing to discuss their status within the 
focus group setting. 
9
For focus group discussions, informed consent will be requested in writing since all the focus group 
discussions will be conducted face-to-face. 
 34 
relationship with the Community Advisory Boards. Only those who consented to take part in the 
study were enrolled. Copies of the IRB-approved informed consent forms for the patient-
participants, clinician-researchers, policy-makers/regulators and focus group participants are 
included in Appendix IV. 
Institutional Review Board Approval  
The non-biomedical Institutional Review Board (IRB) and Human Research Ethics Committee 
of the University of North Carolina at Chapel Hill is the primary and sole IRB for this study. I filed the 
initial IRB application and obtained initial approval on May 18, 2015, before beginning any of the 
proposed research. In August 2015, I amended the survey prior to implementation and based on 
feedback received from patient advocates and obtained IRB approval on September 3, 2015. Survey 
implementation and key informant interviews were initiated thereafter in September 2015.10  
Compensation for Study Participation  
To reward participants who completed the survey, there was a random reward of $25 for 
each 25 completed survey respondents, in the form of a VISA gift card, TargetTM gift card or 
StarbucksTM gift card. To participate in the drawing, respondents needed to complete the survey and 
specifically indicate they wanted to be included in the draw, providing a name and email address or 
phone number to be contacted upon winning a gift card.   
                                                          
10
I amended the focus group discussion guide and procedures in December 2015 and obtained IRB approval on 
January 4, 2016. Focus group discussions will be implemented from January – June 2016. 
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There were 345 respondents who completed the necessary information, and thus 13 gift 
cards were awarded at random.  There was no explicit compensation or non-monetary inducements 
for key informant interviews.11   
Study Management  
I, the Principal Investigator, managed the study, under the supervision of my DrPH 
dissertation chair, Dr. Sandra Greene, and the guidance of the dissertation committee.  
                                                          
11
Focus group participants will receive compensation for their time and effort of $15 each and this amount 
was IRB-approved.   
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CHAPTER 3 | DATA MANAGEMENT AND ANALYSIS 
This section describes the scope of the data management and analysis for this dissertation 
project.  First, I conducted a review of available documents (mostly grey literature) on the topic of 
participation in HIV cure-related research. Second, I implemented the semi-structured survey and 
analyzed the quantitative data in order to achieve the objectives stated in aim 1. Third, I conducted 
the key informant interviews and analyzed the key informant qualitative data to fulfill the objectives 
stated in aims 2 and 3. Finally, I attempted to compare the quantitative data (from the semi-
structured survey) with the qualitative data (from the key informant interviews) in the discussion 
section to highlight concordances, discordances and implications of the research to inform the 
implementation of HIV cure studies and participant recruitment.  
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Document Review 
As described in the methods section, the document review included systematically written 
notes from meetings on the topic of participation in HIV cure-related research. The grey literature 
also included conference reports, published meeting proceedings and working documents from 
subject matter experts relating to the topic of participation in HIV cure-related studies. The 
information derived from the document review is included in the discussion section and the list of 
documents reviewed is can be found in references section. 
Quantitative Data Management and Analysis: Survey Data  
For the quantitative section, the unit of analysis was survey respondents who were self-
disclosed HIV-positive. The primary objective was to determine whether perceived risks of HIV cure-
related studies acted as deterrents to participation in HIV cure-related studies and whether 
perceived (anticipated) benefits (or surrogate clinical endpoints) served as motivators for 
participation in HIV cure-related research. Survey respondents were asked to respond to questions 
regarding their willingness to participate in HIV cure-related studies and their perceptions on 
potential risks and benefits.  
Quantitative Data Management 
I administered the semi-structured survey using the UNC-CH Qualtrics system from 
September 8 – October 31, 2015. By then, 409 respondents had at least partially completed the 
survey, with 9 identifying themselves as ineligible to participate in the survey (they did not meet the 
eligibility criteria), thus leaving a final sample size of 400 qualified respondents. The survey was the 
primary data collection capture and management tool for the quantitative data. One advantage of 
using participant-driven data capture was that participants could key in the data directly, without a 
second transcription or data entry step, thus minimizing data entry errors. Furthermore, the 
anonymity of the data collection process allowed answers that were more faithful.  Prior to 
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launching the online questionnaire, I pilot tested the survey in beta mode with the help of 
community advisory board members to ensure that all necessary skip logics had been incorporated 
and that all possible kinks have been worked out. After survey administration, I downloaded the 
data into Excel spreadsheets and converted them into STATA files at the end of the data collection 
period. I kept the data on my computer dedicated to the DrPH program, which was password-
protected. In order to maintain confidentiality, I removed all data containing information that may 
identify a participant by name, such as text fields requesting participants who may be willing to take 
part in key informant interviews. These data were kept separately from the main database, and 
never stored with the survey responses saved in Excel or STATA files. I only used data that had been 
delinked of all personal identifiers for the analysis.   
During the data collection phase, I periodically monitored the dataset to address any issue 
that arose. I monitored the data using a master Excel spreadsheet downloaded from the UNC-CH 
Qualtrics system approximately every two weeks. I checked data for out-of-range values, missing 
text fields and for reasonableness of answers.  During the monitoring phase, I performed 
preliminary descriptive data analyses to determine possible sampling biases (such as a 
disproportionate percentage of men vs. women). To ensure completion of the survey by most 
respondents, I did not make text fields mandatory as this would have affected survey completion. I 
decided instead to report missing data in the final analysis. In the results, I show the number of 
study respondents who completed each question (out of n = 400).  
Observations that were not applicable, ineligible, incomplete, or for which participants 
answered with “Don’t know/Not sure” for specific questions were discarded and treated as missing 
(see Quantitative Results section for details). Inapplicable and ineligible observations were those 
coming from survey respondents who were not HIV-positive or only answered “I don’t know” or 
“Not sure” to questions pertaining to their willingness to participate in HIV cure-related studies or 
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questions regarding benefits or risks of HIV cure-related studies. Incomplete observations were 
those coming from survey respondents who did not answer questions on their willingness (or 
unwillingness) to participate in any kind of HIV cure study, which formed the key dependent variable 
for the analysis. After the exclusion of the inapplicable, ineligible and incomplete survey responses, I 
prepared a final cleaned data set in Excel for data analysis.   
Quantitative Data Analysis 
Survey Variables 
The survey instrument included questions that captured the respondents’ characteristics 
and attitudes towards HIV cure-related studies, as shown in the IRB-approved questionnaire in 
Appendix V. The questions were designed specifically to quantitatively assess the correlations 
between perceived risks and benefits of HIV cure-related research and respondents’ willingness to 
participate in HIV cure studies, fulfilling aim 1.   
Survey Data Inclusion and Cleaning  
After October 31, 2015, the cutoff date for survey responses, I compiled all of the raw 
survey data into one spreadsheet using the UNC-CH Qualtrics’ built-in software capabilities. Before 
analyzing the survey results, I checked the quality and completeness of the raw survey data and 
made corrections and exclusions where necessary to prepare the survey data for analysis.  The first 
step was to exclude incomplete responses, defined as responses by respondents who did not 
answer any of the questions regarding willingness to participate in types of HIV cure-related studies 
(the dependent variable), perceptions on potential benefits and potential risks (key independent 
variables), or more detailed questions regarding global attitudes towards HIV cure research. In other 
words, these are respondents who may have answered a few demographic questions and nothing 
else, which provides no significant value to the quantitative or qualitative analyses. As a result, five 
survey responses were dropped from the raw survey data.  
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Next, I searched for duplicative responses. One respondent completed the survey twice, 
providing nearly identical responses, and voluntarily including his or her name on both survey 
responses. The first (older) response was dropped and the second (latter) response kept, after filling 
in null responses to specific questions in the second survey response using the answers provided to 
those questions in the first response, if available. Because the survey was only conducted through 
the internet, and the UNC-CH Qualtrics software platform was set up to require individual responses 
for certain questions, skip logic were employed to navigate from one section of the survey to the 
next. Most of the questions were close-ended questions and transcription errors were virtually null. 
However, in some multiple choice questions, respondents were given the opportunity to type in text 
to describe an “Other” multiple choice selection. I reviewed the typed-in text to these questions 
individually. Where I determined the typed-in text and “Other” selection could be changed to 
another multiple choice answer, I modified the response.  
Finally, names and contact information, which were voluntarily provided by respondents to 
participate in the survey prize drawing and to volunteer for follow-up interviews, were separated 
and removed from the survey results. Similarly, all of the answers to open-ended questions were 
separated and removed from the survey results, and were analyzed independently from the 
quantitative survey results as part of the qualitative data analysis. This was necessary in order to de-
identify the quantitative survey results. The final, cleaned quantitative survey dataset did not 
include any names, contact information or answers to open-ended questions that may reveal the 
identity of the respondents. This dataset was imported into Stata statistical software for 
quantitative analysis. 
a) Dependent Variable 
The dependent variable for this analysis was the respondent’s relative willingness to 
participate in HIV cure-related studies. It is formulated from Question 21 in the survey that asked 
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respondents whether they would consider participating in HIV cure-related studies. The question 
listed and asked about willingness to participate in the following 14 different types of HIV cure-
related studies: 
1. Survey/questionnaire research 
2. Interviews 
3. Focus group discussions 
4. Basic blood draw studies 
5. Laboratory procedure where selected immune cells are separated out from the 
participant’s blood and the rest of his/her blood is returned to his/her veins 
(leukapheresis or apheresis) 
6. Studies that involve agents that could reactivate HIV that has become dormant 
inside the cells  (latency reversing agents) 
7. Studies that would involve the modification of some of  the genes in the immune 
cells 
8. Studies that would involve a transplantation of (“autologous”) stem cells 
9. Studies that would involve a transplantation of someone else’s (“allogeneic”) stem 
cells 
10. Studies that would involve therapeutic vaccines (vaccines that control disease in 
people already infected rather than vaccines that prevent infection) 
11. Studies that would involve the intensification of treatment or taking more than 3 
different classes of drugs at the same time 
12. Studies that would involve the use of unique antibodies, proteins or molecules (for 
example, antibodies that have dual functions) 
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13. Studies that would involve totally new treatments or approaches (“first-in-human” 
studies) 
14. Studies about safety and efficacy (or phase II or III studies) 
The survey respondents answered the question for each type with a categorical “Yes”, “No”, 
“Don’t know/Not sure”, or could skip any (or all) of the 14 types of HIV cure-related studies. Beyond 
descriptive statistics, all “Don’t know/Not sure” responses were treated as null responses, similar to 
a respondent skipping a particular type from the list of 14 types of HIV cure-related studies.  
In all, 361 respondents (90%) answered “Yes” or “No” regarding their willingness to 
participate in at least one of the 14 types of studies, constituting the full sample size for the 
dependent variable. The distribution of the number of types of HIV cure-related studies (out of 14) 
that the respondents indicated they were willing to participate in is shown in the results section.  
The dependent variable throughout this analysis is the respondent’s willingness to 
participate in HIV cure-related studies, which can be constructed in different ways from these 
results. By asking survey respondents whether they would be willing to consider participating in 14 
different types of HIV cure studies that span a wide range of intervention and risk (i.e. from 
responding to questionnaires all the way to intensification of treatment and transplanting stem 
cells), it was hypothesized that respondents would reveal a variety of willingness to participate in 
HIV cure-related studies.  Surprisingly, nearly everyone indicated they would be willing to participate 
in at least one type of study. Only 5 out of the 361 people who responded to this question indicated 
they would not be willing to participate in any of the study types, or at least were not sure that they 
would. Thus, the dependent variable could not be measured by willingness to participate in any type 
of HIV cure-related study, due to lack of variability. 
However, there was variation to the degree of willingness to participate, based on the 
number of types of studies respondents specifically indicated they would be willing to participate in. 
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In fact, 26% of the respondents were willing to participate in all 14 types of studies, and nearly half 
of the respondents were willing to participate in 12 or more types of studies, while 13% were only 
interested in participating in 4 or fewer types of HIV cure-related studies. For the latter respondents, 
they were either not sure if they would participate in the other types of studies, or specifically 
indicated that they would not be willing to participate in those types of studies. 
The above results are described in the data analysis section because the number of types of 
studies the respondents indicated they were willing to participate in were not normally distributed. 
A skewness/Kurtosis test for normality rejected the null hypothesis that this variable was normally 
distributed, statistically significant at the 0.1% level. The proportion of respondents generally 
increased with greater numbers of types of studies the respondents were willing to participate in. 
The distribution looks similar to a reversed negative binomial distribution. There is also a significant 
spike at the maximum number of types of studies considered (14).  
Attempting to use the number of types of studies a respondent was willing to participate in 
as the measure of his or her willingness to participate in HIV cure research (and thus as the 
dependent variable) would create difficulties when fitting a regression model. Since this variable 
was not continuous (it is a count variable), and has a lower and upper bound, an ordinary least 
squares (OLS) regression model would poorly fit the data, and particularly when the dependent 
variable was not normally distributed and was skewed. The result of fitting an OLS model using a 
count dependent variable with non-normal distribution was that the model residuals may also not 
be normally distributed and heteroscedastic. In fact, I verified this hypothesis by estimating OLS 
regression models using the sum of types of studies as the measure of willingness to participate in 
the dependent variable, and the residuals were clearly not normally distributed and exhibited strong 
signs of heteroscedasticity. Heteroscedasticity and not normally distributed residuals violated the 
best linear unbiased estimator assumptions of OLS models (originally proposed in my DrPH 
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proposal), and the estimated standard errors would not have been inaccurate. As a consequence, 
statistical tests of significance for the model coefficients would have been flawed. Because the 
purpose of the statistical analysis was to make inferences on the larger population living with HIV in 
the United States and their willingness to participate in HIV cure-related studies (and not simply 
assess willingness to participate among the survey sample), it was important to estimate accurate 
standard errors. There were different regression model types that were better fitted for count 
dependent variables, including two-stage models that account for spikes in responses at the 
boundaries, but the residuals continued to show heteroscedasticity. Thus, I did not use the number 
of types of HIV cure-related studies respondents were willing to participate in as the dependent 
variable measuring willingness to participate.  
Instead, the dependent variable for my analysis was whether respondents indicated that 
they would be willing to participate in all 14 types of HIV cure-related studies, versus those who 
indicated they are willing to participate in 13 or fewer types, but not all types of studies. A 
respondent who answered “Yes” to all 14 HIV cure study types was assumed to be very willing to 
participate in HIV cure-related studies, compared to a respondent who answered “No,” “Don’t 
know/Not sure” or did not answer for one or more types of studies after answering “Yes” to another 
type of study. The latter respondent was classified as a participant who would be relatively less 
willing to participate in HIV-cure related studies. This dichotomous dependent variable was true 
(had a value of 1) if the respondent answered “Yes” to all 14 listed types of HIV cure-related studies, 
and was false (had a value of 0) if the respondent answered “Yes” to 0 to 13 listed types of HIV cure-
related studies, but not to all 14.This particular construct of willingness to participate in HIV cure-
related studies had sufficient variation in values to be used to test several correlations with key 
independent variables to test hypotheses.  
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The dependent variable split the respondents into two groups: those who were “very willing 
to participate” in HIV cure-related studies, and those who were “relatively less willing to participate” 
in HIV cure-related studies. The participants who were very willing to participate indicated in the 
survey that they would consider participating in all kinds of HIV cure-related studies, including types 
of studies that have strong interventions such as intensification of treatment, transplanting stem 
cells, use of latency-reversing agents, modification of genes in immune cells, and first-in-human 
studies. If a respondent was willing to consider participating in all of these types of studies, they 
revealed a very strong willingness to participate in HIV cure-related research in the future. 
Conversely, the participants who were relatively less willing to participate indicated in the survey 
that while they might consider participating in some, or even many (up to 13), types of studies, they 
are specifically not willing to participate in, or at the very least are hesitant or do not know if they 
would consider participating in, at least one type of study. Hence, they were relatively less willing to 
participate in HIV cure research compared to their counterparts who are “very willing to 
participate.” Some of the relatively less willing to participate respondents were actually still willing 
to participate in 11, 12 or even 13 out of 14 types of studies, exhibiting a high degree of willingness 
to participate in HIV cure research. However, relative to those who are willing to participate in all 14 
types of studies, they were relatively less willing. This distinction is important to bear in mind when 
interpreting the results presented in this dissertation.  Among the 361 respondents, 95 (26%) were 
willing to consider participating in all 14 types of HIV cure-related studies, and are thus classified as 
“very willing to participate” in HIV cure-related studies, with a value of 1 in the dependent variable. 
The other 266 (74%) of respondents are classified as “relatively less willing to participate” in HIV 
cure-related studies, with a value of 0 in the dependent variable, as shown in. By comparison to the 
95 respondents who answered “Yes” to all 14 types of studies, these 266 respondents were less 
willing to participate in HIV cure-related studies. 
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Table 2. Summary Statistics of the Dependent Variable 
Dependent variable: willingness to consider 
participating in all 14 types of HIV cure related 
studies 
Value of the dichotomous 
dependent variable 
n Percent 
No (relatively less willing to participate): may 
participate in 13 or fewer types, but unsure of 
or would not participate in at least one type of 
study 
0 266 74% 
Yes (very willing to participate): would 
participate in all 14 types 
1 95 26% 
  Total 361   
 
 
Figure 4. Distribution of Values of the Dependent Variable 
 Among the 266 respondents who were relatively less willing to participate in HIV cure-
related studies, 141 (slightly more than half) specifically answered "No" on considering participating 
in at least one of the 14 types of HIV cure-related studies. The other half either answered "Don't 
know/Not sure" and/or did not answer the question for all 14 types of studies. Nevertheless, even 
respondents who answered "Yes" to some types of HIV cure-related studies and skipped over other 
types of studies or did not know whether they would participate in other types of studies revealed a 
 48 
lower level of willingness to participate in "any kind of HIV cure-related study" than the respondents 
who specifically answered "Yes" to all 14 types. Again, these results are presented in the data 
analysis section as they drove the selection of key dependent variables.  
b) Key Independent Variables 
In the survey, respondents were asked about their perceptions of the importance of 21 
different potential benefits (11 potential personal benefits, 6 potential personal clinical benefits and 
4 potential social benefits) as motivating factors to considering participating in HIV cure-related 
studies. Answers were provided on a Likert scale: very important, somewhat important, barely 
important, not important, don’t know/not applicable. Likewise, respondents were asked about their 
perceptions of the likelihood of 35 different potential risks (23 potential personal risks, 7 potential 
personal clinical risks and 6 potential social risks) to discourage them from considering participation 
in HIV cure-related studies. Answers were provided on a Likert scale: very likely to discourage, 
somewhat likely to discourage, barely likely to discourage, not likely to discourage (does not affect 
decision to participate), and don’t know/not sure. Beyond summarizing the descriptive statistics, all 
“Don’t know/Not applicable” or “Don’t know/Not sure” answers were treated as null responses. 
The key independent variables were formulated from the questions about whether different 
types of potential benefits were perceived by the respondent to be, specifically, “very important” 
motivators to consider participation in HIV cure-related studies (as opposed to “somewhat 
important”, “barely important” or “not important”). The key independent variables were also 
formulated from questions about whether potential risks were perceived by the respondent to, 
specifically, “very likely to discourage” them from considering participation in HIV cure-related 
studies (as opposed to “somewhat likely to discourage”, “barely likely to discourage” or “not likely 
to discourage”). Thus, the Likert scale responses were reconstructed into dichotomous variables for 
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the 21 potential benefits and 35 potential risks key independent variables. Collapsing these 
categories allowed controlling for potential social desirability bias. 
c) Control Variables 
Control variables provided socio-demographic characteristics of the respondents as well as 
their global attitudes towards HIV cure research. The variables were formulated from survey 
questions about the respondent’s gender, age, ethnicity, education, income, location, self-
assessment of health status, self-assessment of whether the respondents believed they were in 
control over their own health care, duration of HIV status as a percent of their life, whether the 
respondents ever volunteered for HIV treatment or HIV cure studies, and whether the respondents 
were generally interested in HIV cure research. Age and duration of HIV status as a percent of the 
respondent’s life were continuous variables. All other variables were categorical. Education, income, 
and self-assessment of health status were ordinal categorical variables. For this analysis, the location 
variable was constructed as a categorical variable describing four regions in the United States: West, 
Midwest, Northeast, and South (including two respondents from Puerto Rico). The four regions 
followed the U.S. Census Bureau’s four region categorization that were based on state boundaries 
that equally divide the geographic land mass of the United States.12  
Baseline (Descriptive) Quantitative Data Analysis  
I started by quantitatively summarizing the responses to all closed-ended survey questions 
in descriptive statistics tables (see Results section). I displayed the number of responses to each 
question and summarized the responses for continuous variables by the mean, median, minimum 
and maximum values. I summarized the responses for dichotomous variables, such as a question 
regarding whether the respondent were currently participating in a health study, by the number and 
                                                          
12
http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. The four regions included the 
following states: 1) West: CA, NV, AZ, NM, UT, CO, WY, MT, ID, OR, WA, HI, AK; 2) Midwest: KS, MO, IL, IN, OH, 
MI, WI, IA, NE, SD, ND, MN; 3) Northeast: PA, NJ, NY, RI, CT, MA, VT, NH, ME and 4) South: TX, OK, AR, LA, MS, 
AL, GA, FL, SC, NC, TN, KY, VA, WV, DC, MD, DE, Puerto Rico. 
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percentage of responses that answered in the affirmative (i.e.: “% Yes”) and negative (i.e. “% No”). I 
also summarized the responses for discrete categorical or ordinal variables by the percentage of 
answers in each mutually exclusive and exhaustive category, including “I don’t know/Not sure,” 
where applicable. All of the discrete questions on the survey asked the respondents to select only 
one answer per question. 
I displayed the descriptive statistics for all questions using data tables and graphs (see 
Results section). The questions regarding the respondents’ perceptions about the 
motivating/deterring factors of potential benefits and risks were asked using a Likert scale. For the 
analysis, these ordinal variables were restructured into dichotomous variables, where the most 
extreme answer (i.e. benefit is a “very important” motivator, and risk is “very likely to discourage” 
participation) is given a value of 1 and all other answers except “I don’t know” given a value of 0. 
Because of the reclassification of these key independent variables, the graphical visualization of the 
descriptive survey responses were centered around the breakpoint in the Likert scale that 
corresponded to the dichotomous construct of the variables.  
I next regrouped answers to questions and summarized responses to broader grouped 
questions. For example, I calculated and revealed the percentage of respondents based on the total 
number of HIV cure-related studies they indicated they would be willing to participate in, and how 
many respondents indicated they would be willing to participate in all 14 types of studies (i.e. very 
willing to participate) versus willing to participate in some but not all types of studies (i.e. less willing 
to participate).  
The primary research question in aim 1 was whether potential benefits would motivate 
participation in HIV cure-related studies and whether potential risks would deter participation. In 
answering this question, the focus of the baseline (descriptive) analysis was to report on the 
respondents’ assessments of whether individually named risks would deter their participation, and 
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whether individually named benefits would motivate their participation in HIV cure-related studies. 
The greater the proportion of respondents indicating that a specific benefit would motivate them or 
a risk would deter them, the stronger the likelihood that the specific benefit or risk applied to 
potential HIV cure study participants with similar characteristics to the sample population. 
Comparison between the different types of benefits and risks revealed that potential HIV cure study 
participants more greatly valued certain types of benefits or disliked or feared certain types of risks. 
The results of these comparisons can inform Principal Investigators and/or implementers of HIV 
cure-related studies on the types of benefits and risks they should focus their attention on in order 
to maximize the willingness of eligible potential HIV-positive volunteers to participate in HIV cure-
related studies.  
Because primary data from potential HIV cure studies are rare, the descriptive statistics 
obtained from this survey provide a rare glimpse at their attitudes and perceptions, and can be very 
informative to researchers and policy-makers in designing and recruiting for HIV cure studies in the 
future. I summarized the key results from the descriptive statistics, drawing attention to particular 
results that revealed important findings.  
Bivariate and Multivariate Quantitative Analysis  
To more fully understand HIV-positive patients’ willingness to participate in HIV cure-related 
studies and their attitude towards potential benefits and potential risks of participation, I conducted 
bivariate and multivariate analyses on the survey responses to test a series of hypotheses. The 
hypotheses were formulated to identify associations between respondents’ perceptions of specific 
benefits and risks and their willingness to participate in HIV cure-related studies, helping to fulfill the 
primary research question in aim 1. Another set of hypotheses was tested to answer secondary 
research questions in aim 1: specifically, how do certain socio-demographic characteristics and 
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global attitudes of HIV-positive patients correlate with their willingness to participate in these 
studies?   
First, bivariate association analysis was conducted to test whether people who were very 
willing to participate in HIV cure studies (as measured by their indication that they would participate 
in any and all of the 14 types of studies listed) have certain perceptions regarding potential benefits 
and potential risks, and have specific socio-demographic characteristics. The bivariate association 
analysis illuminated possible strong and weak correlations and helped inform the structure of the 
multivariate models. Second, multivariate regression models were used to estimate the effects of 
perceptions regarding benefits, risks and characteristics of people on their willingness to participate 
in HIV cure-related studies, controlling for extraneous factors. 
To prepare the survey data for the bivariate and multivariate analyses, I generated new 
variables by combining responses from different variables, which allowed me to include important 
variables in my models that could otherwise be discarded. For instance, I created a continuous 
variable that approximated the percent of the person’s lifetime in which s/he was diagnosed as HIV-
positive. This was created by calculating the number of years since their HIV-positive diagnosis (by 
subtracting the year of diagnosis from 2015) and dividing by the age of the respondent. The higher 
the percentage, the more of that person’s lifetime was spent with an HIV-positive status. This 
composite variable was strongly correlated with willingness to participate in HIV cure-related 
studies, as described in the Results section.  
I also restructured some variables by aggregating their categorical or ordinal answers into 
fewer options based on their response rates and the variability within each question. For example, 
several people chose “Other” in responding to the question of educational attainment, and wrote in 
that they completed a few years of college but did not complete a degree. I recharacterized those 
responses as “Some college” and aggregated the results with “Associate degree” to indicate that the 
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respondent attended college but did not complete a Bachelor’s degree. In the multivariate 
regression analysis, the education variable was restructured in multiple ways and, based on the 
variability of the responses and the best fit to the model,  ultimately ended with three mutually 
exclusive variables indicating whether the respondent completed a graduate degree (Master’s or 
higher), an undergraduate degree (Bachelor’s), or neither (Associate’s, G.E.D., high school, or lower). 
The response rate for all of the key questions were relatively high; at least 350 people 
answered questions about their perceptions of perceived risks, and even more answered questions 
on perceptions of perceived benefits (around 380) and on their characteristics (nearly all 400 
respondents). Because the response rate was high for the dependent variables and key independent 
variables, none of the variables were dropped because of a lack of response. 
For a few categorical and ordinal variables, the responses were not sufficiently variable, with 
more than 90% of the respondents selecting the same answer. However, there were at least 5 
individuals who responded differently than the majority, and thus there were always some variation 
in the responses, even if the variation was small. I tested the bivariate correlations between these 
variables and the dependent variable (willingness to participate in HIV cure-related studies) to 
determine whether the small minorities had significantly different levels of willingness to participate 
in HIV cure-related studies. If the correlation was statistically significant at the 95% level, I included 
the variable in the multivariate models. However, if the bivariate correlation between the variable 
with low variation and willingness to participate was not statistically significant, I excluded that 
variable from the multivariate models because of lack of variability and in order to improve the 
efficiency of my models. I used robust standard errors in all bivariate and multivariate analyses.  
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a) Bivariate Association Analysis 
Bivariate association analysis was used to test correlations between specific sets of 
perceptions of potential benefits and risks, and socio-demographic characteristics and global 
attitudes of potential HIV-positive volunteers on their willingness to participate in HIV cure-related 
studies. The dependent variable was whether the respondent was willing to participate in all 14 
types of HIV cure-related studies that were listed in the survey (very willing to participate) or was 
willing to participate in none/some but not all of the types of studies listed (relatively less willing to 
participate). The dependent variable was dichotomous, with 26% of the survey respondents in the 
very willing category (value of 1) and the remainder in the relatively less willing to participate 
category (value of 0).  
The independent variables were either interval (continuous), ordinal or categorical. Each of 
the 21 potential personal, personal clinical and social benefits variables were reclassified as binary 
variables. The binary variables indicated whether the respondent claimed the potential benefit was 
a “very important” factor to his/her motivation in considering to participate in HIV cure studies 
(value of 1), versus “somewhat important”, “barely important” or “not important” (all value of 0). All 
“Don’t know/Not applicable” answers were treated as null. Likewise, each of the 35 potential 
personal, personal clinical and social risk variables were reclassified as binary variables. The binary 
variables indicated whether the respondent claimed the risk is a “very likely to discourage” them 
from considering to participate in HIV cure studies (value of 1), versus “somewhat likely”, “barely 
likely” or “not likely” (all value of 0). All “Don’t know/Not sure” answers were treated as null 
responses. 
I tested for independence between the dependent variable on willingness to participate and 
each of the independent variables, one at a time, using univariate logistic regression analysis. 
Univariate logistic regressions were used to test the bivariate associations instead of using chi-
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squared tests, even for paired categorical variables, because univariate logistic regressions 
quantifies the odds ratio for each category in the independent variable. The odds ratio indicates the 
direction and magnitude of the association of the independent variable with the dependent variable 
(willingness to participate), whereas chi-squared tests would only reveal whether the variables are 
independent. The odds ratios for the different categorical values for each of the variables is 
summarized in the Results section, along with the p-value for the test of independence of each 
independent variable and the dependent variable. Data were analyzed using Stata 11.2. 
In these tests, the null hypothesis was that the perception of benefit, perception of risk, 
socio-demographic characteristic or global attitude of the respondent was independent of the 
respondent’s willingness to participate in HIV cure-related studies. The alternative hypotheses were 
that the two variables were associated. If the resulting univariate logistic regression test statistic 
was small and produced a p-value less than or equal to 0.05, given the degrees of freedom for the 
paired variables, the null hypothesis was rejected and an association between the two variables was 
established.  
In particular, the following series of null hypotheses were tested. All of the following null 
hypotheses took on the form of testing whether potential HIV-positive volunteers who were “very 
willing to participate” in HIV cure-related studies had certain perceptions or characteristics that 
were statistically different from potential HIV-positive volunteers who were “relatively less willing” 
to participate in HIV cure-related studies: 
1. Ho: Willingness to participate in all types of HIV cure-related studies (very willing to 
participate) is independent of whether the respondent believes that a specific potential 
benefit would be “very important” in motivating them to consider participating in HIV cure 
studies. 
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 This null hypothesis was repeated for every individual potential benefit asked about in 
the survey. Rejecting the null hypothesis and having a positive association (i.e. an odds 
ratio greater than 1.0) would indicate that the respondents who are very willing to 
participate in HIV cure-related studies find that particular potential benefit to be a 
strong motivator for participation; more so than respondents who were relatively less 
willing to participate in HIV cure-related studies.  
2. Ho: Willingness to participate in all types of HIV cure-related studies (very willing to 
participate) is independent of whether the respondent believes that a specific potential risk 
would “very likely discourage” them from considering participating in HIV cure studies. 
 This null hypothesis was repeated for every individual potential risk asked about in the 
survey. Rejecting the null hypothesis and having a negative association (i.e. an odds 
ratio less than 1.0) would indicate that the respondents who are relatively less willing to 
participate in HIV cure-related studies find that particular potential risk to be a strong 
deterrent for participation; more so than respondents who are very willing to 
participate in all HIV cure-related studies.  
 Results from the tests of independence listed above could inform Principal Investigators 
or implementors of HIV cure-related studies about which benefits the potential HIV-
positive volunteers that are more willing to participate in HIV cure-related studies cared 
about. Focusing on the needs of the potential volutneers who are very willing to 
participate could possibly narrow the scope of variables the Principal Investigators or 
implementers should pay attention to in preparing their HIV cure-related studies for 
patient recruitment. 
 Additionally, the results would reveal which risks are more strongly associated with a 
reduced willingness to participate in HIV cure-related studies. If Principal Investigators 
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or implementers are seeking to increase study enrollment by enlisting volunteers who 
are less willing to participate in studies, they should focus their attention in mitigating 
these specific potential risks from their studies.  
 Following these analyses, univariate logistic regressions were used to determine 
whether certain socio-demographic characteristics and attitudes of respondents were 
associated with their willingness to participate in HIV cure-related studies, answering 
secondary research questions in aim 1. In particular, the following null hypotheses were 
tested, with the alternative hypotheses being that the two variables were associated: 
3. Ho: Willingness to participate in all types of HIV cure-related studies (very willing to 
participate) is independent of each socio-demographic characteristic and global attitude of 
the respondent towards HIV cure-related research.  
 This null hypothesis was repeated for every socio-demographic variable and global 
attitude question asked about in the survey, including: gender, age, ethnicity, education, 
income, location, self-assessments of health status and whether respondent is in control 
of their own health, duration of HIV status, history of participation or volunteering for 
HIV treatment or HIV cure studies, and whether the respondent is generally interested 
in HIV cure research. Rejecting the null hypothesis would indicate that there was an 
association between the respondent characteristic variable and their willingness to 
participate in HIV cure-related studies. An odds ratio greater than 1.0 would reveal that 
there is a positive association between the characteristic variable and strong willingness 
to participate in HIV cure-related studies, while an odds ratio less than 1.0 would reveal 
that respondents with this characteristic are less willing to participate in HIV cure-
related studies. This information might help Principal Investigators or implementers 
target who to recruit for HIV cure-related studies, all else being equal.  
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b) Multivariate Regression Analysis 
Bivariate association analyses established which potential benefits and potential risks were 
associated with respondents’ willingness to participate in HIV cure-related studies. These 
associations, however, may have been indirect and bivariate analyses did not control for 
simultaneous effects on the relationship between socio-demographic characteristics, potential 
benefit and potential risk factors, and willingness to participate in HIV cure-related studies. Due to 
the convenient sampling of survey respondents, it is unlikely that the survey responses were 
statistically representative of the universe of potential HIV cure research volunteers, which would go 
beyond people who are aware of HIV cure-related studies and connected to HIV cure listservs and 
networks to include all people living with HIV in the United states who would meet 
inclusion/exclusion criteria of studies and actually enter studies. Thus, it is important to control for 
respondents’ socio-demographic characteristics and attitudes in multivariate regression analyses in 
order to test the correlation between potential benefit and potential risk factors and willingness to 
participate in studies independent of extraneous factors. 
Cross-sectional multivariate logistic regression models were used to answer the primary 
research question in aim 1, which was whether potential benefits motivates participation in HIV 
cure-related studies and whether potential risks deters participation, controlling for extraneous 
factors. Multiple regression models are run to test each key independent variables’ association with 
willingness to participate. I used STATA statistical software to estimate the logistic regression 
models. All of the logistic models take on the general form of: 
ln(WTPi / (1 - WTPi )) =  + b Benefitbi + r Riskri + Σ c Controlci  
 i = 1,…,n;  b = 1,…,21;  r = 1,…,35;  c = 1,…,C  [1] 
where ln(WTPi / (1 - WTPi )) is the expected log of the odds that individual i is very willing to 
participate in HIV cure-related studies (versus relatively less willing to participate); Benefitbi is a 
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binary variable indicating whether individual i considers a potential benefit, b, to be “very 
important” to their motivation in considering participating in HIV cure-related studies (versus 
“somewhat important”, “barely important”, or “not important”); Riskri is a binary variable indicating 
whether individual i considers a potential risk, r, to be “very likely” to discourage them from 
considering participating in HIV cure-related studies (versus “somewhat likely”, “barely likely”, or 
“not likely”); Controlci is a vector of control variables that include individual-specific characteristics 
on gender, age, ethnicity, education, income, location, self-assessments of health status and 
whether respondent is in control of their own health, duration of HIV status, history of participation 
or volunteering for HIV treatment or HIV cure studies, and whether the respondent is generally 
interested in HIV cure research; and α is the model’s baseline constant. Robust standard errors are 
estimated in all of the models, to control for potential heteroskedasticity.  
The multivariate models were estimated in the following three stages: 
1) Multivariate logistic model involving only the control variables 
As a first step, the participant’s willingness to participate in HIV cure-related research was 
regressed on only the individual-level socio-demographic characteristics and global attitudes 
towards HIV cure research, which were used as control variables in Equation 1. Benefits and risks 
were excluded from this model. By including only the control variables, this model revealed which 
individual-level characteristics were more strongly associated with willingness to participate in HIV 
cure-related studies.  






 Household income 
 Region of the country 
 Whether the participant considered themselves to be “not at all healthy” or “not very 
healthy” 
 Whether the participant believed they could control their own health care 
 Whether the participant was taking medications for HIV 
 Percent of life living with an HIV-positive status 
 Whether the participant ever volunteered for an HIV treatment or an HIV cure study and 
 The participant’s general interest level in HIV cure-related research. 
Several models were iteratively fitted to test the association between willingness to 
participate and various combinations and constructs of the control variables listed above, in order to 
determine the best possible combination and construct of control variables that best fit the data. At 
first, a full model involving all of the variables listed above was estimated (unrestricted model). 
Then, a second model was estimated by dropping one or more of the control variables, or 
aggregating dummy variables to reduce the number of categories in a categorical variable (restricted 
model), using the exact same sample that was used in estimating the unrestricted model. A 
Likelihood-Ratio test was conducted to test the statistical significance of the difference in the model 
fits. The null hypothesis is that the model fit of the restricted model is the same as the model fit of 
the unrestricted model. If the p-value of the Likelihood-Ratio test was 0.05 or lower, the null 
hypothesis is rejected, and the unrestricted model is preferred over the restricted model, because 
variables that were dropped or transformed in the restricted model were significant and better 
predicted willingness to participate than by being omitted or reduced. On the other hand, if the p-
value was 0.06 or higher, the null hypothesis is not rejected and the restricted model is preferred 
over the unrestricted model, in order to produce the most efficient number and constructs of 
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control variables possible. In models in which variables were transformed, some of the variables 
(e.g. education, self-assessment on their health status) were tested in ordinal forms as well as 
dichotomous forms, while some categorical variables (e.g. education, gender) were transformed 
into various combinations of aggregated dummy variables in some models. The process of 
estimating and testing nested models was repeated until each of the control variables is tested. 
Finally, alternative constructs for some control variables were also tested and the version of the 
construct that produced a better fit (lower p-value) was judged to be superior and used in 
subsequent models. For example, age produced a better fit as a continuous variable (p-value = 
0.018) than as a categorical variable that divides age into five age groups (p-value of the F-test for all 
age group categories = 0.322).  
At the conclusion of these iterative model estimations and tests, a final set of control 
variables and their constructs was determined as the superior combination of control variables that 
best fit the data with willingness to participate as the dependent variable. These specific control 
variables are described in Equation 2 below, and are used in all subsequent models that introduce 
key independent variables.  
Model 1: 
ln(WTPi / (1 - WTPi )) =   + c1 malei + c2 agei + c3 africanamericani + c4 hispanici + c5 
otherethnicityi + 
c6 bachelorsi + c7 graduatedegreei + c8 income25-50ki + c9 income51-75ki + c10 
income76-100ki + c11 income101-125ki + c12 income126-150ki + c13 income151-ki + c14 
northeasti + c15 midwesti + c16 southi + c17 nothealthyi + c18 controlhealthcarei + c19 
percentlifewithHIVi + c20 volunteeredcurestudyi  [2] 
where: 
 malei is whether the respondent is male (versus female or transgender) 
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 agei is the age of the respondent as a continuous variable 
 africanamericani, hispanici, and otherethnicityi are mutually exclusive dummy variables 
describing the ethnicity of the respondent (versus causasian) 
 bachelorsi and graduatedegreei are mutually exclusive dummy variables that describe the 
maximum education level attainment of the respondent, either completing a Bachelor’s 
degree or a graduate degree (versus Associate’s degree or some years in college or lower) 
 income25-50ki, income51-75ki, income76-100ki, income101-125ki, income126-150ki, and 
income151-ki are mutually exclusive dummy variables that describe the annual household 
income of the respondent in $25,000 intervals, i.e. between $25,001 and $50,000, between 
$50,001 and $75,000, etc. (versus $0 - $25,000)  
 northeasti, midwesti, and southi are mutually exclusive dummy variables that describe the 
location of the respondent (versus west)  
 nothealthyi is a dummy variable indicating whether the respondent self-assessed their 
health status as “not at all healthy” or “not very healthy” (versus “very healthy”, “healthy” 
or “somewhat healthy”) 
 controlhealthcarei is a dummy variable indicating whether the respondent felt they have 
control over their own health care 
 percentlifewithHIVi is the percent of the respondent’s life that was lived with an HIV-
positive diagnosis, as a continuous variable ranging from 1 to 100  
 volunteeredcurestudyi is a dummy variable indicating whether the respondent had ever 
been in or volunteered for an HIV cure study  
The variables measuring whether the respondent is currently taking HIV medication, 
whether the respondent ever volunteered for an HIV treatment study, and whether the respondent 
was generally interested in HIV cure research were omitted because of lack of variation within 
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responses, poor explanatory power of the variable, and/or perfect correlation with willingness to 
participate in HIV cure studies. There were only two respondents who were not currently taking HIV 
medication who were part of the “very willing to participate” group, limiting the variation within 
responses. All five respondents who indicated they were not generally interested in HIV cure 
research were part of the “less willing to participate” group of respondents. Whether a respondent 
volunteered for an HIV treatment study and HIV cure study in the past was perfectly correlated (all 
who volunteered for HIV cure studies in the past had also volunteered for HIV treatment studies, 
and all who never volunteered for HIV treatment studies also never volunteered for HIV cure 
studies). Thus, only one of the two variables should be included a control variable in Model 1, to 
prevent multicollinearity, and the variable volunteeredcurestudy was selected on the basis of a 
stronger correlation with willingness to participate in HIV cure-related studies as determined by the 
bivariate association analysis.  
By estimating Model 1 using a logistic regression model, the coefficients estimated the odds 
ratios of willingness to participate for each socio-demographic variable, controlling for all other 
variables. Whether the odds ratio estimates were greater than or less than 1 indicated whether 
participants with those characteristics were more likely or less likely, respectively, to be very willing 
to participate (in all types of HIV cure-related studies). I tested the statistical significance of the odds 
ratio of each socio-demographic variable against the null hypothesis that the odds ratio was equal to 
1.0 and the alternative hypothesis that it was not equal to 1.0. If the p-value was 0.05 or lower, 
statistical association was established, revealing the socio-demographic characteristics that were 
statistically associated with willingness to participate in HIV cure-related studies. This information 
reveals to Principal Investigators or implementers whether people living with HIV who have specific 
characteristics (e.g. gender, age, lifetime living with HIV diagnosis, etc.) are more or less willing, on 
average, to participate in HIV cure-related studies, which is vital information for improving 
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recruitment for studies. The odds ratio for the control variables listed in Model 1 is reported in the 
Results section, alongside its 95% confidence interval and p-value.  
2) Multivariate logistic models involving a single potential benefit or single potential risk as the 
key independent variable 
Although the general form of the model shown in Equation 1 lists both benefit and risk 
variables in the same equation, only one potential benefit or potential risk is included in the model 
at a time. The logistic regression model is fitted multiple times, each time using a different potential 
benefit or potential risk variable in the model as the sole key independent variable. Thus, none of 
the regression models included multiple potential benefit variables or multiple potential risk 
variables, or mixed potential benefit and potential risk variables in the same model. This was 
necessary for two reasons: 
1) Many potential benefit variables and potential risk variables were very strongly correlated 
with one another. Including multiple variables that were strongly correlated in a regression 
model introduced multicollinearity to the model, making it difficult to assess the effect of 
the key independent variables of interest on willingness to participate. Additionally, because 
of a lack of variation across different benefit and risk variables (due to the strong 
correlations between pairs and groups of benefit and risk variables), adding multiple benefit 
and risk variables in the same model creates perfect collinearity with the dependent 
variable, eliminating the use of the independent variables that created perfect predictions. 
For example, when all 35 potential risk factors were included simultaneously in Equation 1, 
eight of the 35 potential risk variables were dropped from the regression because each one 
predicts failure perfectly, controlling for all other variables. 
2) More importantly, the purpose of this analysis was to determine whether respondents’ 
perceptions of individual potential benefits and individual potential risks were associated 
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with their willingness to participate in HIV cure-related studies, controlling for extraneous 
factors. The extraneous factors, in this case, were socio-demographic characteristics and 
global attitudes towards HIV cure research. It is not the intention of this analysis to 
determine the association between willingness to participate and perceptions on potential 
benefits and potential risks, controlling for perceptions of other potential benefits and 
potential risks. Interpretation of these results would be difficult, and nearly impossible to 
translate into actionable items for Principal Investigators or implementers. For example, a 
regression model that includes multiple potential benefit variables might reveal that, 
controlling for socio-demographic characteristics, individuals that perceive “helping find a 
cure for HIV” as a very important motivating factor are associated with higher willingness to 
participate in HIV cure-related studies, controlling for their perception on the motivating 
importance of “contributing to scientific knowledge,” “helping other people with HIV in the 
future,” “being compensated for study participation,” “receiving more regular access to 
medical researchers” and “controling the viral load in absence of treatment,” 
simulataneously. The interpretation of the key association (between helping find a cure for 
HIV and willingness to participate) is obscured when attempting to understand the multiple 
layers of other perceptions that are controlled for simultaneously, some of which are also 
correlated with the key independent variable. Instead, by only including one key 
independent variable in the regression model at a time, controlling only for socio-
demographic characteristics and global attitudes of the respondent towards HIV cure 
research, it was possible to identify which perceptions of potential benefits and potential 
risks were associated with willingness to participate. This allowed translating the results into 
recommendations on which benefits and risks Principal Investigators or implementers 
should focus on while recruiting and enrolling potential HIV cure research volunteers.  
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Since the dependent variable is a binary variable, we estimated logistic regression models.  
The coefficients b, r, and c estimated the odds ratio of willingness to participate 
perceiving a potential benefit b as a very important motivator, perceiving potential risk r as very 
likely to discourage participation, and socio-demographic characteristic c, respectively, controlling 
for all other variables. Whether the odds ratio estimates were greater than or less than 1 indicated 
whether participants with those specific perceptions were more likely or less likely, respectively, to 
be very willing to participate (in all types of HIV cure-related studies). For example, an odds ratio 
estimate of 1.5 indicated that participants perceiving a potential benefit b as a “very important” 
motivating factor to considering participating in HIV cure-related studies was associated with a 50% 
greater likelihood that they are willing to participate in all 14 types of studies than others who did 
not perceive that benefit b is a “very important” motivating factor, ceteris paribus.  
After a logistic model is estimated, the statistical significance of the odds ratio of the key 
independent variable is tested. The null hypothesis is that the odds ratio is equal to 1.0, and the 
alternative hypothesis was that it was not equal to 1.0, thus using a two-tailed test. If the p-value 
was 0.05 or lower, statistical association was established, revealing the potential benefits and 
potential risks that were statistically associated with willingness or unwillingness to participate, 
controlling for socio-demographic characteristics and individuals’ global attitudes towards HIV cure 
research. The odds ratio for the key independent variable in each model is reported in the Results 
section, alongside its 95% confidence interval and p-value.  
I tested the hypothesis that the odds ratio estimates for the potential benefit variables, βb, 
would be greater than 1.0, indicating that there was a positive correlation between perceiving a 
specific potential benefit as a “very important” motivating factor and a person’s willingness to 
participate in all types of HIV cure-related studies. Likewise, I test the hypothesis that the odds ratio 
estimates for the potential risk variables, βr, would be less than 1.0, indicating that individuals who 
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perceive a specific potential risk as “very likely to discourage” them from considering participation in 
HIV cure-related studies are less likely to be willing to participate in studies.  
Specific potential benefits and potential risks that were statistically associated with 
willingness to participate in HIV cure-related studies were noted and discussed. Unfortunately, it 
was very difficult to infer causality solely using cross-sectional regression models. Collecting 
longitudinal data among actual study participants was beyond the scope of my research, however. 
The results of my logistic models can be used to detect and explore associations between 
perceptions of benefits/risks and willingness to participate in HIV cure-related studies, but not to 
infer causality.  
3) Multivariate logistic models involving the number of potential benefits perceived as very 
important motivating factors and the number of potential risks perceived to be very likely to 
discourage participation as the key independent variables 
In addition to estimating several multivariate models using perception of a potential benefit 
or potential risk as the sole key independent variable in the model, I also estimated multivariate 
logistic regression models that used the total number of potential benefits (or grouped benefits) 
that were deemed to be “very important” motivating factors, and the total number of potential risks 
(or grouped risks) that were deemed to be “very likely” to discourage participation as the key 
independent variables, controlling for socio-demographic charactertistics and global attitude 
towards HIV cure research. Thus, a new model is estimated as follows: 
ln(WTPi / (1 - WTPi )) =  + m NBi + n NRi + Σ c Controlci      i = 1,…,n;  c = 1,…,C    [3] 
where NBi is the tally of potential benefits that individual i perceives to be “very important” 
motivating factors to considering participating in HIV cure-related studies; NRi is the tally of 
potential risks that individual i perceives to be “very likely” to discourage them from considering 
participating in HIV cure-related studies; Controlci is the same vector of control variables estimated 
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in Equation 1; and α is the model’s baseline constant. Robust standard errors are estimated in all of 
the models, to control for potential heteroskedasticity.  
The greater the number NBi, the more potential benefits an individual considers to be very 
important as motivating factors. This may reveal a larger sense of optimism and hope inherent in 
the individual considering participation in HIV cure-related studies. Conversely, the greater the 
number NRi, the more potential risks an individual considers to be very likely to discourage them 
from participating in HIV cure-related studies. In other words, the more potential risks and problems 
the individual perceives as obstacles to participating in HIV cure-related studies. 
In this model, the coefficients m and n estimated the odds ratio of willingness to 
participate for each additional potential benefit that was perceived to be a “very important” 
motivating factor and for each additional potential risk that was perceived to be “very likely” to 
discourage participation, on average and ceteris paribus. I tested the hypothesis that the odds ratio 
estimate for βm would be greater than 1.0, indicating that a respondent that identifies more 
potential benefits as “very important” in their motivation to consider participating in HIV cure-
related studies was more likely to very willing to participate in studies. I also tested the hypothesis 
that the odds ratio estimate for βn would be less than 1.0, indicating that a respondent that 
identifies more potential risks as “very likely to discourage” them from considering participating in 
HIV cure-related studies was less likely to very willing to participate in studies (or, more accurately, 
was more likely to have a lower willingness to participate in HIV cure-related studies, for fear of 
multiple potential risks). 
Presentation of Quantitative Results 
Results from the baseline descriptive data analysis were tabulated and illustrated using 
charts and histograms (see Results section for details). The results of the bivariate analyses were 
presented in the form of tables that listed the categories of each categorical variable, the sample 
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size within each category and the binary dependent variable of willingness to participate, the odds 
ratio of willingness to participate and its 95% confidence interval for each category, and the p-value 
for the odds ratio. Continuous variables, such as age and percent of life living with HIV diagnosis, are 
presented in these tables as continuous variables as well as categorical variables that split the 
sample size across a few categories.  Finally, the results of the multivariate logistics regression 
models were presented in tables that listed the key independent variables and control variables’ 
odds ratio estimates, their 95% confidence intervals, and p-values. Because 56 models were 
estimated using individual potential benefits (21 models) and potential risks (35 models) as the sole 
key independent variables in the regression model, to be succinct, I only presented the odds ratio, 
95% confidence interval and p-value for the key independent variable in each of the models, and not 
for the control variables, although the full set of control variables from Model 1 were also included 
in the 56 models with key independent variables. 
All p-values that were 0.05 or lower were denoted using asterixes.  
I provided a narrative explanation of the variables under analysis, and the interpretations of 
the bivariate association and multivariate regression analyses, noting which variables were 
statistically significantly correlated with willingness to participate in HIV cure-related studies, 
controlling for socio-demographic characteristics. The hypothesis that risk factors were negatively 
associated with willingness to participate in HIV cure-related studies (hence they deterred 
participation), and benefit factors were positively associated with willingness to participate (hence 
they motivated participation) were tested and summarized. Where tests of significance either 
confirmed or rejected my hypotheses, I noted them in the narrative whenever possible.  
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Qualitative Data Management and Analysis: Key Informant Interviews13  
The information obtained from the key informant interviews was qualitative in nature. 
Qualitative data allowed me to explore the meanings and depths behind reasons to want or refuse 
to participate in HIV cure-related studies, as well as perceptions around risks and benefits of 
participation and practical challenges to implement HIV cure-related studies.  
Qualitative Data Management 
For the qualitative data, the units of analysis were patient-participants who were living with 
HIV, clinician-researchers, and policy-makers (regulators), broadly defined. Each key informant 
interview was assigned a unique identification number. Key informant interviews with patient-
participants were assigned number 101 and above; with researchers/clinicians 201 and above and 
with policy-makers (regulators) 301 and above. Most key informant interviews, contingent upon 
receiving permission from study participants, were digitally recorded for the purpose of 
transcription. I performed transcriptions verbatim and as soon as possible following each interview 
to augment accuracy of the transcripts (or took detailed notes and rewrote them immediately 
afterwards when study participants refused to be recorded). Furthermore, I personally verified each 
transcript against the corresponding audio recording and kept a journal to record reflections and 
notes following each interview. I typed all transcripts in Word processing documents, using a key 
informant interview worksheet.  
I employed the following steps to perform qualitative data analysis from the key informant 
interviews:14 
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1. Generate and read raw data (transcripts and field notes) 
2. Organize and prepare data for analysis  
3. Read through all the data   
4. Code the data (manually)   
5. Organize themes and descriptions    
6. Identify interrelationships between themes     





Figure 5. Flow of Qualitative Data Analysis (Adapted from Creswell, Chapter 9, Qualitative Methods, p. 197) 
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Since “[b]eing there is best” [45], I was present for all the key informant interviews. I also 
personally transcribed all interviews to ensure accuracy of the data. These provisions ultimately 
improved analysis since they allowed me to have a very “extensive experience with the data” [45]. I 
performed the transcribed-based content analysis either manually using a low-cost and low-
technology option, also referred to as the “classic analysis strategy” [45]. Manual qualitative data 
analysis included the long-table approach in Word, combined with a color-coding technique, to 
derive key themes. I devised a numbering system in order to retrieve key quotes efficiently and to 
identify the data source as needed.  
Qualitative Data Analysis 
The qualitative data analysis was situated at the juncture between phenomenology and 
grounded theory [42]. In fact, I was most inspired by the phenomenological approach, which sought 
to understand the lived experiences of individuals and capture the essence of a phenomenon. 
Furthermore, phenomenology focuses on the analysis of significant statements, the generation of 
meaningful text units and the creation of an essence description [42]. Grounded theory further 
informed my qualitative data analysis, as I sought to understand the realities grounded in the views 
of the study participants [42].  
The coding process was a key step in the qualitative data analysis process. Codes have been 
referred to in the literature as “themes,” “categories,” “labels,” “thematic units,” “concepts” and 
“tags” [46], among others. Codes serve to ascribe meaning to the descriptive information obtained 
during key informant interviews and to categorize the inferential data obtained during the study. 
During the analysis phase, I assigned themes or codes to “chunks of data, usually phrases, sentences 
or paragraphs that [were] connected to a specific context or setting” [46]. I characterized 
participants’ verbatim statements according to thematic content. The interpretative approach used 
was both deductive and inductive. I used a combination of a priori (or existing, pre-determined) 
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codes and data-driven (or emergent, latent) codes [42] [46]. Code development and ascertainment 
was an iterative process during the qualitative data analysis. These key informant interview topics 
served as headings in the qualitative findings section of my dissertation. They also helped drive the 
plan for change, leadership and implementation.  Each central theme was extrapolated using related 
sub-themes.   
Furthermore, I developed simple a priori codebook that contained three components: code 
name, description and an example [46] (not shown). The final qualitative data analysis narrative 
includes the synthesis of a priori codes as well as the synthesis of data-driven, emergent codes. The 
qualitative data analysis used mainly an inductive approach, during which themes were revealed. In 
this sense,  I aspired to “build (…) patterns, categories and themes from the bottom up by organizing 
the data into increasingly more abstract units of information” [42]. The inductive method thus 
required a conscientious back and forth between the themes and the dataset until I had identified 
the core themes. I then used a more deductive approach to re-examine the data and assess whether 
there was evidence to support the key themes [42]. Thus, both induction and deduction played a 
role in the qualitative data analysis. Codes and their descriptions were iteratively developed, 
compared and assessed throughout the study.  
Main techniques for identifying themes and sub-themes included: repetitions, uses of 
transitions, similarities and differences, omissions/pauses, apparent importance/significance and 
metaphors/analogies [47]. Other possible methods included frequency of themes, specificity, 
emotions of participants and extensiveness of coverage [45]. I paid attention to dominant patterns 
in the speech, but also to “unique or rare events that [had] major consequences” [45]. While “[n]ot 
everything [was] worthy of analysis,” [45] I focused on sections of the discourse that had the highest 
salience and relevance. I supplemented the transcript-based analysis with my field notes. Finally, I 
embraced the process of coding as an opportunity for the data to be 1) reduced and simplified; 2) 
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expanded (via linkages between concepts); 3) transformed (via conversion into meaningful units) 
and 4) re-conceptualized (via redefinition of conceptual framework) [46]. 
Presentation of Qualitative Data and Interpretation of Results  
While I used the themes to answer the main research questions, I also strived to “honor the 
worldview of informants” [48].  I presented the qualitative findings in a narrative format and used 
adjunct visuals, such as tables, to complement the discussion, and these emerged logically and 
organically from the data. Each core theme has a narrative summary, supported by careful selection 
of quotations and specific evidence and endorsements. I also highlighted expected and unexpected 
findings and lessons learned whenever possible.  
Reliability and Validity  
As described above, I conducted the coding of the data and performed all the transcriptions 
in order to ensure consistency and validity during the analysis. I also asked my co-investigator to 
review the main themes and descriptions for congruity on a periodic basis. I used peer debriefing 
during the study to enhance the accuracy of the accounts. While there was no ultimate proof of 
validity and reliability, I attempted to maximize them via a diligent effort at a systematic and 
meticulous analysis of the data. Qualitative data analysis and the selection of key themes required 
judgments on my part. I was partial in that I wished to derive recommendations to ensure the 
ethical and effective implementation of HIV cure-related studies, and to ensure that the voices of 
the patient-participants were adequately and conscientiously represented.   
Comparison between Quantitative and Qualitative Study Results  
Both quantitative and qualitative study results, taken together, provided evidence as to the 
factors that would either facilitate or deter participation in and affect implementation of HIV cure-
related studies. Qualitative findings revealed barriers or facilitators to participation that were not 
previously considered in the quantitative survey.  Following the quantitative and qualitative results 
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sections, I wrote a discussion section inspired from my review of the literature to explore where 
themes agreed or diverged. The discussion section also highlights the implications of the study 
findings as well as the opportunities and barriers to implementation, change and leadership. I used 
the key themes to inform my plan for change, as well as discussions, practice and possible policies 
affecting the participation of potential HIV-positive volunteers in cure-related studies and the 
implementation of studies in general.  I focused on creating added value and identified the 
questions that required further research and inquiry, as well as new and emerging priorities for the 
field. I endeavored to determine how the data were actionable and focused on the areas of 
influence that were under my control. I also separated the study results from the recommendations 
that could be derived from them.  
 
 76 
CHAPTER 4 | QUANTITATIVE SURVEY RESULTS  
The quantitative survey results are presented in three sections, with key findings 
summarized after each section:  
 In the first section, descriptive statistics from the sample of 400 survey respondents are 
presented. Because primary data from potential HIV cure-related studies are rare, the 
descriptive statistics obtained from this survey provide a rare glimpse at their attitudes and 
perceptions, and can be very informative to clinician-researchers and policy-makers in designing 
and recruiting for HIV cure studies in the future. Below, I summarized the key results from the 
descriptive statistics, drawing attention to particular results that revealed important findings. 
 In the second section, bivariate associations of various factors with respondents’ willingness to 
participate – the dependent variable – are presented. The statistical significance and magnitude 
of the bivariate associations between respondents’ willingness to participate in all types of HIV 
cure-related studies and their perceptions of the importance of potential benefits in motivating 
their participation, their perceptions of the likelihood that certain potential risks could deter 
their participation, and their socio-demographic characteristics and global attitudes towards HIV 
cure research are examined. 
 In the third section, I presented the results of the multivariate regression analyses. The 
statistical significance and magnitude of the associations between willingness to participate and 
the respondents’ perceptions of the importance of each potential benefit and potential risk are 




Table 3. Survey Sample Size 
Survey responses Number 
Respondents who completed the survey 343 
Respondents who partially completed the survey (at least through the 
question of willingness to participate in HIV cure studies) 
57 
Respondents identifying they are ineligible to participate in the survey 9 
Total survey responses 409 
Total survey responses included in the analysis 400 
After excluding five survey responses because of incompleteness of the responses, we 
recruited 409 study participants, of which 400 were eligible for the study and thus included in the 
analysis (Table 3). Of those, 343 respondents completed the survey by answering all questions and 
57 partially completed the survey, but answered at least one question of interest regarding HIV cure 
research. Most questions were answered by more than 350 respondents. We did not make all the 
survey questions mandatory as this might have affected the survey completion and caused 
significant attrition issues.  This was a convenience sample derived from willing respondents who 
had access to HIV treatment/cure listservs from which they were recruited. This sample was not 
representative of the entire community of people living with HIV in the United States. We discuss 
the limitations of the survey further in the Discussion section.  
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Figure 6. Gender of Respondents (n=400) 
The gender of the respondents is represented in Figure 7. We recruited 77% males, 22% 
females and <1% transgendered individuals. One individual selected “other” but did not specify 
his/her gender identification. While this sample is not representative of the population of people 
living with HIV in the United States, it may reflect those who are interested in HIV cure-related 
issues. The sample has proportionally more females than a previous U.S. survey conducted in 2010 – 
2011[49].   
 
Figure 7. Age Group of Respondents (n=400) 
Respondents ranged in ages between 19 and 74 years of age (Figure 8). The average age was 
50 years old and the median was 51 years. The highest proportion of survey respondents were 
between the ages of 46 and 60 years old. This may again reflect those with an interest in HIV cure-
related research in the United States. Younger ages may have been under-represented. The sample 
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derived may reflect the aging population of people living with HIV in the United States and this 
should be kept in mind for future HIV cure study design.  
 
Figure 8. Ethnicity of Respondents (n=400) 
Ethnicity of survey respondents is reflected in Figure 9. We obtained a sample that was 
ethnically diverse: 65% Caucasians/Whites, 17% African-Americans/Blacks, 12% Hispanic/Hispanic 
descent, and 4% mixed. This sample was also proportionally more diverse than the one derived from 
the previously completed U.S. survey on willingness to participate in HIV cure-related studies [49]. 
 
Figure 9. Highest Level of Education Completed (n=399) 
Nearly all survey respondents had at least a high school or GED degree, 6% had some 
college, 20% had an associate degree, 26% had completed an undergraduate degree, 17% had 
completed a master’s degree or its equivalent and 6% had completed a doctorate degree (Figure 
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10). Compared to the previous U.S. survey [49], we were able to recruit respondents who were of 
proportionally lower educational backgrounds. This sample may be slightly more representative of 
the HIV epidemic in the United States, although it may remain biased towards those with greater 
income, who have access to the internet and HIV cure research information. 
 
Figure 10. Yearly Household Income (U.S. Dollars) of Respondents (n=399) 
Yearly household incomes of survey respondents are depicted in Figure 11. More than one-
third (37%) earned less than $25,000 annually and another third (35%) earned more than $50,000 
annually. 
  
Figure 11. Residence of Survey Respondents (n=394) 
6 respondents did not specify their place of residence 
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The map in Figure 12 shows the geographic distribution of the survey respondents. There 
were 38 states represented in the survey. The highest recruiter sites were California (n = 104), 
Florida (n = 26) and New York (n = 22). Outside of the continental United States, two respondents 
were from Puerto Rico. There were 6 respondents did not specify their place of residence. 
 
Figure 12. Self-Reported Health Status of Respondents (n=400) 
 
Figure 13. Respondents’ Feeling of Control over Health Care (n=400) 
Most survey respondents (94%) described themselves as either very healthy, healthy or 
somewhat healthy (Figure 13). This may be because most (98%) of them were also taking HIV 
medication (2% were not taking HIV medication) (data not shown). Most (81%) also indicated that 
they had control over their own health, compared to 14% who did not have control (5% don’t 
know/not sure) (Figure 14).  
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Figure 14. Percentage of Respondents’ Lifetime Living with HIV Diagnosis (n=394) 
 Our survey included respondents who have been diagnosed with HIV for less than a year 
(3%) and up to 36 years. Half of the respondents have lived with an HIV diagnosis for 18 years or 
more. The distribution of years since first diagnosis is mostly uniform between <1 year and 30 years. 
We calculated the percentage of respondents’ lifetime living with an HIV diagnosis by dividing the 
difference between the number of years lived with HIV and the age of the respondents (Figure 15). 
If a respondent was first diagnosed with HIV in 2015, we used 0.5 in the numerator (instead of zero). 
The largest group (47%) had lived with HIV for 26 – 50% of their lifetime, followed with those who 
lived with HIV for up to 25% of their lifetime (37%). A significant minority of respondents (16%) have 
lived with HIV for more than half of their lifetime. 
Volunteering for and participation in previous HIV treatment research was relatively high, at 
44%, compared with 55% who never volunteered to take part in an HIV treatment study (figure not 
shown). Volunteering for a study does not necessarily mean than the respondent actually 
participated in a study, but is indicative of their interest in participating in HIV studies.  
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Figure 15. Respondents have Ever Been in or Volunteered for an HIV Cure Study (n=400) 
In comparison, a smaller proportion of survey respondents had ever volunteered for or 
participated in HIV cure-related studies (7%), compared with 91% who had never volunteered nor 
participated (Figure 16). A total of 6.2% indicated that they actually participated in at least one HIV 
cure study. We did not define “HIV cure research participation” so this figure reflected the 
participants’ own interpretation of HIV cure-related research.  Only 7 out of 400 survey respondents 
were currently enrolled in an HIV cure-related study.  
With regards to general interest in HIV cure research, 97% of respondents said that they 
were interested (versus 1% that answered no) and 95% answered that they were generally 
interested in medical issues (versus 3% that were specifically not interested) (data not shown).  
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Figure 16. Willingness to Consider Participating in HIV Cure-Related Studies 
We asked survey respondents to indicate whether they would consider participating in 14 
different types of HIV cure-related studies (Figure 17). We provided the definitions of these different 
cure strategies in lay terms and used the survey as an educational opportunity. Respondents were 
able to answer “Yes”, “No”, or “Don’t know/not sure” for any and all 14 types of studies, or skip any 
of the questions. The response rate for each of the 14 types was approximately n = 350 – 360 out of 
a possible 400. In addition, we asked a separate question asking if respondents would be willing to 
enroll their infant living with HIV in a pediatric HIV cure-related study, which resulted in a much 
smaller response rate (n=169). For each of the main 14 types of HIV cure-related studies, more than 
50% of those who responded indicated they would be willing to participate in that study type. The 
highest rejection rate was 21% for studies that involve latency reversing agents. For many study 
types, the response rate for “Don’t know/not sure” exceeded the response rate for “No.”  
Willingness to participate may not reflect actual participation in the future, the 
inclusion/exclusion criteria of studies, the geographical availability and the studies that participants 
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would quality for or enter. However, the graph shows the hierarchy of the different kinds of studies 
that potential participants would be explicitly willing to join. Respondents were more willing to 
participate in simple studies (e.g. surveys, basic blood draws, interviews and focus groups) than in 
studies that are seemingly riskiest modalities (e.g. transplanting stem cells, use of latency-reversing 
agents and intensification of HIV treatment). The higher the level of intervention, the lower the 
willingness to participate rate and the greater the rejection rate and the unsure rate are. These data 
may underscore the need to better educate potential volunteers about the different types of HIV 
cure studies and their potential risks. While most studies currently enrolling participants are pilot 
studies with small number of participants, these data should be kept in mind as studies get scaled 
up.   
 
Figure 17. Total Number of Types of HIV Cure-Related Studies respondents are Willing to Consider 
Participating in (n=361) 
A total of 361 respondents answered “Yes” or “No” to being willing to participate in at least 
one of the 14 types of studies (Figure 18). Of the 361 respondents, 26% indicated that they would be 
willing to participate in all 14 types of studies, while the other 74% were willing to participate in 
some (or none) of the studies but not all 14. This makes up the dependent variable in the bivariate 
and multivariate quantitative analysis. Respondents who were willing to participate in all 14 types of 
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studies are defined as “very willing to participate” in HIV cure-related studies, while the other 74% 
are defined as “relatively less willing to participate.” It is important to remember that the relatively 
less willing to participate respondents may be willing to participate in several types of HIV cure-
related studies, but they are simply not yet willing to participate in all types of studies that we asked 
about. In general, nearly half (48%) were willing to participate in at least 12 of the 14 types of 
studies, and only 1% were expressly unwilling to participate in any type of HIV cure-related studies, 
including the lowest risk modalities. 
We compared two sets of questions: considering participation in the different types of HIV 
cure-related studies, given that one had previously participated in a similar (HIV or non-HIV) health 
study in the past (Figure 19). The sample size was too small to make any significant observations or 
comparisons for many types of studies and we should be cautious when interpreting claims based 
on a sample of 2, 3, 4 or 5 people for some of the types of studies (e.g. gene therapy, unique 
antibodies or molecules, latency-reversing agents, therapeutic vaccines or first-in-human studies). 
Nonetheless, based on their prior experience, data show that most participants would be willing to 
participate in HIV cure studies that are similar to studies they had participated in the past. 
Participants are most reluctant, however, to consider participating in future HIV cure-related studies 
that would involve: 1) intensification of treatment, 2) phase II or III studies or 3) focus group 
discussions (red bars in Figure 19 below).  
Using Likert scales, we asked participants to indicate which potential benefits would either 
be very important, somewhat important, barely important or not at all important in their motivation 
to consider participating in HIV cure-related studies. Figure 19 below shows each factor in relation 
to the others, but also shows the relative importance of the “personal benefits,” “clinical benefits” 
and “social benefits” categories compared to each other.  The perceived clinical benefits or social 
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benefits appear to be more important motivators, on average, than personal benefits when 
considered as a category.  
 
Figure 18. Willingness to Consider Participating in HIV Cure-Related Studies after Having 
Previously Participated in Similar (HIV or non-HIV) Health Study in the Past 
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Figure 19. Importance of Factors to Motivate Considering Participating in HIV Cure-Related Studies 
Highlighting specific motivational factors (Figure 20 above), we note that:  
 Although HIV cure studies confer little to no benefit, it is possible that potential study 
participants still perceive the likelihood of benefits when deciding to join studies.  
 The data show that we should not underestimate the importance of emotional and 
mental benefits in HIV cure research participation, since feeling good about contributing 
to HIV cure research is the most popular perceived personal benefit (80% very likely to 
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motivate), and social benefits of helping find a cure for HIV, helping other people with 
HIV in the future and contributing to scientific knowledge were three of the four highest 
ranked benefits overall (95%, 90% and 88% very likely to motivate, respectively).  
 Potential participants value gaining knowledge about their health (78% very likely to 
motivate). This is interesting as most of the research data are not given to the study 
participants individually. This raises questions about the need to communicate study 
data (in the aggregate) and advancements in science to study participants and may 
highlight the importance of clinical contact factors for study participants.  
 Hope that health will improve was also a strong motivating factor. Again, research may 
not confer direct clinical benefits and in fact, there is the possibility of harm when 
advancing medical knowledge. The high rating of this factor underscores the need to 
protect against the risk of therapeutic and curative misconception. 
 There are also perceived potential personal clinical benefits, such as the desire to 
improve one’s immune system. 
 Reducing the HIV reservoir was perceived as a clinical benefit although we know from 
research that a reservoir decrease may not confer any direct clinical benefit. Study 
participants would need a substantial (logs worth) reduction in the size of their proviral 
DNA replication-competent HIV reservoir in order to reduce time to viral rebound. 
Scientists need to be careful how reservoir reductions are discussed in the informed 
consent forms.  
 Compensation in the form of meals, reimbursements and transportation costs were the 
three lowest ranked motivating factors overall.  
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Figure 20. Likelihood of Factors to Discourage Considering Participation in HIV Cure-Related 
Studies  
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In terms of the perceived risks likely to discourage considering participating in HIV cure 
research, personal clinical risks appeared to be more likely to demotivate than personal risks or 
burdens or potential social risks (Figure 21). Activation of genes that would cause cancer (49% very 
likely to discourage) and the possibility of developing resistance to HIV treatment (37% very likely to 
discourage) were the most prevalent deterrents. The need for intense commitment did not appear 
to be strong deterrents of participation. Spinal tap (26% very likely to discourage) and bone marrow 
biopsies (22% very likely to discourage) were the least favorite study procedures. Hair loss (32% very 
likely to discourage) was a stronger possible deterrent than more immediate symptoms/side effects, 
such as vomiting (23%), pain (14%), headache (13%) or nausea (13%). The burden categories reveal 
that we should not underestimate the importance of addressing possible obstacles like 
transportation or parking to encourage participation. Finally, the risk of transmitting HIV to others 
(in the case of an unsuspected viral rebound) was a real possible deterrent (28% very likely to 
discourage), and may speak to the desire of study participants to “do no harm” during their study 
participation.    
 
Figure 21. Willingness to Stop HIV Treatment as Part of an HIV Cure-Related Study (n=359) 
An important feature of some HIV cure research design is the need to interrupt treatment to 
assess time to viral rebound or predictors of rebound. Among the survey respondents, 68% of 
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potential HIV cure research participants were very willing or somewhat willing to stop treatment as 
part of HIV cure research (Figure 22). These numbers are somewhat higher than those obtained in 
the previous U.S. survey, whereas one third (34%) of respondents stated that they would be very 
willing or willing to participate in a study that involved treatment interruption, compared to 34% 
who said that they would be somewhat willing and 32% said that they would not be at all willing 
[49]. These results may reflect the different study sample used or the need to better educate 
potential study participants about the possible risks of treatment interruption.  
 
Figure 22. Importance of Factors in Making a Decision about Considering Participation in an HIV 
Cure-Related Study 
Survey participants rated the importance of various practical factors in making a decision to 
participate in an HIV cure study (Figure 23). The HIV cure research modality being investigated (58%) 
was slightly more important than the research site (56%), the way information was given (55%), the 
Principal Investigator (44%) or the study nurse of the study (32%).  
 93 
 
Figure 23. How would Participants Most Likely Describe Themselves in they were to Participate in 
an HIV Cure-Related Study (n=348) 
Potential HIV cure research volunteers would also prefer to be described as “study 
participants” (44%), “partners in research” (25%) or “volunteers” (10%), as opposed to “research 
subjects” (8%), “patients” (7%) or “guinea pig” (Figure 24). These appellations show the importance 
of treating study participants with respect and to be careful with terms used to describe them and 
are consistent with the qualitative study results.  
 
Figure 24. Personal Beliefs about an HIV Cure 
Furthermore, we asked survey respondents to answer whether they thought they could be 
cured versus whether they hoped they could be cured. The hope of being cured (90% of survey 
respondents) was higher than the expected possibility that one could actually be cured (47% of 
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study respondents). Hope to be cured – now or in the future – may possibly be a strong motivating 
factor in whether to join a study. 
 
Figure 25. How Many Years Do Participants Think it will take to Find a Cure for HIV (n=350) 
We were surprised to find that 8% of participants thought a cure for HIV infection was 
presently in existence (Figure 26). This finding seems incompatible with the fact that our 
convenience sample has regular access to HIV-related information about treatment or cure. The 
majority of survey respondents thought a cure would be available within 5 years (27%) or in 6 – 10 
years (33%). Close to a third (27%) thought a cure would take between 11 – 50 years to be 
discovered. A tiny fraction (3%) thought a cure would never materialize.  
 
Figure 26. What does a Cure Mean to Participants? (n=350) 
 95 
A cure for HIV infection should meet the expectations of the people living with HIV. We thus 
asked the survey respondents to report what a cure meant to them (categories were provided). Not 
transmitting HIV to others (68%), completely eliminating HIV from the body (68%) and no more HIV 
treatment needed (65%) emerged as the three strongest categories, above the practical factors of 
no longer testing positive on the antibody HIV test (31%).  
In summary, key descriptive findings from the survey include:  
 Willingness to participate in HIV cure-related research is high, but may not translate into 
actual research participation. Willingness decreases as the risk of HIV cure-related studies 
increases. Potential study volunteers should be better informed about possible risks of 
studies. 
 Although HIV cure studies confer no expectation of direct benefit, potential volunteers may 
still perceive the likelihood of benefits when deciding to join studies. Emotional, mental and 
psychosocial factors (e.g. feeling good about contributing to the biomedical HIV cure 
research agenda) should not be underestimated.  
 The survey results confirm that a mixture of social altruism and perceived personal benefits 
motivate participation in HIV cure research. Willingness to interrupt HIV treatment as part 
of cure study design remains high.  
 Given that a minority of survey respondents (8%) thought a cure was currently available, 
heightened education efforts are warranted. Possible meanings of an HIV cure should also 
be explored further. 
Bivariate Association Analyses 
The results of the descriptive statistics revealed that 26% of the survey respondents were 
“very willing” to participate in HIV cure-related studies, defined as the group of respondents who 
explicitly indicated that they would be willing to participate in all 14 types of studies proposed in the 
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survey. The remaining 74% of the survey respondents were “relatively less willing to participate” in 
HIV cure-related studies. The survey results also revealed that 21 potential benefits of participating 
in HIV cure studies motivated respondents to varying degrees: as few as 24% of respondents and as 
high as 95% of respondents perceived specific potential benefits as “very important” motivating 
factors in their consideration of whether to participate in HIV cure studies, depending on the 
potential benefit. The correlation between each of the 21 dichotomous independent variables 
(perception of an individual potential benefit as a “very important” motivating factor for 
participation) and the dichotomous dependent variable (willingness to participate in all types of HIV 
cure-related studies) was statistically tested using univariate logistic regression analysis.  
Table 4 below displays the sample size of survey participants who responded to both the 
dependent willingness to participate (WTP) question and the individual potential benefits questions, 
alongside the percent of the sample who perceived the individual potential benefit as a “very 
important” motivating factor in their consideration of whether to participate in HIV cure related 
studies. For all potential benefits, 26 – 27% of the sample were “very willing” to participate in 
studies. The odds ratio of participants being “very willing to participate” and claiming that potential 
benefit was “very important” versus “somewhat important”, “barely important” or “not important” 
is shown in the Table 4 below. The statistical significance of the odds ratio is shown as the p-value. 






Table 4. Bivariate Association between Perceptions of Potential Benefits as Very Important Motivators and Willingness to Participate (WTP) 






% claiming that 
benefit is a "very 
important" motivator 
Odds ratio (95% CI) for 
sample claiming that 
benefit is “very important” 
p-value 
Potential Personal Benefits 
    Feel good contributing to HIV cure research  349 79% 3.62 (1.66-7.87) 0.001*** 
Gaining knowledge about own health/HIV 349 77% 1.61 (0.88-2.95) 0.126 
Learning about new treatment options 346 75% 1.91 (1.05-3.50) 0.035* 
Not wanting to give up  336 72% 1.47 (0.84-2.57) 0.175 
Hope that health will improve   346 71% 1.12 (0.66-1.92) 0.666 
More/regular access to medical researchers 346 57% 1.96 (1.18-3.24) 0.009** 
Additional laboratory work free of charge 346 53% 1.85 (1.13-3.02) 0.015* 
Regular access to a study nurse  347 46% 1.67 (1.03-2.69) 0.036* 
Transportation compensation to study site 344 41% 1.03 (0.64-1.68) 0.890 
Being compensated or reimbursed 346 29% 0.87 (0.51-1.49) 0.615 
Being offered a meal at the study site 344 22% 1.10 (0.63-1.94) 0.730 
Potential Personal Clinical Benefits 
    Preserve immune system ability to fight HIV  345 92% 0.92 (0.39-2.16) 0.841 
Reducing HIV reservoir or HIV in entire body 342 85% 2.48 (1.07-5.74) 0.034* 
Control viral load in absence of treatment 339 85% 1.87 (0.87-4.01) 0.110 
Prevent increase in virus for extended time 340 82% 1.86 (0.92-3.75) 0.083 
Less risk transmitting HIV to sex partner(s)  334 81% 1.79 (0.91-3.54) 0.093 
Increased immune cell counts  341 71% 2.12 (1.18-3.83) 0.012* 
Potential Social Benefits 
    Helping find a cure for HIV  348 95% Perfect +ve corr. 0.000*** 
Helping other people with HIV in the future 348 91% 2.81 (0.96-8.23) 0.059 
Contributing to scientific knowledge  347 88% 2.91 (1.10-7.65) 0.031* 
Receiving support from family and friends  338 42% 1.20 (0.74-1.95) 0.467 
*** Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant at the 5% level. 95% confidence intervals are 
estimated using robust standard errors.
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 Out of the perceptions of 21 potential benefits asked about in the survey, 9 were 
statistically significantly correlated with willingness to participate. The p-value for these nine 
variables were lower than 0.05, thereby rejecting the null hypothesis that willingness to participate 
is independent of whether respondents believed that the potential benefit was “very important” in 
motivating them to consider participating. This includes one potential benefit that was perfectly 
correlated with willingness to participate. All respondents who were “very willing to participate” 
ranked helping to find a cure for HIV as a “very important” motivating factor to considering 
participation in HIV cure-related studies.  
 The odds ratios for the other eight potential benefits that were statistically correlated with 
willingness to participate were always greater than 1.0, indicating a positive correlation between 
perception that the potential benefit is a “very important” motivator and willingness to participate. 
Respondents who perceived feeling good about contributing to HIV cure-related research as a “very 
important” motivating factor were 3.62 times as likely to be “very willing” to participate in HIV cure-
related studies than respondents who did not perceive the potential benefit as “very important.” 
This potential benefit had the largest association with willingness to participate in terms of 
magnitude (after the perfect correlation of helping find a cure for HIV).   
The perceptions of potential benefits that were positively and statistically significantly correlated 
with willingness to participate included, in descending order of magnitude: 
1. Helping find a cure for HIV 
2. Feeling good about contributing to HIV cure-related research 
3. Contributing to scientific knowledge 
4. Reducing the amount of HIV in the entire body or making the HIV reservoir (site where HIV 
can persist) smaller 
5. Increasing immune cell counts 
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6. Having more regular access to medical doctors or researchers 
7. Learning about new treatment options 
8. Additional laboratory work done free of charge, such as viral load or CD4+ count testing 
9. Having more regular access to a study nurse 
 It is noteworthy that the three potential benefits that had the strongest positive correlations 
were all altruistic/emotional benefits. Respondents who were strongly motivated by doing a greater 
good were much more likely to be very willing to participate in HIV cure-related studies than 
individuals who did not share a similar sense of motivation. The motivating factors of compensation, 
gaining knowledge, receiving support from family and friends, and several potential personal clinical 
benefits were not statistically correlated with willingness to participate.  
On the list of 35 potential risks, the survey results revealed that as few as 3% of respondents 
and as high as 49% of respondents perceived specific potential risks as “very likely to discourage” 
them from considering participation in HIV cure-related studies, depending on the potential risk. 
The correlation between each of the 35 dichotomous independent variables (perception of an 
individual potential risk as “very likely to discourage” participation) and the dichotomous dependent 
variable (willingness to participate in all types of HIV cure-related studies) was statistically tested 
using univariate logistic regression analysis.  
Table 5 below displays the sample size of respondents who responded to both the 
dependent willingness to participate (WTP) question and the individual potential risks questions, 
alongside the percent of the sample who perceived the individual potential risk as “very likely to 
discourage” participation in HIV cure-related studies. For all potential risks, 26 – 28% of the sample 
were “very willing” to participate in studies.  
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The odds ratio of participants being “very willing to participate” and claiming a potential risk 
as “very likely to discourage” participation versus “somewhat likely”, “barely likely” or “not likely” is 
shown in the Table 5 below. The statistical significance of the odds ratio is shown as the p-value. 







Table 5. Bivariate Association between Perceptions of Potential Risks as Very Likely to Discourage Participation and Willingness to Participate 








that risk is 
"very likely" to 
discourage 
participation 
Odds ratio (95% CI) 
for sample claiming 
that benefit is “very 
important” 
p-value 
Potential Personal Clinical Risks 
    Activation of genes that could cause cancer 324 49% 0.23 (0.13-0.41) 0.000*** 
Possibility of developing resistance to drugs 322 38% 0.36 (0.20-0.64) 0.001*** 
Toxicities or adverse negative effects of drugs 324 31% 0.21 (0.10-0.43) 0.000*** 
Known risks of stopping HIV medications 324 29% 0.27 (0.14-0.54) 0.000*** 
Unable to predict viral rebound 322 27% 0.28 (0.14-0.57) 0.000*** 
Graft-versus-host disease 313 26% 0.16 (0.07-0.38) 0.000*** 
Invasive study procedures (e.g. biopsy) 324 16% 0.26 (0.10-0.68) 0.006** 
Potential Personal Risks: Commitment 
    Long study visits (>4 hours each) 326 9% 0.31 (0.09-1.04) 0.058 
High frequency of study visits (>1 per month) 325 6% 0.27 (0.06-1.20) 0.084 
Long study duration and follow-up (>5 years) 324 6% 0.71 (0.23-2.21) 0.558 
Potential Personal Risks: Study Procedures 
    Spinal tap 321 27% 0.09 (0.03-0.26) 0.000*** 
Bone marrow biopsies 312 24% 0.24 (0.11-0.52) 0.000*** 
Biopsies of lymph nodes 321 13% 0.18 (0.05-0.60) 0.005** 
Rectal biopsies 325 13% 0.26 (0.09-0.75) 0.012* 
Organ donation after death 303 7% 0.41 (0.12-1.44) 0.166 
Isolating white blood cells (may take 2 hours) 326 6% 0.15 (0.02-1.16) 0.069 
Collection of semen or vaginal fluids 323 3% 0.76 (0.15-3.72) 0.732 
Oral biopsies (e.g. saliva samples) 328 3% 0.30 (0.04-2.40) 0.256 






Potential Personal Risks: Symptoms or Side Effects 
    Hair loss 324 33% 0.40 (0.22-0.71) 0.002** 
Vomiting 326 24% 0.11 (0.04-0.30) 0.000*** 
Pre-defined, controlled discomfort or pain 318 14% 0.10 (0.02-0.41) 0.000*** 
Nausea 327 14% 0.16 (0.05-0.53) 0.003** 
Headache 328 13% 0.18 (0.05-0.60) 0.005** 
Potential Personal Risks: Burdens 
    Difficulty finding/paying for parking at the site 326 19% 0.40 (0.19-0.85) 0.017* 
Difficulty finding transportation to the site 325 16% 0.45 (0.20-0.99) 0.047* 
Time away from work or school 318 10% 0.49 (0.18-1.32) 0.157 
Time away from family 322 5% 0.65 (0.18-2.37) 0.517 
Challenges of finding child care 303 5% 1.06 (0.32-3.49) 0.919 
Having to explain study participation to others 319 4% 0.52 (0.11-2.43) 0.408 
Potential Social Risks 
    Risk of transmitting HIV to a sexual partner 321 29% 0.69 (0.39-1.22) 0.197 
Discrimination 327 10% 0.36 (0.12-1.05) 0.062 
Stigma 328 7% 0.42 (0.12-1.45) 0.168 
Being recognized as a person living with HIV 330 7% 0.39 (0.11-1.35) 0.138 
Risk of losing “HIV-positive identity” if cured 319 3% 0.93 (0.18-4.70) 0.931 
*** Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant at the 5% level. 95% confidence intervals are 
estimated using robust standard errors. 
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 Out of the perceptions of 35 potential risks asked about in the survey, 18 were statistically 
significantly correlated with willingness to participate. The p-value for these variables were lower 
than 0.05, thereby rejecting the null hypothesis that willingness to participate was independent of 
whether the respondent believed that the potential risk was “very likely to discourage” them to 
consider participating.  The odds ratios for these 18 potential risks are always less than 1.0, 
indicating a negative correlation between perception that the potential risk is “very likely to 
discourage” participation and willingness to participate, as expected. Respondents who perceived 
having a spinal tap as a study procedure as “very likely to discourage” their participation are only 9% 
as likely to be very willing to participate in HIV cure-related studies as respondents who did not 
share their strong rejection of spinal tap procedures. Similarly odds ratios were calculated for 
potential risk factors of vomiting or having pre-defined, controlled discomfort/pain as symptoms or 
side effects of studies. These three potential risks had the largest associations with willingness to 
participate in terms of magnitude.  
The perceptions of potential risks that were negatively and statistically significantly correlated with 
willingness to participate include, in descending order of magnitude: 
1. Spinal tap as a study procedure 
2. Pre-defined, limited and controlled potential discomfort and/or pain as a side effect or 
symptom 
3. Vomiting as a side effect or symptom 
4. Graft-versus-host disease (GVHD), a possible complication from allogeneic (foreign) stem 
cells transplants 
5. Nausea as a side effect or symptom 
6. Biopsies of one of the participant’s lymph nodes (organs than contain immune cells) as a 
study procedure 
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7. Headache as a side effect or symptom 
8. Toxicities or adverse negative effects of the drugs being studied 
9. Activation of genes in the body that could cause cancer 
10. Bone marrow biopsies as a study procedure 
11. Invasive study procedures such as biopsy or sample of tissue from one of the lymph nodes 
12. Rectal biopsies via sigmoidoscopy or colonoscopy as a study procedure 
13. Known risks of stopping HIV medications such as the potential for a rapid increase/rebound 
in the viral load 
14. Having no way to predict the risk of having the virus become detectable again in the 
participant (viral rebound) 
15. Possibility of developing resistance to the drugs during a structured treatment interruption 
16. Hair loss as a side effect or symptom 
17. Difficulty finding or having to pay for parking at the clinical research site 
18. Difficulty finding transportation to the clinical research site 
 All of the potential personal clinical risks and all of the potential personal risks involving 
symptoms and side effects were statistically significantly correlated with deterrence to participate. 
Likewise, all of the invasive study procedures (i.e. biopsies and spinal taps) and transportation risks 
were statistically significantly correlated with deterrence to participate. Individuals who perceived 
these factors as “very likely to discourage” their participation were less likely to be willing to 
participate in studies than individuals who are not as concerned with these factors.  Or, in other 
words, individuals who were relatively less willing to participate in HIV cure-related studies were 
statistically more concerned about the potential risks of these particular factors than respondents 
who were very willing to participate. It is worthwhile to note that short-term and immediate risks, 
such as those involving pain or discomfort temporarily, have stronger correlation with deterrence to 
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participate in terms of magnitude than some of the longer-term risks, such as the potential for 
enabling cancer or developing viral rebounds over time in the bivariate analyses. This seemed to be 
the opposite when looking merely at the descriptive data.    
 Conversely, none of the potential risks regarding commitment levels, burdens of time and 
non-transportation logistics, non-invasive study procedures, or potential social risks were 
statistically significantly correlated with willingness to participate (although perception that 
discrimination was very likely to discourage participation was negatively statistically correlated with 
willingness to participate at the 10% level but not the 5% level). All but one of these potential risk 
factors were “very likely to discourage” participation for only 10% or less of respondents. Risk 
factors that were more popular (i.e. that worried larger proportions of the respondent sample) were 
statistically correlated with deterrence to participate.  
Finally, the correlation between various socio-demographic characteristics and willingness 
to participate in all types of HIV cure-related studies was statistically tested using univariate logistic 
regression analysis. Table 6 below breaks down the sample by all categories for each characteristics 
variable, displaying the sample size in each category (summing up to 100% within each categorical 
variable) alongside the number and percent of the sample who were very willing or relatively less 
willing to participate in HIV cure-related studies. The odds ratios of participants being “very willing 
to participate” for each category within the characteristics variables is shown in Table 6. The 
statistical significance of each odds ratio, as well as the overall statistical significance of the 
correlation of the categorical variable and willingness to participate is shown as p-values. 







Table 6. Bivariate Association between Socio-Demographic Characteristics and Willingness to Participate in All Types of HIV Cure-Related 
Studies 
    
Willingness to participate in all 











Gender         0.283 
Male 284 (79%) 78 (27%) 206 (73%) 1.00 
 Female 73 (20%) 15 (21%) 58 (79%) 0.68 (0.37-1.28) 0.232 
Transgender male to female, Other 4 (1%) 2 (50%) 2 (50%) 2.64 (0.37-19.07) 0.336 
Age 
    
0.064 
19-29 19 (5%) 6 (32%) 13 (68%) 1.00 
 30-39 42 (12%) 17 (40%) 25 (60%) 1.47 (0.47-4.64) 0.508 
40-49 91 (25%) 27 (30%) 64 (70%) 0.91 (0.31-2.66) 0.869 
50-59 142 (39%) 34 (24%) 108 (76%) 0.68 (0.24-1.93) 0.471 
60+ 67 (19%) 11 (16%) 56 (84%) 0.43 (0.13-1.36) 0.150 
As a continuous variable 361 (100%) 
  
0.97 (0.95-0.99) 0.005** 
Ethnicity         0.224 
Caucasian/White 240 (66%) 71 (30%) 169 (70%) 1.00 
 African-American 52 (14%) 12 (23%) 40 (77%) 0.71 (0.35-1.44) 0.347 
Hispanic or Hispanic descent 43 (12%) 8 (19%) 35 (81%) 0.54 (0.24-1.23) 0.144 
Other 12 (3%) 1 (8%) 11 (92%) 0.22 (0.03-1.71) 0.146 
Mixed 14 (4%) 3 (21%) 11 (79%) 0.65 (0.18-2.40) 0.517 
Education 
    
0.356 
High school or G.E.D., or less 89 (25%) 27 (30%) 62 (70%) 1.00 
 Some college / Associate degree 90 (25%) 26 (29%) 64 (71%) 0.93 (0.49-1.77) 0.832 
Undergraduate degree 97 (27%) 26 (27%) 71 (73%) 0.84 (0.44-1.59) 0.594 






Doctorate or its equivalent 22 (6%) 4 (18%) 18 (82%) 0.51 (0.16-1.65) 0.261 
Household Income         0.471 
Less than $25,000 127 (35%) 32 (25%) 95 (75%) 1.00 
 $25,000 - $50,000 100 (28%) 31 (31%) 69 (69%) 1.33 (0.74-2.39) 0.333 
$50,001 - $75,000 45 (13%) 10 (22%) 35 (78%) 0.85 (0.38-1.90) 0.690 
$75,001 - $100,000 35 (10%) 7 (20%) 28 (80%) 0.74 (0.30-1.86) 0.525 
$100,001 - $125,000 28 (8%) 10 (36%) 18 (64%) 1.65 (0.69-3.94) 0.260 
$125,001 - $150,000 9 (3%) 3 (33%) 6 (67%) 1.48 (0.35-6.28) 0.592 
More than $150,000 16 (4%) 2 (13%) 14 (88%) 0.42 (0.09-1.97) 0.273 
Region 
    
0.699 
Northeast 39 (11%) 9 (23%) 30 (77%) 1.00 
 Midwest 62 (17%) 13 (21%) 49 (79%) 0.88 (0.34-2.32) 0.803 
South 126 (35%) 35 (28%) 91 (72%) 1.28 (0.55-2.97) 0.562 
West 130 (36%) 36 (28%) 94 (72%) 1.28 (0.55-2.95) 0.568 
Current Health Status         <0.001*** 
Very healthy 68 (19%) 16 (24%) 52 (76%) 1.00 
 Healthy 162 (45%) 50 (31%) 112 (69%) 1.45 (0.76-2.78) 0.263 
Somewhat healthy 110 (31%) 17 (15%) 93 (85%) 0.59 (0.28-1.27) 0.181 
Not very healthy/Not at all healthy 20 (6%) 12 (60%) 8 (40%) 4.88 (1.70-14.01) 0.003** 
In Control Over Own Health Care 
    
0.666 
No 48 (14%) 14 (29%) 34 (71%) 1.00 
 Yes 298 (86%) 78 (26%) 220 (74%) 0.86 (0.44-1.69) 0.663 
Taking Medication for HIV     0.892 
No 7 (2%) 2 (29%) 5 (71%) 1.00  
Yes 354 (98%) 93 (26%) 261 (74%) 0.89 (0.17-4.67) 0.891 
Percent of Life Living with HIV 
Diagnosis         <0.001*** 
Up to 25% 129 (36%) 53 (41%) 76 (59%) 1.00 
 26-50% 171 (48%) 29 (17%) 142 (83%) 0.29 (0.17-0.50) <0.001*** 






As a continuous variable 356 (100%) 
  
0.07 (0.02-0.28) <0.001*** 
Ever Volunteered for an HIV Treatment Study       0.075 
No 199 (56%) 60 (30%) 139 (70%) 1.00 
 Yes 156 (44%) 34 (22%) 122 (78%) 0.65 (0.40-1.05) 0.078 
Ever Volunteered for an HIV Cure 
Study         0.014* 
No 329 (93%) 93 (28%) 236 (72%) 1.00 
 Yes 25 (7%) 2 (8%) 23 (92%) 0.22 (0.05-0.95) 0.043* 
Generally Interested in HIV Cure Research         
No 5 (1%) 0 (0%) 5 (100%) Perfect +ve correlation 
Yes 346 (99%) 95 (27%) 251 (73%)     
*** Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant at the 5% level. 95% confidence intervals are 
estimated using robust standard errors. 
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Of all of the different individual-level characteristics, only five were statistically correlated with 
willingness to participate in HIV cure-related studies at the 5% level: 
 Respondents who described their current health status as “not at all healthy” or “not very 
healthy” were nearly five times more likely to be very willing to participate in all types of HIV 
cure related studies than respondents who self-described as “very healthy.”  
 Respondents who have lived with an HIV diagnosis for larger proportions of their life were 
much less likely to be very willing to participate in HIV cure-related studies than respondents 
whose HIV status were relatively new. Respondents who have lived more than half of their 
lives with an HIV diagnosis were only 39% as likely to be very willing to participate in HIV 
cure-related studies as respondents who have lived less than a quarter of their life with an 
HIV diagnosis.  
 When age was analyzed as a continuous variable, older-aged respondents were less likely to 
be very willing to participate in HIV cure-related studies than younger-aged respondents.  
 Respondents who have ever volunteered for or been in an HIV cure study were less likely 
(only 22% as likely) to be very willing to participate in all types of HIV cure-related studies 
than respondents who have never volunteered for an HIV cure study in the past. 
 General interest in HIV cure research is perfectly and positively correlated with willingness 
to participate. All respondents who were very willing to participate in HIV cure-related 
studies were generally interested in HIV cure research. Only five respondents were not 
generally interested in HIV cure research, and all five were relatively less willing to 
participate in HIV cure studies. 
Gender, ethnicity, education (on average), household income, region, control over own 
health care, and taking medications for HIV were not statistically correlated with willingness to 
participate in HIV cure-related studies in the bivariate analyses. Having a Master’s degree, and 
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having ever volunteered for or been in an HIV treatment study was statistically significantly 
correlated with willingness to participate at the 10% level but not the 5% level.  
In summary, key bivariate results from the survey include:  
 
 Perceptions of nine potential benefits as “very important” motivating factors for considering 
participation in HIV cure-related studies were positively and statistically significantly 
correlated with willingness to participate. Individuals who cared about these specific factors 
were more likely to be willing to participate in HIV cure-related studies than others. 
 The potential benefits that were positively correlated with willingness to participate came 
from all three groups of benefits: personal benefits, personal clinical benefits, and social 
benefits. 
 The three potential benefits that had the strongest positive correlations were all 
altruistic/emotional benefits. Respondents who were strongly motivated by doing a greater 
good were much more likely to be very willing to participate in HIV cure-related studies than 
individuals who did not share a similar sense of motivation.  
 Perception of the importance of compensation was not correlated with willingness to 
participate.  
 Perceptions of 18 potential risks as “very likely to discourage” participation in HIV cure-
related studies were negatively and statistically significantly correlated with deterrence to 
participate. Individuals who were more concerned about these particular potential risks 
were relatively less willing to participate in HIV studies than individuals who were not as 
concerned about these risks. 
 The potential risks that were negatively correlated with willingness to participate were 
potential personal clinical risks, symptoms and side effects, invasive study procedures, and 
transportation logistics.  
 111 
 Short-term and immediate risks, such as those that involved pain or discomfort temporarily, 
had stronger correlation with willingness to participate in terms of magnitude than some of 
the longer-term risks, such as the potential for enabling cancer or developing viral rebounds 
over time. The three potential risks that had the strongest negative correlations were the 
use of spinal tap as a study procedure, or symptoms/side effects of vomiting or pre-defined, 
controlled pain or discomfort. 
 None of the potential risks regarding commitment levels, burdens of time and non-
transportation logistics, non-invasive study procedures, or potential social risks were 
statistically significantly correlated with willingness to participate. 
 Poor current health status, younger age, living with HIV diagnosis for smaller proportions of 
lifetime, general interest in HIV cure research, and having not ever previously volunteered 
for or participated in an HIV cure study were positively and statistically significantly 
correlated with higher willingness to participate in HIV cure-related studies. 
 Gender, ethnicity, education (for the most part), household income, region, control over 
own health care, and taking medication for HIV were not statistically correlated with 
willingness to participate in HIV cure-related studies.  
Multivariate Regression Analyses 
Bivariate associations that were statistically significant may be caused by an indirect link 
between the independent and dependent variables. This is particularly possible because socio-
demographic characteristics were also shown to be statistically correlated with willingness to 
participate. Thus, cross-sectional multivariate logistic regression models were estimated to assess 
the statistical significance and magnitude of the correlation between perceptions of potential 
benefits/risks and respondents’ willingness to participate in all types of HIV cure-related studies, 
controlling for extraneous socio-demographic characteristics.  
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A total of 58 logistic regression models were estimated. In all models, the dependent 
variable was whether the respondent was very willing to participate in HIV cure-related studies 
versus relatively less willing to participate. In the first model, Model 1, willingness to participate was 
regressed only on the control variables, comprised of individual-level socio-demographic 
characteristic and attitudes towards HIV cure research. Several versions of this model were 
iteratively fitted, adjusting the combination of and construct of the control variables as described in 
the Methods section. The model (Model 1) that best fitted the data is shown in Table 7 below. 
Hence, for all subsequent models (Models 2 – 58), the same control variables were included as used 
and shown in Model 1 (Table 7) below.  
Table 7. Multivariate Logistic Regression of Willingness to Participate in All Types of HIV Cure-
Related Studies on Individual-Level Socio-Demographic Characteristics (Model 1) 
Control Variable Odds Ratio 95% CI 
p-value 
Male (vs. female, transgender, other) 1.17 (0.57-2.43) 0.666 
Age 0.97* (0.94-0.99) 0.014 
Ethnicity (vs. Caucasian/White) 
   African American 0.64 (0.25-1.60) 0.337 
Hispanic 0.45 (0.16-1.25) 0.128 
Mixed or Other 0.41 (0.12-1.38) 0.149 
Highest education attainment level (vs. some college 
or less) 
   Bachelor's degree 0.78 (0.40-1.50) 0.453 
Graduate degree 0.42* (0.19-0.95) 0.038 
Annual household income (vs. up to $25,000) 
   $26-$50k/year 1.20 (0.62-2.33) 0.584 
$51-$75k/year 0.58 (0.22-1.51) 0.265 
$76-$100k/year 0.74 (0.24-2.28) 0.603 
$101-$125k/year 1.82 (0.63-5.25) 0.268 
$126-$150k/year 1.76 (0.38-8.27) 0.473 
More than $150k/year 0.17 (0.03-1.01) 0.052 
Region (vs. West) 
   Northeast 0.71 (0.28-1.83) 0.480 
Midwest 0.48 (0.21-1.11) 0.088 
South 0.60 (0.31-1.16) 0.132 
Consider self to be "not at all healthy or not very 4.45* (1.36-14.5) 0.014 
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healthy" (vs. healthier) 
Have control over own health care (vs. no) 1.35 (0.60-3.06) 0.467 
Percent of life living with HIV status 0.97** (0.96-0.99) 0.002 
Currently taking medications for HIV 0.89 (0.17-4.67) 0.891 
Ever volunteered for an HIV cure study (vs. no) 0.22 (0.05-1.08) 0.063 
n 329     
Model Prob > chi2 0.0088     
*** Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant 
at the 5% level. 95% confidence intervals are estimated using robust standard errors. 
Collectively, the set of socio-demographic variables used in Model 1 were statistically 
significant, with an overall model p-value of 0.0088. Although the variable measuring whether the 
respondent is generally interested in HIV cure research was included in the model, it was dropped 
due to perfect correlation with the dependent variable after being included in the model with the 
other control variables. Furthermore, the overall model fit (as determined by a Likelihood-Ratio test 
of a restricted and unrestricted model) improved when the variable measuring whether the 
participant was taking medications for HIV was excluded. Thus, this variable is excluded from Model 
1 onwards.  
 The results from Model 1 indicate that only four individual-level characteristics were 
statistically significantly correlated with willingness to participate. The p-value for these four 
variables were lower than 0.05, thereby rejecting the null hypothesis that willingness to participate 
is independent of the socio-demographic characteristic. These four characteristics are: 
1. Respondents who described their current health status as “not at all healthy” or “not very 
healthy” were 4.45 times more likely to be very willing to participate in all types of HIV cure-
related studies than respondents who self-described as “somewhat healthy”, “healthy” and 
“very healthy”, on average and controlling for all other socio-demographic characteristics.  
2. Respondents who have lived with an HIV diagnosis for larger proportions of their lifetime 
were less likely to be very willing to participate in HIV cure-related studies than respondents 
whose HIV status were relatively newer. An increase of one percentage point in the percent 
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of life living with HIV status was associated with a 97% odds ratio (a drop of 3 percentage 
points) in willingness to participate, on average and ceteris paribus.  
3. Older-aged respondents were less likely to be very willing to participate in HIV cure-related 
studies than younger-aged respondents. An increase of one year in age was associated with 
a 97% odds ratio (a drop of 3 percentage points) in willingness to participate, on average 
and ceteris paribus.  
4. Respondents who have completed a graduate degree (Master’s degree or higher) were only, 
on average, 42% as likely as respondents who did not complete an undergraduate degree in 
being very willing to participate in HIV cure-related studies, ceteris paribus. Thus, as 
educational attainment level increased, willingness to participate decreased, when 
controlling for all other socio-demographic characteristics.  
These results are similar to the results of the bivariate association analysis in that the first 
three variables were statistically significantly correlated with willingness to participate – and in the 
same direction – both in one-on-one bivariate associations and in multivariate regressions that 
control for confounding effects of extraneous factors. After controlling for other variables, however, 
achieving a Master’s degree as the highest educational attainment level became statistically 
significant at the 5% level, whereas the bivariate association was only statistically significant at the 
10% level. Lastly, while having ever volunteered for or been in an HIV cure study was statistically 
significant at the 5% level in the bivariate association analysis, it was only significant at the 10% level 
in the multivariate analysis after controlling for other factors. The relative consistency between the 
bivariate association results and the multivariate regression analysis using control variables implies a 
strong degree of robustness in the data and the strength of the correlations between these factors 
and willingness to participate. 
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Individuals who believed that their health status was relatively poor were 4.45 times more 
willing to participate in HIV cure-related studies, on average, than individuals who believed their 
health status was good, ceteris paribus. This may be an indication that individuals are more willing 
to try whatever it takes to eradicate the virus, either for themselves or for society, when they are 
facing greater health obstacles. Conversely, individuals who have lived with their HIV status longer 
were less likely to be willing to participate in HIV cure-related studies than individuals who have 
more recently become infected with HIV. This finding suggests that the longer individuals live with 
HIV, the more accustomed they become to the virus and the less willing they are to consider 
participating in some of the more experimental types of HIV cure studies. Interestingly, people who 
are recently infected with the virus may be more eager and more willing to volunteer for HIV cure 
related studies. Likewise, younger individuals are, on average, more willing to participate in studies 
than older individuals. These results were surprising. 
Willingness to participate was not statistically correlated with six variables in Model 1 (Table 
7): gender, ethnicity, income, region, having control over own health care, and having ever 
volunteered for an HIV cure study. However, three of these variables were statistically significantly 
correlated at the 10% level, but not the 5% level, indicating a possible correlation. Household 
income above $150,000 (versus income below $25,000), living in the Midwest (versus the West), 
and having ever volunteered for an HIV cure study were weakly and negatively associated with 
willingness to participate in all types of HIV cure-related studies.  
 To determine which perceptions of the 21 potential benefits described in the survey were 
associated with willingness to participate in HIV cure studies, controlling for their individual-level 
characteristics, each of the potential benefits was added as the sole key independent variable to 
Model 1. This resulted in 21 new regression models (Models 2 through 22), each with the same 
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control variables shown in Model 1 plus one key independent variable that varied from model to 
model.  
 The key independent variable was whether the respondent perceived a specific potential 
benefit as a “very important” in motivating them to consider participation in HIV cure studies. The 
results for the key independent variable of all 21 models (Models 2 – 22) are shown in Table 8 
below. For the sake of brevity, the odds ratios for the control variables are not shown in this table, 






Table 8. Odds Ratios of Willingness to Participate in All Types of HIV Cure-Related Studies and Perception of Potential Benefits as Very 
Important Motivating Factors for Considering Participation, Controlling for Socio-Demographic Characteristics in 21 Individual Logistic Models 
(Models 2 – 22) 
Model # Key Independent (Benefit) Variable Odds Ratio 95% CI p-value n Model Prob > chi2 
Models Including a Potential Personal Benefit and the Control Variables 
   Model 2 Feel good contributing to HIV cure research  6.96*** (2.73-17.74) 0.000 319 0.0004 
Model 3 Gaining knowledge about own health/HIV 2.06* (1.04-4.11) 0.039 319 0.0082 
Model 4 Learning about new treatment options 1.90 (0.96-3.73) 0.064 316 0.0325 
Model 5 Not wanting to give up  1.28 (0.65-2.54) 0.474 307 0.0259 
Model 6 Hope that health will improve   1.13 (0.61-2.10) 0.691 317 0.0317 
Model 7 More/regular access to medical researchers 1.77 (1.00-3.12) 0.051 316 0.0287 
Model 8 Additional laboratory work free of charge 2.32** (1.29-4.16) 0.005 316 0.0077 
Model 9 Regular access to a study nurse  1.65 (0.95-2.86) 0.075 317 0.0303 
Model 10 Transportation compensation to study site 1.38 (0.73-2.62) 0.320 314 0.0181 
Model 11 Being compensated or reimbursed 1.01 (0.53-1.95) 0.965 316 0.0308 
Model 12 Being offered a meal at the study site 1.05 (0.50-2.23) 0.890 314 0.0256 
Models Including a Potential Personal Clinical Benefit and the Control Variables 
   Model 13 Preserve immune system ability to fight HIV  0.73 (0.28-1.91) 0.516 316 0.0303 
Model 14 Reducing HIV reservoir or HIV in entire body 1.93 (0.74-5.04) 0.180 314 0.0214 
Model 15 Control viral load in absence of treatment 1.33 (0.54-3.22) 0.534 311 0.0186 
Model 16 Prevent increase in virus for extended time 1.54 (0.68-3.51) 0.300 313 0.0295 
Model 17 Less risk transmitting HIV to sex partner(s)  1.55 (0.72-3.35) 0.263 305 0.0199 
Model 18 Increased immune cell counts  1.87 (0.91-3.85) 0.087 312 0.0220 
Models Including a Potential Social Benefit and the Control Variables 
   Model 19 Helping find a cure for HIV  Perfect +ve correlation with "very willing to participate" 
Model 20 Helping other people with HIV in the future 2.66 (0.81-8.76) 0.107 318 0.0231 
Model 21 Contributing to scientific knowledge  5.37** (1.64-17.62) 0.006 317 0.0031 
Model 22 Receiving support from family and friends  0.97 (0.53-1.78) 0.918 309 0.0536 
Each benefit variable was included in a separate model with the control variables listed in Model 1. Odd ratios on the control variables are not displayed. *** 
Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant at the 5% level. Robust standard errors estimated. 
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As shown in Table 8, perception of potential motivating factors does not always associate 
with an increase in willingness to participate in HIV cure studies. Of the 21 potential benefits, only 
five were statistically significantly associated, at the 5% level, with willingness to participate, 
controlling for socio-demographic factors. This includes one potential benefit, helping find a cure for 
HIV, which was perfectly and positively correlated with willingness to participate, after controlling 
for all other factors. The odds ratios for the other four potential benefits were always greater than 
1.0, indicating a positive association between perception that the potential benefit was a “very 
important” motivator and willingness to participate. Respondents who perceived feeling good about 
contributing to HIV cure-related research as a “very important” motivating factor were nearly 7 
times as likely to be “very willing” to participate in HIV cure-related studies than respondents who 
did not perceive the potential benefit as “very important,” controlling for socio-demographic 
characteristics. This potential benefit had the largest association with willingness to participate in 
terms of magnitude (after the perfect correlation of helping find a cure for HIV).  
 After controlling for socio-demographic characteristics, the following five potential benefits 
were statistically significantly correlated with willingness to participate, in descending order of 
magnitude: 
1. Helping find a cure for HIV  
2. Feeling good about contributing to HIV cure-related research 
3. Contributing to scientific knowledge  
4. Additional laboratory work done free of charge, such as viral load or CD4+ count testing 
5. Getting special/additional knowledge about respondent’s own HIV infection and own health 
while being in the study  
 Similar to the outcome of the bivariate association analysis, the three potential benefits that 
had the strongest positive correlations were all altruistic/emotional benefits: helping find a cure for 
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HIV, feeling good about contributing to HIV cure research, and contributing to scientific knowledge. 
In fact, they were the same variables that produced the strongest bivariate associations with 
willingness to participate, and the strength of these associations remained significant even after 
controlling for socio-demographic characteristics. The other two statistically significant variables 
were both personal benefits related to increasing the respondent’s knowledge of their own HIV 
infection.  
 Interestingly, none of the potential personal clinical benefits were statistically significant 
after controlling for socio-demographic characteristics (see Models 13 –18), and fewer potential 
personal benefits were statistically significant than the bivariate association analysis revealed. The 
significance of the correlation between the perception of those factors and willingness to participate 
may be indirectly linked through other variables that may have been controlled for among the socio-
demographic variables. Nevertheless, there were four more potential benefits that were statistically 
significantly correlated at the 10% level but not the 5% level, implying a weak association with 
willingness to participate. These included: learning about new treatment options, increasing 
immune cell counts, having more regular access to medical doctors or researchers, and having more 
regular access to a study nurse.  
 Similar to the previous step, 35 new regression models (Models 23 – 57) were estimated 
using the control variables in Model 1, and adding each potential risk as the sole key independent 
variable to each model. The key independent variable was whether the respondent perceived a 
specific potential risk as “very likely to discourage” them from considering participation in HIV cure 
studies. The results for the key independent variable of all 35 models (Models 23 – 57) are shown in 
Table 9 below. Again, for the sake of brevity, the odds ratios for the control variables are not shown 







Table 9. Odds Ratios of Willingness to Participate in All Types of HIV Cure-Related Studies and Perception of Potential Risks as Very Likely to 
Discourage Participation, Controlling for Socio-Demographic Characteristics in 35 Individual Logistic Models (Models 23 – 57) 








Prob > chi2 
Models Including a Potential Personal Clinical Risk and the Control Variables 
   Model 23 Activation of genes that could cause cancer 0.23*** (0.12-0.45) 0.000 296 0.0010 
Model 24 Possibility of developing resistance to drugs 0.32*** (0.16-0.63) 0.001 296 0.0023 
Model 25 Toxicities or adverse negative effects of drugs 0.24*** (0.11-0.51) 0.000 296 0.0040 
Model 26 Known risks of stopping HIV medications 0.28*** (0.14-0.59) 0.001 296 0.0028 
Model 27 Unable to predict viral rebound 0.30*** (0.14-0.63) 0.001 294 0.0043 
Model 28 Graft-versus-host disease 0.16*** (0.07-0.38) 0.000 287 0.0014 
Model 29 Invasive study procedures (e.g. biopsy) 0.29** (0.12-0.73) 0.009 296 0.1539 
Models Including a Potential Personal Risk (Commitment) and the Control Variables 
  Model 30 Long study visits (>4 hours each) 0.46 (0.13-1.65) 0.234 297 0.0089 
Model 31 High frequency of study visits (>1 per month) 0.42 (0.09-1.99) 0.277 296 0.0086 
Model 32 Long study duration and follow-up (>5 years) 1.09 (0.26-4.49) 0.910 296 0.0093 
Models Including a Potential Personal Risk (Study Procedures) and the Control Variables 
  Model 33 Spinal tap 0.07*** (0.02-0.23) 0.000 294 0.0001 
Model 34 Bone marrow biopsies 0.21** (0.08-0.59) 0.003 288 0.0125 
Model 35 Biopsies of lymph nodes 0.28 (0.07-1.12) 0.071 292 0.0135 
Model 36 Rectal biopsies 0.31* (0.10-0.96) 0.043 297 0.0088 
Model 37 Organ donation after death 0.60 (0.15-2.50) 0.487 278 0.0168 
Model 38 Isolating white blood cells (may take 2 hours) 0.23 (0.02-2.34) 0.216 297 0.0107 
Model 39 Collection of semen or vaginal fluids 1.65 (0.27-10.06) 0.587 294 0.0352 
Model 40 Oral biopsies (e.g. saliva samples) 0.43 (0.03-5.53) 0.518 300 0.0107 
Model 41 Blood draws 1.95 (0.27-14.11) 0.508 302 0.0219 
Models Including a Potential Personal Risk (Symptoms or Side Effects) and the Control Variables 
 Model 42 Hair loss 0.38** (0.18-0.79) 0.009 296 0.0105 














Prob > chi2 
Model 44 Pre-defined, controlled discomfort or pain 0.09** (0.02-0.43) 0.002 291 0.0037 
Model 45 Nausea 0.19** (0.06-0.62) 0.006 298 0.0028 
Model 46 Headache 0.19* (0.05-0.73) 0.016 299 0.0204 
Models Including a Potential Personal Risk (Burdens) and the Control Variables 
   Model 47 Difficulty finding/paying for parking at the site 0.36* (0.16-0.82) 0.015 298 0.0183 
Model 48 Difficulty finding transportation to the site 0.30* (0.11-0.77) 0.013 297 0.0037 
Model 49 Time away from work or school 0.35 (0.11-1.07) 0.066 290 0.0494 
Model 50 Time away from family 0.63 (0.17-2.32) 0.486 293 0.0231 
Model 51 Challenges of finding child care 0.87 (0.25-3.00) 0.825 275 0.0242 
Model 52 Having to explain study participation to others 0.34 (0.07-1.61) 0.174 290 0.0263 
Models Including a Potential Social Risk and the Control Variables 
    Model 53 Risk of transmitting HIV to a sexual partner 0.46* (0.24-0.91) 0.026 295 0.0135 
Model 54 Discrimination 0.23* (0.06-0.96) 0.043 299 0.0144 
Model 55 Stigma 0.33 (0.06-1.90) 0.213 300 0.0191 
Model 56 Being recognized as a person living with HIV 0.21 (0.03-1.23) 0.084 302 0.0213 
Model 57 Risk of losing “HIV-positive identity” if cured 1.13 (0.21-6.13) 0.891 291 0.0497 
Each risk variable was included in a separate model with the control variables listed in Model 1. Odd ratios on the control variables are not displayed. *** 
Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant at the 5% level. Robust standard errors estimated. 
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Of the 35 potential risks, 19 were statistically significantly correlated, at the 5% level, with 
willingness to participate, controlling for socio-demographic factors. The odds ratios for all 19 
potential risks were always less than 1.0, indicating a negative correlation between perception that 
the potential risks were “very likely to discourage” the respondents from participating and their 
willingness to participate in HIV cure studies. Respondents who perceived having a spinal tap as a 
study procedure as “very likely to discourage” their participation were only 7% as likely to be very 
willing to participate in HIV cure-related studies as respondents who did not share their strong 
rejection of spinal tap procedures, ceteris paribus. Again, this was the potential risk that had the 
strongest negative correlation with willingness to participate in terms of magnitude.  
 After controlling for socio-demographic characteristics, the following potential risks were 
statistically significantly correlated with deterrence to participate, in descending order of 
magnitude:  
1. Spinal tap as a study procedure  
2. Pre-defined, limited and controlled potential discomfort and/or pain as a side effect or 
symptom 
3. Vomiting as a side effect or symptom 
4. Graft-versus-host disease (GVHD), a possible complication from allogeneic (foreign) stem 
cells transplants 
5. Headache as a side effect or symptom 
6. Nausea as a side effect or symptom 
7. Bone marrow biopsies as a study procedure 
8. Activation of genes in the body that could cause cancer 
9. Discrimination as a potential social risk 
10. Toxicities or adverse negative effects of the drugs being studied 
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11. Known risks of stopping HIV medications such as the potential for a rapid increase/rebound 
in the viral load 
12. Invasive study procedures such as biopsy or sample of tissue from one of the lymph nodes 
13. Having no way to predict the risk of having the virus become detectable again in the 
participant (viral rebound) 
14. Difficulty finding transportation to the clinical research site 
15. Rectal biopsies via sigmoidoscopy or colonoscopy as a study procedure 
16. Possibility of developing resistance to the drugs during a structured treatment interruption 
17. Difficulty finding or having to pay for parking at the clinical research site 
18. Hair loss as a side effect or symptom 
19. Risk of transmitting HIV to a sexual partner 
 Similar to the outcomes of the bivariate association analysis, all of the potential personal 
clinical risks and all of the potential personal risks involving symptoms and side effects were 
statistically significantly correlated with unwillingness to participate, even after controlling for socio-
demographic characteristics. The correlation between concern over these types of risks and overall 
unwillingness to participate in HIV cure-related studies appeared to be universal. Likewise, nearly all 
of the invasive study procedures (i.e. biopsies and spinal taps) and transportation risks were 
statistically significantly correlated with deterrence to participate. Finally, two new variables were 
statistically significantly correlated with willingness to participate that were not in the bivariate 
association analysis: fear of discrimination and the risk of transmitting HIV to a sexual partner were 
associated with a lower willingness to participate in studies, ceteris paribus.  
 Again, short-term and immediate risks, such as those that involved pain or discomfort 
temporarily, have stronger correlation with deterrence to participate in terms of magnitude than 
some of the longer-term risks, such as the potential for enabling cancer or developing viral rebounds 
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over time.  None of the potential risks regarding commitment levels (Models 30 – 32), burdens of 
time and non-transportation logistics (Models 49 – 52), or non-invasive study procedures (Models 
37 – 41) were statistically significantly correlated with deterrence to participate. There were three 
potential risks that were statistically significantly correlated at the 10% level but not the 5% level, 
implying a weak association with deterrence to participate. These included: biopsies of lymph nodes 
as a study procedure, time away from work or school, and being recognized as a person living with 
HIV.  
Respondents who identified a greater number of potential benefits as “very important” 
motivating factors were more willing to participate in HIV cure studies than others, as shown in 
Table 10 below (Model 58, which has an overall model p-value of <0.0001), confirming the 
hypothesis described in the Methods section. Simultaneously, respondents who identified a greater 
number of potential risks as “very likely” to discourage participation were less willing to participate 
in HIV cure-related studies. Controlling for socio-demographic factors, every additional potential 
benefit respondents considered “very important” was associated with a 13% increase to the odds 
ratio of being very willing to participate, on average and ceteris paribus. Every additional potential 
risk respondents considered “very likely to discourage” was associated with a 0.82 odds ratio (an 18 
percentage point decline) of being very willing to participate, on average and ceteris paribus. Both 
results were statistically significant at the 1% level. Respondents who identified a greater number of 
potential benefits as “very important” motivating factors may generally be more optimistic and 
eager to participate in HIV cure-related studies than respondents who only identified a small 
number of “very important” potential benefits. Conversely, respondents who identified a greater 
number of potential risks as “very likely to discourage” participation in studies may be generally 
more risk-averse (or risk-aware) and more cautious about participation in HIV cure studies.  
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Table 10. Multivariate Logistic Regression of Willingness to Participate in All Types of HIV Cure-
Related Studies and the Number of Potential Benefits Deemed Very Important Motivators and 
Number of Potential Risks Deemed Very Likely to Discourage Motivation, Controlling for Socio-






Total number of benefits deemed to be "very important" 
motivators 1.13** (1.05-1.22) 0.002 
Total number of risks deemed to be "very likely to 
discourage" participation 0.82*** (0.75-0.90) 0.000 
Male (vs. female, transgender, other) 0.84 (0.34-2.06) 0.706 
Age 0.97 (0.94-1.01) 0.108 
Ethnicity (vs. Caucasian/White) 
   African American 0.40 (0.14-1.13) 0.083 
Hispanic 0.55 (0.19-1.60) 0.273 
Mixed or Other 0.24 (0.05-1.21) 0.084 
Highest education attainment level (vs. some college or 
less) 
   Bachelor's degree 0.69 (0.34-1.42) 0.313 
Graduate degree 0.47 (0.18-1.22) 0.123 
Annual household income (vs. up to $25,000) 
   $26-$50k/year 1.18 (0.53-2.59) 0.685 
$51-$75k/year 0.64 (0.23-1.79) 0.392 
$76-$100k/year 0.85 (0.28-2.65) 0.785 
$101-$125k/year 1.44 (0.44-4.64) 0.545 
$126-$150k/year 1.89 (0.37-9.76) 0.445 
More than $150k/year 0.59 (0.05-6.83) 0.671 
Region (vs. West) 
   Northeast 0.77 (0.26-2.34) 0.651 
Midwest 0.28** (0.11-0.73) 0.009 
South 0.43* (0.20-0.92) 0.030 
Consider self to be "not at all healthy or not very healthy" 
(vs. healthier) 3.90* 
(1.01-
15.12) 0.049 
Have control over own health care (vs. no) 1.00 (0.41-2.48) 0.991 
Percent of life living with HIV status 0.97* (0.95-0.99) 0.012 
Ever volunteered for an HIV cure study (vs. no) 0.30 (0.06-1.49) 0.140 
n 302     
Model Prob > chi2 0.0000     
*** Statistically significant at the 0.1% level. ** Statistically significant at the 1% level. * Statistically significant 
at the 5% level. 95% confidence intervals are estimated using robust standard errors. 
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Comparing the results of the control variables in Model 58 and Model 1, without any 
variables regarding perceptions of potential benefits and potential risks, the percent of life lived 
with HIV status and self-assessing current health as poor both were consistently statistically 
significant, and with approximately the same odds ratios. In fact, these two variables were always 
statistically significant at least at the 10% level in all models (Models 1 – 58). Both were statistically 
significant at the 5% level in all models, except that self-assessing current health as poor was 
statistically significant only at the 10% level in Models 17, 27 and 43. In all 58 models, the odds 
ratios were very consistent with those reported in Models 1 and 58. The unusual consistency of 
these results attests to the strong validity of the finding. 
In Model 1, age and graduate degree attainment were both statistically significant at the 5% 
level, but neither is in Model 58. In Model 58, region becomes statistically significant (people in the 
Midwest and South were statistically less willing to participate in HIV cure-related studies, 
controlling for all other factors), but it was not significant in Model 1. These variables were 
sometimes statistically significant and sometimes not throughout Models 1 –58. In some models, 
income above $150,000 was statistically significant, with an odds ratio below 1.0 attesting 
deterrence.  
In summary, key multivariate results from the survey include:  
 Even after controlling for socio-demographic characteristics, perceptions of 5 (out of 21) of 
the potential benefits as “very important” motivating factors were statistically positively 
correlated with willingness to participate in HIV cure-related studies.  
 Even after controlling for socio-demographic characteristics, perceptions of 19 (out of 35) of 
the potential risks as “very likely to discourage” participation were statistically negatively 
correlated with unwillingness to participate in HIV cure-related studies.  
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 The three potential benefits that had the strongest positive correlations with willingness to 
participate were all altruistic/emotional benefits. The other two statistically significant 
variables were both personal benefits related to increasing the respondent’s knowledge of 
their own HIV infection. 
 None of the potential personal clinical benefits were statistically significant after controlling 
for socio-demographic characteristics and fewer potential personal benefits were 
statistically significant than the bivariate association analysis revealed.  
 All of the potential personal clinical risks and all of the potential personal risks involving 
symptoms and side effects were statistically significantly negatively correlated with 
willingness to participate, even after controlling for socio-demographic characteristics. 
Nearly all of the invasive study procedures (i.e. biopsies and spinal taps) and transportation 
risks were negatively correlated with willingness to participate, confirming the bivariate 
association analysis results. Fear of discrimination and the risk of transmitting HIV to a 
sexual partner were also associated with a lower willingness to participate in studies.  
 Short-term and immediate risks, such as those that involved pain or discomfort temporarily, 
had stronger correlation with deterrence to participate in terms of magnitude than some of 
the longer-term risks, such as the potential for enabling cancer or developing viral rebounds 
over time.  
 None of the potential risks regarding commitment levels, burdens of time and non-
transportation logistics, or non-invasive study procedures were statistically significantly 
correlated with willingness to participate.  
 Respondents who identified a greater number of potential benefits as “very important” 
motivating factors were more willing to participate in HIV cure-related studies than others. 
Simultaneously, respondents who identified a greater number of potential risks as “very 
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likely” to discourage participation were less willing to participate in HIV cure-related studies. 
Respondents who identified a greater number of potential benefits as “very important” 
motivating factors may generally be more optimistic and eager to participate in HIV cure-
related studies than respondents who only identified a small number of “very important” 
potential benefits. Conversely, respondents who identified a greater number of potential 
risks as “very likely to discourage” participation in studies may generally be more risk-averse 
(or risk-aware) and more cautious about participating in HIV cure studies.  
 Respondents who believed that their health status was relatively poor were 3.9 – 4.5 times 
more willing to participate in HIV cure-related studies, on average and ceteris paribus, than 
respondents who believed their health status was relatively good. This result was consistent 
across all models.  
 The longer respondents lived with HIV, the less willing they were to consider participation in 
HIV cure-related studies, on average. Or, more accurately, respondents who were more 
recently-infected with HIV were more willing to participate in experimental HIV cure-related 
studies. This result is very consistent across all models. 
 Age, higher educational level attainment, very high income, and living in the Midwest or 
South (versus the West and Northeast) were negatively correlated with willingness to 
participate in HIV cure-related studies in some of the models, but not consistently. 
 Gender, ethnicity, having control over one’s own health care, having previously volunteered 
for HIV cure studies, and the remaining categories for income and education were not 
correlated with willingness to participate in HIV cure-related studies. 
 Even after controlling for socio-demographic characteristics, the results of the multivariate 
regressions were often similar, and always consistent, with those of the bivariate association 
analyses, implying robust and consistent analytical results.  
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CHAPTER 5 | QUALITATIVE STUDY RESULTS 
The following section summarizes the qualitative study results from the key informant 
interviews and the semi-structured questions from the U.S. survey on willingness to participate in 
HIV cure-related research. First, we summarize factors that would be important for potential study 
volunteers to consider when joining HIV cure-related studies. We explore possible motivators and 
deterrents to participation. We then delve into perceived risks, including unacceptable risks of HIV 
cure-related research studies. We also explore possible concerns about, burdens of and barriers to 
participation in HIV cure-related research. Additional domains of inquiry include perceptions of 
safety, perceived benefits and attitudes around analytical treatment interruption. The narrative 
then transitions towards factors facilitating recruitment, retention and implementation of HIV cure-
related research. We devote attention to considerations for the ethical implementation of HIV cure-
related research. We conclude by exploring overall expectations around the science and general 
considerations for the field. We summarized the recommendations received from the key 
informants for moving the field forward in the plan for change section. These do not figure in the 
results section in order to avoid redundancies.  
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Key informant interviews were as follows: 
Table 11. Key Informant Interviews by Type of Informants 
Patient-Participants n = 12 
     Male (more willing to participate) n = 6  
     Female (more willing to participate) n = 2 
     Male (less willing to participate) n = 1 
     Female (less willing to participate) n = 3 
Clinician-Researchers n = 11 
    Represented institutions15 were: 
 Johns Hopkins University  
 NIH 
 University of Pittsburgh 
 Rush University 
 USCF 
 UNC-Chapel Hill 
 University of Utah 
 University of Washington  
 
Policy-Makers (Broadly Defined) n = 13 
Bioethicists/IRB representatives n = 6 
Regulators  n = 5 
Strong community advocates n = 2 
Factors to Consider during Decision-Making 
The narrative around factors to consider when deciding to join HIV cure-related research 
revealed that HIV “cure” research will definitely not be curative in the short term. Biomedical HIV 
cure scientists use clinical experiments as probes to try to understand the pathogenesis of the 
provirus and to identify potential drugs that may eventually lead to a cure, and this should be clearly 
explained to potential study participants during the informed consent process. Biomedical scientists 
in turn need to understand why a specific intervention would confer any promise of future 
“therapeutic benefits” before asking potential candidates to participate in research.  A related factor 
to consider was the quality of the science and strength of the pre-clinical or clinical evidence for the 
strategy under investigation.  
                                                          
15
The main HIV cure research modalities were represented, including latency-reversing agents, stem cell 
transplant/gene therapy, pediatric and combination approaches.  
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Patient-participants and clinician-researchers highlighted the significant time commitments 
required for HIV cure research participation as well as potential health factors/constraints, such as 
the current state of one’s health and the potential impact of the HIV cure research strategy on one’s 
health. The current state of one’s health could be assessed by looking at a person’s immune system 
or viral load, presence of co-morbidities or mental health status. In general, biomedical HIV cure 
scientists require very healthy study participants who have not had any viral blips in the recent past, 
or patients with specific conditions such as lymphomas and associated malignancies. Potential study 
volunteers also need to consider how the proposed HIV cure strategy will affect their current health 
status in the short-term and the long-term.  When considered in the aggregate, it takes very rare 
volunteers to both qualify for and agree to participate in HIV cure-related research, because patient-
participants need to agree to the time commitments, appointments, study procedures and 
interventions/medications.  Overall, HIV cure research participation was viewed as being extremely 
complex. 
Patient-participants were the only group to have brought up people in their life as a factor 
to consider when deciding to participate in HIV cure-related research. One respondent explained 
that he was unattached and therefore was free to participate, while another key informant 
explained that she would not be willing to participate given her family.  Patient-participants and 
clinician-researchers expressed a tension between willingness/interest to participate in research 
versus opportunity to join studies. One patient-participant expressed willingness to participate but 
limited opportunities due to the lack of prominent biomedical HIV cure investigators in his state (e.g. 
state of Mississippi). Clinician-researchers agreed that the field of HIV cure research was 
effervescent but that the willingness to participate may exceed actual opportunities given the 
stringent inclusion/exclusion criteria and geographical access issues. Clinician-researchers expressed 
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that some of the HIV cure-related studies, such as simple reservoir studies, were very tedious and 
not as exciting to study volunteers. 
The possible risks and no prospect of direct benefits of HIV cure-related studies were also 
mentioned as important factors to consider during decision-making. The topic of risks was strongly 
emphasized by both policy-makers/regulators and clinician-researchers, and less so by patient-
participants which could be concerning in itself. Clinician-researchers stressed the need for potential 
study volunteers to have adequate information about potential risks before making decisions. HIV 
cure research was described as being quite different from and potentially more risky than the well-
tolerated HIV treatment that most patients are accustomed to. Study volunteers will not personally 
benefit but will help advance the field forward in incremental steps.  Regulators of HIV cure-related 
research were adamant that study participants should have no expectation of direct or tangible 
benefits and should weigh the risks of being in the study, some of which are known and others are 
unknown. Patient-participants should also evaluate the possible impact of their participation on 
their immediate and long-term well-being and quality of life. One clinician-research conducting 
pediatric HIV cure-research emphasized that decision-making factors may be different for infants, 
since they cannot consent for themselves. Therefore, clinician-researchers should pay attention to 
the education component since “many parents are desperate for their children to be cured or to just 
get better, particularly if they are very sick” (clinician-research, #205). Thus, factors to consider may 
vary between types of HIV cure-related research modalities and types of study participants 
Overall, there appeared to be a consensus between clinician-researchers and policy-
makers/regulators that potential volunteers should verbalize why they want to participate in HIV 
cure-related research. Investigators should probe participants wanting to enroll to ensure that they 
do so with acceptable motivations since the clinical protocols are unlikely to provide them with any 
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direct benefits at this juncture. Study participants also need to determine how the study will fit in 
their lifestyle and consider the possibility of risks (or harms) related to study participation.  
Motivators to HIV Cure-Related Research Participation  
Motivators to study participation ranged from tangible factors (such as compensation) to 
intangible contributors such as the desire to donate to science and give back, altruistic motives, 
clinical contact factors and hope (or desperation). Key informant interviews and survey responses 
revealed the multi-facetedness of the issue of motivation to participate in HIV cure-related research.  
The most frequently cited tangible motivator to study participation, particularly among 
patient-participants, was money or compensation. The most important form of compensation was 
reimbursement for travel costs.  In turn, clinician-researchers acknowledged that HIV cure-related 
studies tend to be lucrative given their intensity. The topic of study-related compensation will be 
explored further in the discussion section since it has ethical implications.  
The most widely endorsed motivator to HIV cure-research study participation was the desire 
to contribute to the science or to give back. This was consistent with the quantitative study results. 
This theme also strongly emerged in key informant interviews with all three groups: patient-
participants, clinician-researchers and policy-makers/regulators. Patient-participants were hopeful 
about HIV cure-related research and wanted to help move medical knowledge forward. One 
respondent underwent a very risky procedure (e.g. stem cell transplant) and recognized that he 
played a critical role in answering an important research question. Two respondents stated that 
since people living with HIV were unable to give blood, clinical study participation was a unique way 
to give back to society or regain a sense of normalcy despite illness. Other respondents felt that 
scientists were getting close to finding a cure. One participant wanted to see a cure for HIV 
materialize so that he would no longer have to take medications. Another African-American/Black 
respondent said that he wanted to join HIV cure studies to make sure that African-Americans/Blacks 
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were represented in HIV cure research and wanted to encourage others to participate. The theme of 
helping find a cure also emerged loud and clear in the semi-structured survey on willingness to 
participate. Survey respondents were willing to participate to contribute to the body of scientific 
knowledge around HIV cure research, and no longer requiring antiretroviral medication would be a 
consequence of drug-free remission. One survey respondent answered that “the potential for a cure 
for [him/herself]” and “to get cured from HIV” were motivators to participation. In a sense, these 
responses are more troubling from an ethical standpoint as they may be indicative of the underlying 
therapeutic or curative misconception. Another survey respondent said that “the simple fact that it’s 
a cure study is enough.” Therefore, the word ‘cure’ is obviously very alluring and should not be 
abused. Clinician-researchers recognized that participation in HIV cure-related research provided a 
positive meaning to an otherwise traumatic diagnosis and wanted to be part of the solution to the 
disease. Patient-participants, they felt, like to be part of something larger than them and the cure 
would not materialize and scientific progress would not occur if they did not step forward. One 
clinician-researcher felt that interacting with patients was by far the most fulfilling aspects of his 
work since patients were so eager to donate and give back. Policy-makers/regulators also 
recognized the patients’ desire to contribute to science in order to repay those who have come 
before them, although stated that these desires may be mixed with the hope of direct benefits. 
Altruism was ubiquitous as a factor motivating participation in HIV cure-related research. Patient-
participants, clinician-researchers and policy-makers/regulators described altruism at length. Some 
respondents distinguished between social altruism and self-altruism and recognized that altruism 
may not be pure since participants may have underlying expectations of personal benefits from 
joining studies. Patient-participants also recognized altruism in others and revealed that personal 
circumstances (e.g. health status (CD4+ count) or financial situation) may affect altruism. Clinician-
researchers expressed gratefulness for the generous altruism of their study participants and agreed 
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that selflessness cannot be under-estimated in HIV cure-related research participation.  Altruistic 
motives, however, are sometimes mixed with other factors, such as scientific curiosity or the desire 
for monetary gain. Clinician-researchers said that, compared to HIV treatment research, HIV cure 
research is far more altruistic. Some HIV cure study participants possess a lot of sophistication and 
understand the process of participation. One clinician-researcher revealed that some of his study 
participants possess “pure altruism” because they refuse to enroll in commercial research and only 
enroll in academic research. Another biomedical scientist recognized that altruism is the key 
question in HIV cure-related research, and human participation is crucial because pre-clinical models 
are imperfect and not completely predictive of clinical outcomes in humans. It is difficult, however, 
to decide when a participant displays “too much altruism” and, thus, there should be safeguards in 
place to protect participants from taking on “too much” risks.  Policy-makers/regulators hoped for 
altruistic motives in early HIV cure research participation, but feared that some participants may 
have unrealistic expectations, either real or subconscious, of direct personal benefits. Caution was 
expressed that there is tremendously variability between participants, and individuals join studies 
for a combination of factors, and therefore motivations should not be lumped together. The topic of 
self-altruism was described in terms of the hope that participants can personally benefit from 
research participation. Since becoming HIV-positive can be a terribly negative and defining event in 
someone’s life, participating in HIV cure research may help people cope with the difficult feelings 
related to identity and acquiring HIV. Self-altruism was also discussed as helping one’s future self. 
In addition to altruism, key informants recognized that study participants like to interact 
with research staff and can personally gain from these frequent interactions and personal 
relationships. Thus, clinical contact factors can be strong motivators to research participation that 
should not be under-estimated.  The way study participants feel treated and whether they feel 
respected can have a tremendous motivational or demotivational impact. Study participants 
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appreciated the friendliness, compassion and engagement of research staff and feeling valued for 
the use of their samples or tissues. Another important clinical contact factor was the availability of 
the study investigators in case of emergency or when participants had questions, good 
communication and the reporting of study results in layman’s terms.   
The narrative of hope (versus desperation) also emerged in the key informant interviews, 
particularly among patient-participants. One respondent took part in a risky HIV cure study and 
admitted that the hope to be cured is what drove him to participate. Another respondent said that 
HIV cure research contributes to giving hope to patients so that they do not give up on themselves. 
Accounts of hope were sometimes intermingled with optimism.  The converse of hope, desperation, 
emerged in the context of pediatric and adolescent HIV cure research. From a parental perspective, 
the prospect of lifelong antiretroviral treatment for the child is difficult to accept. When children 
reach adolescence, parents are concerned with treatment adherence issues and thus would prefer 
their teenagers to be cured.  
Overall, motivators to participation in HIV cure research were multi-faceted. The semi-
structured survey revealed additional themes that were not captured during the key informant 
interviews, such as the scientific method/rationale, the preliminary data, the phase of the research 
study, how studies will contribute to the overall improvement of the public’s health, the reputation 
of the principal investigator and the institution, the site location, the disclosure or clarity of risks and 
adequacy of the informed consent, the level of participant education, the study procedures and 
perceived safety of the intervention, issues with current antiretroviral treatment regimen, and 
likelihood of scientific progress or success.  One survey respondent said that s/he would not join an 
HIV cure study unless s/he “had the guarantee of being cured,” which may be a problematic 
motivation in early phase research where there is no expectation of cure. Other motivational factors 
were intangible, like the desire to help end stigma, discrimination and criminalization of HIV.  A 
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subset of survey respondent indicated that no factor would motivate them to participate in HIV 
cure-related research. Therefore, it is important to remember that some individuals are unwilling to 
participate and that HIV cure research participation is not for everyone.  
Deterrents to HIV Cure-Related Research Participation  
For the most part, deterrents to HIV cure-related research participation reflected the 
aforementioned motivators in the reverse, and were both tangible and intangible in nature. In this 
section, we summarize the narratives around scientific issues, compensation and time factors, study 
procedures, perceived risks and side effects and negative clinical contact factors that would deter 
participation in HIV cure-related research.  
As expected, key informants who were in the “less willing” category were rather loquacious 
as to their reasons for not wanting to participate. Here again, it is important to remember that HIV 
cure research participation is not for everyone. One key informant explained her rationale for not 
wanting to participate despite that she strongly supports the HIV cure research agenda. She had 
lived a fairly normal life with HIV for 25 years and was not willing to risk jeopardizing her current 
health status, especially given other concerns around aging for which there is no cure. This 
participant also mentioned wanting to take care of her grandchildren. She preferred to wait until a 
cure was available before she would take it, since this had been her approach with HIV treatment 
and it had worked fairly well to date.  
Deterrents to HIV cure research participation also related to scientific factors. Sub-themes 
included the modality under investigation, the scientific merit of the approach, the early phase of 
experimentation and the stringent exclusion criteria. A survey respondent stated that the concept of 
a ‘functional cure’ was unremarkable as it sounded more like an expensive treatment with the 
possibility of spontaneous viral rebound and defeated the purpose of ‘cure’ research. Others survey 
respondents indicated that the lack of a strong scientific evidence base or rationale or “shoddy 
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science” would be a deterrent to participation. The early phase of experimentation was also a 
demotivator for some who did not want to serve as pioneers for potentially risky first-in-human 
studies. Survey respondents also cited the robust exclusion criteria as a deterrent to joining studies. 
Practical or logistical deterrents to participant centered on financial incentives, time 
commitment issues and location of the research site. Survey respondents stressed that inadequate 
financial compensation would be a significant deterrent. They felt that study participants should not 
have to pay for study-related interventions, surgeries or medical bills, including those resulting from 
long-term complications. Unfair compensation for time, efforts and commitment would deter 
participation, together with unproductive waiting time at the study clinic and time away from work. 
Clinician-researchers also recognized time factors to be of importance since studies fit within the 
realm of experimental medicine and thus require intensive procedures and monitoring. Willing 
participants may not have the time to commit to a study, so researchers need to be willing to work 
around people’s schedules. A bioethicist wondered how professionals living with HIV can commit to 
such intense studies. Further, distance to travel to/from the research site, accessibility and whether 
participants to have pay for parking affect participation.  
Additional deterrents of participation focused around study procedures, possible side 
effects and risks. Examples of deterring procedures included leukaphereses due to fear of needles, 
as well as invasive procedures (such as gut or bone marrow biopsies) and the need to interrupt 
antiretroviral treatment for some studies. Others mentioned “too much cutting” or “major 
surgeries” as discouraging factors. Overall, it seemed that the more invasive the procedure, the 
more difficult it would be to recruit study participants. Demotivating side effects included loss of 
quality of life, long-term, irreversible or debilitating side effects, other unknown adverse side effects 
or impacts on one’s quality of life. Clinical side effects included increases in viral load, decreases in 
CD4+ count and cancer, among others.  Some patient-participants did not want to risk participating 
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in a study that would worsen their health since they are proud of having HIV under control. In turn, 
discouraging risks ranged from potential clinical risks, mental risks or financial risks. Clinical risks 
included pain or discomfort,  becoming resistant to ARVs, developing cancer, needing to give up 
one’s health care provider, becoming infectious, developing AIDS or death. A survey respondent 
indicated that not having the study risks being well-defined up front was a deterrent to 
participation, and this will be explored further in the discussion section as it has ethical implications 
and relates to the topic of uncertainty. Mental risks and financial risks, such as loss in disability 
insurance status, were reported as possible deterrents. 
The three most prevalent negative clinical contact factors that would deter study 
participation related to the poor treatment of study participants, inadequate communication and 
breaches in confidentiality. With regards to the former, perceived rudeness, coldness, lack of 
empathy, unresponsiveness, discrimination or stigma would discourage participation. Survey 
respondents indicated that they want to feel like important contributors to the study and be treated 
as partners instead of laboratory rats. Their time should not be taken for granted. Patient-
participants stated that nurses can either make or break a study: their enthusiasm and ability to 
humanize the process is key to being able to enroll study participants. Personal attention was also 
seen as crucial and it was clear that interpersonal skills, above scientific skills, were required to run 
effective clinical studies. Example of ineffective communication included perceived dishonesty, 
withholding information, false claims or lack of communication from researchers. Finally, breaches 
in confidentiality were seen as serious violations. 
In sum, deterrents to participation ranged from practical/logistical concerns, study-related 
factors and clinical contact factors. As with motivators, this is a deeply multi-dimensional and 
personal issue and there can be as many demotivators as there are potential study participants. Not 
captured in the above narrative was the fear of greed from pharmaceutical companies and over-
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promotion of HIV cure studies as making breakthroughs in science when there is no cure available. 
There was also a subgroup of study participants who did not foresee any deterrent to participation 
and would be willing to participate in any HIV cure-related study.   
Perceived Risks of HIV Cure-Related Research Participation  
Since perceived risks of HIV cure-related research can be such potent demotivators to 
participation, we exercised more detailed scrutiny on this topic in both the key informant interview 
and the semi-structured survey responses. The topic was discussed at length with patient-
participants, clinician-researchers and policy-makers. It became transparent that clinician-
researchers have the most sophisticated understanding of risks related to HIV cure-related research. 
Policy-makers/regulators appear to have book knowledge of potential risks. A minority of patient-
participants also appeared to be knowledgeable about possible risks, but they remained in the clear 
minority. These findings underscore the need to provide additional information to potential study 
volunteers about study-related risks in language that is accessible to them.  
Clinical or Medical Risks  
Most risks to HIV cure-research participation are perceived to be clinical or medical. Some 
patient-participants were unable to name specific risks related to HIV cure research participation. 
For example, one participant said that s/he “[didn’t] think there would be any risks” (more willing 
patient-participant, #101). One respondent said that the field of HIV cure research presents a brave 
new world, and admitted that there were a lot of risks but could not name any specific risk (more 
willing patient-participant, #111). One participant thought that immune reconstitution was a 
possible risk when in fact immune reconstitution was a good thing and would be a clinical benefit if 
it were possible:  “At this time, I could not think of any risks that could be related to the cure 
research. Except maybe immune reconstitution. And that was one of the things on top of my list 
that I was worried about” (more willing patient-participant, #105). Another key informant thought 
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that the margin of risks was low for HIV cure studies since there are so many strategies being 
investigated at present (more willing patient-participant, #111). Compared to the clinician-
researchers and policy-makers/regulators, patient-participants spent more time on the topic of pain, 
a more subjective perceived clinical or medical risk and also a deeply personal one.  Several 
conversations touched upon individual, unique medical realities and presence of co-morbidities (e.g. 
platelet disorder, diabetes, etc.) that could present additional risks. Patient-participants would need 
to take these concomitant conditions into account when participating in studies.  The two most 
often cited perceived clinical risks of HIV cure research participation were developing resistance to 
ARVs and cancer. Additional clinical risks pertained to study procedures (such as the need to 
interrupt treatment), increases in viral loads, decreases in CD4+ count, opportunistic infections, 
developing AIDS, co-morbidities, becoming ‘sick’, nausea (“sickness of the stomach”), hair loss and 
dementia associated with reactivation of the HIV reservoir in the brain.  Patient-participants 
expressed wanting to live long, healthy lives, like HIV-negative people. The prospect of any 
permanent, irreversible harm, debilitation or death would also be highly demotivating. Finally, 
uncertainty about possible unknown risks would be a deterrent to participation. A survey 
respondent said that the possibility of “cure failure” would prevent him/her from participating in 
studies. We will revisit the topic of therapeutic and curative misconception in the discussion section.  
 As expected, clinician-researchers had more astute knowledge about possible clinical or 
medical risks of HIV cure research. The two HIV cure research modalities that were associated with 
the most clinical or medical risks were latency-reversing agents and stem cell transplant/gene 




Table 12. Perceived Clinical – Medical Risks by Clinician-Researchers 
Perceived Clinical – Medical Risks by Clinician-Researchers 
General 
 Risk of procedures; phlebotomies, leukaphereses, invasive biopsies 
 Risk of pain or discomfort  
 Risk that interventions will have unanticipated immediate or delayed toxicities with 
greater impact to health   
Latency-Reversing Agents  
 Recorded adverse events (AEs) – mild to moderate on the clinical trial scale 




 Toxicities (bone marrow suppression, myalgia, dysphoria)  
 Long-term toxicities (mutagenicity, carcinogenicity)   
Checkpoint Blockers 
 Chronic inflammation on the immune system (try to reduce inflammation as an 
effect on the immune system but then need to worry about infectious risk) 
Stem Cell Transplants/Gene Therapy 
 Risks of infection/contamination 
 In the longer-term, could do something genetically to cells that will make them more 
susceptible to give rise to cancer 
Clinician-researchers were adamant about the imperative to reduce or mitigate risks 
whenever possible. They also cautioned about the need to be careful in interpreting risk 
information, such as side effects of the compounds, especially outside the context of the disease for 
which they were previously approved. For example, latency-reversing agents were developed as 
chemotherapy to treat advanced cancers or malignancies, instead of chronic conditions. Therefore, 
the assessment of potential risks and/or toxicities is very different between cancer versus HIV. 
Whereas side effects would be tolerated by oncology doctors, they would become inacceptable for 
HIV clinicians (clinician-researcher, #207). This was reflected recently in the FDA’s decision to put 
Panobinostat on clinical hold, proposed to be tested in otherwise healthy people living with HIV 
doing well on ART. The main concern is that “if you intervene with a potentially toxic drug with 
unknown benefits with respect to cure, [and] if these drugs have irreversible side effects, then you 
have induced harm in someone without really providing them with any direct benefit.” Therefore, 
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clinician-researchers concurred that they need to stay vigilant with regards to emerging data about 
risks in early phase studies. The history of medical research has taught us that some toxicities simply 
cannot not be detected in pre-clinical models. Clinician-researchers also referred to the progressive 
and incremental nature of scientific knowledge. In the gene therapy world, for instance, “ It’s a scary 
thing to be manipulating DNA and one has to be very aware of the possibility for harm there. [But] 
as much work has gone into it, it would appear to be safe otherwise it would not have moved on 
into cure trials” (Clinician-researcher, #208). Besides potential clinical or medical risks, clinician-
researchers also referred to possible opportunity risks of joining clinical studies (clinician-researcher, 
#209). This would mean that if a person living with HIV volunteers in a study, s/he may not be able 
to participate in a subsequent study of an agent that may prove to be more effective, because one 
of the exclusion criterion may restrict on the basis of past participation.    
What transpired from discussions with clinician-researchers is that we need a lot more 
nuance when discussing risks related to HIV cure-related research interventions, and each modality, 
or even each study, should be assessed individually. This is most apparent in the context of pediatric 
HIV cure studies, for which “Risks [to] infants right now are fairly minimal and basically involve the 
risks of the antiretroviral drugs. As things change and therapeutics get incorporated into pediatric 
studies, those risks will change to be more similar to those of adults like adverse events and things 
like that” (clinician-Researcher, #205). Thus, it is important to emphasize that different HIV cure 
research strategies have varying levels of risks.  Similar to clinician-researchers, policy-
makers/regulators were rather comfortable reciting possible risks of HIV cure-related  research 
participation, but their approach appeared to be more didactic, mechanic and categorical than 
clinician-researchers.  
 144 
Table 13. Perceived Clinical – Medical Risks by Policy-Makers/Regulators 
Perceived Clinical – Medical Risks by Policy-Makers/Regulators 
General  
 Various toxicities and side effects, known and unknown  
         Could cause immediate/short-term, chronic or delayed/long-term morbidity or mortality 
         (e.g. cancer) 
 Risks related to the specific intervention and/or agent 
 Procedure or monitoring-related risks  
 Risks associated with treatment interruption 
Risk of viral rebound or reactivation of disease 
Potential health risks (e.g., reduced T cell levels) if the virus is allowed to replicate freely 
for an extended period of time 
Change in the phenotype of the virus  
Development of resistance to ARVs 
Transmission of virus to partners 
 Development of resistance to antiretroviral treatment 
 Limited treatment options in the future  
 Permanent harm of the intervention being used   
 Relative risks (e.g. agent/intervention vs. treatment interruption) 
 Theoretical risks (e.g. death)  
Latency-Reversing Agents 
 Toxicity risks of the specific agent 
 Possible long-term consequences of reactivating latent virus 
 Risk of stirring up other potential latent retroviruses or reactivating other viruses (e.g. 
herpes simplex virus – HSV) 
Stem Cell Transplants/Gene Therapy 
 Risks associated with chemotherapy and/or conditioning to ablate immune system 
 Compared to the other two groups of key informants, policy-makers/regulators were more 
concerned with normative categories of risks, such as known vs. unknown risks, short-term vs. long-
term risks, and real versus theoretical risks. For example, one regulator said: “Well, it’s the risk of 
the unknown… right? And also the risks of the known” (bioethicist, #310). Policy-makers recognized 
the difficult nature of assessing risks in HIV cure-related research, and contrasted this to the HIV 
treatment field where drugs now have well-quantified risks associated with them. A regulator said 
that “[We are making] apples to oranges comparisons at times, even within the same modality” 
(regulator, #309). Clinical studies are designed not for the best medical interest of the individual 
patient, but to answer a specific research question that will lead to generalizable knowledge 
(bioethicist, #312). Because people living with HIV are relatively healthy, the risks of the tested HIV 
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cure research interventions need to remain acceptable and therefore regulators of HIV cure 
research tend to be more risk-averse (regulator, #307).  
Social Risks  
Patient-participants were the only category of informants to have discussed possible social 
risks related to HIV cure-related research participation. This is revealing in itself and the possibility of 
social risks should be emphasized with clinician-researchers and policy-makers/regulators. Examples 
of social risks included: poor treatment by research staff, transmitting HIV to others, disclosure, 
media attention, identity risks, losing one’s employment, losing access to loved ones or stigma. 
Patient-participants were concerned that they would be treated poorly or taken for granted by 
clinician-researchers and that nursing staff would assume that they did not have a career. The risk of 
transmitting HIV to others in the course of HIV cure-related research experimentation (and 
unsuspected viral rebound) was cited as a concern. Another perceived social risk was inadvertent 
disclosure of HIV status, akin to an “outing,” and this generated distrust in the patient community. A 
subset of survey respondents said that they feared their personal information will not be protected 
properly and could be used for dubious ends. Therefore, Health Insurance Portability and 
Accountability Act (HIPAA) regulations enforcing the use of de-identified information were 
perceived as being critically important to be part of a research study. Disclosure of HIV seropositivity 
remains a challenge for several people in the United States, given the pervasive stigma associated 
with the disease. Furthermore, other breaches in confidentiality, unwanted media attention or 
publicity regarding one’s HIV status were perceived as serious personal and social risks to study 
participation. Identity risks were also mentioned, although some respondents answered the 
question in the reverse, saying that they “would gladly lose [their] HIV-positive identity for a cure” 
or that they “[couldn't] imagine a single sane person who would fear losing their identity of being an 
HIV-positive person.” Other social risks included losing employment or losing access to loved ones in 
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the course of study participation. The discourse around potential social risks strengthens the need 
to capture and address social harm events during HIV cure-related research implementation. 
Financial Risks 
 Besides social risks, there were perceived financial risks related to study participation. 
Examples included concerns around maintaining disability insurance or income (including private or 
Social Security), current health care or insurance coverage. One key informant asked whether 
people living with HIV would be grand-fathered in to these programs, given the high likelihood that 
HIV remission would not be permanent.  
Other Perceived Risks  
 Other perceived risks included whether participation in one study would conflict with 
participation in another study. For example, a survey respondent agreed to donate his brain after 
death and wondered if this would present a conflict. Another survey respondent stated that s/he 
lives in a highly criminalized neighborhood, and therefore would be afraid to have his/her 
medication stolen if s/he were to spend too much time away from home.  Another patient-
participant cited the possibility of medical errors and wanted to ensure that proper safeguards were 
in place before deciding to participate.  
No Perceived Risks 
 Around 40 (10%) of survey respondents answered “None” or “Not Sure” to the question: 
“What other potential risks are “very likely to discourage” you from participating in an HIV cure-
related study?” It is unclear if all the perceived risks of HIV cure research participation were 
previously covered in the survey, or whether respondents truly did not perceive any risks to study 
participation. One respondent said that s/he “[did] not have enough knowledge/information about 
potential risks to make an informed comment.” Another respondent stated that “finding a cure 
outweighs the risks.” Yet another person wrote “All I see is benefits in the search for a cure.” From 
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an ethical standpoint, it is troubling that some potential study volunteers only see benefits to HIV 
cure research participation, when in reality the risks far outweigh the benefits. These results 
underscore the need for robust education efforts around possible risks of HIV cure-related research 
participation in the United States.  
Riskiest HIV Cure-Related Research Modalities 
In addition to asking key informants about perceived risks, we inquired about the riskiest 
HIV cure-related research modalities. Clinician-researchers and policy-makers provided substantive 
considerations compared to patient-participants who did not delve into modality-specific risks. Stem 
cell transplantation/gene therapy, latency-reversing agents and combinatorial approaches were 
perceived as being the most high-risk HIV cure-related research strategies.  
A number of regulators informed that the FDA policy requires evaluating each study on a 
case-by-case basis, and therefore it is difficult to determine which HIV cure research strategy is the 
riskiest. All HIV cure research modalities have the potential for adverse reactions, side effects and 
toxicities. Regulators of HIV cure research mentioned that their division reviews specific kinds of 
strategies (e.g. antivirals versus gene therapy). Consequently, it is difficult to know what goes on in 
the other divisions and each review team has a different opinion about what the riskiest strategies 
are. It is therefore imperative to follow the science and the data signals and to adopt a case-by-case 
policy (policy-maker, #309). In order to determine risk levels, it is also crucial to follow study 
participants for several years – sometimes as long as 10 years or more – in order to assess risk 
reliably (policy-maker, #303).  
Stem Cell Transplants/Gene Therapy 
Stem cell transplants and gene therapy emerged as one of the riskiest HIV cure research 
strategies, given the already high (25%) mortality associated with transplants. For example, in the 
Boston patients A and B, the protocol also administered stem cell transplants in two additional 
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volunteers (patients C and D), who each died from non-HIV related transplant complications. Patient 
C received a gentler form of chemotherapy than Timothy Brown, but died from Hogkin lymphoma 
six months after his stem cell transplantation. Another patient from in Europe underwent 
myeloablative stem cell transplantation with cells homozygous for the CCR5 Δ32/Δ32 depletion, but 
passed away with full chimerism prior to treatment interruption, and therefore it was impossible to 
determine whether he experienced a sustainable remission similar to that of Timothy Brown. His 
cells were not infectable in vivo. While this is no proof for HIV cure, it may indicate that something 
was working to prevent his cells from getting infected with the virus (clinician-researcher, #206).   
Bone marrow transplants for patients who do not have cancer are particularly risky, 
between the conditioning procedures and the receipt of genetically modified cells. Relative to other 
HIV cure research strategies, stem cell transplants have been associated with the largest reduction 
in the size of the HIV reservoir, and thus may have the highest chance of ‘succeeding’ in chronically 
infected patients (policy-maker, #306). Zinc finger nucleases were one type of gene therapy that was 
categorized as being ‘risky’, especially when combined with treatment interruption, since any 
interference with the human genome was perceived as unnerving (clinician-researcher, #205).  
Latency-Reversing Agents  
Latency-reversing drugs, or “shock and kill” approaches, were perceived as being very riskly 
as they attempt to knock latently infected cells out of latency and reactivate quiescent virus. These 
drugs are borrowed from oncology and have “nasty” side effects; and yet have not been associated 
with any substantial reduction in the size of the replication-competent HIV proviral DNA reservoir. 
They have led to transient increases in cell-associated HIV RNA, but they also target important host 
enzymes and processes and may act in ways that could cause secondary malignancies (clinician-
researcher, #302).  
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Combination Approaches 
Clinician-researchers recognized that combination approaches would be most likely to lead 
to sustainable ART-free remission of HIV. This may increase the risks incrementally, but may not 
necessarily compound them (clinician-researcher, #201). Risks also depend on the specific 
compound, the dose of the compound and the duration of the intervention. With combination 
approaches, it is difficult to understand the relative contribution of each agent. 
Overally, stem-cell transplants, latency-reversing drugs and combination approaches were 
perceived as the riskiest. In retrospect, this interview question was highly controversial for some. 
Clinician-researchers seemed highly allegiant to their own HIV cure research modality and would 
never admit that it was “the riskiest.” Asking (and answering) this question was a political act, in a 
sense. Most scientists referred to “the other type of strategy” as being the riskiest, likely because it 
was most unknown to them. A biomedical scientist clearly performing high risk gene therapy 
research said that treatment interruptions was the riskiest aspect of HIV cure-related research.  
In sum, the field should always refer back to the best available information at any given time. Given 
the experimental nature of the interventions, there are high barriers to bringing interventions or 
compounds into human studies. The field of HIV research is victim to its own success, in a way, since 
antiretroviral treatment is so well tolerated, and the patient population of interest is healthy. The 
possibility of exposing patients to anything too risky or toxic appears unethical, and HIV cure 
research protocols need to have clear safety and tolerability criteria and signals that can get acted 
upon promptly during HIV cure-related research conduct.  
“Too Much” or Unacceptable Risks of HIV Cure Research Participation  
Perceptions of what would constitute “too much” or unacceptable risks were assessed using 
multiple data sources, including key informant interviews and survey responses. Narratives cut 
across a number of topics that are summarized below. Overall, perceptions of inadmissible risks 
 150 
were variable and subjective. Each group of stakeholders brought a unique perspective to the 
inquiry.  
Regulations and Clinical Holds   
Policy-makers/regulators confirmed that the evaluation of first-in-human (or investigational 
new drug (IND)) protocols is their primary responsibility. If the FDA does not consider a protocol to 
be agreeable, the agency will issue a set of recommendations to the clinical investigator(s) and will 
use the clinical hold if necessary (policy-maker, #309). There is a category of “too much” risk in HIV 
cure-related studies and protocols have been placed on clinical hold in the past (policy-maker, 
#302). The assessment is usually based on the available evidence or the strong biological plausibility 
of possible severe adverse drug reactions (policy-maker, #302), even though this is more a 
judgement call than a clear science. If severe adverse drug reactions would be expected in more 
than 2 – 3% of participants, this may be “too much” risk (policy-maker, #302).  The FDA recognized, 
however, that there are “black boxes” in the field and this is why the agency remains conservative 
(policy-maker, #303). For repurposed drugs reserved for metastatic cancer used in otherwise 
“healthy people,” there needs to be a clear rationale for moving specific doses of compound 
forward (policy-maker, #303). 
Policy-makers/regulators referred back to the regulations. There are two possible scenarios 
that would constitute “too much risk:” 1) insufficient information to assess risk – either insufficient 
data from animal/pre-clinical studies to make a good assessment about safety, optimal dose or 
duration of product, or 2) insufficient benefits to outweigh the risks (policy-maker, #307).  
Furthermore, risks would be deemed unacceptable if the procedure or drug was known to be 
significantly toxic and there would be no counter-balancing procedure to reduce risk (policy-maker, 
#309), or if a drug was known to be toxic without strong evidence that it would deplete the HIV 
reservoir (policy-maker, #309). Regulators would further be concerned if the study failed to include 
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a well thought-of study design, with insightful endpoints and with the prospect of interpretable 
results to advance the field (policy-maker, #309). For example, HIV DNA (or bulk, “junk” DNA) as a 
measure for reservoir reduction may not be interpretable, since only a minority of DNA cells will 
produce viable or inducible HIV provirus and the measure will not be sensitive enough to yield 
interpretable results (policy-maker, #309). The FDA would expect interpretable endpoints looking at 
replication-competent provirus instead of background noise and indicators of uninducible virus 
(policy-maker, #309). A bioethicist stated that the field should also look up to IRBs to make sure that 
unacceptable studies do not occur (bioethicist, #310). 
Patient-Participant Perspectives  
The perspectives of patient-participants are particularly revealing when it comes to 
assessing unacceptable risks in HIV cure research. There was tremendous variability in the 
responses, contingent upon each patient-participant’s risk threshold.  For some, the mere fact that 
HIV cure studies were in the early phase of investigation presented “too much” risk. Any first-in-
human study that did not have an established underlying proof-of-concept in a pre-clinical animal 
model would be unacceptable. Other potential volunteers pointed out specific clinical risk 
thresholds that would be inadmissible, such as increases in viral load above a specific level (e.g. 
detectable, rebound, vengeful multiplication, etc.). Correspondingly, a decrease in CD4+ T cells 
below a specific threshold would be unwarranted, although the acceptable CD4+ count level varied 
between respondents (e.g. less than 100, 200 (AIDS criterion), 500, 800, etc.). Furthermore, patient-
participants conceded being averse to pain; therefore, for some, any painful procedure would 
constitute “too much” risk. Amongst the most popular unacceptable risks were cancer, permanent 
or irreversible side-effects, hospitalization, debilitation or death.  
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Unacceptable Strategies 
The two most often cited “unacceptable” HIV cure research strategies were stem cell 
transplants and anti-PD1 interventions. One patient-participant explained that since he was healthy, 
he would not be willing to go to the extreme of what Timothy Brown or the Boston patient B have 
done and this is where he drew the line. Clinician-researchers felt that stem cell transplants in 
otherwise healthy participants who were stable and suppressed on ART are already going too far, 
especially as scientists are not yet sure what exactly cured Timothy Brown (clinician-researcher, 
#201). A researcher who performs stem cell transplant stated that treatment interruption during the 
transplantation (similar to what Timothy Brown had) is too risky, and that ART should be maintained 
during the transplantation since there is no benefit of stopping ART during the transplant and 
engraftment will be enhanced. Maintaining ART throughout the transplant would also contribute to 
minimizing risks (personal communication). Few key informants commented on the gene therapy 
aspect, although it has been described as being rather “star trekky” and likely pushing it. With 
regards to anti-PD1 approaches, they have shown significant toxicities in non-human primates and 
studies have ceased in humans (clinician-researcher, #201). With regards to latency-reversing 
agents, scientists have to be careful not to “poke and go too far,” as this would cause global 
activation of T cells as what happened in a study in Europe in 2006. A clinician-researcher 
commented that anything suggesting an irreversible and systemic side effect would be 
unacceptable; however, it will not be possible to know until interventions are tested in humans so 
this may remain a circular argument (clinician-researcher, #206). Clinician-researchers commented 
that we need good monitoring systems in place. Scientists are not being too cautious and they need 
to carefully balance the risks and benefits of experimentations.   
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Treatment Interruptions and Associated Risks  
Treatment interruptions indicated in some HIV cure research protocols, and their associated 
risks, were deemed to be unacceptable for a subset of key informants and survey respondents. A 
clinician-researcher explained that testing latency-reversing agents with treatment interruption 
would be reckless at this point, since the compounds have not yet been associated with a 
substantial reduction in the size of the replication-competent proviral HIV DNA reservoir, and 
therefore viral rebound will be almost certain and automatic (clinician-researcher, #206). Reasons 
given by survey respondents for viewing treatment interruptions as being unacceptable included: 
current low CD4+ count and almost guaranteed viral rebound, possibility of losing undetectable 
status, fear of transmitting HIV to others and developing resistance to ARVs. Since viral rebound is 
unpredictable, it was perceived as being “too risky” for some, or associated with risk of brain 
damage or death. Some of the survey respondents were very treatment experienced and did not 
want to risk losing whatever regimen they had left to viral resistance. Other survey respondents 
were not willing to accept the risk of HIV becoming untreatable and unmanageable. One patient-
participant said that he would need to know there is a rescue plan in place before joining these 
treatment interruption studies: “I would need to know that there is some sort of… what do they call 
it… there is a name for it in clinical research but basically a back-up plan. If this happens, if I become 
resistant and if my CD4+ count gets low and my viral load goes way up…. hmmm, there is a plan of 
action for things like that” (patient-participant, #106). Thus, despite the high willingness of 
treatment interruption seen in the survey (e.g. 26% of respondents said they were very willing to 
interruption treatment), it is important to remember that not all people living with HIV are willing to 
go off antiretroviral treatment.  
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“Healthy Subjects” 
The topic of “healthy subjects” generated recent debate and controversy in the HIV cure 
research field in light of the FDA decision to put a Panobinostat + Interferon study on clinicial hold. 
This debate occurred as I was conducting my key informant interviews and thus shaped some of the 
responses. A regulator of HIV cure research confirmed that: “HIV-infected patients who are 
otherwise healthy and on fully suppressive ART have an anticipated life-span approaching that of 
HIV-uninfected patients. From the standpoint of assessing risk-benefit, the Division has consistently 
stated that we view HIV reservoir research in this otherwise healthy population to be similar to drug 
research in healthy volunteers” (policy-maker, #311). There is a fundamental paradox in HIV cure 
research in that the interventions that will likely lead to a cure are risky (e.g. stem cell transplant or 
latency-reversing agents), but the potential study volunteers are now considered “healthy subjects” 
because most are supressed and undetectable for HIV. Therefore, the possibility of harms must be 
minimized to the fullest.  
We discussed the topic of “healthy subjects” with key informants. A patient-participant 
expressed the dilemma eloquently: “for the younger, healthier ones… I don’t know. We are going to 
expose people to modulators, to drugs that are approved for cancer or chemo… I know that those 
doses are a lot lower but there are fears of immune reactivation, lymphoma, cancers, inflammatory 
issues, auto-immune diseases… We don’t know. But obviously if we knew, we would not be doing 
the studies” (patient-participant, #102). Clinician-researchers also recognized the conundrum of 
“otherwise healthy subjects.” One key informant was rather voluble on the topic:   
Where we hit some issues today is that patients living with HIV are doing tremendously well. 
They are living into their… you know… a normal life span (…) So the question is how do you think 
adding on these additional very toxic agents to try to test the concepts of HIV cure, whether it is a 
LRA, a checkpoint inhibitor or a stem cell therapy. How do you go forward in somebody who is 
doing well clinically and then ask them to take this? (…) We are now in 2015, a very different 
landscape. I mean… if we had been looking at cure… you know 10 years ago, it would have been 
very different because you now have one pill once a day for HIV therapy. So the issue is you have 
great therapies today, people are doing well on their therapy and the reason why we came to the 
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whole structured – the ATIs of – 10 – 15 years ago was because of the burnout of taking 15 pills a 
day, the fatigue and all the side effects of the drugs you are dealing with, whether they be 
metabolic lipodystrophies and so on… that’s a different landscape in 2015 having all the drugs 
you have and combinations now moving into the era of the integrase inhibitors and so on and I 
think that what’s changed so much in terms of how you’re thinking about this... You’ve got a 
great ability to treat and deal with the patients so even if you are just going to test a concept you 
know you want to make sure it’s safe and can be given to the patients safely in terms of the fact 
that these people are doing well and no longer.. they are no longer gonna die in a month or two. 
They are going to live a healthy life. If they are infected today, they can live up to their 70s.  
– Clinician-Researcher (#210)  
 
The background of safety and efficacy provided by ART thus confer a fundamental tension 
for HIV cure researchers, since potential volunteers tend to be relatively healthy and suppressed 
(“the almost cured”). Latency-reversing drugs would be tested in individuals with high CD4+ counts. 
This compares to other modalities, such as gene therapy research that would enroll participants 
experiencing treatment failure or stem cell transplants that would enroll participants with 
lymphomas or other cancers already requiring a transplant.  
The Panobinostat clinical hold provided one of the best cases to study this issue in real-time. 
Obviously, the barriers to move compounds into humans increase if undetectable HIV disease is 
considered a state of normal health or restoration of health with regards to their long-term 
prognosis.  A regulator of HIV cure research explained that the FDA sees a difference between 
“healthy volunteers and stable HIV-infected adults” (policy-maker, #311). This goes back to the early 
HIV cure studies having no prospect of direct clinical benefits and therefore study participants need 
to have a good life expectancy and treatment options (policy-maker, #311); however, this subset of 
participants paradoxically also has the most to lose from HIV cure research participation. Clinician-
researchers need to find a delicate balance between the safety of the experimental agents and the 
efficacy they are hoping for. The FDA thus tends to remain conversative and researchers should not 
give one dose more or a longer duration of a dose than is necessary to study a proof-of-concept 
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(policy-maker, #311). In the case of the Panobinostat study, the dose was arbitrary16 (policy-maker, 
#311). The FDA viewed this as a perfect storm of a problematic situation whereas “ the combination 
of a highly toxic drug with potentially life-threatening risks, no anticipated benefit, and insufficient 
data to know if modifications of trial design (such as lowering dose or total drug exposure) would 
substantially lower participant’s risks” (policy-maker, #311). The FDA had no choice but to place the 
Panobinostat + Interferon study on clinical hold.   
The risk profile is very dissimilar for people living with HIV who have successful treatment 
alternatives than for advanced cancer patients. The FDA considers suppressed people living with HIV 
as “healthy volunteers” in terms of risks and benefits. Clinical investigators must start studying new 
compounds at low dose, or with very small cohorts (sometimes a single patient cohort). The grading 
of risks is different from cancer to HIV and separate scales are used since there is a different 
risk/benefit assessment in advanced cancer patients (policy-maker, #311). Because the optimal dose 
is not always known for new possible “HIV reservoir reduction” or “HIV remission” agents, the FDA 
employs a more conservative approach. It was explained to me that protocols are reviewed on a 
case-by-case basis (policy-maker, #306). Whether an IND gets approved “depends on the overall 
scenario and the study population” (policy-maker, #306).  
Clinician-researchers supported the need for case-by-case evaluations. For example, one of 
them said that “drugs that are known to cause immuno-suppression or to increase risk of later 
malignancies. (…) I would evaluate [these] on a case-by-case basis. Long-term health risks are 
something that I generally advise against without knowing additional information that would 
                                                          
16
The label indication for Panobinostat (Parydak) in refractory multiple myeloma is 20 mg given every other 
day for 3 doses per week for Weeks 1 and 2 of each 21-day cycle for 8 cycles, in combination with bortezomib 
and dexamethasone. Although the mg dose was the same in the Panobinotat + Interferon study, important 
differences were that investigators were proposing to give 3 doses every 4 weeks (in contrast to 6 doses every 
3 weeks) and not giving bortezomib and dexamethasone.  
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mitigate the risks. I think we can go too far with what we do with individuals” (clinician-researcher, 
#209). Another biomedical researcher studying the gene therapy approach commented that:   
That really has to be on a case-by-case basis. Clearly, we’ve done some things like that in terms 
of the inclusion/exclusion criteria [in our studies]. Clearly some of the transplant-based gene 
therapy approaches that require heavy conditioning are obviously only appropriate in situations 
where people need those kinds of chemotherapy for some type of cancer or something like that 
and that’s why some of our trials have been limited to those from the beginning. The risks and 
benefits are very personal decisions. There are risks in a number of things. We’ve seen risks in 
the CAR T-cell world that have been used for cancer, but some people are talking about that for 
HIV cure. There have been substantial toxicities with immune immuno-modulators. LRAs like the 
HDACis may have deleterious effects on cellular gene expression that have been under-
appreciated. We are obligated ethically and I hope people take that seriously in terms of really 
having a conversation with potential participants to get that across. There is an enormous 
benefit to the field when people are willing to take some of that risk on. There is not any study 
that I would tell people absolutely do NOT think about this as a blanket statement. There are a 
lot checks and balances in our system now – thank Goodness – to prevent unethical or 
dangerous studies from ever getting started in our country, so that’s a good thing. 
 – Clinician-Researcher (#208) 
  
The topic of “healthy subject” will likely continue to generate debate in the field of HIV cure 
research. Clearly, it appears that a case-by-case analysis of the participant population, the proposed 
intervention, the dose and the duration of the product is warranted. The FDA examines the safety of 
each proposed intervention and ensures reasonable risk-benefit ratios for what is being 
investigated.  We will explore risk-benefit ratio assessment further in the qualitative analysis 
section, and again in the discussion section.  
Beyond Clinical Risks: Social and Financial Risks  
Patient-participants also touched upon potential social and financial risks that would be 
unacceptable. These included significant changes in quality of life, such as not being able to exercise, 
walk or speak, increased fatigue and lack of normalcy. A study participant was not willing to relocate 
to participate in a study, because it would cause a major disruption in his lifestyle (more willing 
patient-participant, #107).  A subset of survey respondents indicated that becoming detectable for 
HIV and increased risk of passing HIV to sexual partners would be unacceptable. Other social risks 
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included inability to work, care for family and media attention. Unacceptable financial risks were 
also identified such as insufficient compensation for the required biopsies and interventions. 
One of the discussants said that the interview question was “very challenging (…) because 
too much risk is a subjective analysis (…) Certainly, that is a lot of risk even though it may be[that] 
we will find out everything that we need to find out. That’s an individual choice. It’s very hard to 
answer that. It’s for each person and their stage of life (…) I have had a very healthy experience. I 
have certainly have had a medical roller coaster for over 10 years, but manageable. But also my 
emotional personality, I am able to cope with that, compared to someone who might be in late 
stage of life. They might be willing to take less risks than I might [be willing to] take” (more willing 
patient-participant, #112). Clinician-researchers also expressed the importance of case-by-case 
analyses for individual participants. For example, one stated that “I think this is relative to the 
patient so if they are very ill, then I don’t think/know that there would be a definition of too much 
risk for them. But if they are very healthy (…) and their therapy is working and they are suppressed, 
then these would be the ideal patients to be in a cure studies. [I am] [n]ot sure where the line is for 
too much and I am not sure there is a line. That’s a personal opinion and again brings the idea of 
patient education and everyone needs to make that decision for themselves” (clinician-researcher, 
#205). Similarly, another clinician-researcher said that “there are variations from patients to 
patients. Not all investigators are created the same and not all patients are [either]. And some 
patients can handle the anxiety of the treatment interruptions better than others. Some might not 
be good candidates for (…) the gene therapy trials that are around. I would not say that there are 
ethical differences between the types of trials, but certainly different trials appeal to different types 
of patients” (clinician-researcher, #211). Willingness to take risks is thus a very personal choice, and 
the entire make-up of the potential volunteer, including physical and mental state, should be taken 
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into account. Clinician-researchers should also respect the autonomy of study candidates when 
making decisions to participate.  
Further, policy-makers/regulators also recognized the subjective nature of unacceptable 
risks. For example, a policy-maker admitted that “This is a hard question and I know some people 
may have views on risk thresholds. Only a handful of people have tried to evaluate risk thresholds in 
HIV. Let people give kidneys, let people sky-dive, let people volunteer for the military so why can’t 
we let people take on similar levels of risk in research? (…) David Resnick argued that we should not 
allow for more than 1% risk of serious harm or death; yes it is arbitrary but we need to pick 
something. [This is][r]eally gonna depend on the nature of the study, the benefits and the science, 
[and] how the risks are being managed and controlled” (policy-maker, #301). Another bioethicist 
asked us to “Imagine a situation where someone knew they would die in three months, and if the 
worst risk of the cure trial is to die within one month, then it would make sense for such a person to 
volunteer in a cure study because s/he may die sooner. But they would have died in a fantastically 
significant way helping humanity. They could do something really crucial for society and it would be 
rational to take on that level of risk” (policy-maker, #312). Similarly, another policy-maker said:  
Too much for whom? This is one of the things that I don’t know how much has come up in terms 
of actual studies. It comes up as a thought experiment. Patients who are run through all the HIV 
drugs, [with] high viral loads with current regimens, definitely need an intervention but will be 
poor candidates for HIV cure studies (…) The paradox [is] that those who need these the most 
may not be able to join trials. They need an interventions; they may be willing to take on more 
risks; like cancer patients who are more willing to take risks. It could be the only option they 
have. What makes people feel uncomfortable about HIV cure research is because people are 
doing so well on HIV treatment. (…) A lot of the time, risk assessment is done in an imaginative 
way. We just don’t have enough data. Decision making is not entirely rational. We do not have a 
rational process to evaluate the risks/benefits for these interventions and a way to decide on the 
ethical questions. [These] [q]uestions have not yet been solved.   
– Policy-Maker (#304)  
 
Similar discussions occured with bioethicists and IRB representatives. The question of “too 
much risk” is one that will be difficult to answer and that can never be answered definitely once and 
for all. It is difficult to draw a line with risk thresholds, and the determination of what is “too much” 
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depends on the intervention, the population being studied and the pre-clinical work leading up to 
the human study. As evidenced with phase III HIV vaccine candidates that scientists thought were 
protective, yet resulted in increased risk of HIV acquisition, the field of HIV cure research may 
witness surprises (policy-maker, #305). Risk thresholds will also vary depending on the value of the 
scientific intervention for society, but limits have to be placed to preserve trust in the research 
enterprise (policy-maker, #312).  
What compounds the difficulty in determining risk thresholds in HIV cure research is the 
scientific uncertainty. Not having a good indication of what all the risks are – including some of the 
unknown risks – make the assessment more challenging. Interestingly, a subset of HIV-positive 
participants said that they would not place any upper threshold on risks in HIV cure-related 
research. Three patient-participant key informants (#105, #108, #109) (out of 12) said that they 
could not think of anything that would be “too much” risk and that they would undergo stem cell 
transplants or ingest latency-reversing drugs. They expressed that they would be “willing to do 
whatever it takes” (more willing patient-participant, #105). A couple of HIV veterans said that they 
took a lot of risks in their lives, and this is what has kept them alive. They are willing to do anything 
because this is how they have managed to survive up to now (personal communication).  Similarly, 
26 of the 400 survey respondents indicated that nothing would be “too much” risk for them, and 
this may have ethical implications that we will explore further in the discussion section. A clinician-
researcher said that “[nothing] that has been seriously proposed out there that is probably too risky 
for anyone to consider. There are the crazy ideas outside of scientific thoughts, like ozone or bleach 
years ago – horrible things. [But] [o]verall, I think that some of the ideas that people are discussing 
in terms of cure, that have become mainstream, have been vetted quite a bit and we sort of know 
pluses and minuses and the weak points of each” (clinician-researcher, #208).   
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In sum, the topic of “too much” or unacceptable risk in HIV cure research generated a rich 
debate among all types of key informants. The question remains open and the process for 
determining risk thresholds becomes more of a thought process than a definite line researchers 
(and participants) cannot cross. As biomedical scientists continue to diversify and scale-up HIV cure 
clinical studies, perhaps they should never let go of the question of what is “too much” risk.    
Concerns, Burdens and Barriers around HIV Cure-Related Research Participation  
We asked key informants to describe some of the main concerns they had with regards to 
HIV cure-related research. This question was meant to anticipate some of the possible unforeseen 
or unintended consequences of the HIV cure research enterprise. Most of the concerns related to 
the terminology of ‘cure’, safety issues and impacts on current health, treatment interruptions and 
circumstances after study participation or post cure discovery.  
First, the word ‘cure’ was disturbing for some since HIV cure studies will not be curative in 
the short or medium term. A patient-participant summarized the issue beautifully: “There is a big 
concern that the word cure (…) you know using the word cure in any study provides a bias to the 
patients who think there is a benefit to them.  The word cure is hot, sexy and it gets enrollment… 
but it may give unrealistic expectations to patients. We’ve talked a lot about that and I don’t think 
we have found a solution. The word cure is there to stay. The alternative is the word remission.  We 
have come back and forth. My only concern is that some patients may be joining thinking they will 
get benefits. But most studies have risks and that is the ethical part that concerns me” (more willing 
patient-participant, #102). The related risk of curative misconception was highlighted as a concern 
by clinician-researchers. Clearly, the word ‘cure’ generates excitement as an aspirational goal; 
however, potential volunteers may believe there is a chance that they will get cured. The case 
report of Timothy Brown being cured may complicate the matter: “And some patients think that 
they will be the next Berlin patient. (…)There is often more of a focus on the exciting science than on 
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the potential harm to the participant” (clinician-researcher, #207). While it is difficult to abandon 
the word ‘cure’ to describe this research, most of the people living with HIV today will not be cured. 
It is thus important to keep this in mind when discussing these types of studies.  
Patient-participants and clinician-researchers expressed genuine concerns about safety. 
Patient-participants were concerned about how the HIV cure experiment would affect their current 
health status. Patient-participants who were less willing to participate in HIV cure research 
expressed greater causes for concerns. For example, a discussant said that: “If I am participating in 
that kind of study and get sicker and sicker because I participate, that would be the only thing that 
would keep me from doing it. Getting sicker quicker” (less willing patient-participant, #104). 
Similarly, another respondent stated that: “Just the concern of HIV spiking or just the implications of 
not having the treatment or some weird thing coming up that was not thought about happening or 
was not planned” (less willing patient-participant, #110). Clinician-researchers also discussed some 
of the concerns that their study participants have about safety and health impacts of HIV cure 
research interventions. For instance, a clinician-researcher studying latency-reversing agents said 
that “Some of the patients are concerned that they will have the same side effects as people going 
through chemotherapy.  They are [also] concerned about side effects of [the] leukaphereses.  It is 
good that patients are concerned about these things, because these are not risks to be taken lightly” 
(clinician-researcher, #202). A clinician-researcher studying the effects of stem cell transplants 
stated that: “There are folks that we have on the cancer protocols, sort of the Tim Brown [type], 
treat the cancer and find out what happens with the HIV at the same time. One of the very 
important question is will any of this interfere with our cancer treatment? People often ask that and 
the answer is no. The really important thing is that the first thing being treated is the cancer. People 
ask about additional toxicities. We have other questions about whether this will make HIV worse. 
There is a variety of things and not one that stands out” (clinician-researcher, #208). Additional 
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concerns are expressed with regards to the impact of treatment interruptions, and these will be 
summarized in the treatment interruption section (below). Combination approaches have also 
engendered concerns among stakeholders, since factors may be accentuated when combining HIV 
cure-related strategies. There are concerns that combination interventions will complicate the 
process of informed consent since they will be more difficult to explain to potential study 
participants. It will be more difficult to elucidate the distinct effect of each component when 
strategies are combined. There were also concerns with the freedom to collaborate between 
stakeholders on these combinations, as some interventions may be restricted by intellectual 
property rights. Overall, the fact that key informants expressed concerns related to HIV cure 
research is indicative their they are cognizant of the potential risks and consequences of the 
research. Stakeholders voicing concerns is a healthy component of the process to ensure that HIV 
cure-related studies are implemented with minimal unintended or unanticipated consequences.  
Additional concerns were expressed with regards to the consequences of study 
participation, such as long-term possible side effects and risks, including mutagenicity, 
carcinogenicity and teratogenecity. The very prospect of having a “failed cure” was also troubling for 
some. Worries were communicated for the post-study participation period: “Once the study is over, 
you can’t get the drugs anymore. If I find out that I have to take medication for the rest of my life, or 
not have to take medications, it would be nice to know. Also, you need to ensure that people are 
not left hanging dry after the study is over – whether it succeeeds or not. Whether it be with 
medication or immuno-suppressive drugs” (more willing patient-participant, #107). From a 
translational implementation standpoint, it was interesting to find that some people living with HIV 
are already thinking about what a world with a cure for HIV would look like, and what some of the 
anticipated and unanticipated effects may be. Concerns emerged with regards to whether the cure 
will be mandated as standard of care, what the monitoring will look like, impacts on families and 
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relationships, and costs associated with cure. The cure for HIV was compared with the cure for HCV 
which has become an expensive standard of care (more willing patient-participant, #107). These 
concerns may be compounded given that the population of people living with HIV is aging in the 
United States. For example, a respondent examined some of the possible consequences of a world 
with a cure:  
And you find that you have a cure. Then, everything else changes. Now, is it going to be 
mandated that everyone takes this cure? And then you have to follow people for a long time. 
You have to see what happens. You have to see the side effects. The good and the bad. There 
may not be any. What happens then? Then it’s other things that are put into place. Then it will 
cost more to take care of these people who have HIV. Then what happens? They can’t rely on 
the… well, on the system to take care of them anymore. That’s sad. You still need to put 
something into place for the people who are sick. Or now they have to find their own job skills 
and go to work because they are not dying anymore. I am not saying that it can’t happen. It can 
happen. After it’s a proven fact… then would I be willing to take it? Sure. That’s one less disease 
that I have to deal with. Now I have to deal with old age disease…. You know, high blood 
pressure and all that. And there’s no cure for that.  
– Less Willing Patient-Participant (#104) 
 
As biomedical scientists get closer to finding a cure for HIV infection, it will be important to 
anticipate some of the consequences of having a drug-free remission for HIV for individuals, families 
and the health care system. Perhaps there can be lessons to be drawn from previous cures.  A 
couple of key informants, however, admitted having “no concerns at all.” One of them stated that: 
“I believe that people who are involved in HIV cure research are really looking for helping the 
millions of people on this planet that are dealing with it. I don’t think that a Tuskegee is coming, at 
least I hope not” (more willing patient-participant, #111). Another discussant said the he was 
“trusting of the medical research world to do what’s appropriate” (more willing patient-participant, 
#112). These findings show that there is heterogeneity in the types of concerns people have around 
HIV cure research. The snapshot of possible concerns is diverse, yet raises the need to prevent 
unwanted or unintended consequences, harms and impacts on health. We will also need to manage 
the risks of failed cures (which will be very high initially), post-study participation realities and 
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impacts on the health care system. The field should also be tremendously cautious with the use of 
the word ‘cure’.  
Perceived Burdens of HIV Cure-Related Research Participation 
The main burdens associated with HIV cure research participation touched upon side 
effects, time commitments and intensity of study visits, as well as travel-related constraints. Two 
examples of side effects under the rubric of burdens – as opposed to risks – were skin rash or 
diarrhea. Other side effects were mentioned as perceived risks (above).  
Significant time commitments were mentioned by both patient-participants and clinician-
researchers.  Taking time away from work and finding time for study visits were significant burdens. 
Clinician-researchers mentioned that time commitments are real deterrents to study participation. 
They recognized that patient-participants lead complex lives. The complicated study procedures 
may not fit in their schedules. This is especially true for women with children or child-care 
responsibilities. Furthermore, some of these studies may only be adequate for individuals who are 
not working, but these are also usually not the people who are on the healthy side of the spectrum, 
hence another paradox (clinician-researcher, #202).   
The intensity of study visits was described extensively by most clinician-researchers. The 
main reasons for the intense nature of HIV cure research are the need for serial blood draws or 
leukaphereses, frequent monitoring (especially with treatment interruptions), numerous biopsies in 
some cases (e.g. gut, bone marrow, rectal, cervical, lymph node biopsies or lumbar punctures). 
Furthermore, given that the HIV reservoir is present at extremely low levels, in only 1 in a million 
infected cells, large amounts of blood must be drawn. HIV cure research participation can cause 
significant disruption to normal activities. Consequently, key informants commented that study 
participants should be compensated adequately for these time-intensive protocols and women 
should also receive compensation for child care (more willing patient-participant, #102).  
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Travel to and from the research site was also perceived as an important burden by patient-
participants and clinician-researchers. This finding is consistent with the results from the U.S. survey 
on willingness to participate, where the difficulty of finding transportation to the site (17% very 
likely to discourage participation) and of finding parking at the site (20% very likely to discourage 
participation) were cited as the most frequent burdens of research participation.  Other travel-
associated burdens included having to go to another city, finding lodging or parking, and planning 
for public transportation. A clinician-researcher said that transportation issues are the most 
significant deterrents to study participation for some of her participants (clinician-researcher, #202).   
HIV cure research teams must proactively address potential burdens of study participation, 
included side effects, time constraints, intensity of visits and travel/transportation realities for study 
volunteers. Helping alleviate burdens may go a long way in helping study participants attend the 
required study visits. Small steps such as enough advance notice for study visits, gas cards and bus 
passes can go a long way to ensure that travel burdens are minimized. One patient-participant 
wished for a mobile leukapheresis machine to could come to his home regularly to help remove 
some of the burdens of study visits. Overall, clinician-researchers appreciated the “personal 
sacrifice” from their patient-participants.  
Perceived Barriers to HIV Cure Research Participation  
A topic related to burdens of HIV cure research participation was barriers. There was some 
overlap in the responses between burdens and barriers.  For this reason, the themes related to time 
commitments and intensity of study visits were only discussed in the burdens section (above). The 
most prevalent types of barriers to study participation included: general barriers (including 
geographical availability) and other logistical aspects, finding study participants, stringent 
inclusion/exclusion criteria and stigma. 
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With regards to general barriers and access issues, some key informants recognized that 
barriers are not unique to HIV cure research, but applied to clinical research generally (policy-
makers, #307, #310). Examples of general barriers included lack of information about the study, 
difficulty navigating the research setting or understanding the difference between treatment and 
research.  Geographical access to HIV cure studies are real barriers to participation and the 
willingness exceeds availability of studies in some areas. Not all major U.S. cities have an HIV cure 
research site. Some potential volunteers reported that they would be willing to travel to a different 
city in order to participate in research. Besides allowing travel, another solution given was to engage 
additional clinics as satellite sites, although this strategy was not endorsed by all clinician-
researchers who said that HIV cure research is very specialized and should only be performed at 
sites that are sufficiently well-equipped (clinician-researcher, #204). Other logistical barriers, besides 
time commitments and transportation, included flexibility of the workplace to facilitate study visits.  
Finding study participants was another barrier identified, especially for HIV cure research 
strategies that require very specific types of study participants, such as those dealing dually with HIV 
and cancer (requiring a stem cell transplant) or acutely infected individuals who would qualify for 
early ART protocols (in Fiebig stages I – V) (clinician-researchers, #204, #205). Key informants 
recognized that enrollment in early phase HIV cure studies is different than for phase III trials. 
Compared to advanced HIV prevention trials that have fallback methods (e.g.  condoms), the 
calculus may be different for HIV-infected volunteers who may be harmed as a result of 
participation. Furthermore, a policy-maker warned against exploiting participants who have no 
treatment option and may qualify for some of the gene therapy trials meant for candidates with 
advanced treatment failure (policy-maker, #305). For pediatric HIV cure studies, the success of 
prevention-of-mother-to-child transmission means that there are fewer infants infected with HIV in 
the United States: 
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From the pediatric perspective, a good thing is that we know how to prevent mother-to-child 
transmission for the most part, thanks to prophylaxis. So that’s a barrier because we don’t have 
that many infants infected with HIV, so not many can be involved in HIV cure studies, at least in 
the United States. What you end up having are very few individuals are who eligible to be 
enrolled in these studies and they tend to have other factors associated with them, such as low 
socio-economic status and reasons why women were not on ART in the first place that interfere 
in their ability to participate in HIV cure studies. It’s a complicated system of access to care and 
the mother’s status. 
– Clinician-Researcher (#205) 
 
Recruitment of pediatric HIV cure participants touches upon delicate issues around 
treatment and access to care for women living with HIV in the United States. Factors that make 
infants seropositive and thus eligible for studies are tied to additional social vulnerabilities.  
Robust inclusion/exclusion criteria were also mentioned as possible barriers to participation. 
A patient-participant who was extremely willing to participate in HIV cure research said that he 
would be excluded from most protocols since he was also positive for Hepatitis B and had multiple 
drug resistance (more willing patient-participant, #102). Inclusion/exclusion criteria were also 
recognized by policy-makers as major barriers to participation. Clinician-researchers provided the 
main reasons why candidates fail screening. We will discuss this topic further in the recruitment 
section (below). Overall, most HIV cure research protocols mandate that participants be “super 
health or super sick” (more willing patient-participant, #102), but usually the people in the middle of 
the spectrum are the ones who are most willing to participate, another paradox (personal 
communication).  
Clinician-researchers admitted to doing a bit of self-selection when approaching candidates 
for HIV cure-related studies. A double-edge sword was exposed in that investigators want study 
volunteers who are reliable and have their life together, but these individuals have job and are thus 
less available to participate in research (clinician-researcher, #202). It may also possible that 
researchers select candidates on the basis of who is best positioned to respond to a specific agent or 
intervention, although this should not drive their decisions (personal communication).   
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Stigma was stated as a major barrier to HIV cure research participation, and even with 
robust HIV treatment (or cure), stigma would not disappear. HIV/AIDS is still viewed as a gay man’s 
disease in the United States (more willing patient-participant, #101; less willing patient-participant, 
#104). Another root cause of stigma was lack of understanding about the disease, including 
transmission routes (more willing patient-participant, #101). A woman living with HIV described her 
deep and personal experience with stigma:  
I keep coming back to the issue of stigma. If there were not as much stigma, more people would 
seek help. More people would get treatment. More people would feel supported. I feel very 
vulnerable when it comes to this issue. I don’t tell people because I feel very vulnerable. I 
actually had a doctor one time, who said: “How did you get that?” “How did that happen?” you 
know. Oh my God, do you realize how inappropriate that was! I felt so exposed.There is a lot of 
education that needs to happen for the community as a whole but also people who are working 
with the patients. I don’t talk about it and I keep it to myself. I think stigma is the biggest issue 
that is always going to be in the way of getting women involved, especially women who are not 
the usual face of HIV.  
– More Willing Patient-Participant (#109) 
 
In this account, stigma was associated with feelings of vulnerability, even in the health care 
setting. Stigma is also associated with ongoing issues around disclosure, rejection and 
discrimination. Some of the stigma may be internalized or externalized and has a profound impact 
on whether patient-participants decide to join HIV cure research.  
Clinician-researchers indicated that most of their patients remember the exact time when 
they were diagnosed with HIV, since it was such a marking even in their lives:  
Taking a step back, being diagnosed with HIV, you know, as a clinician, when a patient comes in 
and they are diagnosed, our first visit is largely spent going through and talking about that 
diagnosis. What I found is if I try to do a lot more, like explain labs and explain how the clinic 
works and if I start treatment or prevention at that point, they fail, and it’s largely because 
people really struggle with this diagnosis and [this is] normal and healthy. This disease carries 
tremendous stigma even though it’s treatable. People will tell you the exact day, the moment, 
the hour when they were diagnosed. They can remember all of these things because it’s such as 
life-changing event. Also in a very personal way, people acquiring HIV sexually or using drugs, 
these are behaviors… (…) It becomes a part of their lives  
– Clinician-Researcher (#206) 
 
The above quotation reveals that stigma cannot be dissociated with the therapeutic 
trajectory of individual patients and decisions of whether to participate in research may factor in 
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perceptions of stigma. Clearly, stigma remains a real problem for people living in the United States 
and more needs to be done around it to demystify the disease (policy-makers, #301, #308). This 
finding is also consistent with the one of the quantitative study results, which showed that 
discrimination was a major deterrent of study participation. Stigma and discrimination reduction 
should be addressed as part of ethical study design and implementation.  
In sum, it may be important to consider that barriers to study participation can exist at 
multiple levels: structural, personal, social, economic and cultural. Our key informant interviews 
only touched upon a small number of possible barriers, such as geographical access, logistics, finding 
the right participants, inclusion/exclusion parameters, stigma and other possible impediments.  It 
may be important to conduct actual empirical studies that examine actual barriers to HIV cure 
research participation.  
Safest HIV Cure-Related Research Strategies  
Since we investigated perceptions of risks (above), we felt it was also important to inquire 
about perceptions of safety. We hereby summarized general considerations for assessing safety, 
including the need for case-by-case analyses. We also outline the HIV cure strategies that were 
perceived to be “safer” compared to others.  
General Considerations 
Policy-makers/regulators provided general philosophic considerations for the determination 
of safety (and risks). They indicated that safety is based on both the risks of the intervention and the 
population selected for the study (policy-maker, #311). Safety cannot be defined simply by looking 
at the HIV cure research method, but it is based on a combination of procedure(s), intervention(s) 
and patient considerations (policy-maker, #311). Even an HIV cure research strategy that is 
considered “high-risk” may become safer if performed in the right population. For example:  
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A bone marrow transplant would be considered high risk in a participant for whom bone 
marrow transplantation was not clinically indicated.  However, for an HIV-infected patient with 
a malignancy that requires bone marrow transplantation, the additional risks related to such a 
study may be minimal to moderate. For such a patient, the risk of participating in a study 
involving bone marrow transplantation may be less than for an otherwise healthy HIV infected 
patient who is taking part in a kick and kill related clinical study. 
 – Policy-Maker (#311) 
 
Thus, assessments of safety are relative. This is why the FDA performs case-by-case analyses 
to determine whether an intervention is “safe enough” to move forward, although no specific IND 
could be discussed given the confidential and proprietary nature of the information. A regulator said 
that he “would not classify one modality over the other as necessarily risky or safe. (…) Just because 
something is gene therapy or chemotherapy does not mean it is worst or safe” (policy-maker, #302). 
Therefore, protocols need to be evaluated on a case-by-case basis because they are different. 
Reviewers of HIV cure research try to learn as much as possible about safety profiles of 
interventions and agree to keep an open mind, because “the jury is kinda out of what will cure HIV” 
(policy-maker, #304). Furthermore, one cannot assume that lowering the dose of a drug will 
increase safety. The evidence needs to be present and this is what reviewers of HIV cure protocols 
look for. Most of the compounds have long development programs and substantial data on how 
different doses react in the body. The FDA recommended leveraging that information as much as 
possible to avoid working blind.  
Perceived Safe HIV Cure Research Strategies  
Key informants perceived specific HIV cure research modalities to be on the safer side of the 
spectrum, including early ART, vaccinations/immune-based strategies, monoclonal antibodies and 
reservoir assessments. Early ART were considered safest and logical, because the drugs are already 
FDA-approved and have already proven to be potent at stopping viral replication. Vaccinations or 
immune-based therapies were also considered safe, particularly those that use ex vivo expanded 
autologous cell systems because they do not introduce foreign agents in the body. Monoclonal 
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antibodies also received the safety vote by the three groups of key informants, despite the dearth of 
long-term safety information on them. Reasons for why monoclonal antibodies were perceived as 
relatively safe were that  they do not interfere with DNA replication but can kill infected cells. They 
have a different mechanism of action than antiretroviral treatment, such as blocking entry. This is 
also a growing industry with over 50 licensed monoclonal antibodies available to date. Monoclonal 
antibodies, however, have gaps in coverage and therefore must be used in combination.  Of the 
latency-reversing agents, two clinician-researchers mentioned that disulfiram was the safest agent 
since it has a good tolerability profile and is already FDA-approved to treat alcoholism; however, it 
was not proven effective at reducing the HIV reservoir (clinician-researchers, #204, #207). Reservoir 
assessments were also considered safe since they are observational and do not require 
administration of any foreign agents. Interestingly, a minority of key informants said that none of 
the HIV cure research strategies were safe at this time (policy-maker, #309).  
To sum up, this section explored perceptions of safety around HIV cure-related research 
strategies. We summarized considerations for assessing safety and described specific HIV cure-
related strategies that are perceived to be safer.  
Perceived Benefits of HIV Cure Research Participation   
We assessed perceptions of benefits in HIV cure research using key informant interviews 
and survey responses. This topic generated rich answers from the three groups of key informants. 
Policy-makers were adamant that there should be no expectation of direct benefits in HIV cure 
research. Societal benefits of knowledge generation around HIV cure research were highlighted by 
all groups of informants. The most commonly cited personal benefits of HIV cure research 
participation were psychological and intangible in nature. Some patient-participants perceived the 
likelihood of clinical benefits, which raised ethical issues around therapeutic or curative 
misconception. As with risk perceptions, there was tremendous variability around perceptions of 
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benefits in HIV cure studies.  Some patient-participants may have confused the questions of benefits 
of participating in HIV cure research with the potential benefits of an eventual cure.  
No Expectation of Direct Benefits 
Policy-makers stated decisively that HIV cure research confer no anticipation of direct 
benefit to study participants, since the aim is to pursue generalizable scientific knowledge (policy-
maker, #311). Very unlikely will HIV cure research interventions change the course of HIV disease for 
participants. Research may actually increase the likelihood of harms (policy-maker, #312). If there 
are any benefits, these will likely be indirect from engagement with the research staff or screening 
tests that may help identify health problems.  Even when scientists tell participants that there is no 
expectation of direct benefit, it is possible that volunteers still expect direct benefits to occur and 
become disappointed when the cure does not materialize (policy-maker, #303). Expectations of 
personal benefits are thus wrong reasons for joining HIV cure studies (clinician-researcher, #313).  
This is why it is important to manage expectations around what the science can deliver in early-
phase studies and to provide adequate education to prospective study participants.  
Societal Benefits  
The main societal benefits of HIV cure research participation related to advancing scientific 
knowledge around HIV cure. Given that HIV cure research remains in the early stage, the societal 
benefits of finding additional information about HIV latency or basic aspects of virology and 
immunology are paramount. Contributing to the biomedical HIV cure research agenda and helping 
future generations was one of the most commonly cited benefits of the research by survey 
respondents. Studying diverse minority populations also helps ensure that the data are 
generalizable. Some of the survey respondents recognized that HIV cure research may have 
applications to other diseases or conditions.  Another perceived social benefit of participating in HIV 
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cure research identified by survey respondents was contributing to reducing stigma around the 
disease.  
Personal Benefits  
The most prominent perceived personal benefits to HIV cure research participation 
pertained to psychological, emotional and mental benefits of contributing to finding a cure. This was 
consistent with the quantitative survey results. These intangible benefits were recognized by all 
three groups of key informants. It was felt that psychological benefits should not be discounted as 
they lead to overall improvements in the quality of life and removal from isolation after a difficult 
diagnosis. People living with HIV felt it was “the right thing to do” to participate in HIV cure research 
and felt pride and self-esteem for being able to be a part of it. A participant who underwent a risky 
stem cell transplant expressed that he felt tremendous emotional benefits after helping further 
medical knowledge (more willing patient-participant, #112). Another participant was proud of the 
fact that investigators developed a special assay for her and that scientists were speaking to her 
directly (personal communication). Furthermore, some study participants valued their experience in 
a clinical study and these benefits may have nothing to do with the intervention itself. There can 
also be psychological benefits of being in regular contact with clinical staff, of being treated like a 
human beings and feeling valued as a result of research participation (policy-maker, #304). Survey 
respondents also expressed a sense of duty, the need to give back and help others, satisfaction in 
being “pioneers” and feeling empowered about their condition. The need for additional qualitative 
research in this area was identified (policy-maker, #304)  
There were perceived clinical benefits of HIV cure research participation. The most 
commonly cited example was the Sangamo study, which resulted in increased CD4 +T lymphocyte 
cells amongst study participants (more willing patient-participant, #102; clinician-researcher, #208). 
While HIV was not completely gone at the end of the study, the body was able to control it better 
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(clinician-researcher, #208). These unexpected clinical benefits, or “off target positive clinical 
effects” (personal communication) may demonstrate a missing element in HIV cure research: that 
clinical benefits short of a cure for HIV may emerge and be beneficial. The Sangamo study reveals 
the importance of intermediate successes along the way to finding a cure and may encourage 
potential volunteers to participate (clinician-researcher, #208).  Early ART has also been associated 
with clinical benefits and encourage individuals at higher risk for HIV acquisition to come in earlier 
for diagnosis and treatment. 
Additional clinical benefits of HIV cure research participation were mentioned in the survey, 
although some of the respondents may have confused the question of benefits of research 
participation with the potential benefits of an eventual cure. Responses such as “taking charge of 
my own health,” “staying healthy,” “increased life expectancy,” “not having to take medications” 
and “being potentially one of the first people cured” may be problematic from an ethical standpoint. 
Besides the example of the Sangamo study, there are no direct clinical benefits to be expected from 
participation in HIV cure research. Furthermore, some survey respondents mixed the desire to help 
advance HIV cure research with the expectation of personal benefits. Examples of mixed statements 
included: “mostly the possible benefits to myself as well as others in the HIV community,” “helping 
myself and others” and “knowing that I did something to contribute to help people including myself 
manage HIV.” 
An unexpected personal benefit of study participation that emerged from the survey 
responses was acquiring information about HIV and being able to educate others. People living with 
HIV saw benefits from learning about cutting-edge HIV research and felt that this information could 
bolster their advocacy work. Armed with this information, participants felt that they could refer 
peers to HIV cure studies. Survey respondents also identified other personal benefits to 
participation, including getting support from others and being able to offer hope. Other perceived 
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benefits to study participants were actually requirements and expectations of clinical studies and 
are interesting from an ethical standpoint, such as reimbursements, “knowledge about the risks 
involved in studies such as the possibility of virus rebound or creating resistance to current ARV” 
(survey respondent), “privacy and confidentiality” (survey respondent) and that “studies be 
professionally/scientifically conducted and based on previous (animal) studies” (survey respondent). 
Statements such as “receiving free nights in a fancy hotel, more money on gift cards and more 
retreats for everyone to share their stories” may indicate that some potential study volunteers are 
misled about the purpose of research.  
Some of the survey respondents stated that one of the benefits of their participation in HIV 
cure research would be ensuring that under-represented populations, like women and people are 
color, get included and represented in studies. The simple fact of knowing that women and minority 
populations are part of the research would be sufficient to confer a benefit because people know 
their group is being represented. Other diverse benefits included “satisfying curiosity,” “leaving a 
legacy” and “having a second chance at life” (survey respondents).  Despite the rich perceptions of 
benefits identified, the likelihood of harms in HIV cure research remains real. One of the survey 
respondents described his own personal story of harm as a result of research participation:  
I have participated in a vaccine trial through [University] in [City] from 1993 to 1995 and was 
given placebo instead of GP120. I have also been involved with Dr. [Name of Investigator]’s 'elite 
controller' research and [University] with Dr. [Name of Investigator] since 2006. I have only 
taken antiretrovirals for a very short period back in 1999—2000 and remained virtually 
undetectable for the virus all on my own. I currently have only Medicare part A and do not have 
a doctor nor am I taking any prescription meds whatsoever.  The clinical research I was 
dedicated to at [University] will no longer allow me to participate since I do not have a primary 
care physician....this I view as a slap in the face after all the tissue and blood I have donated, 
along with many cardiology procedures done to me over the past decade  
– Survey Respondent 
 
This section described perceived benefits of HIV cure research from three types of key 
informants. These benefits are sometimes embedded with vulnerabilities and risks of harm. 
According to policy-makers, there should be no expectation of direct benefits in HIV cure research. 
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Societal benefits included generation of scientific knowledge and contribution to stigma reduction. 
Psychological personal benefits resulting from HIV cure research participation should not be under-
estimated.  Additional perceived benefits of HIV cure research participation may raise ethical 
questions that will be examined further in the discussion section. Volunteers may conflate benefits 
from what is to be expected as part of clinical studies by regulations.  
 “Risk-Benefit Ratios” and Equipoise in HIV Cure Research  
We asked key informants to describe what a “favorable risk-benefit ratio” in HIV cure 
research meant to them. We received diverse answers from the three types of key informants. For 
the most part, the balance was tilted towards risks in HIV cure studies. We found that it was difficult 
to derive objectives measures for risk-benefit assessments given the complex nature of the 
interventions. 
Clinician-researchers  said that when discussing risks and benefits with study participants, 
they stress that “the benefits are usually zero [and] it’s usually just about the risks” (clinician-
researcher, #204). The benefits are accrued to society instead of the individuals. Therefore, the risk-
benefit calculus entails looking at the risks for the individual participants versus the benefits in terms 
of knowledge to society (clinician-researcher, #204).  Only if one “cured a macaque would it be 
easier to justify exposing people to risks in that case” (clinician-researcher, #209). In the absence of 
potential known clinical benefits, the thresholds of safety and efficacy remain high to move the field 
forward.  Clinician-researchers agreed that it is too early to come up with anything that would not 
be subjective at this point (clinician-researchers, #208, #209). One of the key informants explained 
the complexity of making risk-benefit assessments in HIV cure research given the incremental nature 
of the research:    
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I hope nobody has a real answer to that. I don’t think it’s easy to imagine having a simple 
equation that can take you there. It seems to me that it’s pretty easy for us to calculate risks 
and benefits… you know… (…) [We] know the risks and benefits of conventional treatment. We 
don’t really know all of them yet, obviously, but to me, one of the issues here is that you know… 
it’s unlikely that many investigators with some of the trials that are going on now would expect 
those trials to right there find a cure. You know… I don’t think many people would expect that a 
trial with the latest kind of approach to shock and kill will be suddenly curative. Most of us 
expect that (…) the trials that we do in this part of the epidemic will give us incremental 
information. We know that most of the trials will not result in any evidence of clinical remission 
or do anything to the estimate that we have of the reservoir size. But, if they are well designed, 
and well conducted and well analyzed, they will move us along to making progress. So the risks 
and benefits to the participant in that setting is that I am willing to ask somebody to take a 
risk… that this will ultimately move us to the point where we do have a cure. The benefits are 
more ultimate and societal than they are individual and immediate. But how do you really put a 
number on that, that’s really hard. So I think again, working with social scientists and social 
psychologists to  make sure that we are explaining that correctly, and it’s a tough concept. We 
need to make sure that we are not enrolling people in trials under false pretenses. That’s really 
an important part of this. 
 – Clinician-Researcher, #211 
 
Clearly, HIV cure research protocols are evolving and what is done in one study is used to 
inform the next study. It is important to guard against enrolling study participants under false 
pretense. When investigators write informed consent forms, they should state bluntly that there are 
no expectations of benefits (or cure) to the individual participants for the foreseeable future 
(clinician-researcher, #206). Most study participants tend to be comfortable with this concept 
(clinician-researcher, #206). As HIV cure research strategies advance in the translational pathway, 
however, it may become more important to develop metrics around risks and benefits (clinician-
researcher, #208). 
Similarly, policy-makers said that HIV cure research strategies have a risk-benefit profile 
contingent upon the characteristics of the product/intervention, the type of participants, the stage 
of disease and the standard of care available (policy-makers, #307, #311). Policy-makers were in 
general agreement with clinician-researchers that it is difficult to obtain an objective risk-benefit 
measure. Investigators need to focus on the risks of what they are doing and most HIV cure studies 
present greater than minimal risks (policy-maker, #301). While the regulations do not include clear 
risk thresholds, scientists must ensure that risks are justified and work towards minimizing those 
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risks (policy-maker, #301). A bioethicist explained the difficulty of performing the risk-benefit 
calculus. He said that juxtaposing personal risks with societal benefits would be akin to comparing 
apples to oranges:  
Do you mean a number… or a concept? (…) I don’t think that you would derive a number that 
would be rationally justified, that we derived in some way by principles of ethics. We are not 
there. (…) There are several reasons why we are not there. One is [that we are] comparing 
apples and oranges. How do you weigh against each other medical harms on one hand and 
psychosocial benefits on the other? We just in general do not have very good tools for assessing 
those things. That’s one thing. The other thing is that we lack factual information. We do not 
know the likely impact on the psychosocial of the person and it is going to be very hard to come 
up with reliable numbers on this. We don’t have a simple balance.  
– Bioethicist (#312) 
 
Risk-benefit assessments in HIV cure research thus remain subjective measures given that 
we are dealing with a lot of hypothetical and theoretical risks and benefits. Deriving a neat risk-
benefit ratio becomes almost impossible. One policy-maker rejected the concept of risks-benefits 
and preferred to speak in terms of “investments” (policy-maker, #303). Another policy-maker 
referred to the case-by-case analyses performed by the FDA (policy-maker, #306). Overall, there was 
a consensus that the field is evolving rapidly and risks and benefits remain in flux, and this is another 
reason why reviewing HIV cure studies is a challenging task for regulators (policy-maker, #306). It is 
almost impossible to apply a consistent algorithmic approach (policy-maker, #311). “At the end of 
the day, you have to satisfy yourself that the potential benefits outweigh the risks” (bioethicist, 
#310).  
Key informants also recognized that some of the risk-benefit assessments are specific to the 
individual participants (clinician-researcher, #205). Individuals have different risk thresholds, and 
this is compounded with the fact that each intervention is unique. All in all, some of the patient-
participants interviewed described the thought process for how they were making some of risk-
benefit or  “personal balance account[50]” calculations:    
 180 
If the risk-benefit ratio was like 20 – 80% versus 80 – 20% (…) If the research could really could 
make a change as far as the disease is concerned – but maybe it could hurt me, but ultimately 
there is a 1 in 5 chance, but I happened to be that 1, and if what you could learn from me would 
totally change the world…  It’s an opportunity to help a situation.  
– More Willing Patient-Participant (#103)  
 
Well, Timothy Brown was in salvage therapy. He had failed everything. So his risk-benefit ratio 
was good. 
 – More Willing Patient-Participant (#102) 
 
That’s kind of tough for me to answer. They all have some risk, but like everything, it’s a 
calculated risk. The stem cell transplant for me is a bit too risky personally, but the mAb that 
would be okay. With the kick and kill strategy, I could afford to take a hit with my virus so I 
would be willing to have some health repercussions from something like that.  So I think that 
everything has risk, but the most extreme and radical things are what tend to unnerve me. The 
stem cell transplant for me is extremely radical and I would only undertake it if my life were at 
serious risk. 
– More Willing Patient-Participant (#111) 
 
Even though there are no objective risk-benefit ratios, it is apparent from the accounts of 
people living with HIV that subjective assessments of risks versus benefits come into play when 
making decisions about whether to join clinical HIV cure studies. This raises the need to have deep 
and nuanced discussions with potential participants about the different types of HIV cure strategies, 
the specific study protocols and the possible risks and benefits (or lack thereof). Perhaps even a 
matrix approach would be indicated in order to determine which studies would be truly altruistic.  
Equipoise 
A topic closely related to the risk-benefit ratio was that of equipoise. We asked clinician-
researchers and policy-makers to discuss the role of equipoise in HIV cure research. There was 
variability in the responses, ranging from “equipoise applies,” to “it depends” and “equipoise does 
not apply at all.” Understanding the thought processes around equipoise as it relates to HIV cure 
research proved to be an engaging exercise in ethics. In fact, a clinician-researcher defined equipose 
as “the concept in a trial (…) [where] you are going in without any preconceived notion that the 
treatment is going to work or not” (clinician-researcher, #206). This concept is what allows 
researchers to randomize study participants from an ethical standpoint. For example, one group will 
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receive treatment and the other group will receive placebo (clinician-researcher, #206). Equipoise 
relates to “questions for which we do not have solid answers” (clinician-researcher, #206). In the 
field of HIV cure research, equipoise would need to come with a “reasonable assumption (…) about 
what we currently know and what we don’t know about the way the reservoir can be reactivated 
and the next step which would be to see clearance” (clinician-researcher, #206). 
A number of policy-makers and clinician-researchers agreed that equipoise was relevant to 
the HIV cure research field. A policy-maker said that equipoise is “an element that we always 
consider in any research submitted for review by the FDA. There has to be some level of equipoise 
[and we] cannot quantify that” (policy-maker, #307). Equipoise ensures that a study remains 
unbiased and promotes a healthy sense of skepticism that the proposed intervention may or may 
not work (policy-maker, #307). Equipoise was viewed as being imperative to justify moving a study 
forward. Likewise, a bioethicist said that equipoise is “probably the trickiest ethical issue in [his] 
mind, especially [for] someone who is tolerating ART quite well and [has] the infection (…) under 
control” (bioethicist, #310). He referred to the infectious disease doctors who may not agree with 
their patients joining HIV cure studies if their clinical management is under control: “why take and 
why forego proven treatments that are well tolerated for the chance that something may be 
better?,” he asked (bioethicist, #310). He forewarned that HIV cure research has to be informed 
with the absolute best available evidence at any given time. A third policy-maker thought equipoise 
was a useful concept when it relates to the standard of care discussion (policy-maker, #304). For 
HIV, there is a standard of care for treatment and clinical management of the disease, but no cure 
standard of care. She asked whether it made sense to allow experimental studies that disrupted 
standard HIV treatment, and said that equipoise may become more useful when HIV cure 
interventions start to work (policy-maker, #304).  
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Two clinician-researchers expressed that equipoise is absolutely relevant to HIV cure 
research because it guarantees total objectivity about whether something may work or not. One 
said: “equipoise is the word of the day for cure research. I don’t think anybody has the knowedge to 
be able to say in advance whether or not there is likely to be benefits”  (clinician-researcher, #209). 
From this researcher’s standpoint, equipoise meant that there is no evidence to suggest one 
outcome versus another, so equipoise is applicable to HIV cure research. Similarly, another 
researcher said that equipoise is pertinent because investigators should not be “biased in thinking 
[they] will be curing people because there is not a good track record for this kind of research” 
(clinician-researcher, #207). Equipoise was deemed applicable because success remains limited in 
finding a cure, with the exception of Timothy Brown who was cured via an allogeneic bone marrow 
transplant (clinician-researcher, #207).  
In contrast, a policy maker was categorical that equipoise did not apply to HIV cure research 
or clinical research in general. He believed that equipoise was a fallacy that did not necessarily lead 
to ethical studies:   
I do not belive in the need for equipoise in clinical trials in general. I think it’s a mistake of my 
fellow bioethicists. (…) Equipoise is the concept that before the trial begins the different arms of 
the trial will not be expected… there won’t be a difference in the prospects given our partial 
information about the effectiveness of the interventions... and the risks of the intervention… 
There won’t be a difference in the prospect (…) that we place on the different arms and on how 
people will fair on the different arms of the trial. The onus is on the people who believe in 
equipoise to explain why we need that requirement. They seldom give an argument. They assume 
that equipoise is needed without justifying why. That’s a shame. They assume that equipoise is a 
requirement but they do not give arguments. There are trials that would not be ethical even with 
equipoise.  
– Bioethicist (#312) 
 
Most of the arguments against the use of equipoise in HIV cure research pertained to the 
fact that there is no comparator in the HIV cure field that we can used. Furthermore, the field 
remains in the early phase of experimentation, and equipoise is more useful for later-phase 
randomized controlled trials. The current comparison in HIV cure research is between highly 
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effective HIV treatment (one pill per day) with an HIV cure research modality of unknown safety and 
efficacy. This is not an “apples to apples comparison” (bioethicist, #305). A bioethicist said that it is 
“not fair to ask” the equipoise question at this time in HIV cure research because we cannot 
compare an early-phase HIV cure research strategy with a therapy that keeps the virus suppressed 
(bioethicist, #205). Compared to HIV prevention research such as HIV vaccine trials, these can be 
justified ethically using equipoise because there are effective prevention methods, such as condoms 
or pre-exposure prophylaxis, that can serve as the comparators for equipoise. On the HIV cure side, 
there is no robust comparator. Treatment is not cure. As a result, any attempt at making a 
comparison becomes impossible and misguided (bioethicist, #305). In HIV cure research, the key 
question is not so much one of equipoise, but of getting an accurate representation of the risks that 
people are being asked to take on and how these can be justified vis-à-vis the potential scientific 
benefits that have to be gained (bioethicist, #305).  
In a similar thought process, clinician-researchers stated that equipoise does not apply to 
HIV cure research because the modalities being tested are not proven therapies (clinician-
researcher, #203). Equipoise applies when we compare two therapies. For the START trial[51], HIV-
positive participants were randomized to early versus late HIV treatment. In constrast, HIV cure 
research studies do not test established therapies. They are short-term pathogenesis, virologic, 
immunologic, reservoir and latency reversal studies for which there is zero therapeutic benefit to be 
expected (clinician-research, #203). Correspondingly, another clinician-researcher described the 
thought process that goes on in determining the best use of equipoise:  
I use the term a lot in randomized clinical trials to make sure that I feel in my heart and in my 
head that I could recommend either course of treatment to somebody that I really care for like a 
close relative. If I can’t do that, if I feel like I should have one treatment versus the one, or that I 
would want my brother to be treated with one versus the other, then I do not have equipoise. So 
to me, that is a very important question in a randomized clinical trial. If I am thinking about 
equipoise in the context of treatment on a trial versus treatment off a trial, I am not sure how I 
would answer that. We have a pretty good sense of what’s going to happen off a trial. I can take 
one pill once a day with the current drugs with a reasonable expectation that I am going to be 
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fully suppressed and I am adherent and that suppression will continue indefinitely. We know the 
state of current treatment. With investigational treatment, like what are talking about here, 
there is risk. I would say… hmmm I would not try to say that I have equipoise. (…) The question 
becomes given societal needs or potential benefits of finding a cure, with informed consent, 
would it be ethical for a person to participate in research where the intervention would not be 
better than the treatment itself. And you know, people are willing to do different things. If they 
sense that the risk is small, and the benefits may be not to the individual but to society, and if we 
explain that, then that’s why we do research and that’s why people participate in research. They 
are willing to, for the benefit of society, take a personal risk. And it’s our responsibility as 
investigators to make sure that we are designing trials that limit the risks as much as we possible 
and that are are communicating all we can to the participants.   
– Clinician-Researcher (#211) 
 
For this particular clinician-researcher, the topic of equipoise is a deeply personal one. In 
agreement with the policy-makers, equipoise is most applicable to randomized clinical trials with 
established therapies, as opposed to early-phase experiments. Given that the state of current 
antiretroviral treatment is well-characterized, the key implementation and ethical question becomes 
clearly communicating potential risks to study participants and attemping to minimize those risks.  
On the topic of equipoise, most of the key informants fell somewhere in the middle of the 
spectrum, saying that it whether it applies depends on the study, the intervention and the 
population. A policy-maker said that there is equipoise for some studies but not others and this is 
contingent upon the particular protocol (policy-maker, #311). Instead of equipoise, what is 
sometimes helpful are futility rules and safety endpoints that minimize risks (policy-maker, #306). A 
policy-maker/regulator provided the example of seeing the first five participants on a treatment 
interruption study having a viral rebound within 3 – 4 weeks – this would provide a clear futility 
signal. Instead of equipoise, futility rules and robust safety signals can add objectivity to a study and 
rigor on how to move forward. Correspondingly, most clinician-researchers were equivocal on the 
topic of equipoise and said that it depended on the study because of the intense regulatory 
environment of clinical research in the United States (clinician-researcher, #203). Most HIV cure 
studies up to this point have not used double-blind, placebo-controlled design, so equipoise has not 
been a practical concept, especially for gene therapy studies that do not have control arms 
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(clinician-researcher, #208). Unless one is trying to prove non-inferiority, equipoise may not apply 
(clinician-researcher, #208). In some cases, study participants act as their own controls, so study 
designs are complex – and equipoise may or may not apply (clinician-researcher, #208). Equipoise 
may become more relevant as studies progress and HIV cure research interventions get more 
efficacious. Then, it would make sense to have trial arms, such as one set of zinc finger versus 
another set of HDAC inhibitors or different combinations (clinician-researcher, #208). At this time, it 
may be premature to require equipoise since HIV cure research is in the early phase (clinician-
researchers, #208, #210). There has only been one person cured of HIV, so drug-free remission 
remains an aspirational goal with no proven efficacy. The two Boston patients and the Mississippi 
child no longer meet the ‘cure’ criterion and we are too early for any true successes (clinician-
researcher, #210). A clinician-researcher commented that: “for the field as a whole, it is relatively 
balanced when we compare the risks and the prospect of benefits for the greater good” (clinician-
researcher, #201). This may indicate that the entire field of HIV cure research is in a state of 
equipoise, as opposed to specific studies.  
No other topic related to equipoise polarizes the HIV cure research field more than 
analytical treatment interruptions. In the next section, we examine perceptions of a variety of 
stakeholders around treatment interruptions.  
Perceptions of Treatment Interruptions  
We asked patient-participants, clinician-researchers and policy-makers to provide their 
thoughts on the topic of treatment interruptions. We summarize general attitudes around 
treatment interruptions, possible motivators for undergoing treatment interruptions, as well as 
concerns and considerations to ensure that they are implemented ethically and effectively.   
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General Attitudes around Treatment Interruptions  
First, stakeholders are divided on the topics of whether treatment interruptions are 
warranted in HIV cure research. One group of stakeholders was adamant that treatment 
interruptions should not be done, while others explained that they could be performed under 
certain conditions. A clinician-researcher performing very high risk gene therapy research expressed 
serious concerns with treatment interruptions because study participants will relapse if they are 
taken off therapy (clinician-researcher, #208). Limits of reservoir detection are not sensitive enough 
to determine whether all the HIV provirus has been taken out of the cells. If HIV were to rebound, 
this may reset the entire reservoir to its initial level and the ‘purging’ benefit will be lost (clinician-
researcher, #208). Likewise, another clinician-researcher said that it is premature to implement 
treatment interruptions, especially in the pediatric patient population (clinician-researcher, #205). 
There are risks of drug resistance with perinatally infected children who will need to take ART for 
the rest of their lives. If treatment is interrupted and resistance to the current regimen develops, 
they will have one fewer option (clinician-researcher, #205). The appropriateness of treatment 
interruptions is further complicated by the fact that there may be no direct clinical benefit of 
reducing the size of the HIV reservoir. Some researchers rely on very sensitive assays, such as the 
quantitative viral outgrowth assay (QVOA), without the need for treatment interruptions, to 
determine if experimental agents had any effect on the size of the replication-competent HIV 
proviral DNA reservoir. But these assays are not sensitive enough to detect every latently infected 
cell and they do not serve as clinical endpoints like treatment interruptions (and delayed time to 
viral rebounds). Reservoir assays remain surrogate endpoints that scientist use to determine if the 
HIV reservoir was perturbed in any way and whether these perturbations are meaningful at all. In 
the absence of potent ‘curative’ agents, some scientists prefer to rely on these surrogate markers, 
instead of causing unnecessary harms resulting from ART interruptions. Since latency-reversing 
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agents have not yet been associated with a substantial reduction in the size of the replication-
competent HIV reservoir, it is best to rely on those assays and not combine these experimental 
latency-reversing compounds with treatment interruptions given the overall compounded risks 
(clinician-researcher, #206). Furthermore, some of the people living with HIV have worked very hard 
to become undetectable (clinician-researcher, #202). They are proud of their high CD4+ count and 
are not willing to risk progressing to AIDS or having a viral spike due to a treatment interruption. 
Since HIV cure research remains in the early phase of experimentation, they prefer to stay on ART 
for the time being until interventions become more efficacious at depleting the HIV reservoir.  
On the contrary, there are clinician-researchers who believe in the need for treatment 
interruptions at this time, under specific conditions. For study participants undergoing treatment 
interruptions, there should be close monitoring to assess viral rebound (#207). Participants should 
be clearly informed about the potential risks, including the possibility of developing resistance to 
ARVs (clinician-researcher, #201) or the increased risks of cardiovascular events (clinician-
researcher, #207). Furthermore, treatment should resume if the viral load rises up to a certain 
threshold (clinician-researcher, #201). A clinician-researcher explained his rationale for supporting 
treatment interruptions:  
I think they can be done cautiously and with very careful monitoring. Because if they’re not 
done, I don’t think [that] we will be able to convince anybody that we have achieved an ART-free 
remission. I don’t think any of the current biomarkers or surrogate markers are predictive of a 
change in duration of ART-free remission. We really do have to move forward with ATIs as the 
key indicator of whether we have achieved what are are striving for. With that being said, there 
are all kinds of ATIs, and I am in favor of intensively monitored antiretroviral pauses which 
means that we monitor them until there is appearance of viremia and we monitor frequently 
enough [so] that there is no risk of acute antiretroviral syndrome, and we put patients on 
therapy before the viral load gets very high. Obviously there is risk that the logistics will break 
down and that won’t occur. But I think that if it is done carefully, it can occur. There is proof in 
the literature that ATIs can be done carefully and not expose people to risk. There is some risks 
they will reset the relationship between host and virus and expand the reservoir from what it 
was before. I don’t believe it that and I can explain why but it’s a lengthy explanation. I don’t 
think the reservoir accumulates very quickly. There has to be prolonged high levels of viremia to 
generate the reservoir and by prolonged, I mean weeks.   
– Clinician-Researcher (#209) 
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Based on this account, treatment interruptions can be a clinical endpoint of choice to 
determine whether sustained ART-free remisson has occurred. Furthermore, precautions can be 
taken to minimize risks. All other measures of ‘cure’ or ‘reservoir depletion’ remain surrogate 
endpoints. Ultimately the success of interventions aimed at achieving ART-free remission will be 
judged by their ability to show clinically meaningful results. One of the most clinically relevant 
endpoint is delaying the time to viral rebound and perhaps a predictive value can be derived from 
this outcome. Some scientists are working to identify surrogate markers that could predict viral 
rebound, although not everyone agree about the necessity (and the ethics) of such studies (personal 
communication). Furthermore, in some cases, treatment interruptions may carry fewer risks than 
the actual interventions under investigation (clinician-researcher, #207), so the entire risk profile of 
a study should be taken into account. All in all, treatment interruptions remain “the best outcome 
measure that we have and we need to deploy [them] very thoughtfully and carefully” (clinician-
researcher, #206).  
Motivations for Treatment Interruptions 
We asked key informants about possible motivations for treatment interruptions. Some of 
the responses mirrored the motivations for joining HIV cure studies in general – such as helping find 
a cure, the desire for forward scientific movement and financial incentives – while others were 
unique to treatment interruptions, including past experiences with the same. One of the patient-
participants interviewed explained that he went off treatment because it was part of the stem cell 
transplant protocol (patient-participant #112). He would not have been able to participate had he 
refused to be off treatment since it was the only way to test whether the intervention worked. In his 
case, there was a desire to comply with the study requirements and to help scientists prove the 
premise on which the protocol was predicated. Most motivators around treatment interruptions 
centered on helping find a cure or derive evidence. Some of the patient-participants said that they 
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were very healthy and virally suppressed, and thus would be good candidates for treatment 
interruption studies that could help advance science (more willing patient-participants, #101). 
Treatment interruption “would be just like any other risk in the study” (policy-maker, #301). 
Furthermore, two patient-participants interviewed had prior experience with treatment 
interruptions. Due to the fact that they maintained stable CD4+ counts off treatment (more willing 
patient-participant, #105) and became rapidly undetectable after resuming treatment (more willing 
patient-participant, #109), they would not be afraid to go off treatment again.  
Furthermore, the three groups of key informants wanted definite forward scientific 
movement resulting from treatment interruption protocols, so that the risks could be justified vis-à-
vis the incremental scientific knowledge gained. The scientific and social value ethics criterion was 
clearly reflected in these narratives. A clinician-researcher expressed that, if we are mandating 
treatment interruption, “we need to make sure that we are going to learn something” (clinician-
researcher, #204).  A policy-maker said that treatment interruptions may become more attractive 
when there are major breakthroughs in science, such as a proof-of-concepts established in animal 
models (policy-maker, #306). As the potential for direct clinical benefits increases, so does the 
appeal for treatment interruptions (policy-maker, #306). Timothy Brown, in his personal account 
[52], recognized that having interrupted treatment is what helped demonstrate the scientific break-
through of his cure:  “I stopped taking my HIV medication on the day of the transplant. (This is 
important because a continuation of antiretroviral therapy would have meant that no one would 
have known for a long time that I as cured of HIV.)” Finally, another motivator for stopping HIV 
treatment are the financial incentives, (more willing patient-participants, #107, #109), similar to 
what we found under the general motivators for HIV cure research participation.  
The topic of “drug holidays” as a motivating factor emerged in some of the interviews.  For 
some patient-participants, being off treatment for a defined period of time may be attractive 
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because they experience “treatment fatigue” (policy-makers, #302, #303). A policy-making 
explained the phenomenon as follows: 
[Some] people have different reservations about taking drugs. For example, in the START trial, 
when they started enrolling, patients did not have trouble being randomized to delaying 
treatment. They found more people who wanted to delay treatment. My caution would be that 
we should not presume that not all patients are really excited about being on treatment all the 
time. Some people may be glad to be off the drug for some time (…) People have different 
attitudes.  
– Policy-Maker (#304) 
 
This statement reveals that there may exist a phenotype of study participants for whom 
treatment interruptions are attractive or easier to tolerate. Perhaps these are the types of 
participants that should be approached for ART interruption studies. While treatment fatigue may 
be real, asking people to do something they would not normally do (e.g. coming off treatment) just 
to qualify for a study may be unethical, however. Similarly, scientists need to ensure that 
participants understand that the study is likely not going to cure them before they come off their 
antiretroviral medications. Treatment interruptions must be done with caution, and while there are 
participants who may be better suited for these types of protocols, treatment interruptions are 
clearly not for everyone. 
Concerns around Treatment Interruptions 
Below, we compiled the main concerns around treatment interruptions expressed by the 
three groups of key informants. We used a summary table because we felt that it more clearly 
encapsulated the compedium of concerns uncovered as part of the study.  From a study 
implementation standpoint, this may provide a checklist for clinical investigators to use during 
protocol design and/or the informed consent to ensure that all possible concerns are addressed 
with the different groups of stakeholders.  
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Table 14. Concerns around Treatment Interruption 
Concerns around Treatment Interruptions  
From Patient-Participants: 
 Study participants unknowingly going from being undetectable to being detectable 
(“ticking time bomb”) (more willing patient-participant, #102) 
 Risk of developing resistance to ARVs (ATIs not recommended for patients on salvage 
therapy) (more willing patient-participant, #102) 
 Increased  risk of opportunistic infections (more willing patient-participant, #107) 
From Clinician-Researchers: 
 It is possible to minimize the risks but not completely eliminate them. Virus can re-
emerge from a single or multiple clones leading to increased viremia (clinician-
researcher, #201) 
 Need sensitive enough ways to measure recrudescence (clinician-researcher, #204) 
 Need to concomitantly enhance the immune system in a durable manner (clinician-
researcher, #204) 
 Kinetics of rebound and or viremia are unknown (e.g. Mississippi child was 
asymptomatic during rebound) (clinician-researcher, #205) 
 Additional risks for acutely infected participants (e.g. repopulation of the HIV 
reservoir, virus diversification, impairment of the HIV-specific immune response 
(personal communication) 
From Policy-Makers 
 Older populations may be more concerned with interrupting drugs because they 
have fewer options available at this point (policy-maker, #311) 
 Unsuspected drug resistance could spread, potentially causing public health disaster 
(policy-maker, #311) 
 Cost to the community for late failure (parallel to PrEP in terms of monitoring) 
(personal communication) 
 Spontaneous failures have a huge impact on when (and whether) interventions can 
become cost-effective (personal communication)  
Shared concerns: 
 Risk of transmission to others during an unsuspected relapse of viremia  
(too heavy of a burden to be in an HIV cure study?)  
Considerations for Treatment Interruptions 
Similarly, we used a table to summarize the various considerations for treatment 
interruptions that emerged as part of the key informant interviews. This table may provide a 
checklist to HIV cure research practitioners for possible ways to implement treatment interruptions 
in an ethical and effective manner to optimize their application.  
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Table 15. Considerations for Implementation of Treatment Interruptions 
Considerations for Implementation of Treatment Interruptions   
From Patient-Participants: 
 Adequate support to study participants enrolled in treatment interruption protocols 
(less willing patient-participant, #110)  
 Is there a maximal amount when participants can be off treatment safely? (more 
willing patient-participant, #102) 
From Clinician-Researchers: 
 Need to continue research to obtain sensitive measures of the HIV reservoir, 
including tissues (clinician-researchers, #203, #211) 
 Need criteria or matrix for when treatment interruptions may be indicated (e.g. 
vaccinations; early ART; if think cured someone) and when they are not (e.g. 
latency-reversing agents; TLR agonists) (clinician-researcher, #204) 
 Functional cure (e.g. ART-free clinical remission demonstrated by treatment 
interruption) is more likely than sterilizing cure; need to implement in the 
experimental (and potentially real-world) setting (clinician-researcher, #211) 
 Treatment interruptions are not indicated for infants as they face a prospect of 
lifelong ART and need all treatment options possible (clinician-researcher, #205) 
 When should treatment interruptions be the primary endpoint? (personal 
communication) 
 What is the actual endpoint – the time to viral rebound or the viral set point post-
rebound? (personal communication) 
 Does monitoring antiretroviral pause actually increase risks? (personal 
communication)  
 Should control arms undergo treatment interruptions? (personal communication) 
 HIV reservoir reduction of 2 logs or less will not delay time to viral rebound by much; 
need at least 3 – 4 logs worth reduction for ~1 year ART-free remission (personal 
communication) 
 How to account for tremendous patient-to-patient variability and stochastic nature 
of viral rebound? (personal communication) 
From Policy-Makers 
 Establish relationship between reservoir assays and time to viral rebound 
determinations (policy-maker, #309) 
 Which participants to enroll in treatment interruption studies 
     Appropriate CD4+ threshold prior to ATI 
     Plan for ART restart for clinical issues, pre-determined CD4+ or HIV RNA 
thresholds  
     Minimum duration of ART to test hypothesis 
     Assure acceptable ART alternatives beyond current regimen in case of 
development of resistance    
     Address issues related to variable half-life of components of ART regimen 
     Counsel study participants on risk of HIV transmission during treatment 
interruptions  
     Criteria to define therapeutic success after treatment interruptions? (personal   
     communication) 
Shared Considerations: 
 Intensive and frequent monitoring (e.g. viral load, CD4+ count)  
 Need back-up regimen for study participants in case ART resistance develops 
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 Provision and criteria for reinstituting antiretroviral treatment 
 Provision of information to study participants about potential risks (e.g. informed 
consent process)  
We assessed perceptions of treatment interruptions among our group of stakeholders.  We 
highlighted the general attitudes, possible motivators, concerns and considerations around 
treatment interruptions. The latter two were provided in a tabular format (above) to facilitate the 
ethical and effective implementation of treatment interruptions as part of HIV cure studies that 
mandate them.  
Factors Facilitating Recruitment in, Retention in and Implementation of HIV Cure Studies  
As HIV cure studies get scaled up in the United States and around the world, it is important 
to understand the factors that can faciliate recruitment of people living with HIV in these studies. 
The table below provides the compilation of recommendations to improve recruitment of study 
participants in HIV cure studies. We felt that this way of summarizing the information was most 
useful from a clinical study management and implementation standpoint. Checklists are known to 
enhance organization, motivation, productivity and delegation. The tabular format allows us to 
clearly and quickly see what needs to be done to faciliate recruitment and can in turn directly inform 
the plan for change.   
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Table 16. Possible Recommendations to Facilitate Recruitment in HIV Cure Studies 
Possible Recommendations to Facilitate Recruitment in HIV Cure Studies   
Overcoming Logistical and Stigma Barriers: 
 Flexible study clinic hours  
 Remove transportation and parking barriers 
 Address stigma-related issues 
Inclusion/Exclusion Criteria and Study Design Issues: 
 Liberalize entry criteria whenever possible 
 Minimize intensity of study visits whenever possible 
 Ensure adequate sample size to test research question (especially for small pilot 
studies) 
Safety and Efficacy Issues: 
 Have adequate pre-clinical safety data or robust proof-of-concepts from animal 
models 
 Clearly communicate potential risks to study participants (during informed consent 
process) 
 Ensure adequate risk-benefit (or risk-knowledge) ratio 
 Ensure that robust risk mitigation strategies are in place 
Screening and Recruitment Process: 
 Hire research screener dedicated to recruit study participants (link between clinical 
care and research efforts) 
 Maintain regular communications with and build a referral process from the 
infectious disease doctors (frontier out in the community) 
 Find people where they are (e.g. support groups) 
 Maintain regular contacts and provide frequent updates about new studies even if 
candidates did not qualify for previous studies (e.g. emails) 
 Build authentic relationships with potential study participants 
 Build a recruitment ‘apt’ to match potential study participants with clinical 
researchers 
 Maintain up-to-date and robust databases of potential study participants (e.g. 
registries of individuals who have HIV and cancer and need CCR5 transplants; 
registries of potential donors with Δ32/Δ32 CCR5 mutations) 
Clinical Contact Factors: 
 Maintain trust between study participants and clinical researchers  
 Have one-on-one conversations (personalized approach) 
 Create a more level playing field between investigators and potential study 
participants  
Peer Recruitment, Community Outreach and Education: 
 Have previous study participants act as peer recruiters (e.g. story telling) – but 
exercise caution with issues of confidentiality when using peers 
 Maintain “patient voice” in recruitment activities 
 Implementation education activities to manage expectations without crushing hope 
 Incorporate long-term research perspective into educational programs 
 Involve primary care physicians in education activities around HIV cure research  
 Utilize existing platforms where the HIV community is already engaging and raise 
awareness of HIV cure research in the (HIV) community 
 Ask for regular feedback and do not be afraid to have a dialogue 




 Provide assistance to pay for study-related complications (e.g. following treatment 
interruptions) if issues (e.g. resistance) come up (may require more expensive 
drugs) 
Special Recruitment Considerations for Women: 
 Take into consideration the fact that women are also care-givers; provide 
additional support if needed 
 Proactively address issues related to reproductive health risks in HIV cure research  
 Ensure that the HIV cure research equipment is compatible with women’s anatomy 
(e.g. smaller veins and may be knocked out of studies due to newer models of 
leukapharesis machines) 
 Make HIV cure studies (and meetings) relevant to women   
Special Recruitment Considerations for Minorities: 
 Make sure that “under-to-reach” populations do not become self-fulfilling 
prophecies  
 Do not make the diversity of study participants in HIV cure research an afterthought 
and learn lessons from HIV treatment trials 
Table 16 above summarizes the key recommendations received by the key informants to 
faciliate recruitment in HIV cure studies. We focused on practical aspects to facilitate the effective 
recruitment of study participants in HIV cure research. The action plan provided considerations to 
overcome logistical and stigma barriers to participation, study design issues, safety and efficacy 
aspects, screening and recruitment efforts, clinical contact factors and peer recruitment and 
community outreach components. We also provided special considerations for recruiting women 
and minorities. This list may be expanded or modified by practitioners as different elements are 
found to be relevant to recruitment of study participants in HIV cure-related studies. Similarly, as 
more study participants get enrolled into studies, we need to understand the factors that can 
facilitate retention of study participants. Below, we provide a summary of recommendations from 
key informants on this topic. Table 17 provides a clear checklist of what can be done to faciliate 
retention of study participants in HIV cure clinical studies.  Most of the considerations relate to 
clinical contact and safety factors.  
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Table 17. Possible Recommendations to Facilitate Retention in HIV Cure Studies 
Possible Recommendations to Facilitate Retention17 in HIV Cure Studies   
Clinical Contact Factors: 
 Explain importance of adhering to the study protocol and explain at the outset what 
will be involved in terms of time and effort  
 Treat study participants with respect (including respecting their time and schedule)  
 Show gratitude  
 Be kind (basic kindness); good bedside manners 
 Treat study participants like normal people 
 Continued communication (e.g. safety labs; progress to date) 
 Ensure an open, collegial atmosphere (study participants as partners and 
collaborators in research)  
 Maintain regular contacts with study participants (e.g. phone calls, text messages) 
(should be IRB-approved); obtain information technology support 
 Listen to the study participants  
 Validate study participants’ experience and make them feel valued and appreciated 
for what they are doing 
 Care about study participants’ needs (e.g. mental health, health insurance, housing)  
Safety Considerations: 
 Explain the importance of long-term follow-up (e.g. treatment interruptions; 
monitoring of carcinogenicity, mutagenicity, teratogenicity)  
 Ensure that the proper follow-up registries are in place and adhered to (e.g. cancer 
registries, etc.)18  
Design Issues and Study Procedures: 
 Only perform study procedures when they are absolutely needed 
 Cut down the number of study visits that are not critical  
 Avoid very painful or uncomfortable conditions  
 Ensure fair, adequate IRB-approved compensation for study visits (without being 
coercive) 
Overcoming Logistical and Stigma Barriers: 
 Flexible study clinic hours  
 Remove transportation and parking barriers 
 Sufficient advance notices of days and times of study visits 
 Address stigma-related issues 
 Understand the reasons why study participants are dropping out 
 Provide ongoing support whenever necessary and facilitate study visits 
 Consider having a mobile van to go see study participants for lighter study visits 
  
                                                          
17
Retention was found to be “not applicable” for some of the HIV cure research modalities that are 
irreversible, such as gene therapy/stem cell transplant. Once a study participant commits, they are in all the 
way and this becomes a one-way decision (clinician-researcher, #208). For other studies where salvage 
therapy is needed, losing people to follow-up may not be an option. 
18
Study participants who take part in a latency-reversing agent study must be registered in a cancer database. 
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Table 17 above provides a succinct checklist of possible factors that may facilitate retention 
of study participants in HIV cure studies. Most of the issues identified related to clinical contact 
factors or safety issues. As there is no magic bullet, implementers of HIV cure research need to 
remain vigilant as to the factors that ensure adequate follow-up of participants and statistical study 
power, despite small numbers. Further, one of the aims of the study was to derive factors that could 
facilitate effective implementation of HIV cure studies. Table 18 summarizes the key 
recommendations from stakeholders on factors that would help execute such studies. The checklist 
is not exhaustive and can be augmented or amended as necessary by HIV cure research 
implementers.  
Table 18. Recommendations to Help Execute HIV Cure Studies Effectively 
Recommendations to Help Execute HIV Cure Studies Effectively  
Trial Design Issues (Early Phase Development HIV Cure Studies): 
 Consider toxicity profile in study drug(s) selection  
 Conservative enrollment criteria and stopping rules for safety-related issues (e.g. 
participants, cohorts and overall study) 
 Informed consent (IC) process that fully addresses potential risks and conveys no 
expectation of individual benefits and time-intensity of studies 
     Consider using assessment of understanding as component of IC process  
 Start with small number of subjects 
 Stagger enrollment into two or more cohorts with progression (including dose 
escalation) based on acceptable safety from earlier (sentinel) cohorts 
 Use lowest dose and duration necessary  
 Provide any safety-exposure data available to support dose selection  
 Consider drug interaction related to antiretroviral treatment  
 Provide adequate scientific justification (e.g. supportive data from animal studies or 
justification of why animal studies are not feasible or supportive) 
 Support for selection of assays that will be used 
 If possible, incorporate of a control group to aid interpretability of the data 
generated 
 Proper selection of the study population 
     Allow scientific hypotheses of interest to be tested while maintaining acceptable 
safety balance 
     Enroll participants on stable ART with higher CD4+ counts and undetectable HIV 
RNA (e.g. participants best able to tolerate study treatments and treatment 
interruptions) 
     Overlapping populations of interest (e.g. stem cell transplantation (SCT) in 
participant for whom SCT is already indicated for cancer treatment) 
     All studies: mechanism for long-term follow-up of participants administered 
 198 
products  with potential long-term risks (including products known to be genotoxic, 
mutagenic and/or carcinogenic)  
 Clear rationale for conducting the study (e.g. avoid redundancies) – regimen, dose, 
duration and study population  
 Ensure clarity of study procedures (e.g. avoid vague language subjective to different 
interpretations) 
 Ensure clearly defined and appropriate study endpoints and well-characterized 
assays for assessing endpoints 
 Plan for rationally designed combinations 
 Work closely with FDA during the pre-IND stage 
 Scientific success (e.g. answering research question and advancing scientific 
knowledge) does not equate with having a ‘curative’ intervention – criteria for 
success will not be ‘curative’ 
     Systems make the maximum benefits of people’s participation 
     Learn from ‘failures’ 
Study Conduct: 
 Promote good recruitment and retention practices (see above) 
 Prioritize planning and organization  
 Be willing to be flexible  
 Conduct dry runs of study visits 
 Implement one-time leukapheresis protocol before asking study participants to 
commit to long-term follow-up 
 Provide fair compensation for study visits  
 Ensure the processing of specimens does not break down 
Safety Issues: 
 Implement robust risk mitigation strategies 
     Stopping rules for treatment arms that fail to show an effect or associated with     
    development of serious adverse events (SAEs) 
 Enroll study participants who have an alternative ART regimen in case their current 
ART regimen gets compromised  
Efficacy Issues: 
 Ensure good baseline (and follow-up) data for all the samples 
Interpersonal, Communication and Management Issues: 
 Ensure good communication between investigational team, clinical staff and study 
participants 
 Communicate honestly 
 Ensure emergency contacts outside of regular office hours 
 Ensure investigators have enough time to supervise study operations 
 Build very strong and highly trained clinical study teams (including study coordinator) 
 Have adequate time for face-to-face interactions between principal investigators or 
nurse and study participants 
 Diverse clinical research study workforce  
 Place study participants first (e.g. respect for persons)  
 View study participants as holistic individuals  
 Ensure study participants are comfortable during study visits 
 Provide adequate support to study participants, including mental support and social 
services if needed 
 Insure health insurance status of study participants does not get affected as a result 
of study participation 
 Build long-term partnerships and trust with health care providers (and their patients 
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– even if they do not qualify for studies) 
Community and Education Issues: 
 Forethought around community engagement 
 Ensure positive collaboration with the community from beginning to end  
     Ensure patient group provides feedback on protocol  
     Make patients feel a part of the research process (true partnerships) 
 Share study outcomes (aggregate findings) to study participants and community in 
lay terms (results dissemination) 
 Include education component as part of study implementation and community 
engagement 
 Educate from a place of compassion 
Boarder Considerations for the Field: 
 Set realistic expectations for the study with clinical study team and study participants 
 Incrementalism and planning for the long-term are key; let science drive the next sets 
of experiments  
 Be careful about how result findings are reported in press releases and the media  
 Consider standardizing endpoints between studies to derive more power from small 
numbers (e.g. requires agreement) 
 Conduct clinical studies as part of well-established networks with well-resourced and 
deep infrastructure in place (e.g. ACTG) 
 Build strong research collaborations  
 Bring scalability of HIV cure approaches to the forefront of study design 
 Ensure that the health care system would be able to provide the level of monitoring 
needed for ART-free remission cases (becomes an implementation question) 
Developing Country Considerations: 
 Identify which HIV cure research strategies are best suited for the developing world 
(e.g. early ART, pediatric HIV cure studies) 
 Invest in capacity building, technology transfers and research partnerships  
 Informed consent issues (lower literacy levels combined with difficult scientific 
concepts) 
 Ensure access to treatment (and prevention-of-mother-to-child transmission 
interventions) to those who need them; invest in health-systems strengthening  
 Continue HIV prevention and HIV treatment research (and implementation science) 
even as try to find a cure for HIV 
 Understand that there can be different co-morbidities that could affect safety and 
efficacy 
 Appreciate the different set of implementation and ethical considerations (e.g. ethics 
of incentives) 
 Appreciate cultural and socio-economic differences 
Funding Issues and Policy Issues: 
 No HIV cure research without funding; long horizon requires funding and investment  
 Revise HIV criminalization laws and lobby U.S. Congress to update Ryan White Care 
Act to remove criminalization provisions in the law   
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Table 18 above consolidated the main considerations to help facilitate the implementation 
of HIV cure studies. Recommendations were compiled into the following categories: study design 
issues, study conduct, safety and efficacy issues, interpersonal, community and management 
factors, community and education, broad considerations for the field and developing country 
considerations, and funding and policy issues.  
Expectations and Hopes in HIV Cure Research  
We asked potential study participants to describe their expectations from the HIV cure 
study experience as well as their hopes related to HIV cure research. Table 19 below summarizes the 
main expectations of people living with HIV while participating in HIV cure research. The most 
common expectations related to study conduct such as adequate support, clinical contact factors 
and scientific progress or forward movement as a result of HIV cure study participation.  
Table 19. Main Expectations from the Study Participation Experience 
Main Expectations from the Study Participation Experience   
Study Conduct: 
 “I would expect constant follow-up and support. (…) Also, the researchers should 
communicate with our current HIV providers, for sure.” (Patient-Participant, #110) 
 “I would expect quality of the study” (Patient-Participant, #101)  
Clinical Contact Factors: 
 “I would expect to be treated like a normal person, not like someone with HIV” 
(Patient-Participant #108)  
 “I would expect people to care about my well-being” (Patient-Participant, #110) 
 ”I would expect to know what’s going on. I would need to know why people are 
taking my blood.” (Patient-Participant, #108) 
Scientific Progress: 
 “If I were to be accepted to participate, I would expect forward movement. Like I 
would expect some kind of outcome that would be beneficial to the world. Even if it 
is not the outcome that I am after. Trial and error is definitely part of the study. But 
if I participate in the research and I am not cured and there were all these risks and I 
end up getting a different genotype and drop below 200 T cells and my viral load 
runs up to like a million. That’s what I would expect. Forward movement. Whether I 
were cured or not. Knowing that forward movement happened is what would make 
it all worth it.” (Patient-Participant, #103) 
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We also asked study participants and clinician-researchers about “curative” expectations. As 
early HIV cure research will not be curative, it is important to better understand how “hopes to be 
cured” factor into decisions to participate in research in order to avoid therapeutic misconception. 
There was a broad range of responses from study participants. Some of study participants had no 
expectation of being cured from HIV cure-related research, while others expected to be cured. 
Among the study participants who had no expectations of being cured, they realized that a cure for 
HIV is a long-term endeavor that may not materialize for another 20 years. They understood the 
incremental nature of the science and that HIV cure studies are scientific experiments that meant to 
be iterative. One study participant mentioned that she would still practice safe sexual practices 
regardless of whether she was found cured or not (patient-participant, #108). Another study 
participant alluded to the fact that there is a belief that pharmaceutical companies are hiding the 
cure (patient-participant, #102). There has also been much abuse in the past related to “miracle HIV 
cures” – in the United States and abroad, mostly Africa. Other people believe that HIV is a 
conspiracy created by the government and it is difficult to combat these misperceptions in the 
community.   
In contrast, one patient-participant reported that he would expect to be cured from HIV 
cure studies. His expectation for a cure was very high and he thought that the science had evolved 
to be close to finding a cure for HIV infection. This example points to the possible existence of 
curative misconception among potential volunteers and would need to be investigated further. 
Expectations to be cured from HIV cure research should be distinguished from hopes of finding a 
cure – one day. Some of the study participants thought a cure for HIV would be possible in the 
future. This was an important motivator to participation in HIV cure research, but these individuals 
did not necessary think that they would be cured right away or as a result of research participation.   
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Clinician-researchers mentioned emphasizing to study participants that HIV cure research 
will not be curative. They recognized the double-edged sword of using the expression “HIV cure 
research” – while HIV cure-related research will not cure them, study participants need to 
understand that a cure is a goal that scientists are working towards.  One clinician-researcher 
referred to the fact that participation in HIV cure research is part of a therapeutic journey for study 
participants, who have gone through a transformative diagnosis and can find meaning in HIV cure 
research participation (clinician-researcher, #206). Study participants also recognize what HIV 
research can provide over time given the discovery of potent antiretroviral treatment and a cure for 
HIV would be the next logical scientific step. One clinician-researcher emphasized the importance of 
letting study participants know what they are not cured in order to avoid unwanted public health 
consequences resulting from patients stopping their medications, thinking they have been cured 
(clinician-researcher, #210).  Further, clinician-researchers emphasized that the informed consent 
process is an important step to explain to study participants that they will not be cured. It is also 
imperative to understand the reasons behind study participation. One clinician-researcher said that 
he asks volunteers to repeat back what they understand the possible outcomes of HIV cure research 
participation to be (clinician-researcher, #207). While the hope to be cured is prevalent, it does not 
necessarily mean that study participants think they will be cured right away. It is important to listen 
to the language used by study participants to understand the hopes and meanings that motivate 
them and whether these are irrational or not. Participants who are very sophisticated and well-
informed may still have hopes to find a cure or to be cured, and bring these hopes with them in the 
study interactions. While there should be a conservation assumption that everyone participating in 
HIV cure research can believe in the possibility of a cure for HIV one day, what is more dangerous 
are the cognitive dissonance or the unrealistic or irrational hope or optimism that may prevail, as 
explained by a policy maker/bioethicist: 
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It is like cognitive dissonance – they understand that there is no risk/benefit to them, no magic 
bullet but they keep at the back of their mind that something really cool might happen. There 
are people who are genuinely motivated because they want to help science and the field (…) But 
some people have denial or dissonance that they may get something out of it (…) The few 
reasons that would make me pause would be the unrealistic optimism [and] the source of 
unrealistic optimism is human nature. I did not want to use the term therapeutic misconception 
because it is too strong of a phrase. It was brilliantly coined originally; a brilliant thought; 
oftentimes true, but it implies that one fully believes something will happen. What I am talking 
about is not that someone fully believes that they will get cured. This is early phase research and 
there is no direct benefit. People do not think they will get cured. They know that there is no 
direct benefit but people still hope for something great to happen anyway. 
– Policy-Maker (#304) 
 
In sum, there was a broad range of opinions expressed with regards to expectations from 
HIV cure research participation and hopes to be cured. Clinical research implementers should 
safeguard against unrealistic or irrational hopes and more subtle cognitive dissonance that study 
participants will derive direct clinical benefits. They should also try to better understand the 
motivations behind study participation and whether they are rational or not. Study participants 
should not enroll in study because of the hype or the perception of direct clinical benefits in terms 
of HIV control.  
Factors Facilitating Ethical Implementation of HIV Cure Research   
One of the study aims was to derive factors that could facilitate the ethical implementation 
of HIV cure studies. Below, we summarized the main recommendations from stakeholders on the 
factors that could help promote the ethical conduct of HIV cure research. The checklist represents a 
cross-section of the responses given. It is by no mean exhaustive and can be augmented or 
amended as necessary by bioethicists and implementers of HIV cure research.  
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Table 20. Recommendations to Facilitate Ethical Implementation of HIV Cure Studies 
Recommendations to Facilitate Ethical Implementation of HIV Cure Studies   
Design Issues and Requirements of Research Ethics: 
 Research should meet all the requirements of research ethics (per regulations)  
     Ensure safety of study participants is paramount while minimizing risks 
     Adequate risk-benefit ratio (balance between benefit to society and risks to  
     individuals) 
     Thoughtful review by proper regulatory bodies (e.g. FDA, IRBs, Recombinant   
     DNA Advisory Committee (RAC)); Data Safety Monitoring Board (DSMB)  
 Proper study design with strong scientific underpinning  
             Ensure that the bar is held high when it comes to study designs 
             Ensure people can call on improper study designs       
 Study conducted with the highest ethical standards possible  
 Strong foundation in the possibility that something definite will be learned from the 
research 
 Get as much scientific information as possible from HIV cure experiments and honor 
people’s participation so that we have learned as much as possible  
 Sample size ethics  
     Reduce duplication of similar studies (to put the fewest number of participants    
     at risk) 
 Clear futility criteria  
 Need for long-term follow-up of study participants, especially during treatment 
interruptions 
 Fairly compensate study participants  
Safety Considerations: 
 Clear safety endpoints monitored frequently  
 Minimizing harm as a result of research participation; not subjecting study 
participants to unnecessary risks  
Informed Consent Considerations: 
 Risk undertaken is understood by study participants and is appropriate compared to 
potential benefits that can be gained  
 Ensure “true” informed consent – participants should be well-informed of risks and 
should not expect direct benefits in most cases 
 Observe balance between explaining what the risks are in terms that are easy to 
understand, but still accurate  
 Separate optional informed consent for ancillary procedures (e.g. sigmoidoscopy, 
etc.)  
 Informed consent should be a continuous process throughout the study  
Treatment of Study Participants and Clinical Contact Factors 
 Strong confidentiality  
 Basic respect and consideration 
 Study participants treated like people and not like a disease 
 Honest communication with participants during study  
 “Mental health analysis” of study participants to ensure that they are in the right 
mindset and resilient enough prior to joining studies  
Fair Representation of Study Participants 
 Study participants should be representatives of those living with HIV (justice) 
Collaboration and Partnerships: 
 Need a true partnership between the researchers and the study participants  
 205 
 Investigators, IRBs, FDA and patient advocates need to work together as much as 
possible  
 Need for more collaboration between scientists and standardized endpoints  
 Collaboration with social scientists through study implementation   
Community Input and Education: 
 Community members should review study protocols  
 Plan for long-term community engagement  
 Education at every levels – community members, individuals interacting with the 
study participants and IRB representatives  
General Considerations: 
 Constantly asking what makes HIV cure research ethical and never letting go of the 
question 
 Be cautious about any claims for a cure unless there has been ≥5 years of follow-up  
 Make sense of the data that we have or from large studies (such as the START trial 
result) and what they mean for HIV treatment and cure research; focus on 
treatment adherence  
Table 20 above consolidates the main considerations received from key informants to 
facilitate the ethical implementation of HIV cure studies. Recommendations were compiled into the 
following categories: design issues and requirements of research ethics, safety considerations, 
informed consent, treatment and representation of study participants, collaboration and 
partnerships, community input and education and general considerations.  
General Considerations in HIV Cure Research 
The final qualitative results section summarizes general considerations for HIV cure research 
that emerged during the key informant interviews. These factors did not belong to a specific 
question or category but were still felt relevant to the effective and ethical implementation of HIV 
cure research. Most of the reflections pertained to the rationale for HIV cure research, the meanings 
of HIV cure and the language/terminology around HIV cure research. 
Justification for HIV Cure Research 
Some of the key informants alluded to the fact that scientists need to continually be able to 
justify the need for HIV cure-related research – ethically, scientifically, and logistically (clinician-
researcher, #209). The field needs to be able to defend why money is going towards HIV cure 
research when tremendous gaps exist in HIV prevention and HIV treatment. It was felt that scientists 
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need to come up with a consistent rationale for why a cure for HIV infection is required by the 
scientific community. There further needs to be more granularity as to what an actual HIV cure 
would look like and how HIV cure would be defined (clinician-researcher, #204). Knowing why the 
pursuit of an HIV cure is important – including the challenges around HIV treatment adherence, 
negotiation of the HIV ‘care continuum’, HIV drug resistance and cumulative toxicities over time, 
and the fact that HIV treatment may not be economically and logistically feasible for the 35 million+ 
people infected with HIV around the world– are some of the facts that are needed to help the 
community understand why HIV cure scientists are searching for the holy grail.  
Meanings of HIV Cure  
Key informants – particularly patient-participants – felt that it was necessary to pay 
attention to the different meanings of HIV cure. A cure for HIV may have different meanings for 
different groups of stakeholders – including, but not limited to: not transmitting HIV to others, not 
having to take HIV medication, testing negative on the HIV antibody test or no longer harboring 
replication-competent HIV virus. Key informants wanted a better understanding of what HIV cure 
meant in different contexts (policy-maker, #310). There can be discrepant notions of cures and 
meanings of cure between study participants, scientists and policy-makers/regulators. It was felt 
that these needed to be reconciled and better understood.  
The meaning of HIV cure research was highlighted by one of the two Boston patients 
interviewed as part of this study when he explained his transition from “feeling cured” after 
receiving a bone marrow transplant to “no longer being cured” following his viral rebound: 
Although the study failed and mine is an emotionally monumental failure. I am very biased here.  
There was a period for few months where I felt like I was HIV-negative because of the study… (…)  
Even if the study itself was a failure at that time, in that it did not find a cure at that moment, it 
still moved the field forward. The personal side is so touching.  
– More Willing Patient-Participant (#112) 
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For a moment, the Boston patient thought he was actually cured of HIV and that he was 
HIV-negative. He “felt” cured even though he was not cured. Despite the viral rebound, he still 
considered the study a success because it answered an important scientific question. It took several 
months for the virus to become undetectable and for him to be virally suppressed again. The study 
participant had to cope with the reality of being “HIV-positive” and “detectable”again after thinking 
he was cured. The emotional toll of “feeling cured” and then “not being cured” should be taken into 
considerations when designing studies. The different meanings of HIV cure should also be examined 
further. Despite that study participants may “feel” cured, they may not be cured in reality and this 
may have implications for HIV cure research implementation. 
Interestingly, one study participant felt that getting HIV is what cured him: 
I have to be honest with you. Having HIV is part of what cured me. Like, there is a moment that I 
was told that I was positive. I stopped being the person I was and started to be the person I 
wanted to be. As far as healing, I would be worried that curing someone would take that away. 
You know… like perhaps counseling would be an important point of that. (…) There are people 
who have been living with it since 1983. Almost 30 years of this one lifetime and getting used to 
something. There will need to be re-adjustment and counseling. Maybe not everyone of them. 
But a psychological evaluation at the beginning would probably be a smart start. And support. 
They would also need to go back to the clinic to monitor their viral load to make sure that they 
are still cured. And having the support of the other participants would be really important. They 
need to share their stories in order to  adjust and grow. This is part of their story and their 
therapeutic journey.  
– More Willing Patient-Participant (#103) 
 
This quote reveals the need to better understand meanings around HIV cure and identities 
surrounding HIV-positive diagnoses. Cure is also closely intertwined with discourse around healing 
and therapeutic trajectories. Meanings around HIV cure should be further explored via formative 
research. A case in point could be the disconnect between scientists who target functional cures and 
study participants who wish for a sterilizing cure.  
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Language of HIV Cure Research 
Beyond the meaning of HIV cure research, narratives focused on the language used to 
describe HIV cure. Several respondents felt that it was like learning a new language with its own set 
of rules. The use of language is particularly important when interacting with the community. Even 
the vocabulary used in scientific manuscript changes rapidly. Key informants felt that it was 
important to define what was meant up front and to be cognizant of the perspectives of community 
members, otherwise communication can rapidly break down (clinician-researcher, #205). The term 
HIV cure research was thought to be a misnomer because the term is divorced from its existence : 
“Oh, we don’t really think we are going to cure you but the title is HIV cure whatsoever” (policy-
maker, #311). The “kick and kill” approach was also misleading, since scientists are simply trying to 
poke latently infected cells and clear out latent virus (policy-maker, #311). The “kick and kill” 
approach was described as a “cure study that won’t cure them with an anti-cancer drug” (clinician-
researcher, #202). The term functional “cure” was problematic and incongruous, because of the 
word “cure” is used to describe someone still living with HIV (patient-participant, #103; policy-
maker, #311). The term remission was more clearly understood, in that it implies that the virus can 
come back (more willing patient-participant, #103).  
Key informants felt that the word cure had tremendous powerful appeal but can be 
misleading. Cure is different than treatment research, and one should distinguish between cure as 
an “intervention” and a “state of being.”  One key  informant felt that the word “cure” was more 
problematic with respect to study participants themselves, as there was a tendency to sometimes 
only hear the word cure and get excited about what the science can deliver. The cure terminology 
should not be used as a form of false advertising, and more nuanced terms, such as “viral reservoir 
research,” should be used instead (clinician-researcher, #207).  Key informant also pointed out that 
there were inconsistent interpretations between cure, eradication, post-treatment control, 
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sterilizing versus functional cure and virological suppression off treatment (VSOT) (and its various 
permutations). These various appelations of HIV cure research were found to be unwieldy for the 
development and regulatory processes because they failed to define clear endpoint criteria and did 
not offer a framework for standardized measurement of an HIV cure. Overall, these was a general 
consensus that more precise language and nomenclature was needed to advance HIV cure drug 
development and the regulatory aspects associated with HIV cure research. Other examples were 
provided of problematic terminology in HIV cure research (not reported here).  
Overall, we need to bridge the divide between scientists and community and better 
understand how study participants understand HIV cure research terminology. Further, key 
informants felt that the debate and nuances should also be accomplished in the press as much as 
possible. Community advocates have a role to play in policing the language. There should be an 
ongoing dialogue around the terminology used to describe HIV cure concepts as the field evolves.  
After all, “it’s not all about the lab science. It’s about the context as well” (clinician-researcher, 
#211). 
In summary, key qualitative study results were as follows:  
 Factors affecting decision making are multi-faceted.  Key motivators to HIV cure-related 
research participation related to tangible motivators as well as the desire to contribute to 
HIV cure science and give back. Altruism was also a significant motivator to participation. 
Important deterrents to HIV cure research participation related to the modality under 
investigation, the early phase of experimentation, practical and logistical deterrents, study 
visit procedures, side effects and potential risks, and negative clinical contact factors, among 
others. 
 Perceived risks of HIV cure-related research participation included clinical or medical risks, 
opportunity risks, social risks, financial risks and other perceived risks. The perceived riskiest 
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HIV cure-related research strategies were stem cell transplant/gene therapy, latency-
reversing agents and combinatorial approaches. “Too much” or unacceptable risks were also 
assessed. 
 Main concerns around HIV cure-related research encompassed unforeseen or unintended 
consequences, impacts on health and circumstances after study participation or post-cure 
discovery. There were perceived burdens of HIV cure-research participation, including, but 
not limited to side effects, time commitments, intensity of study visits and travel-related 
constraints. Perceived barriers to HIV cure research participation included general barriers 
(such as geographical availability), logistical aspects, finding study participants, stigma and 
other miscellaneous barriers. 
 The perceived safest HIV cure-related research strategies were early ART, monoclonal 
antibodies and reservoir assessments.   
 Perceived benefits of HIV cure research participation included none, societal benefits such 
as advancing scientific knowledge, personal benefits (such as psychological, emotional and 
mental benefits), clinical benefits (for some), and the acquisition of information around HIV 
cure research. 
 Interpretations of “risk-benefit ratios” were discussed among the variety of key informants, 
and the balance tilted towards greater risks in HIV cure studies. It was difficult to derive an 
objective measure for risk-benefit assessments. We discussed equipoise with clinician-
researchers and policy-makers. A range of opinions was expressed and proved to be a 
meaningful engagement with research ethics concepts. 
 We inquired about perceptions of treatment interruptions, and summarized general 
attitudes around treatment interruptions, possible motivators as well as concerns and 
considerations to ensure the effective and ethical implementation of these interventions. 
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 We prepared a checklist of factors facilitating recruitment and retention in HIV cure-related 
studies. We also summarized factors facilitating the effective implementation of HIV cure-
related studies. 
 We conveyed general expectations from the HIV cure research experience as well as hopes 
related to HIV cure research. Besides the topic of therapeutic or curative misconception, we 
learned about the risk of cognitive dissonance and unrealistic or irrational hope and 
optimism. 
 We compiled a checklist of factors facilitating the ethical implementation of HIV cure 
studies, according to key informants.  
 We highlighted general key considerations for the field of HIV cure research, such as the 
need to constantly justify HIV cure research, assess the meanings of HIV cure and cautiously 
use HIV cure-related terminology.   
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CHAPTER 6 | DISCUSSION OF STUDY RESULTS 
This dissertation section reviews the implications of the main quantitative and qualitative 
study results as well as significance for the effective and ethical implementation of HIV cure studies. 
Overall, there was a convergence and complementarity between the quantitative and qualitative 
datasets, despite slight contradictions noted. The mixed methods approach added tremendous 
richness to the inquiry. In fact, the use of a mixed methods approach was critical to better 
understand factors that can facilitate participation of people living with HIV in cure research in the 
United States. We showed that mixed methods deepened our understanding of meanings that were 
not captured in the quantitative data analysis. In turn, issues were identified in the qualitative data 
that were not captured quantitatively a priori, and this limited our ability to identify more 
convergent issues. For examples, perceptions around risks and benefits were only limited to the 
categories provided by the survey, but qualitative interviews delved deeper into perceptions and 
nuances of unacceptable risks. Formative inquiry can help uncover the rich context that surround 
decision-making in HIV cure clinical studies. Much more research will be needed to understand the 
key elements of motivation related to actual decision making processes in early HIV cure research, 
including participants’ reasons for participation (or refusal) and their experiences related to 
participation.   
After discussing study results, we engage with principles of ethics and implementation 
science to inform the conduct of HIV cure studies. While the results section was biased towards 
descriptive ethics, we explore some normative ethical aspects in the discussion [53]. We complete 
the chapter by examining the strengths and limitations of the research. 
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Discussion of Quantitative Findings  
Survey respondents indicated whether they would be willing to participate in 14 different 
types of HIV cure-related studies. It remains unclear if survey respondents fully understood the risks 
and benefits of HIV cure-related research participation. The result that >50% of people would be 
willing to join all 14 types of HIV cure-related studies was surprising, as we would have expected a 
greater skewness towards risk aversion. The high apparent willingness to participate in HIV cure 
research underscores the need to better educate study candidates about the potential risks of 
different types of studies, since the desire to participate does not necessarily mean informed 
participation. There may be individuals who rationally want to participate in studies who perhaps 
should not participate, as highlighted in the key informant interviews. Nevertheless, the seemingly 
riskiest modalities appeared to have been the least popular altogether, as expected. This finding was 
in agreement with the published literature that if more risks are expected in clinical studies, 
volunteers are more likely to decline participation [54][50].  
Although HIV cure studies conferred little to no benefit, it is possible that study participants 
still perceived the likelihood of benefits when deciding to join studies. Data showed the importance 
of not under-estimating the contribution of emotional and mental benefits in HIV cure research 
participation. Participation in HIV cure research may truly change the meaning of one’s HIV 
diagnosis from a traumatic to a meaningful, empowering experience. Our finding that social and 
personal benefits were most often psychological in nature was consistent with similar studies from 
the HIV prevention and treatment literature [55] and with the Voice of the Patient report prepared 
by the FDA’s patient-focused drug development on HIV cure [43]. Furthermore, the finding that 
most common perceived benefits of participation are emotional and psychological suggests that HIV 
cure scientists should strongly appeal to the scientific altruism of study participants when 
conducting recruitment efforts.  
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In terms of the perceived risks likely to discourage HIV cure research participation, personal 
clinical risks were more likely to demotivate participation than personal risks, burdens or potential 
social risks in the descriptive analysis. Survey respondents viewed long-term risks as more 
worrisome than short-term risks. In contrast, when looking at the bivariate and multivariate results, 
short-term and immediate risks had stronger correlation with deterrence to participate in terms of 
magnitude than some of the longer-term risks, such as the potential for enabling cancer or 
developing viral rebounds over time in the bivariate analyses. This finding is more consistent with 
what transpired in FDA’s Voice of the Patient report [43], where study participants reported making 
decisions to participate based on short-term impacts as opposed to long-term risks, although this 
report relied on anecdotal evidence. 
The need for intense time commitments for study visits did not appear to be strong 
demotivators of participation in the survey. This finding was inconsistent with key informant 
interview narratives. Clearly, the degree of burdens and efforts imposed on study participants (such 
as site visits and study procedures) place a strain on a person’s willingness to participate. The risk of 
transmitting HIV to others (in the case of an unsuspected viral rebound) was a real possible 
demotivator (28% very likely to discourage) and may speak to the study volunteers’s desire to “do 
no harm” when participating in research. This result was reminiscent of a similar prior survey 
conducted among >450 people living with HIV in the Netherlands, which suggested that no longer 
being able to transmit HIV to sexual partners was a more desirable outcome of HIV cure than 
stopping HIV treatment [41]. Similarly, in the McMahon et al. survey, conducted among 20 
participants who completed a Vorinostat study in Australia, the greatest possible benefit to an HIV 
cure was placed on stopping HIV transmission (47% of respondents) [56].There is also a parallel to 
be drawn between the desire to no longer be infectious in HIV cure research with the HIV vaccine 
and prevention literature. In a study on willingness to participate in HIV vaccine trials, protection 
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against HIV from vaccines was associated with a high (75%) willingness to enroll in studies [57]. 
From a trial implementation and ethical standpoint, we should emphasize to study participants that 
HIV risk reduction practices should not be relaxed during study participation –in both prevention or 
cure-related research [57]. 
Like previous surveys on willingness to participate in HIV cure research [49][58], we asked 
about willingness to interrupt treatment as part of HIV cure research. We found that 68% of 
potential HIV cure research participants were very willing or somewhat willing to stop treatment as 
part of HIV cure research. These numbers were slightly higher than those obtained in Arnold et al. 
survey [49], whereas one third (34%) of the 2,262 respondents stated that they would be very 
willing or willing to participate in a study that involved treatment interruption, compared to 34% 
who said that they would be somewhat willing and 32% said that they would not be at all willing. 
Our data are more aligned with a more recent (2014) survey conducted in the United Kingdom with 
982 people living with HIV, where treatment interruption was found acceptable for 62% of study 
respondents [58]. The results that we obtained on the treatment interruption variable may reflect 
the different study samples used or the need to better educate potential study participants about 
the possible risks of treatment interruption. It is clear that health risks such as those related to 
treatment interruptions create barriers to study enrollment and may increase the difficulty of 
implementing HIV cure-related studies ethically. More formative research is needed to explore the 
influence of altruism in willingness to undergo risks such as treatment interruptions.  
It was surprising that 8% of participants thought a cure for HIV infection was presently in 
existence. This finding was incompatible with the fact that our convenience sample had regular 
access to HIV-related information about treatment or cure. It may have been indicative of the 
inflated HIV cure news that people hear in the media. Furthermore, the awareness of Timothy 
Brown’s cure likely must have skewed the results as to whether people thought a cure for HIV was 
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presently available, although his cure remains a unique case report. The finding underscores the 
need to better support educational programs around HIV cure-related research, especially as the 
HIV cure science gets scaled up and more complex in the United States and around the world. We 
need to encourage HIV cure scientists and universities to report on the incremental nature of HIV 
cure science development in a responsible way, in press releases or other media. We also need to 
do a much better job at being consistent with portraying a realistic picture of the science without 
generating false hopes. Expectations around what HIV cure science can deliver should be managed, 
without unduly crushing the hope. We also need to find a balance between engaging communities 
now versus getting ready for the long journey ahead and not burning out people living with HIV and 
community advocates.  
Discussion of Bivariate Study Results 
The bivariate study results revealed that nine potential benefits were “very important” 
motivators to participation in HIV cure-related studies as they significantly correlated with 
willingness to participate. The potential benefits that were positively correlated with willingness 
came from all three categories of benefits: personal benefits, personal clinical benefits and social 
benefits. Those with the strongest positive associations were altruistic and emotional in nature, thus 
underscoring again the need to appeal to study participant’s altruistic motives when conducting 
recruitment efforts. 
There were 18 potential risks that were “very likely to discourage” study participation in HIV 
cure research, and all were statistically significantly correlated with unwillingness to participate. The 
potential risks that were negatively correlated with willingness were personal clinical risks, 
symptoms and side effects, invasive study procedures and transportation logistics, and these results 
were consistent with those from the qualitative analysis. None of the potential risks and burdens 
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such as time commitment levels, non-transportation logistics, non-invasive study procedures and 
potential social risks were statistically significantly associated with unwillingness to participate.  
Interestingly, general interest in HIV cure research was perfectly and positively associated 
with willingness to participate. Thus, more HIV cure-related research recruitment efforts should 
focus on the individuals and communities who are actively engaged in HIV treatment and cure 
studies, such as those who are obtaining information about HIV cure research (e.g. such as the 
CUREiculum) or those who have already volunteered but are not currently enrolled in other HIV 
treatment or cure studies at present. These individuals may also be able to recruit peers in studies, 
although there are confidentiality issues to be aware of. 
Discussion of Multivariate Study Results 
Multivariate analyses showed that, after controlling for socio-demographic characteristics, 
perceptions of 5 (out of 21) of the potential benefits were “very important” motivators to 
participation in HIV cure studies. Three potential benefits with the strongest positive associations 
were altruistic and emotional benefits and two were personal benefits related to increasing the 
respondent’s knowledge of their own HIV infection. HIV cure researchers should focus on these 
benefits when recruiting for higher-risk studies in order to improve enrollment and enhance 
participants’ satisfaction in joining studies. 
After controlling for socio-demographic characteristics, 19 (out of 35) of the potential risks 
were “very likely” to discourage participation in HIV cure-related studies. All of these risks involved 
symptoms and side effects. Further, nearly all of the invasive study procedures, such as biopsies and 
spinal taps, and transportation risks were negatively correlated with willingness to participate, 
confirming the bivariate analysis results. Fear of discrimination and risk of transmitting HIV to sexual 
partners were associated with deterrence to participate. HIV cure scientists should address the risk 
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of discrimination and properly counsel study participants about sexual transmission risks of HIV as 
part of research design.  
Interestingly, willingness to participate was not statistically corrected with six socio-
demographic variables: gender, ethnicity, income, region, having control over own health care, and 
having even volunteered for an HIV cure study. This is interesting given that women and non-whites 
have traditionally been under-represented in HIV cure studies[30][29]. It may be that despite their 
willingness to participate, women and non-whites have to overcome other barriers to participation. 
Despite the lack of statistical significance, HIV cure scientists should still exert special efforts to 
recruit these groups in HIV cure-related research since the willingness is there. This is also where we 
need to exercise caution with interpretation of the data.   
People who were recently infected with the virus were more eager and more willing to 
volunteer for HIV cure-related studies. Younger individuals were also, on average, more willing to 
participate in studies than older people living with HIV. These results were surprising, given that 
older individuals have done everything to stay alive and well up to this point. Given that the 
population of people living with HIV is aging in the United States, HIV cure scientists should exert 
special efforts to recruit younger and newly infected individuals as these individuals will be the 
primary targets of HIV cure research initiatives in the future. Further, people who believed that their 
health status was relatively poor were 3.6 – 4.5 times more willing to participate in HIV cure-related 
studies, on average and ceteris paribus. The finding may indicate that people who are sicker are 
more willing to help advance the science or try whatever it takes to eradicate the virus, either for 
themselves or for society, when faced with greater health obstacles. This is paradoxical given that 
HIV cure studies focused on the “healthier subjects” who  have the least to gain (and the more to 
lose) from HIV cure research participation. 
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Discussion of Qualitative Findings  
The study employed a semi-structured survey (with people living with HIV) and key 
informant interviews (with people living with HIV, clinician-researchers and policy-makers) to elicit a 
range of opinions around factors that influence participation in HIV cure research. We were able to 
explore these factors in greater depth along with the implications for the effective and ethical 
implementation of HIV cure research. We used a non-probabilistic purposive recruiting strategy for 
the qualitative interviews. Implementation issues and implications raised were best explored via rich 
dialogue. In our systematic qualitative analysis (above), we used quotations as the primary form of 
evidence to support our interpretation of the raw data [44].  
Our exploration of the perspectives of key informants uncovered that participation in HIV 
cure research is a complex multi-dimensional experience.  The qualitative analysis revealed that it 
was difficult to adhere to the strict dichotomy of risks/deterrents versus benefits/motivators to 
participation. Several themes were revealed as part of the inquiry that stretched beyond risks and 
benefits as factors influencing decisions to participate in HIV cure studies. It is thus important to 
appreciate the entire clinical study experience and overall quality of life of people living with HIV 
when designing and implementing HIV cure research. Furthermore, study participants, clinician-
researchers and policy-makers/regulators ascribed meanings to HIV cure research. Undoubtedly, 
formative research to assess those understandings may provide an empirical foundation to facilitate 
recruitment and retention of people living with HIV in studies and community engagement efforts 
that support long-term HIV cure clinical developments.  
Among the key findings from the qualitative data, we found that motivators to HIV cure-
related research participation were both tangible and intangible in nature, with psychological, 
emotional and mental benefits playing a significant role. This finding was consistent with what has 
been found in the early-phase cancer literature [59] and with our quantitative data. Deterrents to 
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HIV cure-related research participation were manifold but centered on perceived risks, negative 
clinical contact factors and practical and logistical obstacles to participation. Concerns, barriers and 
burdens of HIV cure research participation were revealed. We found that the risk-benefit ratio was 
biased towards risks and that study participants should not expect any direct clinical benefits from 
study participation. We gathered perceptions around analytical treatment interruptions that 
complemented the quantitative survey data.  
On a more practical level, we derived lists of factors facilitating the recruitment, retention 
and effective implementation of HIV cure studies. The qualitative research also described factors 
facilitating the ethical implementation of HIV cure research, and these will be further explored later 
in this chapter. We learned about the perceived roles of study participants, clinician-researchers and 
policy-makers, along with general expectations around and hopes related to the HIV cure research 
experience. We also obtained general key considerations for the field of HIV cure research, such as 
the need to manage expectations and to use language thoughtfully.   
All-inclusively, qualitative data showed that decisions to enter HIV cure studies were “often 
relational, dynamic, iterative, provisional and/or conditional” [60]. In that regard, HIV cure research 
is not different than other types of medical research where complex decisions must be taken in the 
face of scientific uncertainty [60] [59]. While we attempted to understand willingness to participate 
in HIV cure research on a community or societal level, it is clear that decisions to participate are 
deeply individual and personal. Key informant interviews with study participants showed that there 
are both extremely willing and extremely unwilling individuals and that willingness to participate 
falls on a spectrum. Despite the tremendous altruism shown, there is clearly a phenotype of people 
living HIV for whom participation in HIV cure research is absolutely out of the question – either due 
to risk aversion, lack of interest, concomitant medical conditions or other reasons. There is another 
 221 
phenotype of people living with HIV who do not place any upper limits on acceptable risks and 
would do anything to help move the field forward. 
Furthermore, decisions to participate in studies are not divorced from the impact of HIV on 
the daily life of study participants or their views on currently available therapeutic options [43]. A 
case in point was that one of the most feared risks of participation in HIV cure research, as revealed 
during the qualitative interviews, was that HIV could rebound and become unmanageable. People 
living with HIV appreciate the potency and ease of using currently available HIV drugs. Furthermore, 
it is important to interpret the study results in view of the fact that intentions around HIV cure 
research participation may never be truly absolute and once-and-for-all. Even Timothy Brown, in his 
personal account of how he became the Berlin Patient, reported being unenthusiastic about 
whether to participate in research because he did not want to become a guinea pig:  
I said “No” to the transplant thinking that it would not be necessary were the leukemia to 
remain in remission because I could continue to take my antiretroviral medication indefinitely. I 
did not need to be a guinea pig and risk my life receiving a transplant that might kill me. The 
survival rate for stem cell transplant is not great; normally it is about 50/50.(…) This is important 
because a continuation of antiretroviral therapy would have meant that no one would have 
known for a long time that I was cured of HIV (…) The recovery from that [second transplant] did 
not go well. I became delirious, nearly went blind, and was almost paralyzed. [52] 
 
As illustrated by this quote, willingness and intentions to participate in research must be 
interpreted carefully, because even the most willing study participants may have reservations about 
participation. In turn, decliners may have openness towards participation. Key informant interviews 
further emphasized the critical importance of clinical contact factors in decisions to participate. As 
with the cancer field, developing positive, meaningful researcher – participant interactions may be 
important to facilitate recruitment in research, as opposed to wide marketing of HIV cure studies.  
Furthermore, from a clinical and public health perspective, much of the U.S. population of people 
living with HIV is aging. There is a greater need to better understand how the challenges of treating 
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other chronic conditions – such as diabetes, cancer, cardiovascular events – impact decisions, 
eligibility or risks to participate in HIV cure studies [43].   
One aspect of the qualitative research that was most intriguing was discovering perceptions 
of risks (and benefits) in HIV cure studies. The inquiry richly complemented the survey results. It was 
surprising to find that latency-reversing agents were considered to be amongst the riskiest HIV cure 
strategies in both the survey and the key informant interviews, as I had was previously reported that 
“This method may represent the safest, most scalable, and accessible strategy to eradicating HIV-1 
in the longer-term” [11] based on previous work with the Collaboratory of AIDS Researchers for 
Eradication (CARE). Narratives around perceived risks and benefits of HIV cure modalities revealed 
possible disagreements between clinician-researchers and the perceptions of study participants 
added a degree of complexity to the inquiry. The fact that potential study participants weighed 
perceived social benefits with clinical risks was in alignment with Verheggen’s “personal balance 
account” assessment underlying decisions to participate in clinical studies [54][50], although the 
calculus may not be systematic.  Unquestionably, perceptions of what represent “too much” or 
unacceptable risks should be taken into account when designing studies as they influence the ethical 
development and implementation of research. 
One topic that received more attention was that of (social) altruism, an important motivator 
to HIV cure research participation. This is consistent with connected bodies of literature, including 
HIV prevention research [61]. Altruism is defined as “individual[s] weighing potential social benefits 
for research participation over and above any personal risks associated with trial participation” [61]. 
In social altruism, study participants feel that the social benefits of study participation outweigh 
potential personal, health, clinical or social risks [61]. There is a positive relationship between 
altruism and quality of life in the HIV prevention field, as research participation adds purpose and 
meaning to someone’s life [61]. It was found that nurturing a sense of altruism among study 
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participant could increase recruitment in trials, and altruism is very important in clinical studies that 
involve greater personal risks [61]. Nevertheless, in our key informant interviews, wishes to 
contribute to scientific knowledge around HIV cure were often mixed with desires for personal 
benefits. The topic of mixed altruism (or personal, self-altruism) has been under-explored in 
research around decision-making toward HIV cure clinical studies. While study participants may be 
motivated to join studies for perceived personal benefits, they can still understand that the overall 
intent of the endeavor is to gather generalizable scientific knowledge [37].  
Stigma was another important topic discussed during the key informant interviews. It was 
no surprise that stigma deterred participation in HIV cure research, as it also discourages access to 
HIV testing, uptake of HIV care and initiation and compliance to HIV treatment [62]. In our study, 
stigma and discrimination were both a social risk and a major barrier to HIV cure research 
participation. Key informant described their close and personal encounters with HIV-related stigma 
in daily life. More work should be done to understand and reduce stigma as part of ethical HIV cure 
research design and implementation. 
The next portion of the discussion reflects on the implications of our findings as they relate 
to key concepts in research ethics. The inquiry contributes to the aim of understanding factors 
facilitating the ethical implementation of HIV cure studies. Subsequently, we consider the effective 
implementation of HIV cure studies. 
Reflections on the Ethical Implementation of HIV Cure Studies 
In their Principles of Biomedical Ethics [63], Beauchamp and Childress describe that “ethics is 
a generic term for several ways of examining the moral life (page 9).” Biomedical ethics involves 
collecting information, assessing its reliability, identifying moral dilemmas and mapping out 
solutions to the ethical challenges that have been identified [63]. Unquestionably, HIV cure studies 
are cutting-edge and they are challenging, not just from a scientific standpoint, but also ethically. 
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They involve long-standing questions in bioethics such as the protection of research participants, 
minimization of risks or harms and distribution of burdens and benefits [64]. Yet, no absolutes exist 
for the ideas of right and wrong at any given time. Ethics and moral behaviors must engage with the 
situations and they are a function of time and space [65]. They may create obligations where the law 
remains silent [63].  
Bioethics involve hierarchical levels such as ethical theories (integrated bodies of principles 
that govern choices – such as utilitarianism or deontological theories), principles (general concepts 
that serve to justify rules – such as respect for persons), rules (specific to context) and judgments 
and actions (expressed in decisions, verdicts of conclusions) [63]. In our inquiry of factors that 
facilitate participation of people living with HIV in cure research, we focus on discussing ethical 
principles as they have the most direct application. The Belmont Report summarizes ethical 
principles and guidelines for research involving human participants into three core principles: 
respects for persons, beneficence and justice [34]. The Belmont Report provides a useful framework 
to organize our inquiry around the ethical implementation of HIV cure research, although it may not 
encompass of all possible requirements for ethical research [27].19 
Principle of Respect for Persons   
According to the Belmont report, we show respect for persons by honoring their right to 
make informed and voluntary choices [64]. The principle of respect for persons is embodied in the 
informed consent (or informed refusal) to participate in research [63]. There are issues of 
autonomous decision-making in research, however, that extend beyond the step of informed 
consent. Beauchamp and Childress argued that there is a distinction between autonomous agents 
                                                          
19
Emanuel and colleagues highlighted 7 requirements for ethical research: 1) value, 2) scientific validity, 3) fair 
selection of subjects, 4) favorable risk-benefit ratio, 5) independent review, 6) informed consent and 7) 
respect for enrolled subjects. We explore some these requirements using the overarching organization of the 
Belmont Report.   
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and autonomous choices: “Being autonomous and choosing autonomously are not the same as 
being respected as an autonomous agent. To respect an autonomous agent is, first, to recognize 
that person’s capacities and perspectives, including his or her right to hold views, to make choices, 
and to take actions based on personal values and beliefs.” [63] In medical research, respecting a 
participant as an autonomous agent requires an obligation to disclose information, to ensure 
understanding and voluntariness, and to foster autonomous decision-making [63]. Nevertheless, 
there exist “paradoxes of autonomy” in scientific research given the unequal distribution of research 
knowledge or the frequently shared nature of decision-making [63].  
No other topic has received as much attention in the ethical implementation of research as 
informed consent. Informed consent is a fundamental component of all important documents 
dealing with research ethics, including The Nuremberg Code, the Declaration of Helsinki, The 
Belmont Report and ICH GCP E6. Informed consent has two main components: an informational 
element and a decisional element. The informational component includes the adequate disclosure 
of information and comprehension by the study participant. The decisional element refers to the 
voluntary decision as to whether to participate. As expected, informed consent was one of the most 
frequent answers to the key informant interview question of “What facilitates the ethical 
implementation of HIV cure studies?” While necessary for ethical clinician research, authors have 
argued that informed consent is by no means sufficient. [27] The signature on an informed consent 
form does not provide any guarantee of a participant’s comprehension of what s/he has signed [50]. 
Therefore, clinician-researchers must make conscious efforts to communicate clear information to 
the study participants and answer their questions prior to making a decision to participate. The 
informed consent form must also state the alternatives to study participation. Furthermore, it is well 
accepted that informed consent should be an ongoing process and not a one-time event before 
screening can begin [28][66]. New knowledge may be acquired during the course of a study that 
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modify risks and benefits and influence a participant’s willingness to be retained. While a lot has 
been written on informed consent, the literature on informed refusal remains relatively silent.  
In her essay on “How do Patients Know,” Rebecca Kukla argued that the epistemic 
component of a participant’s autonomy is a necessary condition for autonomy [19]. More 
importantly, participants exercise their autonomy through the act of making a decision once they 
are well-informed. Kukla contends that the participants’ practices of collecting information may play 
a more integral role in autonomy and informed consent. While the bioethics literature has focused 
on the obligations of researchers to inform the participants, there has been little consideration for 
the fact that participants often enter the clinical study visits as “active inquirers” who have already 
been exposed to information, and this information requires “active negotiation, not just passive 
reception” [19]. HIV cure research implementers should thus not view candidates are mere passive 
recipients of cure information. In fact, some participants have reported “shopping” for studies as 
their bodies is what they have to offer and they try to obtain the best deal. HIV cure research 
participation may even become an enterprise for the more astute and professional research 
participants who act like empowered consumers of research and also expect a return on 
investment. The skills and strategies exercised by potential volunteers to access, assess and balance 
information is important in the act of decision-making: “we cannot “measure” the autonomy of this 
choice without attending to whether it resulted from a competent, responsible process of inquiry – 
that is, whether the patient manifested autonomy not only during the moment of choice itself, but 
also in the epistemological process that led up to that moment” [19]. The act of informed consent 
goes beyond the exact moment when a study participant signed an informed consent form. S/he has 
acquired information organically and must negotiate a decision-making pathway. Kukla insisted that 
competent inquiry requires basic health literacy skills because one cannot understand medical or 
scientific information unless s/he can access it, and whether the information is understood depends 
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on how it is presented [19]. What this essay teaches us for the implementation of HIV cure research 
is that scientists should respect and recognize their participant’s capacity for autonomous inquiry. 
This changes the meaning of patient autonomy and informed consent. Study participants are not 
mere recipients of information but active inquirer of scientific knowledge.  
A related literature has focused on “gist knowledge” – defined as “qualitative, more general 
cognitive representation of understanding” [67]. This literature focuses on the role of heuristics – or 
cognitive shortcuts – in medical decision making, suggesting that trade-offs are negotiated by study 
participants to reduce the cognitive burden of decision-making, even at the risk of reducing 
decisional accuracy [67]. Gist knowledge is found to have a strong influence in decisions to 
participate in research, often above verbatim knowledge found in informed consent forms. 
Furthermore, for good or for bad, study participants may form opinions about HIV cure strategies 
via other settings, such as the popular media, study recruitment materials or advocacy pieces that 
contribute to shaping public perceptions around the research [64]. This underscores the need to 
provide adequate information about HIV science in all platforms. 
Similarly, research has found that prospective study participants may have already made a 
decision as to whether to participate in a clinical study before they come in the door or receive an 
informed consent form [66]. This shows that the process of informed consent may actually begin 
before the potential risks, benefits and objectives of a study are explained to a study candidate. HIV 
cure research implementers should therefore pay attention to the process of recruitment, provided 
that candidates may have already made a decision to participate before they are consented [66]. 
Needless to say, the language used in the informed consent form is paramount and there should be 
conscientious efforts to streamline and increase the readability of informed consent forms.  
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Additional informed consent considerations related to HIV cure research relate to the fact 
that some kinds of consent are non-retractable. For example, with gene therapy research, the 
decision to go into a stem cell transplant is a one-way track decision. Other types of HIV cure 
research strategies may make informed consent more difficult, such as with pediatric HIV cure 
research, where a mother would need to provide assent for her child’s research participation during 
labor, although women routinely give or withhold consent for epidurals, C-sections, forceps and 
oxytocin during labor [32]. The issue of informed consent also becomes complicated for donations 
that are not tied to a specific study – such as leukaphereses or cell or sample donations that are 
meant to conduct experiments now or in the future (e.g. for reservoir assessments, effects of 
latency-reversing agents or other broad purposes), since study participants may not know exactly 
what they are consenting to. 
It is important to explore the topic of shared or joint decision-making in HIV cure research. 
Oftentimes, a study participant’s decision to participate in studies cannot be viewed as a discrete, 
isolated event, but rather be understood as a set of interactions with the research or medical 
establishment. The shared decision making literature received extensive attention in the cancer field 
[60][67][68][69] but less so in the HIV cure research field. Clinician-researchers help study 
candidates understand that a decision should be made, describe risks, benefits, uncertainties and 
possible options and work together to make a decision [68]. Shared decision making helps promote 
(earned) trust between the clinician-researchers and the patient-participants and helps manage 
uncertainty [67]. As explained by Epstein and colleagues: 
Engaging patients in constructing preferences in the face of complexity, inadequate 
evidence, and irreducible uncertainty involves more than provision of information and an 
invitation to choice. It also involves dialogue about the communication process itself; that 
is, what patients want to know, what information is relevant, how patients prefer to be 
informed, patient’s roles in decision making, and who else (if anyone) should be present. 
Seen in this way, constructing preferences (…) involves building relationships, providing 
information, and exploring preferences, which then strengthen relationships, 
understanding, and involvement in decisions. [60] 
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The topic of shared decision making adds a new inflexion to the need for autonomy. In such 
highly innovative HIV cure research, investigators should try to interact with study participants as 
study partners and collaborators. Clinician-researchers should not under-estimate the interpersonal 
dynamics of the informed consent process and the importance of the researcher – participant 
relationships. This theme clearly emerged in the key informant interviews.  Establishing a climate 
that makes it easier for study participants to ask questions may be more important than having the 
study candidates understand very fine detail of the disclosed information [63]. Study participants 
must still be free to make a decision and be free of coercion, manipulation or undue persuasion [63] 
and they should feel like they can ask questions about their study participation at any time. 
Therapeutic Misconception or Fallacy 
Therapeutic misconception or fallacy has received attention in the HIV cure research 
literature given that most studies are in the early stages of experimentation. Therapeutic 
misconception refers to the overestimation of clinical benefits resulting from clinical research or an 
underestimation of the possible risks of harm [37][70]. With therapeutic misconception, there is 
unrealistic or unreasonable optimism that one can benefit from the research intervention and the 
experimental research is confused with clinical care[38]. Therapeutic misconception is different than 
therapeutic misestimation in that study participants overestimate benefits and underestimates the 
risks [71]. In therapeutic optimism, participants hope for the best possible personal outcome [72]. 
Most of the research on therapeutic misconception, misestimation and optimism is derived from the 
cancer field, but also applies to HIV cure research. It is apparently a well-established fact than when 
an outcome has a low probability, but a very high value, study participants may be inclined to place 
disproportionate weight on the small odds in decision-making [59]. Not helping the field of HIV cure 
research is the powerful word “cure.” Cure-associated terminology can lead to false hopes and 
incorrectly bias risk-benefit assessments. It is difficult for HIV cure scientists to balance the 
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aspirational language with the reality of first-in-human clinical studies with a low likelihood of 
individual medical benefit. Some scholars have debated whether to use the word “cure” at all [73]. 
While the “cure research” language is important to explain the long-term goal and potential future 
value of the research, not to mention the benefit to society, expressions such as “HIV reservoir 
research”, “long-term ART-free remission” or “HIV remission research” may be less prone to 
inducing therapeutic misconception. 
The term curative misconception has been distinguished from therapeutic misconception, 
which is the false belief in the possibility of being cured from an HIV cure research strategy or 
experiment [73]. Curative misconception could disproportionately influence willingness of people 
living with HIV to participate in studies, distort perceptions of risks and uncertainties associated with 
the research interventions [73]. In her analysis of HIV cure-related informed consent forms, Gail 
Henderson found that long-term aims associated with HIV cure-related research are often presented 
in overly optimistic terms such as “to achieve HIV remission,” “to eradicate hidden virus… unmask or 
flush out the latent HIV in your cells,” “to improve the body’s ability to fight infection” and “to 
remain healthy” [74]. These research objectives are obviously misleading, because HIV cure research 
experiments will not lead to eradication of latently infected cells at this juncture. HIV cure scientists 
should replace language in the informed consent forms with more precise and realistic goals, such 
as “to see if it would be possible to perturb the HIV reservoir.” In order for HIV cure studies to be 
implemented ethically, it is important for scientists to remain honest because unrealistic 
expectations can prove harmful and contribute to disappointing and embittering study volunteers 
when the benefits they hope for fail to materialize. Furthermore, HIV cure clinical studies – such as 
gene “therapy” or “therapeutic” vaccinations – are not truly therapeutic and we should find better 
alternatives to name this falsely therapeutic research.  
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Moreover, with the growing literature on HIV cure research, some accounts are blatantly 
misinformed and may contribute to creating the perception that a cure is close to being 
materialized. When peer-reviewed journal articles state that HIV cure can be functional or 
sterilizing, it implies that scientists already know what a cure for HIV looks like or that a cure is 
already in existence.  For example, the following was recently published by Buell et al.:  
HIV cure can be functional, a state whereby HIV positive patients have clinically 
undetectable viral loads in the absence of therapy, or sterilizing, whereby all traces of the 
virus, including the reservoir of latently infected CD4+ cells, are permanently removed (…) 
Numerous studies have found that HDACis such as Vorinostat, Panobinostat,and 
Romidepsin are potent inducers of viral transcription from the latent HIV reservoir [62]. 
 
In this account, it would have been preferable to use the conditional tense to denote 
hypotheticals around HIV cure. Furthermore, HDACis – including Vorinostat, Panobinostat, and 
Romidepsin – have failed to substantially reduce the size of the replication-competent HIV 
reservoirs, and therefore are not potent inducers of viral transcriptions in vivo. Latency-reversing 
agents very much remain at the proof-of-concept stage and absolutely no claim toward efficacy 
should be made. These types of statements contribute to inflating hopes and may cause more harm 
than good. They violate the ethical norms of veracity and non-maleficence [73] and may fuel the 
belief that a cure for HIV is in existence, as shown in the survey.    
Research has shown that therapeutic misconception may be a phenomenon that is difficult 
to eradicate in early phase experimentation [75]. Oftentimes, study participants may register 
perceived benefits of study participation, not so much to communicate understanding about actual 
benefits, but to register optimism about the study, especially when asked to express something 
positive about study [76]. Nevertheless, perceived benefits of early phase research should be 
discussed in a nuanced way, especially when they are likely to be limited. There needs to be a 
balance between getting study participants motivated to participate without overselling the 
research. There are inherent methodological challenges to assessing therapeutic misconception in 
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HIV cure clinical studies, and it remains unknown whether specific types of HIV cure modalities are 
more prone to therapeutic misconception – such as pediatric HIV cure research (e.g. given the near 
missed cure of the Mississippi child) or stem cell transplant/gene therapy research (given the 
sterilizing cure of Timothy Brown). 
In order to avoid therapeutic misconception, there are specific dimensions that must be 
understood by study participants, including the scientific purpose of research, study procedures, 
uncertainty, adherence to the research protocol and the medical staff being researchers [37]. Nancy 
King and colleagues also provided a helpful checklist of recommendations for informed consent 
forms using examples from gene therapy research. These are worth revisiting in the context of early 
HIV cure experiments: 
Table 21. Recommendations for Informed Consent Forms in Early Phase Clinical Studies 
Recommendations for Informed Consent Forms in Early Phase Clinical Studies[77] 
Avoid Inconsistent and Confusing Terminology 
 Keep terms clear and simple; define them succinctly when necessary 
 Describe potential direct benefits consistently throughout the consent forms, or limit 
their description to one consent form section only 
 Limit variation in use of terms referring to experimental interventions  
Avoid  Misleading “Treatment” Implications 
 Present benefit to society as the role of primary goal of the research 
 When direct clinical benefit is not possible or unlikely, say so 
 Describe surrogate endpoints as measurement goals only 
 Consistently use “research” terminology to refer to investigators, study participants 
and experimental interventions   
Avoid Vagueness about Potential Benefits  
 Discuss each type of benefit (societal, direct and inclusion) separately and distinctly 
 When direct benefits are reasonably possible, describe them precisely, including their 
nature, magnitude, duration, likelihood and limits   
It may also be worth exploring the topic of curative hope, as there is a fine balance between 
fostering realistic hope and creating unrealistic expectations around the science. As borrowed from 
the cancer literature, hope is a broad concept that can have different meanings for each person 
[78]. Hopes can be defined as the feeling that something good will happen. More empirical work 
and ethical analysis are needed to be able to analyze hopes as they related to reasonable versus 
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unreasonable expectations in early HIV cure research. Surely, “hopes to be cured” should not be 
part of decision-making or the referral process in these early-phase HIV cure clinical experiments 
[11]. Related to hopes, HIV cure scientists must avoid deceiving study participants [27]; however, 
research has found that study participants can also commit deception while participating in research 
by failing to disclose important or accurate information to scientists. [79]. Self-reported endpoint 
data are known to be spurious.  
Revisiting the Principle of Respect for Persons 
We explored the principle respect for persons in terms of ensuring true informed consent 
and avoiding therapeutic misconception. Respect for autonomy means more than just having study 
participants make decisions, but also respecting their capacity to learn and evaluate values, 
meanings and context. In a sense, it may be time to adopt a broader and more fluid definition of 
respect for persons that extend beyond mere autonomy. Respect for participants mean respecting 
them at all stages of recruitment – including before, during and after study participation [27]. This 
wider participant-centered focus may be currently missing from the HIV cure research enterprise. 
Research projects must respect people living with HIV whether or not they enroll in studies. The 
need for respect must also be reconciled against the fact that experimental interventions are 
designed to produce generalizable scientific knowledge, and not meant to address participants’ 
individual health needs. Further, the roles of researchers versus caregiver must constantly be 
balanced, and deciding upon which one to use at any given time may represent an ever-present 
ethical dilemma for HIV cure research implementers[80]. 
Study participants should feel appropriately valued in research beyond the health 
assessments that they routinely get during study visits. They should feel valued as human beings. 
One key informant commented that although she was oftentimes called a “valuable biological 
specimen” – something that could have been completely dehumanizing – however, the way it was 
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done by the study nurse was with the upmost respect and therefore she felt the opposite of being 
objectified and dehumanized. She explained that the approach and interaction with the study nurse 
matter a lot. The respect for persons cannot be achieved solely by relying on procedural safeguards, 
such as informed consent. There are more subtle issues related to the recruitment, retention and 
treatment of study participants that stem from interactions with the research staff. HIV cure 
research implementers must appreciate the entire personal experience and the therapeutic journey 
of study participants. Some authors have even advocated that study participants should have their 
own stopping rules for research participation, particularly in the psychosocial dimension [53]. 
Undoubtedly, HIV cure research participants have undergone a life-altering event and the 
HIV-positive diagnosis can be troubling. Some participants may be relatively healthy, others not. 
Some are long-term survivors, while others were newly diagnosed or even acutely infected. It is 
important to treat the study participants as holistic individuals. In their account on the ethics of 
talking about HIV cure, Rennie and colleagues remind, invoking Van Eys [81], that there are actually 
three components of a cure: biological, psychological and social. To truly cure a person requires that 
all three dimensions are covered. Similarly, borrowed from Chinese medical tradition, Qiao argued 
that a cure for HIV would not only require the science of eradicating pathogens, but also the art of 
restoring harmony between mind and body. Healing becomes interpersonal and social, in addition 
to biological, and involves both HIV participants and their entire social environment (Qiao, 
Foundation Brocher workshop, May 2014).  
Furthermore, as shown in the key informant interviews, we need to be cautious about how 
study participants are described. People enrolling in early HIV cure research experiments should not 
bear the degrading label “subject;” instead, they are “participants” or “volunteers” who are actively 
contributing to the research endeavor. The literature on clinical research participation has also 
called for more humane and compassionate language in order to minimize the distance between 
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researchers and participants and to signal “ethical protection” and “trust-based obligations” as 
opposed to “exploitation” [82]. Research participants can wear multiple hats and serve multiple 
functions – such as community advisory board members, patient advocates, co-investigators, and 
volunteers, and these roles may change over time [82]. It is important to embrace these new 
research relationships at all stages. These may make the upholding of ethical obligations more 
complex, however, and inflect the very meaning of respect. In short, respect for persons in clinical 
research is much more than the general requirements of autonomy and informed consent.  
Principles of Nonmaleficence and Beneficence 
Next, we review the principles of nonmaleficence and beneficence. Nonmaleficence is the 
concept of not inflicting harm and can be associated with the maxim Primum non nocere (“Above all 
[or first], do not harm”) [63]. It encompasses the moral requirement of protecting the well-being of 
study participants, providing basic standards of care and ensuring risk-benefit assessments [27][63]. 
In turn, the principle of beneficence, contained in the Belmont Report [34], refers to the moral 
obligation of acting for the benefit of study participants [27][63]. In a sense, the principle of 
beneficence requires positive steps to help others and may even suggest the provision of benefits 
and acts of kindness, mercy or charity [63]. In the case of HIV cure research, given the high 
standards of care and tremendous safety of HIV antiretroviral treatment, it becomes difficult to 
justify the need for low benefit and high risk. HIV research has evolved to attempting to find 
treatment for very sick individuals, to now searching for a cure for relatively healthy participants. 
The burden of safety is very high and scientists need robust safety and efficacy data before exposing 
study participants to risks. 
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Risks in HIV Cure Research  
It is worth exploring the concept of “risks” and “benefits” in the context of HIV cure 
research. According to Beauchamp and Childress, risks can be both a descriptive and an evaluative 
concept [63]. Risk analysis is different than risk assessment: risk analysis serves to identify risks 
whereas risk assessment estimates the probability of a negative event occurring or may evaluate the 
acceptability or the significance of risks [63]. HIV cure research, in its current early phase, rests on 
the risk side of the benefit-risk continuum. Our study data revealed that the greater the risks, the 
more likely potential volunteers are deterred from participating in research. We also asked key 
informants about perceptions of risks related to various types of HIV cure studies as well as 
perceptions of “too much risks.” There was tremendous variability in the responses given. The 
literature has emphasized that potential volunteers’ perceptions of risks may sometimes differ from 
expert opinions[83]. Overall though, risk perceptions may play a tremendous role in deciding what 
interventions get moved forward. The more honest investigators are about potential risks and the 
lack of direct benefits, the more difficult recruiting study participants may become.   
HIV cure investigators have an ethical duty to convey risks to potential study participants. 
According to the ethics literature, two criteria must be fulfilled in order for risks to be accepted. 
First, risks must be minimized. Second, they must be “reasonable in relation to the importance of 
the knowledge that may reasonably be expected to result (45 CFR 46.111.(a)(2)” [39]. Risks can 
result from study interventions but also study visit procedures, and the very monitoring can also add 
risks [84], together with the deviations from standards of care, as with treatment interruptions. 
Scholars have appreciated the stochastic nature of risks; for example, interventions that may work 
in >80% of study participants may also cause harm in <20% of participants [83]. As we increasingly 
start to embrace a public health and epidemiological approach to HIV cure research, it is important 
to account for individual variations in risks [83]. We need to minimize risks because unexpected 
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serious harms to study participants could trigger a crisis of confidence that could set the field back 
(as with gene therapy research in 1999). We also need to ensure that data points derived from HIV 
cure research participants, either on their own or in the aggregate, are as valid and informative as 
possible to move the field forward in order to justify the risks taken by study participants. 
The Forum for Collaborative HIV Research, during its June 2014 meeting, provided a 
framework for how to portray potential risks of participation. Types of risks of HIV cure studies 
identified and ways to tackle those risks included: 
Table 22. Types of Risks in HIV Cure Research and Ways to Tackle 
Types of Risks in HIV Cure Research and Ways to Tackle  
Types of Risks in HIV Cure Research 
 Risks of highly invasive procedures 
 Reproductive risks 
 Risks of analytical treatment interruptions  
(e.g. deviations from standards of care) 
 Risks of intensification of ARV treatment 
 Risks of antibody formation, viral drift, mutagenesis and blood cancer 
 Risks of being ineligible for future trials or treatments 
 Risk of loss of private or confidentiality of personal information  
[Forum for Collaborative HIV Research, 2014] 
Ways to Tackle Risks in HIV Cure Research 
 Proceed to human experimentation only after rigorous, non-human animal 
studies, laboratory tests and mathematical modeling 
 Develop rigorous criteria for discontinuation and restarting if needed 
 Recruit participants who need intervention anyhow (for co-morbidity) 
 Recruit participants with allegedly little to lose20 because they have a terminal 
condition 
 Make sure that we have done as much as we could before interventions go into 
humans  
 Assume that there will be misadventures in some studies; prepare for that  
 Focus on known risks because unknown risks are unknown; but know that there 
are unknown risks 
       [Adapted from: Forum for Collaborative HIV Research, 2014] 
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However, relatively “healthy subjects” may be the ones who have more to lose from HIV cure research 
participation given their  high CD4+ count and low viral load.  
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The literature has further discussed whether we need to place upper thresholds on risks 
that are acceptable. A case in point was an AIDS activist who, in 1995, underwent a bone marrow 
transplantation based on the hypothesis that a baboon’s immune cells would resist HIV infection.21 
In our study, there were potential volunteers who did not place any upper limits on acceptable risks. 
Ethical guidelines are very clear that scientists have an obligation to protect study participants from 
unjustified or excessive risks [85]. The placement of limits on permissible risks is warranted by the 
need to protect the research enterprise and the study participants, sometimes from themselves 
[85]. Currently, IRBs provide the risk determination of risk permissibility, but assessments of risks 
can vary greatly as there is no objective yardstick with which to assess risks. Furthermore, maximum 
(or minimal) risks can be flexible concepts – they can be transient and dynamic with the evolving 
state of knowledge or science [39].  
The extreme heterogeneity of clinical study designs and interventions and the great 
uncertainty of interventions make the reliability of risk-benefit judgements difficult, and call for 
prudence in exposing otherwise “healthy subjects” to substantial likelihood of serious risks [85]. 
Scholars have advocated for the standardization of language and methods used to communicate this 
uncertainty and has promoted participant-centeredness in representing risk uncertainty [86].  The 
literature is also rather silent, however, on interpreting and communicating risks to others – for 
example, as in the case of an HIV transmission during an unsuspected viral rebound in HIV cure 
research. Little has been written about how to evaluate future risks, such as the risk of developing 
future cancer, or about how the different types of risks, beyond clinical risk, affect overall well-being 
related to research participation, such as psychological risks, emotional risks, financial risks, identity 
risks, opportunity risks and social risks. Clinical study implementers are not always good at capturing 
social harm events either [87].  





Benefits in HIV Cure Research 
Benefits are oftentimes portrayed as referring to something positive that occurs during 
study participation [63]. At this time, clinical experiments in HIV cure research are proof-of-concept 
activities with no expectation of clinical benefit accruing from experimental interventions [11]. 
Furthermore, whether such experimental interventions, which are thought to be initial steps at 
attempting to purge persistent HIV infection, will lead to a reduction in the size of the latent 
reservoir and whether this partial reduction will lead to clinical benefits, remain highly unclear [88]. 
HIV cure studies are experiments that evaluate basic safety and whether interventions are capable 
of perturbing the latent HIV reservoir. They are not efficacy studies against disease. They are meant 
to generate knowledge to benefit future people living with HIV and thus study participation relies 
fundamentally on altruism [64]. Researchers have the responsibility to report the inherent lack of 
benefit in early HIV cure-related experiments.  
But what constitute benefits, exactly? Would a (temporary) HIV remission even be 
considered a benefit? Our study showed that potential volunteers still expect tremendous 
psychological and mental benefits from study participation and that these should not be under-
estimated. According to the literature, it is important to distinguish between benefits to study 
participants (e.g. benefits of study participation) from benefits to society (producing scientific 
knowledge) [75]. Further, advances in science and knowledge may not all translate into actual 
health or clinical benefits [64]. There is also a distinction between benefits from the interventions, 
and inclusion benefits (or indirect, collateral benefits) [75]. Examinations, study interventions and 
laboratory tests should not be considered benefits [66], even these were found to be perceived 
benefits in our survey.  
Interestingly, it is possible that clinical HIV cure studies may have positive clinical off-target 
effects. A case in point is the study by Tebas and colleagues who evaluated engineering cellular 
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resistance to HIV. This study observed that zinc-finger nucleases restored and sometimes doubled 
the study participants’ CD4+ T cells [89]. Certainly, explaining possible benefits – or lack thereof – in 
HIV cure studies can be extremely complex. Besides personal benefits and altruistic societal 
benefits, there could also be benefits to future self – or delayed personal benefits – in case a cure 
for HIV could materialize. More empirical research is definitely needed on speculative benefits in 
HIV cure-related studies.  
The Forum for Collaborative HIV Research, during its June 2014 meeting, provided a 
framework to tackle possible benefits in HIV cure research:  
Table 23. Ways to Tackle Benefits in HIV Cure Research 
Ways to Tackle Benefits in HIV Cure Research  
 Rely on the potential psychosocial benefits to participation 
 Rely on the fact that sometimes, early phase studies show clinical effect 
 Provide ancillary care 
 Insist that the adverse risk-benefit ratios for study participants are justified 
by the social value of finding a cure for HIV  
       [Adapted from: Forum for Collaborative HIV Research, 2014] 
Risk-Benefit Ratios  
Our study further asked key informants to provide perceptions of risk-benefit ratios in HIV 
cure research because this most closely embodies the principles of nonmaleficence and beneficence 
[90]. While risk-benefit ratios may be “best conceived in terms of a ratio between the probability 
and magnitude of an anticipated benefit and the probability and magnitude of an anticipated harm,” 
[63]it is important to note that there is no objective, quantifiable measure of risks to benefits. Risk 
assessments in clinical research require both moral and scientific judgment [91]. Importantly, 
potential risks to participants must be minimized, and potential risks must be enhanced and benefits 
to participants and society should be proportionate and outweigh the risks [90]. Undoubtedly, the 
field of HIV cure research has sharpened debates around risk-benefit assessments. It is difficult to 
evaluate risks and benefits for novel interventions, particularly when the nature, magnitude, 
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likelihood or severity of risks are unknown [92]. Instead of the risk-benefit ratio, Weijer has called 
for a “risk-knowledge calculus” to determine whether the risks of research can be justified against 
the societal benefits that can be gained from the research [27]. This is reminiscent of the criteria of 
scientific validity to advance research [27]. Early HIV cure experiments should be designed to answer 
important scientific questions towards an HIV cure [28]. While the likelihood that there will be 
benefit will be small, there should be a high likelihood that there will be any scientific progress, or 
“forward movement” as described by our key informants. Certainly, the NIH is pushing for end-of-
pipeline translational research in funding cycles. There may be ethical issues associated with over-
emphasizing human studies over cell model or animal experiments given the tremendous 
uncertainty of outcomes and the newness of the pre-clinical science.   
Rid and Wendler provided a constructive framework to evaluate risks and benefits in 
biomedical research [84]. Their framework provides a process for making risk-benefit evaluations 
and identifying unresolved questions to evaluate research risks and benefits. The framework can be 
highly applicable to the field of HIV cure research. The main steps are summarized in Table 24.  
Table 24. Steps to Evaluate Risks and Benefits in Biomedical Research 
Steps to Evaluate Risks and Benefits in Biomedical Research[84] 
1. Ensure and enhance the study’s social value  
2. Identify the research interventions and procedures used to ensure safety of 
interventions 
3. Evaluate and reduce the risks to participants 
4. Evaluate and enhance the potential benefits for participants 
5. Evaluate whether the interventions pose net risks 
6. Evaluate whether the net risks are justified by the potential benefits of other 
interventions 
7. Evaluate whether the remaining net risks are justified by the study’s social value 
Equipoise 
We now turn to the topic of equipoise. The term was introduced by the philosopher Charles 
Fried to denote the “controversy within the scientific community about whether the new 
intervention is better than standard therapy” [27][92]. The term is usually associated with 
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randomized clinical trials [39] and its relevance to early phase experiments is unclear. In our study, 
key informants varied in their responses around the relevance of equipoise – from accepting to 
denying its relevance in HIV cure research. It is worthwhile to explore the concept – and possible 
alternatives – further.  
Equipoise is one of the prevailing abstract frameworks to evaluate clinical studies. It adopts 
primarily a therapeutic lens. Advantages of equipoise are that it prevents redundant research and 
defines some of the prerequisites for conducting clinical research [92][93]. Critiques of clinical 
equipoise have argued that the concept is insufficient for ethically justifiable clinical trials [93]. In a 
sense, equipoise is conflicted because it “attempts to have it both ways: to view the clinical trial as a 
scientific experiment, aimed at producing knowledge that can help improve the care of future 
patients, and as treatment conducted by physicians who retain fidelity to the principles of 
therapeutic beneficence” [94]. Equipoise is a highly subjective notion that is biased by the optimism 
surrounding an intervention [95] and ill-informed when it comes to implementing research in 
developing countries that lack robust treatment options [96].  
Few alternatives to equipoise have been proposed in the literature that may be relevant and 
applicable to the field of HIV cure research. These are summarized in Table 25.  
Table 25. Alternatives to Equipoise Relevant to HIV Cure Research 
Alternatives to Equipoise Relevant to HIV Cure Research 
 Carefully investigate all aspects of the design of a clinical study, along with social 
and cultural context, including the motivations of study participants [93] 
 Adapt non-exploitation as central to clinical research ethics [93] 
 “The pertinent question is not whether the two treatments are in equipoise, but 
instead whether the potential benefits to third parties are sufficient in this case to 
justify the less-than-optimal care given to some of the patients in the study” [96] 
 Modest translational distance criterion: incorporates study-by-study evaluation of 
the expert scientific community [Kimmelman, in [97]] – similar to what is done by 
the FDA 
 Close examination of the entire structure of experiments across the continuum of 
biomedical research [98]: 
     Normative obligations that govern the work of the laboratory researcher at the 
bench, research with laboratory animals, research with healthy volunteers and 
research on sick patient-subjects [98] 
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Of the above alternatives to equipoise, my favorite is the one by Joffe and Miller [98], 
because it calls for a new conception of clinical research ethics based on a scientific orientation. In 
fact, this framework is much more applicable to HIV cure research than equipoise, which is best 
suited to randomized clinical trials. The paper defines normative obligations across the entire 
continuum of biomedical research – from laboratory bench work to research with healthy and sick 
participants. The key benefit of the scientific orientation is the appreciation of the entire 
translational research spectrum and the insistence on methodological rigor. The scientific 
framework also clarifies the acceptability of research procedures, such as biopsies, that are 
important to answer scientific questions that will not provide benefits to participants. The entire 
emphasis is on professional integrity and scientific value and validity. I recommend that the scientific 
framework be looked at closer in the context of HIV cure research. 
“Healthy Subjects” 
Related to equipoise, the topic of “otherwise healthy subjects” received recent attention 
given the FDA clinical hold of the Panobinostat + Interferon clinical study, as described in the 
qualitative results section. HIV cure research embodies the perfect storm of recruiting relatively 
healthy participants – otherwise “healthy” besides their HIV status –to undergo potentially 
significant risky interventions. The calculus of what is tolerable is obviously different between sick 
cancer patients and virally suppressed people living with HIV. Long-term treated HIV disease by no 
means represents a perfectly “healthy” state, however. That people living with HIV are considered 
“otherwise healthy” also somewhat conflict with data that co-morbidities are more prevalent in this 
population, including cardiovascular disease and diabetes. HIV suppression is not the same as being 
healthy. Moreover, inflammatory diseases occur at much higher rates in people living with HIV, 
despite their long-term HIV suppression. The cumulative toxic effects of HIV treatment are 
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unknown, and there are tremendous unmet needs surrounding HIV treatment cascades, both in the 
United States and globally.  
What is more, several people living with HIV may not perceive themselves as “otherwise 
healthy” volunteers, but instead fragile individuals who may still experience great health risks. 
Health may become an illusion for several people living with HIV. From an ethical implementation 
standpoint, it is important to ensure that HIV cure studies include proper safeguards so that if harms 
occur, procedures in place to mitigate these harms.   
Standard of Care and Treatment Interruptions  
Duties of nonmaleficence and beneficence require not imposing risks of harm and therefore 
observing standards of care [63]. Given the fast evolving state of HIV research, standards of care are 
not static, but evolving constantly with newly emerging drugs. There are also standards of care 
considerations during and after a clinical study has been completed. In HIV cure research,treatment 
interruptions go counter to standards of care. It is unclear to what extend treatment interruptions 
motivate or deter participation in HIV cure studies, although in our study, we asked general 
willingness to undergo treatment interruptions. It might be that some volunteers find the notion of 
a “drug holiday” to be a motivating factor, as we saw in the qualitative section. Treatment fatigue 
has also been reported to exist, although it should not be used as a way to attract volunteers in a 
study. Furthermore, to prevent sexual transmission of HIV to sexual partners during HIV cure 
research (and unsuspected viral rebound), it is clear that both standards of care and standards of 
prevention apply in HIV cure research and more guidelines are needed surrounding both. 
Scientific Uncertainty  
The literature on biomedical research ethics emphasizes that risks are distinct from scientific 
uncertainty [63]. While both imply a lack of predictability or knowledge about future outcomes, risks 
refer to the probability and magnitude about possible future hazards, while uncertainty means the 
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lack of predictability or knowledge about future outcomes because of insufficient scientific evidence 
[63]. One author has defined uncertainty as the “subjective consciousness of ignorance” [86]. Early 
phase research carriers inherently more uncertainty [27]. The Institute of Medicine (IOM) outlined 
three main sources of uncertainty: clinical, statistical and methodological [99]. Clinical uncertainty is 
derived from the use of randomized clinical trials as the primary methodology. Statistical 
uncertainty stems from the inability to quantify risks and benefits. Methodological uncertainty 
results from the pre-clinical and pre-market context [99]. Other sources of uncertainty that have 
been identified include: probability, ambiguity and complexity uncertainty [86].22 Doubtlessly, 
uncertainty has implications for recruitment study participants and for the ethical and effective 
implementation of clinical studies. It also has scientific, practical and personal implications.   
Our study assessed how risks and benefits affected willingness to participate in early HIV 
cure studies. There will always be a measure of uncertainty in characterizing those risks and benefits 
– some of which are known, others unknown. How the uncertainty is communicated to and 
understood by potential study candidates is of key importance and relevance here, especially during 
recruitment and retention activities. Neither benefits nor risks can ever be defined in absolute terms 
– they are relative and contingent upon a host of factors. They lie on a dynamic continuum that 
must take into account the experimental interventions, study population, visit procedures and 
standards of care. The characterization of the uncertainty is initiated in the pre-clinical phase of 
experimentation and continues throughout clinical research and marketing of products. It is known 
that pre-clinical models do not fully predict how compounds will behave in humans, and the 
interpretation of clinical data in early phase experimentation requires extrapolation and subjective 
judgment [91].  
                                                          
22
See page 16S of the article for a discussion on the probability, ambiguity and complexity with infographic. 
Politi et al. [68] used the categories of stochastic uncertainty (related to chance), ambiguity uncertainty 
(conflicting strength of scientific evidence) and informational uncertainty (lack of available evidence).  
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HIV cure research is fraught with uncertainty, as was demonstrated by the cases of the 
Boston patients [4] and the Mississippi child [100] who experienced a viral rebound following 
announcement of their “cures.” What if Timothy Brown, who received a donation from a 
CCR5Δ32/Δ32 donor, were to experience a CXCR4-induced rebound? Scientists just do not know all 
the factors that predict relapse and viral rebound is highly stochastic. The topic of scientific 
uncertainty is particularly relevant for study participants who interrupt HIV treatment. Why should 
they choose to replace a safe, effective drug regimen with uncertainty and unknown risks? HIV cure 
research participation raises questions around uncertainty management for study participants. 
Informed consent guidelines around disclosure of scientific uncertainty are unclear. Should scientific 
uncertainty even become a separate category of disclosure in informed consent forms, along with 
risks and benefits? In the field of HIV cure research, we simply do not know where all the thresholds 
of evidence lie. Factors such as small size sizes, observational study designs (as opposed to 
randomized trials), varying outcome measures and study endpoints exacerbate uncertainty. 
Communication of uncertainty also has ethical implications, including what is being communicated 
to the study participants and how the uncertainties are being communicated to them [86]. It is 
worth borrowing from the scientific uncertainty literature to improve the quality of clinical research 
decisions. Politi and colleagues [68]offered four steps to facilitate decision-making in situations of 
uncertainty using a participant-centered approach:  
Table 26. Four Steps to Facilitate Decision-Making in Situations of Uncertainty 
4 Steps to Facilitate Decision-Making in Situations of Uncertainty [68] 
1. Allow study participants and clinician-researchers to clarify the decision 
2. Explore the decision – options, benefits, risks and uncertainty 
3. Identify decision-making needs (information, support, values clarification) 
4. Plan next steps focusing on exploring participant values and preferences  
Better appreciation of scientific uncertainty is needed to help implement HIV cure studies 
effectively and ethically. Furthermore, it is important not to conflate the concept of uncertainty with 
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the extent of risks. Uncertainty should not be mixed with the willingness of study participants to 
accept those risks, either [99].  
Gaining Medical Knowledge and Returning Study Results  
Finally, a topic that has received attention in research ethics is that of returning research 
results to study participants. Do participants have the right to know their individual study results 
while participating in HIV cure studies – such as their reservoir size? There are three types of study 
results, including screening results (e.g. diagnostic tests at baseline), study results (e.g. research 
results)  and results from research on stored specimen [74]. In HIV cure research, the last two are 
emphasized, and these are research results, not diagnostic or clinical results. HIV cure studies mostly 
generate results that are not clinically relevant or even interpretable. Returning surrogate marker 
results to study participants may risk transmitting information that is confounding or confusing to 
their clinical care. In the worst case scenario, results could be interpreted as stopping HIV 
medication, which could be harmful. In HIV cure studies, it may be better for clinician-researchers to 
communicate aggregate study results to participants as opposed to individual results, since research 
results are only meaningful in their aggregate. Furthermore, clinician-researchers should have a duty 
to disseminate study results to participants and communities in lay terms. Our key informant 
interviews showed the importance of having scientists explain results to study participants and their 
significance. This can be a retention strategy in a study. 
Principle of Justice 
We next explore the Belmont principle of justice. This principle emphasizes the just 
distribution of burdens and benefits in clinical research. According to some moral philosophers, 
justice can be explained in terms of fairness or fair opportunity [63] and contributes a human rights 
dimension.  According to Lo and Grady, the selection of study participants and research sites must 
be equitable and research sites must have the capacity to carry out procedures safely [28]. While 
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noble, this principle is violated in research ethics because early phase studies are proof-of-concept, 
and they can only be conducted at specific research sites with the requisite expertise and capacity. 
Furthermore, study participants may be excluded if they have conditions that could affect their 
adherence to the protocol, such as substance abuse, homelessness, and co-morbidities. Therefore, 
the principle of justice is much more difficult to uphold in early phase HIV cure research 
experimentation, but remains critical to ensure the generalizability of study results [101].  
The principle of justice is important and relates to the ethics of participant selection in 
research [27]. Emanuel and colleagues discussed some of the dimension of fairness. The scientific 
goals of the study, not vulnerability or privilege, should drive recruitment decisions [27]. 
Furthermore, efficiency should not override fairness in recruiting study participants [27]. The issue 
of access to HIV clinical studies is also relevant here, since access is not equitable and limited by 
geographical availability (and capacity), means or time. Justice and fairness can be enhanced by 
paying attention to the processes of recruiting study participants [64]. 
It is also worth looking at specific groups of study participants who are “under-represented” 
in research, although these issues are not unique to HIV cure research. Rowena Johnson et al. 
reported that participation in HIV cure studies do not reflect the national or international burden of 
HIV infection in women, older adults and non-Whites [30]. With regards to women, a study found 
that they represented a median of 11.1% of participants in HIV cure research [29]. The moral 
imperative to increase women’s representation in HIV cure studies is supported by the existence of 
biological differences (such as clinical outcomes), physiological differences and pharmacokinetic 
responses, as well as social factors. In our survey, while 27% of males were willing to participate in 
all 14 types of studies versus 21% of females, the difference between males and females was not 
statistically significant at the 5% level. Thus, in this sample, males and females were as likely to be 
“very willing to participate” in HIV cure-relate studies (there were more males in the survey sample 
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than females – 284 versus 73). Still, while overall willingness may not vary, actual study participation 
may differ. Recommendations to help with representation women in HIV cure studies include 
ensuring that reviewers check for adequate female representation before funding studies, ensuring 
that female enrollment data are reported consistently, and avoiding “over-protecting” women. 
Other groups that have been under-represented are racial minorities. In our survey, people 
who identified as Caucasians/Whites were slightly more likely to be "very willing to participate" in 
HIV cure-related studies than people who identified with other ethnicities.  We found 30% of 
Caucasians who were very willing to participate, versus 23% of African-Americans, and 19% of 
Hispanic or people with Hispanic. The difference between the ethnicities was not statistically 
significant at the 5% level, however. Factors contributing to overall under-representation of racial 
minorities in HIV research may include the difficulty navigating the clinical trial system [102] and 
poor referral rates in studies [101]. Future HIV cure studies certainly need to incorporate strategies 
to increase representation of minority groups. Authors have also insisted on looking at the role of 
medical insurance as a barrier to participate in research, as fear of losing insurance is a major 
deterrent [101]. Other issues to be investigated further include the role of trust issues, awareness 
and information about clinical studies and characteristics of clinical studies [101]. Further, for some 
minority groups such as Hispanic populations, lack of access to the health care infrastructure 
translates into low research participation. Adolescents and children living with HIV are also under-
represented and potentially vulnerable.  
Another group that is under-represented in research includes transgender women. While 
the NIH recently created a cross-network transgender working group to address factors that impact 
transgender inclusion in biomedical HIV studies, there remains issues with transgender persons 
feeling comfortable and welcome to participate in studies. There are also challenges reported with 
using consistent and respectful terminology on clinical study data collection instruments. Some 
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transgender women do not want to be identified as transgender, since their transition to 
womanhood is complete and they no longer consider themselves transgenders. Other 
transgendered individuals may experience legal discrimination and social stigma.  Other potential 
groups that require representation are heterosexual men, since they are less likely to participate in 
HIV clinical studies compared to men who have sex with men [101][103]. Further, while scientists 
have been focused on reproductive risks to women, little has been written about potential 
reproductive health risks to men (and infertility may be a possible risk of HIV cure research 
interventions). Given the aging population of people living with HIV in the United States, it is also 
important to pay attention to aging issues. Other types of study participants in HIV cure research 
that may require special attention are: mother-children pairs, women being asked to donate cord 
blood after giving birth, tissue donors (before or after death) and HIV controllers.  
More attention is needed to the group of elite controllers in HIV cure research. In fact, elite 
or viremic controllers are currently threatened by universal HIV treatment. Public health officials 
recommend that people living with HIV be placed on treatment, regardless of their ability to 
suppress the virus. Elite controllers are technically functionally cured, and HIV treatment can 
actually jeopardize their much “cured” status. This raises serious ethical questions about subjecting 
individuals who are able to control the virus naturally to the effects of HIV treatment. For physicians 
not well informed on the subject of elite control of HIV infection, sole reliance on the 
recommendations from the U.S. Department of Health and Human Services (DHHS) Guidelines for 
the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents for ART in individuals with 
greater than 500 CD4+ T cells (as is typical in a majority of elite controllers), may lead to a pointless 
prescription for ART and to a much greater difficulty to recognize this group in the future –  and 
perhaps even the disappearance of this group that represents the model for functional cure. This is 
highly paradoxical for a field that is moving towards a cure.  
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Furthermore, in HIV cure research, there needs to be a much deeper understanding and 
appreciation for the types of study participants that are needed, in order to facilitate referral. The 
field has moved beyond simplistic “acutes” versus “chronic” categories and study participants are 
not homogeneous with regards to age, sex, biology, reservoir size, immune function, treatment 
initiation, co-morbidities and psychological status. Furthermore, comprehensive care and support 
are needed for the holistic persons as it is rare that HIV will be the only “infection” that people are 
dealing with.  There are certainly complicating factors in people’s lives and underlying vulnerabilities 
that need to be taken into account. While people living with HIV may be virally suppressed, they 
may have uncontrolled diabetes, cancer or cardiovascular disease. The HIV population is also getting 
older and these associated risks and vulnerabilities should also be taken into account.  
Categories of study participants that are considered “vulnerable” per regulations include 
children, prisoners, pregnant women and mentally disabled persons [104]. Certainly in HIV cure 
research, children are vulnerable because they cannot provide consent [32]. Pregnant women also 
have specific vulnerabilities when consenting for HIV cure studies [32]. More research is needed to 
determine to what extends HIV cure research makes people living with HIV vulnerable. Adding to 
the burden of participation is the risk of infecting others during an unsuspected viral rebound. One 
of the key informants asked if the burden of study participation in HIV cure research was too high 
due to the risk of infecting others. There are also vulnerabilities beyond those that are clinical, such 
as privacy and confidentiality issues, social vulnerabilities and financial vulnerabilities. While not all 
HIV cure study participants are “vulnerable” per say, there should be processes in place to 
determine the extent to which they are “not merely predisposed to harm but actually harmed – 
vulnerated” as a result of research participation [92]. 
Finally, it may be worth discussing the topic of coercion and the ethics of incentives in the 
context of justice for HIV cure research. As the survey results revealed, there is great diversity in the 
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people living with HIV in the United States. Some live close to the federal poverty line while others 
do fairly well. Clinical studies have been recognized as a way for people to earn additional income 
[66]. The ethics literature emphasized that remuneration should be proportionate and recognize 
participant time and contribution, but should not cloud participants’ perceptions of risks and 
benefits [28]. The ethics of incentives can be improved by engaging community advisory boards in 
helping evaluate reasonable, non-coercive compensation [105]. Other authors have cautioned that 
incentives should not undermine the autonomy of study participants [106]. When incentives help 
study participants overcome barriers to participation, they may actually be “autonomy enhancing” 
[106]. 
Reflections on the Effective Implementation of HIV Cure Studies  
In addition to seeking factors facilitating the ethical implementation of HIV cure studies, we 
want to understand preconditions of effective implementation of HIV cure clinical studies. Effective 
implementation requires the ability to define the need for change, formulate a blueprint for 
strategic objectives, build a strong research team and communicate the mission and vision. 
Implementation science can assist with determining factors for effective implementation. As per 
Rohit Rasmawany, implementation science is a specified set of activities designed to put into 
practice a program of known dimensions.23 The primary purpose of implementation science is to 
promote the successful application of implementation strategies. The goal is to make a difference, 
improve effectiveness, quality, efficiency and equity (and some of these goals may be in conflict). 
Yet, providing a set of enabling factors does not suddenly make implementation easy, but it provides 
a foundation. 
                                                          
23
Rasmawani R. Where is Implementation in Implementation Science? Presentation to DrPH Program 13 May 
2015. 
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So why should we care about implementation science in the context of HIV cure research? 
Should we simply leave the implementation of clinical research protocol and the recruitment of 
study participants to the individual scientists and study teams? While implementation science has 
been defined as the study of methods to promote the integration of existing interventions and 
evidence into healthcare policy and practice,24 I would argue that implementation science is also 
relevant to the conduct and management of clinical research (e.g. T1 – T2 translational paradigm). 
We need the HIV cure research field to start thinking in terms of effective implementation and 
appreciate that the entire translational research continuum – from pre-clinical to clinical research – 
requires effective implementation strategies. There is also a need to appreciate that issues that 
occur at the beginning of the translational research pipeline affect the entire implementation 
pathway, including the application of existing interventions. And it is important to begin to 
understand these factors early in the translational continuum. In HIV cure research, we must 
appreciate the entire journey, beyond the mere destination. Recruitment of study participants thus 
presents the ideal platform to discuss these implementation factors as it touches on a critical 
implementation question. Without study participants, there is no T1 to T2 translation.  
A parallel can be drawn between the adoption of innovations[107] and the desire to 
participate in them (e.g. decisions to be screened, to be recruited, to go through the informed 
consent process, to be retained and to participate again – i.e. serial participation). Clinical research 
provides the setting to begin to understand how innovations and interventions will work in the real 
world. Furthermore, recruitment in clinical research is increasingly being viewed as a science[66]. 
The goals of effective implementation could be to remove obstacles to study participation – 
including recruitment and retention. Many  individuals who have participated in clinical trials have 
reported that what mattered to them more were the study logistics, rather than the risks of the 
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Ibid. (NIH definition) 
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interventions[66], and this is also consistent with our study results. People who cannot make the 
clinical study fit their lives and their realities must decline study participation[66]. 
Our qualitative research results highlighted factors that can both facilitate the recruitment 
and retention of study participants in HIV cure research studies. There are measures that can be 
taken to facilitate participant accrual in HIV cure clinical studies, and this is consistent with the HIV 
prevention and treatment literature.[105][101] There is also a science of retaining study participants 
[60], especially when faced with potentially complex outcomes. Preferences to study participation 
can be provisional, conditional and evolving, and we must appreciate the entire journey of study 
participation. No doubt that it would be interesting to conduct additional research on factors 
facilitating retention of study participants as part of actual HIV cure clinical studies.  
Because measuring HIV remission is complex, long-term follow-up of study participants is 
required.  The decision as to which study endpoints to adopt represent another critical 
implementation science question. Scientists have not yet reached consensus on determining which 
assay(s) to use for measuring reversal of HIV latency. They remain divided on the use of the 
quantitative viral outgrowth assay and cellular-associated HIV DNA or RNA, for example. There are 
also clear limit of surrogate endpoints in HIV cure studies. We discussed the challenges associated 
with HIV treatment interruption – the ultimate test for a cure – in the qualitative results section. 
Furthermore, it is possible to make an HIV reservoir undetectable and still get viral rebound (as in 
the case of the Mississippi child), and open-ended designs that require long-term follow-up can be 
very worrisome to study participants. 
Another question that belongs in the realm of implementation science is that the impact of 
HIV cure research on health care systems, and potential future impacts once we find a cure for HIV 
infection. While innovative cures may transform health care services – such as those for 
tuberculosis, syphilis and now hepatitis C infections – we should not forget that diseases may have 
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unintended consequences that can be perversely related to the overall intended goal of decreasing 
disease prevalence.25 We are reminded of Robert Merton’s theory of unintended consequences. 
Unintended consequences are outcomes that were not originally intended [108]. Furthermore, the 
terms unintended and unanticipated consequences are not synonymous: unintended implies the 
lack of purposeful action or causation, while unanticipated means the inability to predict what will 
happen[108]. These consequences can be desirable or undesirable, direct or indirect, and latent 
versus obvious[108].  
The potentially future impact of an HIV cure and its influence on the health care systems 
must be carefully considered in the process of translational development, because factors that we 
did not anticipate can have profound social and health care consequences. For example, the health 
care system may not be able to handle the level of monitoring required for ART-free remission cases 
and these tests may be more expensive than HIV treatment. We should therefore advocate taking a 
health systems approach to HIV cure research. For example, implementation of pediatric HIV cure 
research should be done with the intent to prevent mother-to-child transmission of HIV in the first 
place. Similarly, early treatment should be implemented by first attempting to prevent new HIV 
infections. We should also try to improve early diagnosis and access to HIV treatment for all. 
Translating clinical research findings into implementation also presents challenges, as we have seen 
with the findings from the Mississippi child, whereas early treatment (e.g. as close to birth as 
possible) can be beneficial to prevent negative outcomes, but it is not universally implemented. 
Once an effective HIV cure is found, we will need implementation science to determine how 
best to operationalize it in the real world[41]. For example, the recent example of hepatitis C cures 
reminds us about the importance of integrating these factors early in cure development. There 
could be negative impacts of these “high-cost” cures that can exacerbate health care inequalities. 
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Tucker J. Notes from Brocher Foundation Meeting May 2014.  
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There can also be unintended consequences associated with the research enterprise itself.26  We 
must plan for and guard against potential unintended consequences of HIV cure research at all 
stages of the translational continuum.  
The Role of Implementation Research 
We consulted the implementation science literature to extract factors that may be relevant 
to the effective implementation of HIV cure research. Implementation science requires an 
appreciation of both the processes used in the implementation of programs as well as an 
appreciation of the contextual factors that affect these processes [109]. Implementation science 
also helps us address or explore any aspect of implementation, including factors that affect 
recruitment or implementation of general. It also offers a window into the actual practical 
challenges presented by the implementation of HIV cure studies, and draws from various disciplines, 
including public health, sociology, psychology and management theory [24]. Furthermore, 
implementation science focuses on leadership and creative problem solving [110]. 
Table 27 below summarizes implementation science perspectives that are directly relevant 
to the effective implementation of HIV cure research. It also touches on factors that were described 
in the qualitative results section. Informed by the literature, it attempts to bridge theory and 
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Examples of unintended consequences from the HIV cure research enterprise include: 
 Negative results (or viral reactivation with potential drug resistance). This is why consultation with 
local health authorities in advance of a study (e.g. pediatric or early ART study in resource-limited 
settings) would be critical, in order to ensure that second-line antiretroviral treatment would be 
accessible to study volunteers post-participation[32]. 
 HIV cure research may increase non-adherence to HIV treatment. For example, a study in Tanzania 
showed that when traditional healers proclaim that they have cured HIV, there were negative 
consequences to HIV treatment adherence that result[134]. 
 Possibility that study participants neglect their care thinking they have been cured or HIV providers 
may view the care of “cured” participants as a lower health priority [135]. 
 There can be conflicting information about HIV cure from HIV physicians and the media that can 
present potential health risks in the post-Timothy Brown era. For example, after learning about 
scientific HIV cure research efforts, people living with HIV may be more willing to pursue 
experimental interventions and treatments advertised as being able to cure HIV, without the proper 
biomedical scientific underpinning. There could be increased “quackery” in HIV cure research[136]. 
 Understanding why study results did not worked (or worked) is critically important. Failure to do so 
may upset study participants if there is a feeling that results remain inconclusive.  
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practice and provides an appreciation of the complex and multi-faceted factors that affect 
implementation, beyond mere risks and benefits of interventions. It also provides a foundation for 
understanding effective implementation.  
Table 27. Factors Relevant in the Effective Implementation of HIV Cure Research – Perspectives 
and Opportunities from the Implementation Science Literature 
Factor Relevant in the Effective Implementation of HIV Cure Research – Perspectives and 
Opportunities from the Implementation Science Literature 
Glasgow RE, Eckstein ET, Elzarrad J. Implementation Science Perspectives and Opportunities for 
HIV/AIDS Research: Integrating Science, Practice and Policy. JAIDS 2013: 63(1): S26 – S31[23]: 
 Risks and benefits incurred 
 Trialability: whether intervention can be first tested at low risk 
 Simplicity: difficult of implementing the intervention 
 Observability: readiness with which we can observe the results of an intervention 
 Compatibility/congruency: whether intervention can “fit” in a given organization or system 
 T1 – T4 translation: describes the development of scientific knowledge from basic discovery 
(T1) to evidence-based guidelines (T2), practice (T3) and improved population health (T4) 
Feldstein AC, Glasgow RE. A Practical, Robust Implementation and Sustainability Model (PRISM) 
for Integrating Research Findings into Practice. The Joint Commission Journal on Quality and 
Patient Safety 2008; 34(4): 228 – 43 [111]: 
 Comprehensive, prescriptive and robust, yet practical, model to help researchers 
understand factors that need to be considered for implementation; predictors of effective 
implementation   
 Patient[Participant] perspectives: 
Patient[Participant]-centered approach – providing choices, addressing barriers, providing 
access, minimizing burden, getting feedback, understanding demographics, disease 
burdens, knowledge and beliefs, health literacy   
 Organizational perspectives: 
Addressing barriers of frontline staff 
Coordination between departments and specialties 
Burden (complexity and cost) 
 External environment: 
Regulatory environment 
Community resources 
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering Implementation 
of Health Services Research Findings into Practice: A Consolidated Framework for Advancing 
Implementation Science. Implementation Science 2009; 50: 1 – 15[112]: 
The intervention 
 Intervention source 
 Evidence strengths and quality  
 Complexity and cost 
The inner setting 
 Structural characteristics: 
Implementation team 
 Networks and communications: 





 Implementation climate  
Absorptive capacity for change 
Tension for change 
Compatibility 
Relative priority 
Goals and feedback 
Learning climate 
Readiness for implementation 
Leadership engagement 
The outer setting 
 Patient [participant] needs and resources 
Extent to which patient[participant] needs, as well as barriers and facilitators, meet those 
needs 
Patient[Participant]-centeredness 
 External policies and incentives 
Policies and regulations 
In addition to the implementation science frameworks provided above, there are additional 
implementation science concepts that could inform the field of HIV cure research implementation. 
Meyers and colleagues[113] have  emphasized a quality implementation framework, where 
effective implementation is documented via manuals, guides, worksheets and toolkits.  Braithwaite 
and colleagues[21] explored emergent success factors, including preparing for change and 
appreciating the capacity for implementation, resources, leverage and sustainability. They 
recognized that various stages of implementation do not happen automatically.  Certainly, the 
history of international HIV clinical trial shutdowns – such as pre-exposure prophylaxis in Cameroon, 
illustrates that clinical trials do not occur on their own and that successful implementation factors 
must be appreciated. 
As we conclude the section on implementation science, there are themes have we have not 
fully explored in the context of effective implementation. These include clinical trial management, 
adaptive clinical trial design and implementation and capacity for effective research (e.g. basic 
thresholds of conditions that must be present). Unquestionably, HIV cure clinical research is an 
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exercise in management. Researchers are often focused on the protocol endpoints, and they are 
often reluctant to document lessons learned in terms of participant recruitment, retention or overall 
implementation. Lessons learned are rarely factored in, and short-term funding horizons of grants 
often preclude the development of best practices. In academia, where most HIV cure research 
occurs, incentives can be misaligned. Clinical research with people living with HIV requires longer-
term visions as opposed to short-term focuses. With industry (e.g. pharmaceutical companies), 
profitability and the need to mitigate risks often come first. Further, some HIV cure research 
implementers may also have conflicts of interest due to different types of agreements and 
engagement – between academia, public-private partnerships, publicly-funded collaboratories with 
industry sponsors, and various consultancies. As this segment described, the entire context of HIV 
cure research implementation must be taken into account. 
Towards a Possible Implementation Ethics Framework in HIV Cure Research 
We now attempt to combine ethical and effective implementation by asking the question: is 
there an implementation ethics to HIV cure research? The expression “implementation ethics” was 
coined by Stuart Rennie and Frieda Behets in the context of rationing AIDS care and treatment in 
sub-Saharan Africa (existing AIDS treatment interventions) [114]. Here, implementation ethics also 
affect HIV cure research by forcing us to appreciate the ethical pathway to effective 
implementation. What ethical issues are raised by the implementation of HIV cure research in the 
United States and around the world? Are there ethical conundrums and factors related to the 
ethical implementation of research [115]? Do case-by-case analyses of HIV cure protocol – as done 
by the FDA – constitute an issue in implementation ethics?  I argue that HIV cure scientists must 
adopt on “implementation ethics” in addition to research ethics. For example, a serious safety 
signal, a demonstration of futility of a specific intervention, emerging information about scientific 
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details to measure HIV latency or any other factor can affect the dual effective and ethical 
implementation of research. 
Rennie and Behets pointed out that bioethics must keep pace with times and science [114]. 
As research protocols are implemented, there can be unexpected challenges, dilemmas and conflicts 
that arise. The “ethical odyssey” of HIV clinical study implementation has been documented in the 
context of HIV treatment as prevention trials [116]. Ethical challenges arise over the course of a trial 
implementation that requires deliberation and response, not only from the investigators, but also 
funders, community members, regulatory bodies and bioethicists. In the case of the HPTN 052 trial, 
the lack of ART availability at the research site reflected long-standing issues in global justice and 
access to HIV treatment, and thus the trial was deemed non-coercive. Furthermore, a prevention 
package had to be developed with broad consensus from stakeholders. As clinical trial data were 
emerging, scientists had to balance the need for keeping existing public health guidelines current 
while generating better evidence. Some of the ethical challenges to implementation were 
anticipated and others were not. Clinical trial implementers in HPTN 052 argued that HIV clinical 
teams should think about developing “ethics plans” comparable to data management, or statistical 
analysis plans [116].  
In the field of HIV cure research, the implementation of ethical analytical treatment 
interruptions brings about implementation ethics questions. For example, we must be careful how 
these “negative” reports of HIV treatment are being interpreted. For example, Buell and colleagues 
wrote: “A cure for HIV would obviate these intrinsic disadvantages of ART” [62]. Portraying a cure 
for HIV as mitigating the negative effects of ART for people living with HIV is short-sighted. HIV 
treatment saves millions of lives each year and there was a time when there was no treatment for 
HIV at all. While it is true that a cure for HIV may mean the freedom to live without medication, we 
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must be careful not to categorically reject the benefits of live-saving HIV drugs while advancing HIV 
cure science. There is a greater need for nuance when describing the “negative” effects of ART. 
As illustrated with the HPTN 052 and treatment interruption example, implementation of 
HIV cure clinical studies engenders questions that are not covered merely by research ethics. 
Logistical, social, cultural and economic issues affect the ethical and effective implementation of 
studies – at the individual, institutional, national and even global levels.  As with the rationing of 
AIDS treatment in sub-Saharan Africa, there can also be conflicts between equity and efficiency. 
While the NIH aspires for a simple, safe and scalable cure,27 that may be a distant possibility. 
Further, HIV cure research resources are insufficient to build capacity for research on a broad scale 
and execute research concurrently, so the field must rely on well-equipped sites with reputable 
investigators. As we discussed under the concept of justice, beyond the “where” question (selection 
of research sites), we are also confronted with the question of “who” should take part in HIV cure 
studies. Assuredly, as with the rationing of AIDS treatment, there are difficult trade-offs that must 
be negotiated in HIV cure research as well.  The concept of scalability [117][118] of an HIV cure can 
also fall under the category of implementation ethics. By scalability, we mean the absorptive 
capacity of research sites or health care settings. We must pay attention to the scientific, 
community and participant absorptive capacity for HIV cure research. The concept of cure 
replicability can also stem from implementation ethics. As we have one case of cure (e.g. Timothy 
Brown), scientists are devoting significant resources to attempting to replicate that cure and these 
involve trade-offs. 
Other examples that can fall under the realm of implementation ethics may include sample 
size ethics and side effect ethics (e.g. insufficient sample sizes to detect size effects). With HIV cure 
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Simple cure: tertiary care is not needed. Safe cure: not worse than current HIV treatment. Scalable cure: 
relevant to the millions of people infected with HIV.  
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research, small studies can only detect large effects. Scientists must attempt to minimize the 
number of study participants exposed to risk, and they must also maximize the value of small 
numbers. How do we ensure that scientists do not reject a therapy with a modest benefit just 
because the study was underpowered to show any meaningful effect? Furthermore, what are the 
incremental steps and how do we determine if we have the appropriate intermediate endpoints? 
With small sample sizes, there can be conclusions of uncertain validity because interventions and 
study populations are subject to undetermined fluctuations.  Some clinical investigators pre-screen 
for agent sensitivity, others do not. With small sample sizes, there can also be negative unknown 
consequences of serial participation in research if the same study participants are selected over and 
over again for studies. With small sample sizes, confidentiality and anonymity are even more 
important. When races/genders are reported in journal articles with small numbers, it may be 
possible to deduce the identity of the actual study participants. Further, the field of HIV cure 
research should attempt to use systematic reviews of studies to overcome the effects of small 
numbers. 
Beyond small sample sizes, there are design issues that belong to the class of 
implementation ethics. In research, the ethical principles of respect, beneficence/nonmaleficence 
and justice must also be operationalized in study design, protocols and methodologies, as we 
discussed earlier. Ethically speaking, the most appropriate study designs are those that will address 
the research questions while exposing study participants to the least risk. A case in point is stem cell 
transplant research that focuses on curing cancer. Stem cell transplant implementers attempt to 
learn as much as possible about HIV in the process. Thus, HIV cure scientists run behind 
hematologists to see what happens to the HIV reservoir following a stem cell transplant. This 
constitutes a wonderful example of implementation ethics and risk minimization in practice. Risk of 
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harm is minimized because studies are implemented with cancer patients for whom the transplant is 
already indicated. 
The field of HIV cure research is in great need of standardized endpoints in order to make 
meaningful comparisons between studies. Currently, HIV cure studies are designed with different 
endpoints and measures of the HIV reservoir. What is more, the current measures of the HIV 
reservoir are not sensitive enough to detect very low levels of HIV persistence. A case in point is the 
Mississippi child who had no detectable replication-competent provirus in her resting CD4+ T cells, 
yet the HIV came back 27 months following treatment interruption [119]. Furthermore, surrogate 
endpoints are not clinical endpoints or benefits – and there is little real, if any, clinical benefits in 
HIV cure research participation. With surrogate endpoints, correlation does not equal causation, and 
surrogate endpoints do not predict cures. There can be different surrogate markers for different 
interventions that are difficult to reconcile, and social factors can also impact biomarkers.  Issues 
with describing surrogate endpoints were found in informed consent forms in the context of gene 
therapy transfer research. These are important to keep in mind with HIV cure research as well. King 
and colleagues found that surrogate markers were not only described in terms of study objectives, 
but also mentioned as potential benefits to participation [75]. Referring to surrogate markers as 
direct benefits is ethically problematic in clinical studies because surrogate endpoints are rarely 
meaningful in early phase research. They may not have any direct correlation with the clinical 
endpoints that actually have values for the patients [70]. “A reduction in the size of your HIV 
reservoir” may be an overstatement in HIV cure research consent forms.  Thus, specificity with 
regards to the lack of benefits about surrogate markers is supreme. Furthermore, there must be 
clear distinctions between activity of an agent and efficacy of that agent. An agent is showing sign of 
activity does not mean that it will be efficacious. Being cautious with the portrayal of clinical 
outcomes will prevent the overestimation of benefits.  
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Furthermore, HIV viral elimination is an extremely high bar to achieve. There could be 
intermediate endpoints that may have value for the study participants on the road to complete HIV 
remission. It would be important for scientists to better understand what these intermediate 
endpoints would look like. Defining those intermediate endpoints would also be consistent with 
taking a realistic and progressive approach to HIV cure research. These could include, for example, 
shorter periods of drug-free remissions, or an increase in CD4+ T cells.  
Under the rubric of implementation ethics, it is important to discuss the value of research to 
society. Authors have argued that to be ethical, clinical research must be valuable, meaning that it 
would lead to improvements in health [27].The intervention would also need to be implementable if 
found effective. Different judgments can be made as to what constitutes “socially valuable” 
research. Is scientific value a sufficient criterion for social value? Stuart Rennie28 outlined social 
value criteria for patients/participants29 as well as for public health.30 Further, will HIV cure research 
save lives? Or should we rely on robust implementation science of existing HIV prevention and 
treatment interventions that are population-focused instead?  Whether a treatment or a cure is 
experimental or existing, the criterion of likelihood of success is important, because scarce medical 
resources should be distributed to people who are likely to benefit most from them [63].  
Allocation of scarce resources between HIV prevention, treatment and cure research is 
another implementation ethics issue for the broader field. It relates to principles of distributive 
justice and responsiveness of research to local health priorities. The utilitarian approach would 
require us to opt for interventions that would maximize social utility[63]. Approximately 2 million of 
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Rennie S. CUREiculum Ethics Module: http://www.avac.org/cure-curriculum/module14.  
29
Suspension of lifelong cART and its short and long-term side effects, potential for reduced stigma. 
30
Impact on the HIV epidemic by lowering transmission, reduction of high-cost expenditures related to HIV 
care and treatment. 
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new HIV infections occur each year and we should thus not forget about HIV testing. With the 
release of the START trial results[51], universal HIV treatment is recommended and we have a long 
way to go to bridge the gaps in the HIV treatment cascade.  There are also other infectious diseases 
that require attention, such as tuberculosis that is now the number one infectious disease killer in 
the world. Tuberculosis provides a cautionary tale of what can happen even in the existence of a 
treatment and cure, and enthusiasm for an HIV cure should not go unchecked by the reality of other 
prevalent infections. 
Setting realistic expectations about what the science can deliver is also extremely important. 
We simply just cannot get carried away with the science and we must adopt a nuanced, incremental 
approach that is also iterative [11]. As we learned from recent cases, future research will build a 
stepwise approach on the incremental successes and failures of early studies [13]. The need for 
prudence is paramount. As a cautionary example, clinicians adopted high-dose chemotherapy with 
autologous bone marrow transplantation as a therapy for breast cancer in the 1990s, even though 
the treatment was highly toxic and did not confer any advantage over the standard of care [120]. 
Continued scrutiny, skepticism, and discourse in ethics and implementation of HIV cure research will 
be healthy. The field of HIV cure research should also address the rationale for a cure and there 
should also be independent review of protocols [27][28]. 
Broader issues of public policy, law and human rights are also brought to the forefront by 
the prospect of a cure for HIV. Public policy constitutes the set of enforceable guidelines. For 
example, some authors have emphasized that HIV transmission and criminalization laws in the age 
of treatment-as-prevention are antiquated and need to be revised [121]. It would be worthwhile to 
appreciate the interpretation of these laws in the context of HIV cure research, where a study 
participant may inadvertently transmit HIV to a sexual partner following an analytical treatment 
interruption. Authors have argued that laws criminalizing HIV transmission can be 
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counterproductive to a broad human rights-based public health approach [121].  Furthermore, HIV 
cure research implementation should not be devoid of considerations for basic human rights. Rights 
are defined in terms of those claims that demand our respect [63]. 
In sum, this section reviewed potential implementation ethics issues in HIV cure research, 
including the need to appreciate the inherent ethical odysseys involved, potential trade-offs, 
scalability and replicability considerations, sample size ethics, study endpoints (including 
intermediate endpoints), allocation of scarce resources, value of research to society, setting realistic 
expectations and broader issues of public policy, law and human rights. Choices of moral behavior 
cannot be made in absolute terms. In the end, the art of the application of ethical reasoning must be 
required for each individual case. Should HIV cure study implementers be taught about ethics? 
Eckenweiler goes further by asking us to extend the scope of responsibility for ethical 
implementation of research to pharmaceutical companies, research funders and elected officials to 
prevent the perpetuation of vulnerabilities [122]. Implementation ethics is not devoid of politics and 
must be concerned with issues of patent protections for the commercial enterprise, global trade 
rights, public health systems and clinical research in resource-limited settings and its implications. 
Strengths and Limitations of Research  
The strengths and limitations of this dissertation project stem from the selection of research 
methods under each aim. These are summarizes in the table below.31   
                                                          
31
Strength of focus group discussions (deferred) includes the richness of information. Limitations of focus 
group discussions include possibility of “group think” and researcher’s bias(es) that shape interpretation of 
data.  
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Table 28. Strengths and Limitations of Methods 
 Strengths Limitations 
Survey  Reach a large pool of 
respondents efficiently  
 Anonymity of study 
respondents  
 Cross-sectional data; inferences 
should be made with caution 
 Participants recorded stated 
preferences, not revealed 
preferences (i.e. reliance on 
hypotheticals)  
 Self-reported data (e.g. false 
HIV-positive)  
 Possibility of bias due to non-
responses or incomplete 
responses 
 Inability to control self-selected 
respondents or veracity of 
information given 
 Possibility of sampling errors  
Document 
Review 
 Documents and notes 
are extant and available  
 Data collection is not 
contingent upon having 
access to study 
participants  
 May be of low quality  
Key Informant 
Interviews 
 Richness and depth of 
information collected  
 Relatively easy to 
implement 
 Cost-effective  
 Allows researcher to 
establish rapport with 
key informants and 
clarify questions  
 Improves ability to 
discuss issues in-depth  
 Expert opinion given  
 
 Possible selection bias (e.g. 
selecting the “right” key 
informants may be difficult)  
 Researcher’s bias that shape 
interpretation of data; 
qualitative research is deeply 
“interpretive”    
 Possibility of social desirability 
bias (over-reporting of 
successful/effective strategies 
and minimization of those that 
are less effective)  
 Lack of generalizability of study 
findings such as experiences, 
beliefs, perspectives  
 Telephone interviews have the 
drawback of not being in 
physical proximity to the 
participants; therefore, visual 
clues were lost  
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Our survey on the willingness to participate in HIV cure studies was very comprehensive and 
extensive, focused on risks and benefits. The survey was a unique contribution to the field of HIV 
cure research over previous surveys. The survey appeared to have been somewhat representative of 
the U.S. population of people living with HIV who would have been genuinely interested in HIV cure 
research. Possible limitations may have included a biased sample of respondents (e.g. those who 
had access to HIV cure/treatment listservs and internet). The sample was not representative of the 
overall population of people living with HIV in the United States and may have excluded those who 
never or rarely access these listservs. Communities of people living with HIV are highly 
heterogeneous. While the data represent an aggregate picture, there can be a high degree of 
variability between individual people living with HIV. Children and adolescents were excluded from 
the survey due to the need for parental assent. The questionnaire was not available in Spanish. The 
complexity of the survey wording may have limited full understanding of items, although we 
mitigated this risk by using survey completion as an educational opportunity and we provided 
definitions of key concepts. Further, we did not ask about sexual orientation in the survey and 
assessed whether it affected willingness to participate. We barely included any psychosocial factors 
such as self-efficacy beliefs that may have proved to be important motivators to participation in HIV 
therapeutic vaccine trials, such as Remune and ALVAC[103]. We likely missed additional possible 
motivators and deterrents to participation given the structured nature of the questionnaire. 
Demographic characteristics such as “having children” as a potential deterrent to study participation 
were not assessed. We did not directly compensate each study respondent in the survey, and thus 
lack of financial reward (except for the $25 gift card drawing for each 25 survey respondents) may 
have affected motivations to complete the survey. Social desirability bias may have also been an 
issue, as shown by the high willingness to participate in the 14 categories of HIV cure studies (above 
50% for all types, despite the risks).  The sample size could have been expanded further to reduce 
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confidence intervals around point estimates, increase the generalizability of results and stabilize the 
willingness to participate of different factors. A prospective, longitudinal study, nested within an 
actual HIV cure study, would have also made the data more valid about actual motivators and 
deterrents to participation. Another study limitation is that only data from survey respondents were 
analyzed, while data on study decliners could not be systematically collected. There were 9 survey 
decliners – the reason was that they did not meet the eligibility criteria (assuming they were HIV-
negative). Future HIV cure studies should attempt to compare study decliners with study accepters 
on various factors to clarify the role of altruism and risks and benefits in decisions to participate in 
research. Finally, macroscopic factors such as demographic, political, cultural and economic 
influences could not be assessed in the survey.   
With regards to qualitative research, we interviewed a broad range of patient-participants, 
clinician-researchers and policy-maker key informants. Pharmaceutical company contacts were not 
represented due to time constraints. The choice for the key informant interviews was based on 
contact lists based on the perception that they would be interesting key informants or that they 
would be responsive to the request for an interview.   
In order to address some of these limitations, I employed careful validation techniques, 
including those identified in the validity and reliability sections of the methods section. In 
retrospect, some of the key informant interview questions may have been leading questions (e.g. 
“Do you think information about HIV cure research should be shared in your community?”). 
Furthermore, since qualitative research is deeply interpretive and that personal biases and values 
may influence the interpretation of results, acknowledging one’s own bias is important. My main 
bias while conducting this research was the recognition of the need to minimize risks to study 
participants, while ensuring that the fundamental ethical principles were met such as the fair 
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selection of research participants, favorable risk-benefit ratio, informed consent and respect for 
study participants.  
While the selection of individuals who were fairly knowledgeable about HIV cure research 
may have biased the results, recruitment of people living with HIV into social science research is 
difficult outside of established community networks, unless embedded as part of a clinical study. For 
convenience of sampling and by necessity as part of the study, not to mention the complexity of the 
science, I was purposively limiting the sample pool of people living with HIV who may have already 
been aware of or connected to information about HIV cure studies.  As someone who has worked in 
the field of HIV research for >10  years, and more recently HIV cure research, I have also come to 
appreciate the upmost importance of the ethical implementation of research. While I strived to 
maintain objectivity during the data collection and analysis, I was also cognizant that my biases may 
influence my downstream findings. I was surprised to find that most respondents thought latency-
reversing agents were risky, as explained above.  In terms of data coding and analysis, codes that 
were mentioned consistently and discussed in detail during the interviews were identified as 
themes. Although the key informant interviews represented a wide variety of backgrounds and 
perspectives, there was a balance between consistency and variability of the ideas expressed. In the 
end, the data have valuable implications for the ethical and effective implementation of HIV cure 
studies.  
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CHAPTER 7 | PLAN FOR CHANGE/LEADERSHIP/IMPLEMENTATION 
“I have been impressed with the urgency of doing.Knowing is not enough; we must 
apply. Being willing is not enough; we must do!” 
                                                                                                    -Johann Wolfgang von Goethe (1749 – 1832) 
Plan for Change Overview  
In the field of HIV cure research, we are witnessing a unique policy window to address 
emergent implementation and ethical challenges related to participation. It is imperative that 
we carefully design and plan these studies from the outset, putting participants’ needs and 
expectations at the forefront in order to avoid unintended and unanticipated consequences. 
We must further attempt to preserve the public trust in the research towards an HIV cure now, 
so that any future scientific interventions that arise from it are not tainted by the negative 
decisions that we make [123]. 
What are some of the leadership and change opportunities at this juncture, and why do 
these require leadership? How do the data collected fit in the overall plan for change and 
create added value in the practice of HIV cure research? And finally, how do the data and 
evidence collected inform a plan for change, implementation and leadership for the future?  
My plan for change is centered around promoting the ethical and effective 
implementation of HIV cure-related studies through research, public discourse and practical 
action. I focus on the inherent implications of the research findings as they relate to the 
implementation of HIV cure-related studies as an emergent field in the social sciences. I also 
emphasize the need to translate findings into action and describe how the resultant work can 
be used in practice. 
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I relied on three main theoretical foundations to implement my plan for change, 
namely 1) community engagement and participation, 2) implementation science and 3) 
research ethics; however, these fields overlap as with “implementation ethics” [114][115] (see 
Discussion section). Further, my plan for change and leadership is informed by four schools of 
leadership: team and servant leadership, authentic leadership and ethical leadership. During 
my key informant interviews, I have come to realize the role that implementation leadership 
and discovery leadership play in HIV cure-related science. The intended practical outcomes 
include participative processes as well as effective and ethical implementation of HIV cure 
studies. The plan for change below describes the proposed intersection of these force fields.   
For my plan for change/leadership/implementation to be effective, meaningful and 
relevant, it is imperative that I focus on what I can control. Thus, I intend to use my role as a 
middle manager to effect change as an emergent process and within evolving systems. 
According to the literature, middle managers have a key role in strategic change management 
[124]. Not only do they coordinate and implement strategic programs, but they are also 
relationship managers, networkers and interpreters of expectations. Additionally, middle 
managers perform translation, mediation and negotiation tasks, increasing the ability of others 
around them to respond to change by providing resources, structure and a safe place for 
learning [124]. Middle managers also work to reduce the impact of problems as they arise and 
serve as “change intermediaries” and “change catalysts” [124]. Implementing strategic change, 
however, requires a lot of time and energy [124] and middle managers must find ways to make 
time to implement the vision. In fact, my most scarce resource at the moment is sufficient time 











































Realistic expectations, avoidance of unintended consequences and public trust in research 
Informed decision-making in the face of uncertainty 
Greater recognition for need to give voice to research participants 
Meaningful community partnerships and effective/ethical implementation of HIV cure studies 
Preparedness and acceptability of HIV cure studies and support from stakeholders 
Increased consciousness and literacy around HIV cure research 
Ultimately, improved quality of life of HIV cure research study participants 
 










Implementation Science Research Ethics 
Plan for Change/Leadership/Implementation 
Figure 27. Building Blocks for Proposed Plan for Change/Leadership/Implementation 
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Principles of Leading Change and Inspired Actions  
 The theories of change management that have inspired me thus far include those of Kotter 
[125], Aguirre [126], Kidder [127] and Kuyvenhoven [124]. Below are the principles that have made 
an impression on me and that I am incorporating into my toolbox as a public health practitioner. I 
also included a list of inspired actions that stem from these principles. 
 
Figure 28. Principles of Leading Change and Inspired Actions 
1. Form a powerful coalition (Kotter) or Concentrate on Relationship Building (Kidder) 
INSPIRED ACTIONS: Community engagement & coalition with researchers and participants 
via HIV cure research training curriculum; advocacy for ethical & effective implementation   
2. Create a sense of urgency (Kotter)  
INSPIRED ACTIONS: Identification of key opinion leaders; engagement in emergent policy, 
research and ethics dialogues   
3. Create a vision for change (Kotter) or Maintain deep reserves of moral courage (Kidder)  
INSPIRED ACTION: Bring ethical issues to the forefront and encourage healthy dialogue  
4. Engage, engage, engage (Aguirre)  
INSPIRED ACTIONS: Sustained participation, engagement and communication, overcoming 
compassion fatigue    
5. Communicate the vision (Kotter)  
INSPIRED ACTIONS: Dissemination of research results and implications, utilization of media 
and training technologies    
6. Build on the change (Kotter) and Keep the ethics flame alive collectively (Kidder) 
INSPIRED ACTIONS: Honest and nuanced messaging via HIV cure research training 
curriculum, creation of local advocates, enablement of future HIV cure research participants 
to become opinion leaders      
7. Find ways to make time (Kuyvenhoven) 
INSPIRED ACTION: Seeking of independent funding to implement vision  
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Participative Processes  
The first component of my plan for change includes participative approaches, centered 
around community/stakeholder engagement as well as a patient-centered philosophy. Participative 
management, in turn, is informed by principles of team and servant leadership.  Community 
engagement and participation of individuals living with HIV should be considered primary in the 
design of HIV cure research or dissemination of research results, rather than an afterthought. While 
advocating for opportunities to integrate science, practice and policy in HIV research in general, 
Glasgow and colleagues argue that researchers and communities will need to establish ways to 
collaborate effectively moving forward, including the establishment of transdisciplinary and 
participatory approaches [23]. The determination of best practices in research will need to include 
considerations for community engagement as a fundamental building block in order to effectively 
integrate research, policy and practice [23]. Furthermore, the iterative feedback loops between 
communities and researchers will permit a healthy and open dialogue that will enable 
opportunities for frontline ownership of the change process [23].   
This vision for change is consistent with the new FDA framework on patient-focused 
drug development [13], which proposes that people living with HIV should be empowered from 
the outset to make informed choices about HIV cure-related research participation. They 
should not be mere recipients of the research enterprise, but should actually be actively 
involved in the design and implementation of studies, as they have something very valuable to 
contribute. As partners in research, their participation should be regarded as a key success 
factor driving study implementation, especially since most of them are already virally 
suppressed thanks to advances in HIV treatment. Most of them are also leading relatively 
normal lives, are considered “healthy subjects” and their participation in research does not 
involve an end-of-life care decisions. Furthermore, when they feel that their voices are heard 
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and responded to, they may have more of a stake in the clinical research enterprise and may be 
more willing to respond to the inevitable challenges that arise. As ‘frontline people’, they are 
“rich repositories of knowledge about where potential glitches may occur (…) Not only does 
more information surfaces [when involving them], but [they] are more invested when they’ve 
had a hand in developing a plan.” [126]. Active participation and engagement is also known to 
decrease the likelihood of misunderstandings and can help build support for the research 
enterprise.  
Guiding Leadership Theory: Team Leadership [128] 
“[T]he leader is to do whatever is necessary to take care of the unmet needs of the group.”  
Team or participative leadership theory is informative as it recognizes that teams are 
composed of individuals who are interdependent. Team leadership, when effective, is also 
known to lead to better decisions and problem solving as well as greater innovation and 
creativity. For teams or participative processes to be succesful, there needs to be support for 
the involvement of team members and mechanisms to promote upward communication. 
Furthermore, teams must encompass the leadership reportoire of the entire team. Processes 
such as trusting, adapting and learning are given centerstage in team leadership. Effective 
teams also keep an eye on the larger context. Their tasks include networking, forming alliances, 
advocating, negotiating, buffering and assessment the environment. Criteria for effective teams 
or participatory leadership include clear and elevating goals, result-driven structure, unified 
commitment, devoted team members, collaborative climate, standards of excellence and 
principled leadership.  
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Guiding Leadership Theory: Servant Leadership [128] 
“This is not about me… this is about them! (My own interpretation of servant leadership)” 
Although servant leadership involves an inherent paradox and is counterintuitive, it 
should be the cornerstone of an approach aimed at encouraging greater participation. Servant 
leaders commit themselves to putting the needs of others at the forefront. They are attentive 
to the concerns of others, nurture them and empathize with them. Servant leaders are also 
ethical and develop strong long-term relationships with fellow individuals. By encouraging 
others to make decisions on their own, building their confidence, servant leaders endeavor to 
empower others and to bring out the best in them.  Core values of servant leadership include 
respect, trust, empathy, healing, awareness, (ethical) foresight, and stewardship, commitment 
to the growth of others, building community, humility, emotional intelligence, altruism and 
humanism. In the end, servant leaders envision a fairer society.  
I strongly believe that we can harness the talents of communities of people living with 
HIV towards a cure. In fact, I would like to help create an addendum to the Good Participatory 
Guidelines (GPP) [129] for the field of HIV cure research, in collaboration with AVAC. As in the 
past, community engagement is crucial to help anticipate and resolve ethical challenges as they 
arise. Communities provide the potential for checks and balances and they allow safe, efficient 
and effective conduct of research. Focusing on communities also represents a long-term 
investment in the HIV cure research enterprise. The success will depend upon sound 
leadership, community and stakeholders already engaged and invested in the research.  
Effective Implementation  
The second component of my plan for change includes considerations for the effective 
implementation of HIV cure-related studies. I informed this component with teachings from 
implementation science and authentic leadership. Appreciative inquiry in the data collection 
 278 
phase served to identify success factors facilitating implementation of HIV cure studies (see 
Qualitative Results section for details).  
Implementation science seeks to focus attention on the execution, achievement and 
accomplishment of an action. In a sense, both implementation science and translational 
research (as in the case of HIV cure-related research) refer both to an ideal and an endeavor: 
“As an ideal, [they] aim to capture evidence produced by scientific or social scientific processes 
and get [them] into practice. As an endeavor, [they] recognize that these stages do not happen 
automatically, often to no great extent, and sometimes not at all” [21].Yet the provision of a set 
of factors that either ‘facilitate’ or ‘hinder’ implementation does not necessarily make 
implementation easy, since implementation occurs in a complex environment [21]. But the 
knowledge of these factors help prepare for the upcoming change and inform detailed and 
effective planning. 
Effective implementation also includes the intention to avoid unintended 
consequences and to incorporate lessons learned into practice. Drawing on the law of 
unintended consequences, careful planning from the outset and knowledge of possible 
roadblocks and landmines help ensure a more effective implementation of an intervention. For 
example, in the context of HIV cure research, the topic of analytical treatment interruption or 
‘intensively monitored antiretroviral pause’ is deeply controversial at the moment, as we 
explored in this report. Some argue that treatment interruption is absolutely necessary to 
assess viral rebound and effectiveness of an intervention, while others contend that it is 
completely unethical at this early stage of HIV cure research because it may lead to several 
negative long-term health outcomes. Social sciences studies such as the one presented in this 
dissertation can be useful to diagnose existing and potential challenges and controversies for 
the implementation of HIV cure studies.  
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In turn, path dependency theory provides a useful lense to conceptualize the variables 
that guide the deployment of an intervention or a set of interventions. The fied of HIV cure 
research is currently ‘exploding’ and will be greatly influenced by the discussions, dialogues and 
decisions that we have/make at this juncture of the policy window. Path dependency theory 
provides us the modus operandi or instrument to determine how certain policies or decisions 
are implemented and deemed socially desirable while others are not [130]. It reminds us to 
keep everything into a historical perspective but also invites (ethical) foresight. Path 
dependency also supports learning and incremental change, together with an overtone of 
caution since the deployment of interventions may have long-term, and sometimes negative 
and irreversible consequences [130]. Path dependency further gives insights into what can lead 
to sustainable change that survives over time. Conscienscious efforts must be made to push the 
implementation of interventions onto the ‘right’ path.  
Guiding Leadership Theory: Authentic Leadership [128] 
“Authentic leaders are genuine, have a real sense of purpose and serve catalysts for change.” 
Authentic leadership is one of the most practice-oriented leadership theories. 
Authentic leaders find what is true in themselves, in their organizations and in the world. They 
focus on locating the problems and selecting appropriate actions to resolve them. They are 
genuine, have a real sense of purpose and serve as catalysts for change. They proceed with 
confidence, hope, optimism, resilience and moral reasoning. They also have self-knowledge and 
self-regulation and analyze information objectively yet act from their heart. They also view 
leadership as a process and incorporate meaning, mission, structure and appropriate resources 
into their leadership style.  
 280 
Ethical Implementation, Moral Courage and Professional Issues 
The third component of my plan for change includes considerations for ethical 
implementation, moral courage and professional issues in the conduct of HIV cure research as 
they relate to participation of people living with HIV. I informed this component with teachings 
from research ethics and ethical leadership. I also attempted to expose how the evidence 
derived from my research relates to ethics and regulatory principles for the protection of 
human participants in research, including respect for persons, beneficence and nonmaleficence 
and justice (see Discussion section for details).  
 One of my main inspirations for this segment is Rushworth Kidder’s book How Good 
People Make Tough Choices.  Kidder defines ethics with the concept of “ought.” “[Ethics] is not 
about what you have to do because regulation compels it (…) It’s about what you ought to do – 
have an obligation to do – because it is right.” And with ethics, “as with the rest of life, there 
are no magic answer systems (…) Making ethical decisions depends on judgement, character, 
moral awareness, perception, discrimination – a whole host of imponderables.” [127] In fact, 
tough choices often operate in territories where laws and regulations do not reach. Kidder 
teaches us about the need to develop our ethical fitness and to embrace our core values, such 
as responsibility, compassion, honesty, fairness and respect. “What is needed,” he says, “is a 
capacity to recognize the nature of moral challenges and respond with a well-tuned conscience, 
a lively perception of the difference between right and wrong, and an abilty to choose the right 
and live by it.” One is only ready to sustain an effort or change over the long-term if s/he 
remains mentally engaged with and if s/he ultimately cares about the issue. Of course, this 
requires a moral compass and moral courage – an attribute essential to leadership. “Developing 
(…) ethics requires that intelligence fuse with intuition, that the process be internalized, and 
that decisions be made quickly, authoritatively, and naturally.”  
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Guiding Leadership Theory: Ethical Leadership [128] 
“And little wonder, finally, that as we practice resolving dilemmas we find ethics to be less a 
goal than a pathway, less a destination than a trip, less an inoculation than a process.”  
Ethical leadership is rooted in the Greek word ethos and translates into conduct and 
character of a person. Ethics is concerned with the values that individuals or societies find desirable 
or appropriate. In fact, to implement change carries with it great ethical burden and responsibility. 
Ethical leaders are those who use authority to pay attention to issues, to frame issues and to 
facilitate ethical decision-making. Principles of ethical leaderships include respect, service and 
honesty. Ethical leaders strive to build the community around them.  
Thus, embodying ethical action in practice entails meeting the highest ethical standards in 
each action and interactions. It means having continuous ethical awareness. McCullough 
[53]outlined several additional ethical principles that should be considered in the face of clinical 
uncertainty that are highly relevant here:  
Table 29. Ethical Principles under Conditions of Clinical Uncertainty 
Ethical Principles under Conditions of Clinical Uncertainty [53] 
 Candor: The professional virtue that obligates the practitioner to acknowledge and 
correct errors using evidence-based reasoning. Candor is an antidote to 
enthusiasm. 
 Enthusiasm: Clinical judgement undisciplined by evidence-based reasoning. 
Enthusiasm should be regarded as an infectious process in clinical decision making 
that can spread rapidly between practitioners. 
 Integrity: The professional virtue that obligates the practitioner to follow standards 
of intellectual excellence and seek to “always do the right thing.”  
 Expectation: The belief that a future state of affairs will occur. 
 Hope: The concept of hope has two components: a probability >0 and <1 that a 
future state of affairs will occur; and the desire for a future state of affairs. 
 Prudence: The virtue that schools us in the discipline of identifying our legitimate 
interests and acting to protect and promote them. 
[Adapted from [53]]  
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Plan for Change/Leadership/Implementation Deliverables 
There are five concrete ways that I hope my dissertation project can help improve 
practice: 1) through the dissemination of research findings, 2) community engagement and 
coalition building, 3) involvement in research and policy dialogues around HIV cure research 
and preparation of considerations, best practices, lessons learned and decision aids for HIV 
cure research, 4) development and implementation of a comprehensive HIV cure research 
training curriculum (CUREiculum), and 5) through the identification of future research 
questions. I describe these five elements below.   
Dissemination of Research Findings  
I would like to share the findings from my research through the publication of journal 
articles, submission of abstracts at major international HIV conferences and HIV cure-related 
workshops and through the preparation of blog posts. I hope that my research findings will be 
relevant to both HIV cure scientists and communities affected by HIV. Since this is an emergent 
field, I expect that the data will add to the body of knowledge and advance/inform HIV cure 
research implementation and policy/ethical considerations. The collection and publication of 
data will in turn give me more authority, credibility and even legitimacy in the field, and help 
me be recognized as a ‘leader’.  
Journal Articles and Abstracts (Formal Channels) 
I would like to prepare manuscripts to be submitted for publication and to present 
findings at international HIV conferences and HIV cure research workshops. I would like to use 
the summarized findings (e.g. tables and narratives) for my dissertation research and prepare 
manuscripts for submission on the topic of barriers/facilitators to participation in HIV cure-
related studies in collaboration with the DrPH committee members.The data derived could 
further generate evidence to support the ethical decision-making and effective implementation 
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of HIV cure-related studies. Below, I also provide suggestions for future empiral research and 
hopefully contribute to the formulation of an enhanced research and policy agenda for the 
social sciences of HIV cure-related research. Ultimately, I aspire to continue studying factors 
that affect participation in HIV cure studies via a larger prospective, quantitative study of 
barriers and facilitators to participation and retention.  
In addition to publishing manuscripts and presenting at HIV conferences, I plan to 
disseminate the results to patient advocacy groups, as this would constitute a critical transfer 
of knowledge. I am also in the process of implementing the focus group discussions with 
leaders of the national Martin Delaney community advisory board (until June 2016), the results 
of which will be summarized separately. 
Completed manuscripts to peer-reviewed and practice-oriented journals include: 
 
 Framing expectations in early HIV cure research (published in Trends in Microbiology 
in October 2014, lead author with David M. Margolis and Gail E. Henderson) [11] 
 Participation in HIV cure-related research: a scoping review of the proxy literature 
and implications for future research (published in the Journal of Virus Eradication in 
October 2015, lead author with Dr. Sandra Greene) [40] 
 Towards a multidisciplinary HIV cure research: integrating social science with 
biomedical research (published in Trends in Microbiology in January 2016, middle 
author (lead author: Cynthia Grossman)) [41] 
Planned manuscripts to peer-reviewed and practice-oriented journals include, but may not be 
limited to: 
 Paper(s) reporting results from semi-structured survey from DrPH dissertation project 
(e.g. descriptive statistics, bivariate and multivariate results)** 
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 Paper(s) reporting results from the key informant interviews and discussion section 
from the DrPH dissertation project** 
 Paper on the ethical issues inherent in analytical treatment interruption with the 
Division of AIDS (DAIDS) of the National Institutes of Health (NIH) (submitted to 
Lancet Infectious Diseases; co-author with Stuart Rennie)  
 Paper on the ethics of HIV cure clinical research among acutely infected adults: points 
for consideration (submitted to the Journal of the International AIDS Society, co-
author with Stuart Rennie)  
 TBD 
**direct product of DrPH dissertation research; to discuss with DrPH committee members 
 
Conference abstracts presented and/or submitted: 
 
 Dubé K, Taylor J, Jefferys R, Sharp M, Wakefield S, Handibode J. Results of a community 
needs assessment and pilot test of a novel HIV Cure research training curriculum. 
Presented at 2015 IAS Towards an HIV Cure Symposium, July 2015, Vancouver, Canada.  
 Taylor J, Handibode J, Sharp M, Jefferys R, Wakefield S, Dubé K. Decoding HIV cure 
science: A CUREiculum seminar. Presented at the 2015 United States Conference on AIDS, 
September 2015, Washington, D.C. 
 Dubé K, Taylor J, Evans D, Sylla L, Burton A, Skinner A, Greene S. Emerging results of an 
extensive survey of potential participant’s willingness to take risks and donate to HIV cure 
research in the United States. Presented at 7th International Persistence during Therapy 
Meeting in Miami, Florida on December 10, 2015.  
 Sylla L, Taylor J, Evans D, Weiner B, Skinner A, Greene S, Dubé K. Perceived benefits of HIV 
cure-related research participation in the United States. Abstract submitted to 2016 IAS 
meeting July 2016. Outcome pending. 
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 Taylor J, Evans D, Sylla L, Dee L, Weiner B, Skinner A, Greene S, Dubé K. Perceived risks of 
participating in HIV cure-related research in the United States. Abstract submitted to the 
2016 IAS meeting July 2016. Outcome pending. 
 Taylor J, Evans D, Sylla L, Dee L, Weiner B, Greene S, Rennie S, Dubé K. What is “too much 
risk” in HIV cure clinical research in the United States? Abstract submitted to the 2016 IAS 
meeting July 2016. Outcome pending. 
 Dubé K, Evans D, Taylor J, Sylla L, Dee L, Rennie S, Weiner B, Skinner A, Thirumurthy H, 
Greene S. Multivariate results of an extensive survey of potential volunteers’ willingness 
to participate in HIV cure-related research in the United States. Abstract submitted to the 
2016 IAS meeting July 2016. Outcome pending. 
 Evans D, Taylor J, Sylla L, Garner S, Weiner S, Skinner A, Greene S, Rennie S, Dubé K. 
Treatment interruptions in HIV cure studies in the United States: perceptions, 
motivations and ethical considerations from potential HIV-positive volunteers. Abstract 
submitted to the 2016 IAS meeting July 2016. Outcome pending. 
 Garner S, Rennie S, Ananworanich J, Dubé K, Margolis D, Sugarman J, Tressler R, 
Gilbertson A, Dawson L. Interrupting HIV treatment in cure research: scientific and ethical 
considerations. Abstract submitted to the 2016 IAS meeting July 2016. Outcome pending. 
 Dubé K, Weiner B, Taylor J, Garner S, Rennie S. Is there an implementation ethics to HIV 
cure-related research? Abstract submitted to the 2016 IAS meeting July 2016. Outcome 
pending. 
 Salzwedel J, Hannah S, Taylor J, Dubé K. Community engagement in HIV cure-related 
research: applying Good Participatory Practice (GPP) principles to community education 
efforts. Abstract submitted to the IAS 2016 meeting July 2016. Outcome pending. 
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Blog Posts (Informal Channels) 
Furthermore, I hope to be able to use more flexible technologies and blog posts to 
continue promoting the ethical and effective implementation of HIV cure-related studies. Blog 
posts are an excellent way to share best practices, lessons learned alerts and to react quickly to 
issues related to HIV cure-related research implementation. This is also a way to “find my 
voice” and to contribute to policy dialogues. See blog posts under the searcHIV website at: 
http://searchiv.web.unc.edu/blog/.  
Community Engagement and Coalition Building/Strengthening  
Community engagement and coalition building/strengthening may prove to be a key 
ingredient and a chief indicator for change as it relates to HIV cure research implementation. 
The key principles guiding my community engagement will be co-agency, trust, openeness, 
fairness and shared decision-making in the face of uncertainty. I will continue my community 
engagement in the National Martin Delaney Collaboratory CAB since I have been elected as a 
new member in January 2016. I will also continue my involvement in the UNC-CH Center for 
AIDS Research (CFAR) Community Advisory Board (CAB). Community engagement and coalition 
building/strengthening will aim to promote the ethical and effective implementation of HIV 
cure studies and will focus on relationship building and process values. I will encourage fellow 
CAB members to have a say in research and policy issues that affect them. I further hope to 
conduct debriefing sessions of my research with CAB members and will ask them what they 
would like to do with the information. 
In fact, a primary driver for my research is the potential utility of the findings for 
patient advocates. By creating findings that are accessible and useful to patient advocates, and 
by involving them in the research procress, the policy-making and implementation process can 
be influenced and facilitated in a meaningful grassroots approach. In a sense, I am inspired here 
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by the teachings of Paulo Freire, whose critical consciousness or conscientização emphasizes 
co-learning, shared leadership and ultimately transformation. Critical consciousness focuses on 
taking action against the oppressive elements of one’s life, on achieving a deep understanding 
of the world and on exposing social contradictions as a liberating process [131]. Further, 
because advocates then to be more informed and assertive than the general public, they are 
more likely to make substantive contributions to research practice and policy [64]. 
For my plan for change to be successful, coalition building and engagement with 
opinion leaders, champions and agents of change will be important. In fact, “successful [change 
and] implementation [are] more likely if leverage and enablers are harnessed.” [21] For 
example, together with CAB members, we may produce position statements and participatory 
practice guidelines for HIV cure-related research. Communities are asking for a return to the 
Denver Principles developed in 1983 aimed at protecting the rights of AIDS patients. One of 
these rights is for people living with HIV to be included in all AIDS forums with equal credibility 
as other contributors and to be able to share their lived experiences and knowledge of the 
disease.  In order for community engagement and coalition building to be truly impactful 
moving forward, it will be important to engage more women and people of color in the process. 
This is a real challenge facing the entire HIV research field. However, community engagment 
will not serve as a substitute for true, meaningful social sciences around HIV cure research. 
Engagement in and Contribution to Research and Policy and Implementation Dialogues and 
Development of Tools to Facilitate Research Implementation 
I would like to continue contributing to research and policy dialogues around HIV cure-
related research. Ultimately, I would like to find a position that will allow me to become an 
“ethical voice” in the field of HIV cure research. My aspiration is to be recognized as a leader in 
the social sciences of HIV cure research and in infectious disease implementation.  
There are three mechanisms through which I can accomplish this at the moment: 
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 UNC-CH R01 Team on the Social and Ethical Consequences of HIV Cure Research  
 Forum for Collaborative HIV Research – Social Sciences Working Group (Patient 
Recruitment, Education and Informed Consent)  
 International AIDS Society Psychosocial Working Group 
I believe that involvement in and participation to working groups and workshops is 
what facilitates communication and accelerates progress. Discussions often contribute to the 
shaping and creation of policy statements and journal articles that are later published.  It is also 
a way to become recognized as a leader in the field. For example, I presented the results of my 
literature review at the International AIDS Society psychosocial working group meeting in 
Melbourne, Australia in July 2014. This workshop was dedicated to request increased funding 
to study crucial social sciences issues around the implementation of HIV cure-related research. I 
also presented my literature review  at the Brocher Fondation workshop in Geneva, Switzerland 
in May 2014 on the Intended and Unintended Consequences of HIV Cure Research.32 My 
literature review was also highlighted at the Forum for Collaborative HIV research HIV cure 
meeting in Washington, D.C. in June 2014.33  
An aspirational goal would be to contribute to the development of considerations, best 
practices, lessons learned and decision aids around HIV cure-related research. While some 
practitioners argue that it is too early or pretentious to implement firm guidelines at this 
juncture, others think that some sort of shared guidance has become necessary to minimize 
unintended consequences.  We are waiting for the right “policy window” for this to occur, but it 
may only be a matter of time before such considerations become necessary. I would like to 







help generate considerations around effective and ethical HIV cure research implementation, 
focusing on recruitment of study participants. While it is too early to speak in terms of 
guidelines, perhaps the field is ready to begin discussing best practices. Since we are still in the 
process of discovery in the field of HIV cure research, it may still be too early for true or 
emerging consenses at present. Yet, there is tremendous value in fostering dialogue, especially 
given the current state of the HIV cure research field where so many questions include “well, it 
depends.” Thus, instead of premature practice guidelines, it may be best to call for more robust 
dialogues among stakeholders to define a pathway that will eventually lead to normatively 
sound evidence-based guidelines. 
Considerations for effective and ethical implementation of HIV cure-related research 
could take the form of checklists or decision aids as well as specific recommendations around 
recruitment. This will obviously take consensus building – and the consensus, if any can be 
reached, will be evolving. Another useful tool would be the provision of reliable and sustained 
flow of information about research opportunities as well eligibility requirements for HIV cure-
related studies. The development of considerations may be viewed through difference lenses – 
either as enhancing facilitators (e.g. appreciative inquiry), preventing barriers or contributing to 
shaping the field in general. In order to meet the translational challenge of moving HIV cure 
research forward (and later of moving scientific discoveries into practice), we will need to be 
able to leverage and integrate this information into useful formats.  
John Kidder, in his book on ethics, argued that sometimes, what is more powerful is 
“not necessarily a checklist that is applied in the heat of the moment, but (…) a guide to the 
underlying structure of ethical decision-making” [127]. These constitute the “widely shared 
codes of conduct within a profession” [127].  Having a moral compass and simply knowing 
where one stands on the ethical line can be impactful to set standards.   
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The following tables summarizes responses received from the key informant interviews to the 
questions: 
 What guidance is needed for patient-participants wanting to participate in HIV cure 
studies? 
 What guidance is needed for clinician-researchers implementing HIV cure studies? 
 What guidance is needed for policy-makers/regulators regarding HIV cure studies? 
Reponses to these interview questions were not summarized in the results section. I 
felt that it was much more appropriate to summarize them in the plan for change section, as 
they have immediate applicability to facilitating the effective and ethical implementation of HIV 
cure studies.   
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Table 30. Possible Considerations for Stakeholders to Facilitate Effective and Ethical 
Implementation of HIV Cure Research 
Possible Considerations for Stakeholder to Facilitate Effective and Ethical Implementation 
of HIV Cure Research  
General Considerations  
 Considerations for language used in HIV cure research 
 Considerations to facilitate acceptability of HIV cure studies for study participants 
 Considerations surrounding risks and benefits of HIV cure studies, using a nuanced, 
matrixed approach to evaluate risk-benefit ratios and ethical considerations across 
various types of studies 
 Considerations to address ethical issues in HIV cure studies with analytical treatment 
interruptions  
 Advocate for the need to apply lessons learned from previous work as well as 
consider the unique circumstances raised in HIV cure research (requires careful, 
nuanced analysis) 
 Advocate for cross-dialogues and interactions between basic sciences, translational 
research, animal research, clinical research, bioethicists, social medicine, 
anthropology, economics, health policy, law (e.g. workshops) 
 Ensure the right setting to promote dialogue and create safe environments; stay 
opened to possible landmines (usually find them upon stepping on them)    
For Patient-Participants 
 Decision-making algorithm so patient-participants can better understand where they 
fit in the HIV cure research continuum  
 Use of technologies for decision-making and help study participants navigate the 
field (e.g. apt for clinical trial decisions, simple updated websites for knowing what 
studies are enrolling, use of social media) 
 Decision aids for HIV cure research34 or personal decision guides[68] (consult 
International Patient Decision Aids Standards (IPDAS) 
 Explore different, more effective mechanisms to present informed consent 
information to potential study volunteers (e.g. procedural videos, peer education 
with past study participants, etc.) 
 Standard list of questions that participants should ask themselves prior to joining HIV 
cure studies (e.g. values and priorities) 
 Encourage and facilitate peer-to-peer recruitment in HIV cure studies  
 Educational materials such HIV/AIDS cure glossaries35 (also see CUREiculum section 
below) 
Make information accessible  
Press that we are in the early days of research  
Focus on risks and benefits information, emphasize expectations 
Emphasize importance of participating in HIV cure studies, focusing on altruistic 
motives 
Need more innovative teaching methods (videos, cartoons, infographics)  
                                                          
34
Decision aids lead to better knowledge, more accurate perceptions of risks, greater comfort with and 
participation in decision-making and fewer people remaining undecided [12]. They are also known to decrease 




Use educational tools to help relationships between patient-participants and 
clinician-researchers; organize forums for meaningful interactions 
Debunk myths, misperceptions, misunderstandings and mistaken reporting  
 Advocate for funding for educational initiatives 
For Clinician-Researchers 
 Refreshers on ethical research guidelines; draft “ethics plan” [116]  
 General considerations to facilitate acceptability of HIV cure studies for study 
participants 
 Considerations for HIV cure clinical study protocols and designs, including safety 
monitoring and escalation of interventions, and criteria that the FDA sets  
 Considerations for risk mitigation plans in early HIV cure studies 
 Considerations for recruitment materials to ensure that they are ethical and 
participant-focused, focused on potential risks, benefits, probabilities, uncertainties 
and alternatives36 
 Standard list of questions that clinician-researchers should use prior to enrolling 
study participants to ensure readiness  
 Draft for an informed consent template with proper terminology to be used to 
describe research 
 Draft comprehensive checklists for HIV cure research, as assurance of understanding 
of the informed consent is essential[54]  
 Tools to help clinician-researchers explain HIV cure research to study participants 
(e.g. humanoid with images of where the HIV reservoir is)  
 Education to clinician-researchers about the motivations, needs and interests of 
study participants 
 Systems to stay in touch with potential study volunteers, so that if they do not qualify 
for one study, they may still qualify for other future studies  
 General rules of behaviors (e.g. since numbers are so small, need to give a lot of 
consideration and attention to each individual participant; avoid “tokenism” with 
people living with HIV; cultural competence and sensitivity trainings; 
communication skills) 
 Ensure that there is a team about the HIV cure scientists and the participants (e.g. 
mental health professionals, social workers, etc.) 
 Better information for HIV providers about available HIV cure studies to facilitate 
referrals of potential study participants 
 Advocate for standardization of assessments to allow for better comparability 
between studies and interpretation of results 
 Better collaboration between researchers to refer study participants to study (e.g. 
trans-collaboratory partnerships) 
For Policy-Makers/Regulators 
 Regulatory considerations for HIV cure research (e.g. pre-IND process, early 
discussions with clinical investigators)  
 Policy and legal considerations for HIV cure research  
  
                                                          
36
Recruitment materials need to receive IRB approval. Should funding agencies also require investigators to 
report their plans for recruiting study participants?  
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With Jessica Salzwedel from AVAC (formerly the AIDS Vaccine Advocacy Coalition), I co-
chair a novel, comprehensive HIV cure research training curriculum (the CUREiculum). The 
CUREiculum is a collaborative project aimed at making HIV cure research science accessible to 
the community and the HIV research field.  
The three main CUREiculum goals are to: 
 
 Provide basic scientific knowledge on a range of HIV cure research related topics 
 Strengthen community capacity to participate in and make decisions about HIV cure 
research 
 Promote the ethical development and implementation of HIV cure clinical studies 
The objective of the CUREiculum is the creation of an international learning community 
around HIV cure research and a clearinghouse to disseminate research results in a way that is 
comprehensible to the lay community. The CUREiculum is a well-coordinated program that 
brings together scientists and community members to discuss key topics around HIV cure 
research. The CUREiculum will also introduce transparency and accountability to enhance 
safeguards around HIV cure research, possibly providing checks and balances. There are 
currently around 15 modules, focused on the main HIV cure research modalities. In addition to 
highlighting key research findings, the CUREiculum teaches main ethical and implementation 
issues (see below) and discusses past and future (planned) HIV cure studies. Powerpoint 
teaching sets, pre-/post test assessments, webinar series, participatory activities and case 
studies are prepared and live on a central website. Additionally, the CUREiculum committee 





organizes town hall meetings at various locations around the United States and around the 
world, adjacent to major HIV (cure) research conferences and workshops.  
There are currently few resources that are dedicated to fostering a broad, informed, 
credible and informed dialogue between researchers, participants, advocates and the lay 
community around HIV cure research. The CUREiculum provides a communication 
infrastructure to facilitate such relationships, since communication is key to developing and 
implementing change initiatives and to promoting participation. In fact, “[p]olicy analysis is not 
just an exercise in truth-telling (…). It is a pragmatic and responsible effort to facilitate 
reasonable discourse about a policy future that is inherently uncertain.” [132] In point of fact, 
the idea of an educational process in policy making has been recognized. This is where I am to 
“[take] responsibility for opening up a dialogue and perhaps [try] to infuse it with reason and 
insight, and then [allow] the political process to take over.” [132] The CUREiculum is definitely a 
way to expand my moral perimeter and improve on my communication skills. I draw 
tremendous inspiration and emotional energy from my interactions with scientists and 
community advocates. 
In leading strategic change, John Kotter advised to put in place a structure for change, 
to permit an honest dialogue and obtain support and to openly address people’s concerns and 
anxieties and ideas [125]. The CUREiculum aims at doing just that, providing a feedback 
mechanism to solicit feedback about the HIV cure research process. 
Researchers have a vested interest in listening and responding to participants’ concerns 
and the CUREiculum opens a transparent public and political dialogue about the science. The 
multi-faceted techniques used has several advantages, encouraging dialogue, clarifying 
meanings and helping promote ‘buy in’ for ethical science.  The CUREiculum is also a product 
and a process that both researchers and community can rally around while waiting for concrete 
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scientific results. It provides focus to the community efforts, while encouraging literacy and 
learning about the science. In response to servant leadership, it is necessary to have a process 
to give people the knowledge they need in order to sustain the change over time, especially 
when the science is so complex. The CUREiculum further instils great appreciation and 
recognition for people living with HIV who take part in HIV cure studies and also ensures that 
their voices are heard. In a sense, the CUREiculum aims at injecting democracy into the HIV 
cure research scientific process. It requires “a conscious effort to cultivate mutual respect and 
trust among collaborating laypeople and technical experts” [64].  
There is a growing recognition in the field that researchers and communities need to 
bridge the epistemic gap to ensure adequate preparedness and acceptability of HIV cure 
studies. The CUREiculum is an attempt to respond to the growing need for a reliable source of 
information on HIV cure research and HIV cure research participation. The CUREiculum is 
entirely evidence-based and is intended as a vehicle for reflective dialogue and to encourage 
ethical and effective implementation of studies.  In fact, [t]he task of any sort of conscious 
reflection (…) is to make explicit what’s often left unsaid, to help systematize the fragmentary 
and order the haphazard.” [127] The CUREiculum provides that collaborative and supporting 
environment and promotes a culture of safety and teamwork.  
In addition to co-leading the entire effort, I was able to obtain funding for the initiative 
via the national Martin Delaney collaboratory community advisory board (programmatic 
component) in collaboration with AVAC, from January – June 2016. The immediate goal is to 
revamp the CUREiculum modules that will be relevant to the International AIDS Society 2016 
conference in Durban, South Africa (including introduction to HIV cure research, stakeholder 
and community engagement, informed consent and ethics, pediatric HIV cure research and 
early antiretroviral treatment). I am also preparing fact sheets to accompany the modules. I 
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hope to implement the marketing plan for the CUREiculum effort developed as part of HPM 
962 class and the business plan developed as part of the HPM 959 class.  
The main HIV cure research modalities are covered as part of the CUREiculum. I am 
leading the module on participation in HIV cure research. I consider the CUREiculum the main 
product, process and instrument to prepare for change that is within my control.  I am in the 
process of preparing and implementing a needs assessment to better comprehend literacy 
needs around HIV cure research. In turn, these results will have implications for the informed 
consent of participants in HIV cure research. I also presented an abstract about the CUREiculum 
at the 2015 Towards an HIV Cure Symposium meeting of the International AIDS Society in 
Vancouver, Canada in July 2015 and presented a CUREiculum seminar at the United States 
Conferenc eon AIDS in Washington, D.C. in September 2015 The CUREriculum concept emerged 
at the 2014 Conference on Retroviruses and Opportunitistic Infections (CROI). The CUREiculum 
committee officially launched the initiative at the 2015 CROI in Seattle, WA. An update was 
presented at the pre-CROI 2016 HIV cure community workshop in Boston, MA. 
Example CURE-riculum website and products: http://www.avac.org/cure-curriculum 
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Figure 29. The CUREiculum 
As a direct outcome of my DrPH research, I wanted to incorporate nuanced and ethical 
considerations for various HIV cure research modalities into the CUREiculum. The table below 
summarizes some of these considerations.  
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Table 31. Ethical Considerations for Various HIV Cure Research Modalities – The CUREiculum 
Ethical Considerations for Various HIV Cure Research Modalities – The CUREiculum38  
Latency-Reversing Agents 
 May not require analytical treatment interruption in the short-term 
 But have not been shown to cause a substantial reduction in the size of the 
replication-competent HIV reservoir to date 
 Possible consequences of reactivating latently infected cells 
 Will not be sufficient alone and will need to be paired with an immune strategy 
 Benefits of research accrue to science and society 
 Ethical considerations of using anti-cancer drug  
 Likely need to be used in combination 
Therapeutic Vaccines 
 Therapeutic vaccines often (although not always) include ART interruptions to 
assess if vaccine-induced immune responses can exert an anti-HIV effect in the 
absence of ART (ethical issues assocated with risks of treatment interruptions) 
 Possible risk that a therapeutic vaccine could increase rather than decrease HIV 
replication by creating additional CD4+ T cell targets for the virus  
 Participation in a clinical trial of a therapeutic vaccine candidate may preclude 
participation in future trials of other therapeutic vaccine candidates 
 Multiplicity of factors that can influence adaptive immunity (e.g. sex, age and 
genetics) means that diversity of trial participants is particularly key for 
understanding the spectrum of potential responses to therapeutic vaccine 
candidates (as for vaccines generally) 
 Use of the word “therapeutic” to describe the research is problematic  
Gene Therapy/Stem Cell Transplant 
 Gene therapy studies involve different gene editing/modifying techniques 
 Precision is key – a serious concern if “off target” editing 
 If the genes other than those targeted are modified (off target editing), the 
potential for serious adverse events exist, including cancer  
 Scalability of approach 
 Risk to participants who are otherwise “healthy”  
 Potential race and clade differences 
 Likely need to be used in combination 
Pediatric Studies[32] 
 Consent issues during labor and delivery 
 Pressure to discontinue ART 
 Drug fatigue in adolescence 
 Frequency of viral rebound assessment 
 Ability to emotionally support parent 
 Higher risk of therapeutic misconception? 
 Blood volume issues with infants 
 Ability to assess rebound (e.g. frequency) in case of a treatment interruption 
 Issues related to consent/assent – infants cannot consent themselves 
 Drug fatigue in later years of life 
 Emotional support for the mother – having baby go through this experience is hard  
 Ability of mothers to provide informed consent for a neonate who would start a 




study immediately after delivery – is a woman in labor able to make an informed 
decision, particularly if she has just learned that she is HIV-positive?  
Early Antiretroviral Treatment39 
 Treatment interruption is not medically necessary and potentially harmful 
 Early treatment is not curative but the combination approaches may first be 
available for those treated early 
 Treatment fatigue 
 Consenting issues 
Possible Avenues for Future Research 
The last component of my plan for change consists in summarizing possible questions for 
future social sciences research around HIV cure. While HIV cure research will fundamentally be 
biomedical, I strongly believe that the social sciences can add tremendous value. I will remain a 
fervent advocate to sound social sciences in HIV cure because I see the synergies between the 
biomedical and social sciences in HIV cure research. Social sciences guide meaningful community 
and stakeholder engagement and ensure the ethical conduct of research. They also enhance 
patient-participant and clinician-researcher communications and ensure basic inclusion of 
communities. They also facilitate research-policy synergies, assist in health systems preparedness 
and ultimately help us reduce HIV stigma. Of course, there are also several unresolved conceptual 
and normative questions related to HIV cure research and research ethics.  
  
                                                          
39
See manuscript led by Gilberton A et al. “The ethics of HIV cure clinical research among acutely infected 
adults: points of consideration” Submitted to Journal of the International AIDS Society. Outcome pending. 
 300 
Table 32. Future Possible Social Sciences Questions around HIV Cure Research 
Future Possible Social Sciences Question around HIV Cure Research40 
Meanings of Cure 
 What are the various meanings of HIV cure research and how can we reconcile 
patient-participants, clinician-researchers and policy-makers/regulators’ 
perspectives? 
 What are the various meanings of “success” in HIV cure research (including 
intermediate outcomes) 
 What do potential participant understand about HIV cure research and how does 
that affect their willingness to participate? 
Role of Altruism 
 What role do altruism (versus desperation), expectations, optimism and hope play 
in HIV cure research? 
Research with Prospective Study Participants 
 How do demographic characteristics (such as age, gender, socio-economic status, 
nationality) relate to HIV cure understanding, acceptability and willingness to 
participate? 
 How do people view their health and undersand the purpose and risks of HIV cure 
studies? 
 Discrete choice experiments borrowing from economic, cognitive psychology and 
decision-making literature – what are common trends in HIV cure research decision 
making (e.g. anchoring, judmental heuristics, defaulting to patterns, etc.) 
 How can we increase recruitment of women and under-represented groups in HIV 
cure studies? 
 Would asking for long-term follow-up of study participants negatively affect overall 
recruitment? Or would long-term follow-up make study participants feel better? 
 How can we begin to study therapeutic (or curative) misconception in HIV cure 
research? 
 Is there rogue HIV cure research participation? What motivations are ethically 
questionable?  
 How does long-term survival with HIV affect willingness to participate and actual 
participation in HIV cure research?  
Research with Actual Study Participants 
 Research with actual HIV cure research participants, either retrospectively or 
prospectively as part of actual HIV cure studies (e.g. nested social sciences 
research); would require collaboration from biomedical HIV cure scientists 
 What does HIV cure research mean for quality of life outcomes (such as Short-
Form-36 Health Survey) 
 What factors predict retention in HIV cure studies? 
Research with Study Decliners (more difficult) 
 What are some of the reasons people living with HIV decline participation in HIV 
cure research? 
Research with Clinician-Researchers and Policy-Makers 
 How do clinician-researchers and policy-makers view risks in HIV cure research? 
                                                          
40
For additional social sciences questions, see the backgrounder document prepared for the NIH-NIHM 
Meeting on Social, Ethical and Behavioral Issues in HIV Cure Research, 22 – 23 September 2014.  
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Research Ethics Questions 
 Are there groups who are more vulnerable than others in HIV cure research? 
 How can HIV cure researchers best measure effective management of scientific 
uncertainty? 
 How can we prevent unintended consequences of HIV cure research? 
Research Implementation Questions 
 What are some of the benefits of collaboration in HIV cure research and how can 
we evalaute effective research collaborations? 
Additional critical questions to be addressed in the integration of the social sciences and the 
biomedical research agenda can be found in the Grossman et al. article championing 
multidisciplinary HIV cure research [41]: 
 
Figure 30. Critical Questions to Address in the Integration of Social Science in the HIV Cure 
Research Agenda[41] 
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CHAPTER 8 | CONCLUDING REMARKS  
“Cure is far more complex as a concept than getting rid of the disease.” – Van Eys  
 
Figure 31. Research with Ebola Survivors 
Photo Credit: Karine Dubé – Monrovia, Liberia 
To conclude, my ultimate goal and vision for change would entail greater recognition on the 
part of the entire HIV cure research community of the importance of giving a voice to study 
participants and to address their unique concerns. This would in turn lead to more effective and 
ethical implementation of HIV cure studies, stronger community partnerships and greater 
preparedness for and acceptability of HIV cure studies in the long haul. Ethical implementation of 
HIV cure research starts with setting realistic expectations for these studies as well as conscious 
attempts to avoid unwanted consequences. Moving forward, it will be important to foster public 
trust in the research and ensure true informed consent of study participants in the face of scientific 
uncertainty. A long-term investment in a sound HIV cure research enterprise will require a 
meaningful involvement of people living with HIV, together with servant and participatory 
leadership skills, better articulated ethical considerations and support from a wide range of 
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stakeholders.  I hope that my dissertation research will, in a small way, faciliate the design and 
implementation of effective and ethical HIV cure-related studies by helping understand factors that 
affect participation in research. I also hope that the plan for change will make a small difference in 
the lives of potential study participants.  
With my DrPH, I aspire to become more adept at contributing to the social sciences of 
infectious disease research in both an academic setting and in a practical way. The skills learned in 
my DrPH courses and throughout the dissertation process will make be a more effective manager of 
clinical research and student of the social sciences. The DrPH program will also allow me to 
implement my vision of a comprehensive international HIV cure research training curriculum with 
greater energy and focus. Ultimately, I aspire to obtain a faculty position to be able to contribute to 
the the social sciences related to infectious diseases and inspire students to implement positive 
change. I also want to be a continuous student of consilience [133], infectious diseases and the 
social sciences. 
I started my DrPH journey in Mozambique, where I was developing research capacity for HIV 
vaccine trials. I transitioned to working on the social sciences of HIV cure research and completed 
the program working with Ebola survivors in Liberia. In a way, I feel like I have come full circle and 
that I have covered the spectrum of public health, from ultimate prevention research (e.g. vaccines) 
to cure and research. The issues identified in my DrPH dissertation have ramifications that extend 
far beyond HIV. I now hope to be able to contribute the skills learned to implementing a successful 
natural history study with Ebola survivors in Liberia funded by the Bill and Melinda Gates 
Foundation. I have grown cognizant of the factors that influence the effective and ethical 
implementation of infectious disease research in general. I see many parallels between HIV research 
and Ebola research. In fact, the way Ebola was talked in the recent outbreak in West Africa was 
reminiscent of the early days of the AIDS epidemic, when fear, isolationism and xenophobia were 
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predominant in the public discourse and there was little in the way of accurate and meaningful 
information.  Hopefully, the Ebola survivor study will help generate more accurate information 
about long-term Ebola disease and implications for public health and the lives of survivors. There are 
so many issues that apply to both HIV and Ebola research, including the need to reduce stigma and 
discrimination and to foster altruism among study participants. HIV and Ebola research represent an 
opportunity to find hope in what have been enormous tragedies in the lives of patient-participants. 
Furthermore, Ed Wilson’s concept of consilience [133] changed the way I work as a public 
health practitioner. I now fully appreciate the complex matrix of social, ethical, experiential and 
evidence-based related factors in the implementation of infectious disease clinical studies. My 
literature review examined the lessons learned from proxy fields of study. I hope to continue this 
personal journey of consilience throughout my career as a public health practitioner and scholar. I 
consider the implementation of infectious disease research not simply as a scientific matter, but also 
a social and deeply moral one. Researchers need to have tremendous insights into both the personal 
and the scientific dimensions of a disease. The following quote from Rebecca Dressler has inspired 
my work: 
It would be acknowledging that research results are not simply numbers, but descriptions of real 
events in real lives. It would be an act that could remind researchers of the human side of their 
investigation and perhaps encourage greater sensitivity toward participants at other points in 
the research process. This is the sort of insight that advocates could contribute to research 
ethics. Advocates could help ethicists see research from the point of view of research 
participants and patients in the community.[64] 
 
No matter whether I work on HIV, Ebola or other public health issues, I want to remain 
attuned to the realities, perceptions, motivations, desires, fears and vulnerabilities experienced by 
the people who live with the infection or condition. Throughout the process of investigation, I grew 
increasingly convinced that study participants have much to offer clinical research scientists and also 
bioethicists. People living with HIV are hungry to know where they fit in the HIV cure research 
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agenda. More work needs to be done to discover what study participants value or resent and what 
they appreciate or would change about their research experience.  
HIV cure research is an extremely complex field, and no one knows what the cure will look 
like. It is important to acknowledge that advocacy around HIV has changed tremendously in 30+ 
years of research. HIV cure research is very different than the research conducted in the early days 
of the HIV epidemic. Now, most people living with HIV are doing well on treatment and desperation 
does not drive research participation. It will take an enormous appreciation for the altruism of the 
“otherwise healthy volunteers” to advance the field of HIV cure research. As the study showed, 
those who may most want the cure (the “least healthy”) are also the ones who are also the least 
likely to qualify for studies, paradoxically. With Ebola research, most of the survivors are 
convalescent cases who are “functionally cured.” Scientists are still trying to determine the 
mechanism of Ebola persistence and the significance of the diagnostic and research tests. Sexual 
transmission of Ebola has occurred. New vaccine, treatment and cure research is currently occurring 
in West Africa, and there is a greater need to uncover the psychosocial consequences of having 
survived Ebola.  With HIV, much remains to be done to close the prevention and the treatment 
cascade gap. With both diseases, we must appreciate the entire public health continuum of what it 
will take to eradicate infections, together with meaningful community engagement efforts to get 
there and listening to the voices of the patients. 
All things considered, I am extremely appreciative to have been part of the DrPH journey at 
UNC-Chapel Hill. The DrPH program has given me a calmer confidence to continue pursuing my 
passions and has made me a better-rounded person. I am extremely thankful and feel very blessed 
to be a student in this truly amazing program and to have been a part of ‘C9’. 
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APPENDIX 1: LIST OF RECRUITMENT CHANNELS AND/OR KEY INFORMANTS 
PATIENTS/PARTICIPANTS 
The list of patient/participant key informants was derived from the survey and remains strictly 
confidential. 
 
Possible recruitment sources for HIV-positive patients/participants: 
 Immune-based therapy listserv (ibt-listserv) 
 Martin Delaney Collaboratories Community Advisory Board (CAB) listserv (mdc-national-listserv) 
     Collaboratory of AIDS Researchers for Eradication Community Advisory Board (CARE CAB) 
     Delaney AIDS Research Enterprise Community Advisory Board (DARE CAB) 
     defeatHIV Community Advisory Board (defeatHIV CAB)  
 AIDS Treatment Activist Coalition (AVAC) listserv (ATAC-drug dev listserv) 
 AIDS Clinical Trials Group Community Advisory Board (ACTG CAB) 
 Center for AIDS Research Community Advisory Board (CFAR CAB) 
 Women’s HIV Interagency Study (WHIS)  
 Referrals by study participants; see participant lists below. 
 
Participant lists from: 
 Forum for Collaborative HIV Research – Regulatory Pathway for HIV Cure Research: Developing 
Consensus; Washington D.C. (June 17, 2014) 
 NIH/NIHM Think Tank on Social, Ethical and Behavioral Issues regarding HIV Cure Research; 
Bethesda, MD (September 22 – 23, 2014) 
 NIH-Sponsored Workshop on HIV Cure Research; Bethesda, MD (October 15 – 17, 2014)  
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APPENDIX 2: SAMPLE RECRUITMENT EMAILS/SCRIPTS FOR LISTSERVS (APPROVED BY UNC IRB) 
Key Informant Interviews 
 
A Request for your Participation  
 
Dear [Name],  
 
In order to learn about the factors affecting participation in HIV cure studies, we are 
[conducting a series of interviews with clinicians/researchers or stakeholders/regulators like yourself] 
or [implementing a survey with potential study participants]. 
 
Attached, you will find a document that describes the main goal of this research study and 
includes information that you will need in order to provide your informed consent, should you agree 
to participate. You will be asked to provide your verbal consent [on the next page or over the phone 
prior to our interview].  
 
If you choose to participate in the [survey or interview], we are the only persons who will 
have access to your responses. Your name will not be disclosed to anyone and will not be used in any 
report or summary that comes from this [survey or interview]. Records of the [survey or interview] 
will be stored electronically in password-protected files. Any hard copy information linked to an 
individual’s response to interview questions will be stored in a locked file.  
 
If you agree to participate, we will send you a copy of the [verbal] informed consent form, together 
with a list of the possible interview questions, to better help you prepare.  
 
[Interview only: Would you be available on [Date] at [Time] to conduct a call? If this date/time is not 
convenient for you, can you please suggest a day/time when you would be available? Please confirm 
the best phone number we should use for this call. If you have any questions in the interim, please 
feel free to contact us as well.]  
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Thank you very much for considering participating in this study to discuss factors that influence 
participation in HIV cure studies as well as effective and ethical implementation of these studies. 
 
We know that you are very busy, and we greatly appreciate your time and assistance with this effort.   
 
Sincerely,  
Karine [and Jeff] 
 
Enclosure: Dissertation Project Fact Sheet  
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APPENDIX 3: PROJECT FACT SHEET (APPROVED BY UNC IRB) 
This research study seeks to examine the factors that influence the participation 
of HIV-positive patients/participants into HIV cure-related studies. By HIV cure research, 
we mean any investigation that evaluates a therapeutic intervention that would control 
or eliminate HIV infection to the point where no more HIV treatment would be required 
to preserve health. There are two main approaches being investigated: 1) a sterilizing 
cure, which would clear all latent viral reservoirs in the body (eradication); and 2) a 
functional cure, which would allow a person’s immune response to control HIV without medication. A 
functional cure may be easier to achieve than a completely sterilizing cure. In addition, most of the 
HIV cure-related research modalities remain in the very early-stage of development. We do not have 
a lot of information about what factors influence HIV positive patients/participants to participate (or 
refuse to participate) in these cure-related studies.  
 
The U.S. Food and Drug Administration (FDA) recently launched a new initiative aimed at placing the 
needs and perspectives of HIV positive patients/participants at the forefront of the drug development 
process for an HIV cure. The U.S. government and other funders are also investing more money into 
HIV cure research than ever before. As of [April 2015], there were more than [100] ongoing HIV cure-
related clinical studies conducted around the world.  
 
The social sciences have not kept the pace with the basic, translational and clinical research. It is 
important to understand the factors that would motivate or deter HIV positive patients/participants 
to enter these studies to ensure that they are implemented effectively and ethically.  
 
We also wish to engage individuals living with HIV in a significant and sustained dialogue to 
understand their concerns, perceptions and understandings of HIV cure studies. The perspectives of 
clinicians/researchers implementing these studies as well as other stakeholders are also critical in 
order to ensure that we preserve the public trust in the HIV cure research agenda.  
 
Thus, this study has three main objectives:  
1. To better understand the factors that act as motivators and/or deterrents of participation in HIV 
cure studies;  
2. To explore how various stakeholders perceive the risks and benefits of HIV cure studies; and  
3. To understand some of the practical or pragmatic issues that affect participation of HIV positive 
patients/participants in cure studies.  
 
The findings generated from this dialogue will be used to create recommendations as well as 
decision/communication aids in order to facilitate the effective and ethical implementation of HIV 
cure studies. Since HIV cure studies are complex, we wish to avoid unintended harm or consequences 
during the design and implementation phases. The tools generated from this research will be shared 
with various stakeholders working on HIV cure studies.  
 
We thank you in advance for your participation and support. 
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APPENDIX 4: INFORMED CONSENT FORMS (APPROVED BY UNC IRB) 
1. Patient/Participant       
 Participant ID#: ___ ___ ___  
 
Title of Study:  




Karine Dubé, MPhil, DrPH (candidate), Department of Health Policy and Administration and Collaboratory 
of AIDS Researchers for Eradication (CARE), Institute of Global Health and Infectious Diseases (IGHID), The 
University of North Carolina at Chapel Hill (UNC-CH)  
Jeffrey Taylor, Collaboratory of AIDS Researchers for Eradication (CARE)  
 
Informed consent (5 – 10 minutes): Online for semi-structured survey; Verbal for interview or focus 
group discussion  
 
Purpose:  
Throughout this interview, we want to know your opinions about HIV cure studies. We want to more fully 
understand patients’ perceptions, attitudes and understandings of HIV cure studies, with an emphasis on 
exploring facilitators and barriers to participation in research studies. We would also like to make 
recommendations to facilitate implementation of these studies. We will first ask you some questions 
about demographics and then ask for your opinions about HIV cure studies, such as the factors that 
(would) either motivate you or deter you from participating in HIV cure research. We also want to know 
more about your perceptions of the risks and benefits of HIV cure studies. Finally, we would like to hear 
about the practical challenges of implementing these studies or about any concerns that you have. You 
can choose not to answer, but any support will be appreciated. This interview will take approximately 30 – 
45 minutes to complete.  
 
The University of North Carolina at Chapel Hill Institutional Review Board (IRB) approved this study.  
 
Potential Benefits and Harms:  
There is no direct or indirect harm that could result from your participation in this study. Throughout your 
participation in this study, you may benefit by being able to explore some important issues or questions 
related to HIV cure studies.  
 
Voluntary Participation and Anonymity:  
Participation in this study is voluntary. You may refuse to join or withdraw from the study at any time. We 
will maintain your anonymity at all times during this study. No information that you share will ever be 
traceable back to you. The final reports will provide only aggregated data. All data files will be stored on a 
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password-protected laptop and held in a secure location. We will destroy all files – including audio files – 
once the final analysis is completed.  
 
If you agree to have this interview recorded, we will record it using a digital recorder. If you do not want to 
have this interview recorded, you can still participate and we will take notes. 
 
Compensation: There is no compensation from participating in the key informant interviews. 
 
Consent:  Do you have any question at this time about participating in this study? 
 
I, ________________________ (survey participant or interviewee’s name), understand that I am being 
asked to participate in a research study conducted by the University of North Carolina at Chapel Hill to 
answer questions related to my attitudes and perceptions about HIV cure studies. I understand that it is 
my voluntary choice to participate in this study. I also understand that I may refuse to answer during the 
interview and/or withdraw from the study at any time. A summary of the results will be made available to 
me upon completion of the study, should I request a copy. I understand what this study involves and I 
freely agree to take part.   
 
Consent given:   Yes      No        Date: 
___________________________ 
 
Agreement to Record:  Yes      No      N/A      Date: 
___________________________ 
 
If you have any questions or concerns, either prior to or following your participation, please do not 
hesitate to contact us.  
 
Karine Dubé at (919) 962-0993 or by e-mail at karine_dube@med.unc.edu.   
Jeff Taylor at 760-835-1926 or by email at jefftaylorps@gmail.com.  
UNC-CH IRB and Office of Human Research Ethics, CB #7097, Medical School Building 52, 105 Mason Farm 
Road, Chapel Hill, NC 27599; Phone: 919-966-3113 
 
2. Clinician/Researcher       
 Participant ID#: ___ ___ ___  
 
Title of Study: Assessing Factors Affecting Participation in HIV Cure Research: Implications for 
Effective and Ethical Implementation 
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Co-Investigators:  
Karine Dubé, MPhil, DrPH (candidate), Department of Health Policy and Administration and Collaboratory 
of AIDS Researchers for Eradication (CARE), Institute of Global Health and Infectious Diseases (IGHID), The 
University of North Carolina at Chapel Hill (UNC-CH)  
Jeffrey Taylor, Collaboratory of AIDS Researchers for Eradication (CARE)  
 
Informed consent (5 – 10 minutes): Verbal for interview 
 
Purpose:  
Throughout this interview, we want to know your opinions about HIV cure studies. We want to 
more fully understand your patients’/participants’ perceptions, attitudes and understandings of HIV cure 
studies, with an emphasis on exploring facilitators and barriers to participation in research studies. We 
would also like to make recommendations to facilitate implementation of these studies. We will first ask 
you some questions about the factors that would motivate you or deter your patients/participants from 
taking part in HIV cure research. We also want to know more about your perceptions of the risks and 
benefits of HIV cure studies and the factors that lead you to refer possible participants in HIV cure studies. 
Finally, we would like to hear about the practical challenges of implementing these studies or about any 
concerns that you have. You can choose not to answer, but any support will be appreciated. This interview 
will take approximately 30 – 45 minutes to complete.  
 
The University of North Carolina at Chapel Hill Institutional Review Board (IRB) approved this study.  
 
Potential Benefits and Harms:  
There is no direct or indirect harm that could result from your participation in this study. Throughout your 
participation in this study, you may benefit by being able to explore some important issues or questions 
related to HIV cure studies.  
 
Voluntary Participation and Anonymity:  
Participation in this study is voluntary. You may refuse to join or withdraw from the study at any time. We 
will maintain your anonymity at all times during this study. No information that you share will ever be 
traceable back to you, and the final reports will provide only aggregated data. All data files will be stored 
on a password-protected laptop and held in a secure location. We will destroy all files – including audio 
files – once the final analysis is completed.  
 
If you agree to have this interview recorded, we will record it using a digital recorder. If you do not want to 
have this interview recorded, you can still participate and we will take notes. 
 
Compensation: There is no compensation from participating in the key informant interviews. 
 
Consent:  Do you have any question at this time about participating in this study? 
 
I, ________________________ (survey participant or interviewee’s name), understand that I am being 
asked to participate in a study conducted by the University of North Carolina at Chapel Hill to answer 
questions related to my perceptions about HIV cure studies. I understand that it is my voluntary choice to 
participate in this study. I also understand that I may refuse to answer during the interview and/or 
withdraw from the study at any time. A summary of the results will be made available to me upon 
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completion of the study, should I request a copy. I understand what this study involves and I freely agree 
to take part.   
 
Consent given:   Yes      No        Date: 
___________________________ 
 
Agreement to Record:  Yes      No      N/A      Date: 
___________________________ 
 
If you have any questions or concerns, either prior to or following your participation, please do not 
hesitate to contact us.  
Karine Dubé at (919) 962-0993 or by e-mail at karine_dube@med.unc.edu.   
Jeff Taylor at 760-835-1926 or by email at jefftaylorps@gmail.com. 
UNC-CH IRB and Office of Human Research Ethics, CB #7097, Medical School Building 52, 105 
Mason Farm Road, Chapel Hill, NC 27599; Phone: 919-966-3113 
 
3. Policy-Maker/Regulator       
 Participant ID#: ___ ___ ___  
 
Title of Study: Assessing Factors Affecting Participation in HIV Cure-Related Research: Implications 
for Effective and Ethical Implementation 
 
Co-Investigators:  
Karine Dubé, MPhil, DrPH (candidate), Department of Health Policy and Administration and Collaboratory 
of AIDS Researchers for Eradication (CARE), Institute of Global Health and Infectious Diseases (IGHID), The 
University of North Carolina at Chapel Hill (UNC-CH)  
Jeffrey Taylor, Collaboratory of AIDS Researchers for Eradication (CARE) Community Advisory Board (CAB) 
 





Throughout this interview, we want to know your opinions about HIV cure studies. We want to more fully 
understand your perceptions, attitudes and understandings of HIV cure studies, with an emphasis on 
exploring facilitators and barriers to participation in studies and practical challenges of implementing 
these research studies. We would also like to make recommendations to facilitate implementation of 
these studies. We will ask you some questions about perceptions of the risks and benefits of HIV cure 
research. Finally, we would also like to hear about any concerns that you have. You can choose not to 
answer, but any support will be appreciated. This interview will take approximately 30 – 45 minutes to 
complete.  
 
The University of North Carolina at Chapel Hill Institutional Review Board (IRB) approved this study.  
 
Potential Benefits and Harms:  
There is no direct or indirect harm that could result from your participation in this study. Throughout your 
participation in this study, you may benefit by being able to explore some important issues or questions 
related to HIV cure studies.  
 
Voluntary Participation and Anonymity:  
Participation in this study is voluntary. You may refuse to join or withdraw from the study at any time. We 
will maintain your anonymity at all times during this study. No information that you share will ever be 
traceable back to you, and the final reports will provide only aggregated data. All data files will be stored 
on a password-protected laptop and held in a secure location. We will destroy all files – including audio 
files – once the final analysis is completed.  
If you agree to have this interview recorded, we will record it using a digital recorder. If you do not want to 
have this interview recorded, you can still participate and we will take notes. 
 
Compensation: There is no compensation from participating in the key informant interviews. 
 
Consent:  Do you have any question at this time about participating in this study? 
 
I, ________________________ (survey participant or interviewee’s name), understand that I am being 
asked to participate in a study conducted by the University of North Carolina at Chapel Hill to answer 
questions related to my perceptions about HIV cure studies. I understand that it is my voluntary choice to 
participate in this study. I also understand that I may refuse to answer during the interview and/or 
withdraw from the study at any time. A summary of the results will be made available to me upon 
completion of the study, should I request a copy. I understand what this study involves and I freely agree 
to take part.   
 
 
Consent given:   Yes      No        Date: 
___________________________ 
 
Agreement to Record:  Yes      No      N/A      Date: 
___________________________ 
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If you have any questions or concerns, either prior to or following your participation, please do not 
hesitate to contact us.  
 
Karine Dubé at (919) 259-2489 or by e-mail at karine_dube@med.unc.edu.   
Jeff Taylor at 760-835-1926 or by email at jefftaylorps@gmail.com.  
UNC-CH IRB and Office of Human Research Ethics, CB #7097, Medical School Building 52, 105 
Mason Farm Road, Chapel Hill, NC 27599; Phone: 919-966-3113 
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APPENDIX 5: PATIENT/PARTICIPANT QUESTIONNAIRE (APPROVED BY UNC IRB) 
AMENDED SURVEY V2.0 – APPROVED BY UNC IRB 30 AUGUST 2015   
 
Social Sciences Survey on HIV Cure Research: Your Opinion Matters 
 
There has been an increase in HIV cure research in the recent years. We would like to find out how people 
living with HIV (or potential HIV cure research volunteers) perceive HIV cure research, including their 
willingness to participate in HIV cure studies. We would also like to find out what would help implement 
HIV cure studies. Your answers to these questions will be kept strictly confidential.  
 
You are eligible to complete this survey if you: 
 Are at least 18 years of age  
 Are living with HIV  
 Are willing to give your opinion about HIV cure research 
 Live in the United States  
 
We are interested to find out what you think about:  
 The possible risks and benefits of HIV cure research 
 How willing you would be to volunteer in clinical studies related to HIV cure research 
 How willing you would be to take risks as part of HIV cure research 
 Things you think could help or hinder HIV cure studies 
 
Note: By answering the questions in this survey, you are not obligated to actually participate in 
any HIV cure study. This survey will assess whether you would be willing to participate in different types of 
HIV cure-related clinical studies, but you will not be signed up for a study as a result of this survey. 
HIV Cure Research 
By HIV cure research, we mean studying anything that could help control or eliminate HIV to the point that 
medications would no longer be needed to keep someone healthy.  
 
There are two main approaches being investigated:  
1) A sterilizing cure, which would clear HIV from the body (eradication); and  
2) A functional cure, which would allow a person’s immune response to control HIV without 
medication.  
 
Engaging People Living with HIV in Dialogue 
We wish to find out what people think about HIV cure studies. The understanding of perspectives of 
people living with HIV is important in establishing and maintaining public trust in and support for the HIV 




Informing Implementation of HIV Cure Research 
The findings generated from this study will be used to help conduct HIV cure-related studies. Since HIV 
cure-related studies are complex, we wish to avoid unintended consequences during the design and 
implementation of research.  
 
Time to Complete 
This survey will take from 45 – 60 minutes to complete. 
 
Thank You and Questions  
We thank you in advance for your participation and support. If you have any questions about this 




At the end of the survey, you have the opportunity to enter a prize drawing ($USD 25 for each 25 
survey respondents – either VISATM, TargetTM or StarbucksTM gift card). If you want to be considered for 
the drawing, you will need to provide an email address or a phone number to be contacted if you win. 
 
Would you like to go ahead with the survey?  Yes  
No     
 





If No, can you please tell us why you do not wish to participate? 
This will end the survey for you. 
 
Do not have time  
No interest 
Do not meet the eligibility criteria 





What is your gender?  Female  
Male  
Transgender (male to female) 
Transgender (female to male)  
Other, Specify_______________ 
What is your age? (Years) 
What is your ethnicity? Caucasian/White 
African-American 
Hispanic or Hispanic descent 
American Indian or Alaska Native 





What is the highest level of education that you completed?  
Less than high school 




Doctorate or doctoral-level degree 
(e.g. PhD, MD, JD, etc.)Other, 
Specify_______________ 
What is your yearly household income (in U.S. dollars)? <$25,000 
$25,000 – $50,000 
$50,001 – $75,000 
$75,001 – $100,000 
>$100,000 
In which U.S. state or territory do you live in  
? 
(Select from a list of state 
abbreviations and territory initials) 
  
 
Health Perceptions  
How would you describe your current health status? Very healthy 
Healthy  
Somewhat healthy 
Not very healthy 
Not at all healthy  
Do you feel you have control over your own health care?  Yes 
No 
 I don’t know/not sure 
Are you currently taking HIV medication? Yes 
No 






Have you ever 
participated in any of 
the following types of 
health research 
studies (whether HIV 
related or non-HIV 
related)? Please 
select all that apply. 
 Survey research  
 Interviews  
 Focus group discussions 
 Basic blood draw studies  
 Laboratory procedure where selected immune cells are separated out 
from your blood and the rest of your blood is returned to your veins 
 Studies that involve agents that could reactivate HIV that has become 
dormant inside your cells  (“latency reversing agents”) 
 Studies that involve the modification of some of your genes in your 
immune cells  
 Studies that involve a transplantation of your (“autologous”) stem cells 
 Studies that involve a transplantation or someone else’s (“allogeneic”) 
stem cells 
 Studies that involve therapeutic vaccines (vaccines that control disease in 
people already infected rather than vaccines that prevent infection)  
 Studies that involve the intensification of treatment or taking more than 
3 different classes of drugs at the same time  
 Studies that involve the use of unique antibodies, proteins or molecules 
(for example, antibodies that have dual functions)   
 Studies that involve totally new treatments or approaches (“first-in-
human” studies) 
 Studies about safety and efficacy (or phase II or III studies) 
 
In what year were you diagnosed with HIV? (Year) 
I don’t remember 
Have you ever been in (or volunteered for) an HIV treatment study?  Yes 
No 
I don’t know/not sure 
Have you ever been in (or volunteered for) an HIV cure study of any 
kind? 
If No, skip to X (question on general interest in HIV cure research). 
Yes 
No 
I don’t know/not sure  
     If Yes: 
     How many HIV cure-related studies have you participated in? 
(Number) 
     Can you please name the HIV cure research that you participated 
in? 
(Name(s))  
     Are you currently participating in an HIV cure-related study? Yes, Specify __________ 
No 
I don’t know/not sure/don’t want 
to disclose 
Are you generally interested in HIV cure research? Yes 
No 
 I don’t know/not sure 
Are you generally interested in medical issues? Yes 
No 





Types of HIV Cure Studies 
Would you consider participating in any of the following HIV cure-related studies – now or in the future? 
Note: There is no obligation to participate in HIV cure-related studies if you answer “Yes”  
Survey research  Yes 
No 
 I don’t know 
Interviews  Yes 
No 
I don’t know 
Focus group discussions Yes 
No 
I don’t know 
Basic blood draw studies  Yes 
No 
I don’t know 
Laboratory procedure where selected immune cells are separated 
out from your blood and the rest of your blood is returned to your 
veins (leukapheresis or apheresis) 
Yes 
No 
I don’t know 
Studies that involve agents that could reactivate HIV that has 
become dormant inside your cells  (“latency reversing agents”) 
Yes 
No 
I don’t know 
Studies that would involve the modification of some of  your genes 
in your immune cells  
Yes 
No 
I don’t know 




I don’t know 
Studies that would involve a transplantation or someone else’s 
(“allogeneic”) stem cells 
Yes 
No 
I don’t know 
Studies that would involve therapeutic vaccines (vaccines that 
control disease in people already infected rather than vaccines that 
prevent infection)  
Yes 
No 
I don’t know 
Studies that would involve the intensification of treatment or taking 
more than 3 different classes of drugs at the same time  
Yes 
No 
I don’t know 
Studies that would involve the use of unique antibodies, proteins or 
molecules (for example, antibodies that have dual functions)   
Yes 
No 
I don’t know 




I don’t know 
Studies about safety and efficacy (or phase II or III studies) Yes 
No 
I don’t know 
If you had an infant living with HIV, would you let them participate 
in a pediatric HIV cure-related study (for example, ARV treatment as 
close to birth as possible)?  
Yes 
No 
 I don’t know 




Potential Personal Benefits 
How important are the following to your motivation to participate in HIV cure studies? 
  
Getting special/additional knowledge about your own HIV infection 
and your own health from being in the study  
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable  
Having (more) regular access to medical doctors/researchers Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Have regular access to a study nurse  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Feeling good about contributing to HIV cure-related research  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Hope that your health will improve   Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Not wanting to give up  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Being compensated or reimbursed for participation in a study   Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Learning about new treatment options Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Additional laboratory work done free of charge, such as viral load or 
CD4+ count testing  
 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
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Being offered a meal at the study site Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Receiving gas money, transportation compensation or public 
transportation passes to help come to the study site 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
 
Potential Personal Clinical Benefits 
How important are the following clinical factors to your motivation to participate in an HIV cure-related 
study? 
Increased immune cell counts  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Reducing the amount of HIV in your entire body (not just your 
blood) – or making your HIV reservoir (site where HIV can persist) 
smaller 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Controlling the amount of virus in your body in the absence of 
treatment 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Not having the amount of virus in your body increase  for an 
extended period of time (i.e. one year) 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Having your immune system preserve its ability to fight HIV  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 
Less risk of transmitting HIV to your sexual partner(s)  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know/not applicable 





Potential Social Benefits 
How important are the following factors to your motivation to participate in an HIV cure-related study? 
Helping other people with HIV in the future 
 
Very important  
Somewhat important  
Barely important 
Not important 
I don’t know 
Helping find a cure for HIV  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know 
Contributing to scientific knowledge  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know 
Receiving support from your family and friends  Very important  
Somewhat important  
Barely important 
Not important 
I don’t know 
  
 
Other Potential Benefits 
What other potential benefits are “very important” to your motivation to participate in an HIV cure-
related study? _____________________________________ 
 
Potential Personal Clinical Risks 
How likely will any of the following potential risks discourage you from participating in an HIV cure-related 
study? 
 
Known risks of stopping HIV medications (such as the potential for a 
rapid increase in your viral load or “rebound”) 
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Toxicities or adverse negative effects of the drug(s) being studied Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Possibility of developing resistance to the drug(s) during a 
structured treatment interruption  
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
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Having no way to predict the risk of having your virus become 
detectable again (“viral rebound”)  
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Activation of genes in your body that could cause cancer  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Graft-versus-host disease (or GVHD) (a possible complication from 
allogeneic (foreign) stem cells transplants, although rare) 
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Invasive study procedures (such as a biopsy or sample of tissue 
from one of your lymph nodes) )   
  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
  
 
Perceptions of Clinical Risks  
How willing would you be to stop your HIV treatment as part of an 
HIV cure-related study?   
Very willing 
Somewhat willing 
Not very willing 
Not willing 
I don’t know 
What level of CD4 count would be acceptable to you if your CD4 





Other, Specify________ cells 
I would not go off treatment 
I don’t know  
What do you think would be “too much” risk for you to be in an 




Other Potential Personal Risks and Burdens  
How likely will any of the following potential risks discourage you from participating in an HIV cure-related 
study? 
Long (more than 4 hours) study visit(s)  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
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I don’t know  
High frequency of study visits (more than 1 time per month) Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Long (more than 5 years) duration of study and follow-up Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Study Procedures:   
Blood draws  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Procedures that separate your white blood cells from the rest of 
your blood cells (may take up to 2 hours)  
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Spinal tab (“lumbar punctures”) Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Biopsies of one of your lymph nodes, organs that contain immune 
cells 
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Collection of semen or vaginal fluids  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Rectal biopsies (via sigmoidoscopy or colonoscopy) Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
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Oral biopsies (such as saliva samples taken from your mouth)  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Bone marrow biopsies  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Organ donation after death  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 






Symptoms or Side Effects:  
Nausea Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Vomiting Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Headache  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Hair loss  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Pre-defined, limited and controlled potential discomfort and/or pain Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
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Not likely to discourage (does not 
affect my decision) 
I don’t know 
  
Burdens:  
Difficulty finding transportation to the clinical research site Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Difficulty finding or having to pay for parking at the clinical research 
site 
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Challenges of finding child care Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Time away from your work or school  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Time away from your family  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Having to explain your study participation to your partner(s) or 
others 
Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 




Potential Social Risks 
How likely will any of the following potential risks discourage you from participating in an HIV cure-related 
study? 
Being recognized as a person living with HIV    Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know  
Risk of transmitting HIV to a sexual partner Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Stigma  Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
Discrimination   Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
If there is a cure, the risk of losing your “HIV-positive identity”   Very likely to discourage 
Somewhat likely to discourage 
Barely likely to discourage 
Not likely to discourage (does not 
affect my decision) 
I don’t know 
  
 
Other Potential Risks 
What other potential risks are “very likely to discourage” you from participating in an HIV cure-related 
study? _____________________________________ 
 
Factors Affecting Participation  
Are any of the following factors important to you in making a decision about whether to consider 
participating in an HIV cure-related study?  




I don’t know  
The nurse for the study Yes 
No 
I don’t know 
The research site where the study is being done Yes 
No 
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I don’t know 
The way the information is given about a clinical study  Yes 
No 
I don’t know 
The HIV cure research method being investigated  Yes 
No 
I don’t know 
  
Facilitators of Participation and Implementation  
What (other) factor(s) are likely to make you want to participate in 
HIV cure-related studies?    
(Text)  
In your opinion, what factors would help with the conduct of an HIV 




Barriers to Participation and Implementation  
What (other) factors are likely to make you NOT want to participate 
in an HIV cure-related study?    
(Text)  
In your opinion, what factors would make the conduct of an HIV 





If you were to participate in an HIV cure-related study, how would 
you describe yourself: 
A Partner in the Research 
A Patient 
A Study Participant 
An Experimental Subject 
A Research Subject 
A Volunteer 
A “Guinea Pig” 
Other, Specify________  
Do you think that you can be cured by participating in an HIV cure-
related study now or in the near future? 
Yes 
No 
I don’t know 
Do you hope that you can be cured by participating in an HIV cure-
related study now or in the near future? 
Yes 
No 
I don’t know 
How many years do you think it will take to find a cure for HIV? There is a cure available now 
Within 5 years 
6 – 10 years 
11 – 15 years 
16 – 20 years 
21 - 50  years 
More than 50 years 
Never 
What does a cure for HIV mean to you (check all that apply)? No more HIV treatment needed now  
No more HIV treatment needed 
ever  
No risk of transmitting HIV to others 
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Negative HIV test 
HIV completely eliminated from the 
body 
There is no risk of opportunistic 
infection 
Other, Specify________ 






Would you be willing to be contacted for an individual interview 
(about 1 hour)?    
(If Yes, please provide contact details below) 
Yes 
No  
Would you be willing to be contacted for a focus group discussion 
(about 1 hour)? 





 (Only if “Yes” above) Contact Information: 
Please provide your contact information in order to be contacted regarding participating in an individual 
interview and/or focus group discussion.  






Prize Drawing and Future Contact 
Thank you for completing the survey!  
Would you like to be included in a prize drawing of a $25 gift card (25 survey respondents will be randomly 
chosen)? If so, please provide your contact information below. 
 







Preferred Gift Card  







Thank you very much for taking the time to complete this questionnaire. Your assistance is very 
much appreciated. If you have any questions or concerns, please contact Karine Dubé 
(karinedube2003@gmail.com) or Jeff Taylor (jefftaylorps@gmail.com).  
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APPENDIX 6: KEY INFORMANT INTERVIEW GUIDES (APPROVED BY UNC IRB) 
[General Introduction for Patients/Participants, Clinicians/Researchers and Policy-Makers/Regulators] 
 
We are implementing a research study looking at factors affecting participation in HIV cure studies in the 
United States.  
 
The purpose of the key informant interviews is to learn more about how patients/participants, 
clinicians/researchers and policy-makers/regulators perceive the risks and benefits of HIV cure studies. 
The key informant interviews will also help understand some of the practical issues affecting HIV cure 
studies.   
 
We would like to understand the factors that facilitate or hinder participation in HIV cure studies. Around 
[12 – 15 patients/participants, 6 clinicians/researchers and 6 policy-makers/regulators] will participate in 
these interviews. The interviews should take between 30 minutes to an hour.  
 
The interviews will be completely confidential. Your name will not be used in any study report, final report 
or publications. Once the data have been compiled, all identifying information associated with your 
answers will be removed.  
 
With your permission, we would like to record our interview. This would ensure that none of your 
important insights are missed. The audiotape will not have any names on it (only an identifier code) and 
will be kept in a secure location. Tapes and transcriptions will be destroyed at the end of the study. The 
interview will not be recorded if you prefer. If you prefer it not to be, we will take detailed notes.  
 
  Before we begin, do you have any question about the study or the interview? 
 May we record the interview? 
 
PATIENT/PARTICIPANT INTERVIEW GUIDE (APPROVED BY UNC IRB) 
 
Introduction  
What motivated you to participate in today’s interview? 
Can you please tell us more about your history of participating in HIV research?  
Have you participated in HIV cure research? (If so, probe for details.) 
What factors do you think are important to consider when participating in HIV cure research? 
 
Risks and Benefits  
Do you think HIV cure research is a good thing?  
What benefits do you think are there to participate in HIV cure studies?  
Do you have any concerns about HIV cure research? If so, what are they? 
What risks do you think are there to participate in HIV cure studies?  
What do you think would be “too much risk” in HIV cure studies? 
Are there studies that you would not participate in? Why? 
What are some of the burdens to participate in HIV cure research? 
What do you consider the safest HIV cure research method? Can you please tell us why? 




Barriers and Facilitators  
What do you think are the main motivators to participate in HIV cure studies?  
What do you think would motivate someone doing well on HIV treatment to participate in an HIV cure 
study? 
What do you think are the main barriers to participate in HIV cure studies? 
 
Programmatic Considerations  
Do people in your community know about HIV cure research? Do you think information about these 
studies should be promoted in your community?  
What do you expect from HIV cure studies?  
Would you expect to be cured from early HIV cure studies? 
What can be done to facilitate recruitment of patients/participants into HIV cure studies? 
What can be done to facilitate retention of patients/participants into HIV cure studies? 
What can be done to make sure that HIV cure studies are implemented well? 
What can be done to make sure that HIV cure studies are implemented in an ethical way? 
What kind of guidance is needed for patients/participants wanting to participate in HIV cure studies? 
Do you think any guidance is needed for clinicians/researchers about HIV cure research? If so, please 
explain. 
 
Clinicians/Researchers and Policy-Makers Roles and Responsibilities  
What do you believe is the role of clinicians/researchers in HIV cure studies? 
What do you believe is the role of policy-makers (such as institutional review boards) in HIV cure studies? 
Is there anything that you consider unethical?  
 
Wrap Up and Closing 
Would you like to add anything or make additional comments?  
 
Thank you for taking the time to answer these questions. Your participation in this interview greatly 
contributes to the research project and to increasing our understanding around the issues affecting 
participation in HIV cure studies. Your answers will be compiled with the answers of all other interviewees. 
Please feel free to contact us at anytime if you have any questions about this interview or the research 
project. 
 
CLINICIANS/RESEARCHERS INTERVIEW GUIDE (APPROVED BY UNC IRB) 
 
Introduction  
First, thank you so much for your time.  
Can you please tell us more about your role in implementing HIV cure research?   
What factors are important to consider for patients/participants wanting to participate in HIV cure 
research? 
 
Risks and Benefits  
Why do you think your patients/participants want to join HIV cure research? 
Are there studies that you would not recommend your patients/participants to participate in? If 
so, what are they? 
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What are your patients’/participants’ concerns about HIV cure research?  
Do your patients/participants incur risks while participating in HIV cure studies? If so, which ones? 
What do you think would constitute “too much risk” in HIV cure studies? 
Do you think treatment interruption should be done? Why or why not? 
What are some of the most significant burdens for your patients/participants to participate in HIV cure 
research? 
What do you consider the safest HIV cure research method? Why? 
What do you consider the riskiest HIV cure research method? Why? 
 
Barriers and Facilitators  
What do you think are the main factors motivating your patients/participants to participate in HIV cure 
studies?  
What factors have facilitated the implementation of HIV cure studies in the past? (Probe for 
anecdotes.) 
What do you think are the main barriers from participating in HIV cure studies for your 
patients/participants? 
What are the main reasons for why your patients/participants are ineligible for HIV cure studies? 
What factors have made the implementation of HIV cure studies difficult in the past? (Probe for 
anecdotes.) 
Programmatic Considerations  
What can be done to facilitate the recruitment of patients/participants into HIV cure studies? 
What can be done to facilitate retention of patients/participants into HIV cure studies? 
What can be done to make sure that HIV cure studies are implemented well?  
What can be done to make sure that HIV cure studies are implemented in an ethical way? 
What kind of guidance is needed for patients/participants wanting to participate in HIV cure studies? 
Do your patients/participants think they will be cured from early HIV cure studies? 
 
Patients/Participants and Policy-Makers Roles and Responsibilities  
What do you believe is the role of patients/participants concerning HIV cure studies? 
What do you believe is the role of policy-makers (such as institutional review boards) concerning HIV cure 
studies? 
 
Wrap Up and Closing 
Would you like to add anything or make additional comments?  
 
Thank you for taking the time to answer these questions. Your participation in this interview greatly 
contributes to the research project and to increasing our understanding around the issues affecting 
participation in HIV cure studies. Your answers will be compiled with the answers of all other interviewees. 





POLICY MAKERS/REGULATORS INTERVIEW GUIDE (APPROVED BY UNC IRB) 
 
Introduction  
Can you please tell us more about your role in HIV (cure research)?   
What factors are important to consider for patients/participants wanting to participate in HIV cure 
studies? 
 
Risks and Benefits  
Do you think that there are benefits to participate in HIV cure studies? If so, what are they? 
What do you consider the safest HIV cure research method? Why? 
What are some of the risks to participate in HIV cure studies?  
What do you think would constitute “too much risk” in HIV cure studies? 
[If regulator] Are there studies that you would not approve?  
[If advocate] Are there studies that you would not recommend HIV-positive patients to participate 
in? If so, what are they? 
What do you consider the riskiest HIV cure research modality? Why? 
 
Barriers and Facilitators  
What do you think are the main motivators to participate in HIV cure studies?  
What do you think would motivate someone doing well on HIV treatment to participate in an HIV cure 
study? 
What do you think are the main barriers to participate in HIV cure studies? 
 
Programmatic Considerations  
What can be done to facilitate the recruitment of patients/participants in HIV cure studies? 
What can be done to facilitate retention of patients/participants in HIV cure studies? 
What can be done to make sure that HIV cure studies are implemented well? 
What can be done to make sure that HIV cure studies are implemented in an ethical way? 
What kind of guidance is needed for patients/participants wanting to participate in HIV cure studies? 
Do you think guidance is needed for clinicians/researchers about HIV cure research? If so, please explain. 
 
Patients/Participants and Clinicians/Researchers’ Roles and Responsibilities  
What do you believe is the role of patients/participants about HIV cure studies? 
What do you believe is the role of clinicians/researchers about HIV cure studies? 
 
Wrap Up and Closing 
Would you like to add anything or make additional comments?  
 
Thank you for taking the time to answer these questions. Your participation in this interview greatly 
contributes to the research project and to increasing our understanding around the issues affecting 
participation in HIV cure studies. Your answers will be compiled with the answers of all other interviewees. 




ADDENDUM TO INTERVIEW GUIDES: LIST OF POSSIBLE PROBES 
 Can you please expand a little on this? 
 Can you please explain what you mean?  
 Can you please tell us more? 
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3. Eron J. Challenges in Designing Clinical Trials in Cure Research. Presentation at the 7th HIV 
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8. Forum for Collaborative HIV Research, Meeting Proceedings – Regulatory Pathway for HIV Cure 
Research. 17 June 2014.  
9. Forum for Collaborative HIV Research, Working Group #3 Survey Mapping Sub-Group. Proposed 
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KEY INFORMANT INTERVIEWS 
 
Patients-Participants 
1. ID# 101: Key Informant Interview Patient-Participant – Male More Willing, 3 September 2015 at 
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2. ID# 102: Key Informant Interview Patient-Participant – Male More Willing, 17 September 2015 at 
4 pm ET. 
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